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Abstract:  
This project focused on the development of an effective gene replacement therapy 
for the Duchenne muscular dystrophy (DMD) in its mouse models [(X-linked 
muscular dystrophy, mdx) and mdx-βgeo mice]. Earlier studies on the DMD 
replacement therapy (usually using mini-dystrophin) were largely not successful 
because dystrophin is being recognised as an antigen upon re-expression in 
dystrophic muscles and initiates the specific immune response. This leads to a 
short-lived or no expression of mini-dystrophin as was found in both human clinical 
trials and in animal models. It had been shown that the presence of pre-existing T-
cells responding to dystrophin was responsible for this effect and 
immunosuppressive drug treatments in a canine model of DMD (cxmd) resulted in 
a stable expression of dystrophin for 2 years.  
This study investigated the potential of using immunomodulatory factors such as 
IDO (Indoleamine 2,3-dioxygenase) and TDO (tryptophan 2,3-dioxygenase) to 
prolong expression of newly synthesised antigenic products in dystrophic mice. IDO 
and TDO are the rate-limiting enzymes of the tryptophan catabolism pathway, which 
regulate the production of kynurenines. These enzymes are known to increase the 
survival of grafts in transplantation by targeting dendritic cells, which play an 
important role in the T-cell activation. The plasmid with the general CMV promoter 
was used for expression of these enzymes in cell lines (HEK 293 cells and SC5 
dystrophic myoblasts) and in skeletal muscles in vivo. To achieve targeting of the 
immunomodulatory constructs specifically into dendritic cells, the CD11c minimal 
promoter has been used. The plasmid driven by the CMV promoter was used for 
expression of the mini-dystrophin (an intracellular, structural protein) or the E.coli 
b-galactosidase (cytoplasmic but also secreted, strongly antigenic protein) in cells 
in vitro and muscles in vivo. Another plasmid construct expressing the mini-
dystrophin gene under the muscle- specific creatine kinase promoter and the 
myosin light chain 1/3 enhancer combination was also used for studies of the effects 
of muscle-specific expressions of the transgene.  
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The cloning resulted in the generation of plasmids with the mini-dystrophin driven 
by MCK or CMV promoters and IDO transcripts under the control of CMV or CD11c 
minimal promoter (Chapter 3). The Western blotting analyses confirmed the ability 
of plasmids to drive specific transgenes’ expression in HEK 293, mouse myoblasts 
and RAW 264.7 macrophage cell lines in vitro. The RT-PCR analyses confirmed 
the expression of specific plasmids (Chapter 4). 
The single plasmid expression experiment using the mini-dystrophin construct 
targeted into muscles was analysed by Western blotting, RT-PCR and 
immunohistochemistry. While RT-PCR confirmed its expression, the Western 
blotting results were ill-reproducible and immunohistochemistry did not confirm 
transgene expression. Moreover, there was no significant difference in the 
expression of mini-dystrophin driven by CMV or the muscle-specific MCK 
promoter/MLC enhancer combination (Chapter 5). The use of Pluronic SP1017-2 
did not yield any significant improvement in the expression profile of plasmids as 
compared with normal saline. Hence, normal saline was used in subsequent 
experiments as a vehicle of choice. Moreover, to support the hypothesis, there was 
a requirement to analyse the fold increase of the target plasmid expression in the 
presence of immunomodulatory factors. This could not be achieved using the mini-
dystrophin plasmids due to low expression and lack of reproducibility. Therefore, 
the expression profile of b-galactosidase used as a model transgene was analysed 
instead. This protein is immunogenic due to its E.coli origin and is a 120 KDa 
protein, which is very close to 125 KDa size of the mini-dystrophin. The timeline of 
b-galactosidase expression was established based on the presence of this protein 
at 7 and 14 days and its absence 21 days post-injection, as assessed by Western 
blotting.  
The expression profiles of IDO1 driven by CMV or CD11c were analysed and 
confirmed using RT-PCR; IDO1 did not show detectable expression in Western 
blotting. (Chapter 5). 
The effects of co-injection of b-galactosidase with IDO1 driven by CMV or CD11c 
were analysed by Western blotting, RT-PCR and qPCR. In the control samples, 
25% of muscles expressed b-galactosidase two weeks after the injection. This 
increased to 42% (5 out of 12 muscles) in samples co-injected with CD11c-driven 
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IDO1 and 69% (11 out of 16 muscles) in samples co-injected with IDO1 driven by 
the CMV promoter. This confirmed the hypothesis that the presence of IDO1 has a 
potential to sustain the expression of an immunogenic transgene and indicated that 
the more widespread rather than targeted expression of IDO1 in antigen-presenting 
cells was more effective in supporting such an expression (Chapter 5). 
The RT-PCR data showed IDO1 expression in most samples, also some that were 
not showing b-galactosidase in Western blots, and confirmed the plasmid-driven 
IDO1 expression. The qPCR data also confirmed significantly increased expression 
of b-galactosidase and IDO1 in co-injected samples compared to b-galactosidase-
only controls. This further supported the hypothesis that co-expression of 
immunomodulatory IDO1 increases the transgene expression (Chapter 5).  
The X-gal staining identified the expression of b-galactosidase in very few 
myofibres, which correlated with the Western blotting data and confirmed the low 
efficiency of the “naked” plasmid uptake by skeletal muscles. The presence of 
infiltrating immune cells surrounding these b-galactosidase positive myofibres was 
probed by immunohistochemical methods (Chapter 6).  
The qPCR analyses of a selection of the immune cell markers showed statistically 
significantly higher expression of CD4, CD8a, FoxP3 and COX2 in co-injected 
samples while expressions of IL-10 and IL-12 were statistically significantly lower 
in co-injected muscles.  
The levels of antibodies against beta-galactosidase were quantified by ELISA in 
control, b-galactosidase-only injected samples and IDO1 co-injected samples. The 
anti-b-galactosidase antibody levels were significantly lower in co-injected samples 
compared to the controls (Chapter 6). 
 
These results indicate that co-expression of genes encoding 
immunomodulatory enzymes of the kynurenine pathway can be a feasible 
strategy for preventing loss of expression of transgenes targeted into 
muscles with pre-existing inflammation. 
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Hypothesis: “Co-expression of immunomodulatory factors (IDO/TDO) with mini-
dystrophin or beta-galactosidase transgenes in skeletal muscles of the mdx mouse 
prolongs the expression of these transgenes.” 
 
Aims:   
1-To prolong expression of immunogenic transgenes in dystrophic muscles with 
pre-existing inflammation.  
2-To prevent this loss of transgene by exploiting co-expression of genes encoding 
enzymes controlling kynurenine pathways instead of global immunosuppression. 
 
Objectives: 
1-To modify and validate expression profile of plasmids expressing target genes 
(mini-dystrophin and beta-galactosidase) and immunomodulatory genes 
(IDO1/IDO2/TDO/FoxO3) both in vitro and in vivo.  
2-To check the effects of immunomodulatory genes on the prolongation of target 
genes expression in vivo. 
3-To assess the occurrence of the tolerance induction.  
	
  
	 6	
Declaration: 
“Whilst registered as a candidate for the above degree, I have not been registered 
for any other research award. The results and conclusions embodied in this thesis 
are the work of the named candidate and have not been submitted for any other 
academic award” 
Dishant Sharma 
February 2017 
Word Count: 52,654 
 
 
 
 
  
	 7	
Acknowledgements 
Most importantly, I would like to thank my father Mr Dinesh Kumar Sharma and my 
younger sister Ms Pracheta Sharma for their support. I would not have could come 
to England in the first place without their help. I remembered my mother Late Mrs 
Triyama Sharma. I remembered my spiritual guide Abhaya Charanavinda 
Bhaktivedanta Swami Prabhupada, founder Acharya of International Society for 
Krishna Consciousness (ISKCON) for spreading the knowledge about KRISHNA 
and process of making a connection with him. Without him, I might not able to know 
the KRISHNA, perform devotional service towards him and would never be able to 
make a connection with him in the form of Hare Krishna Maha-Mantra: - “Hare 
Krishna Hare Krishna Krishna Krishna Hare Hare, Hare Ram Hare Ram Ram Ram 
Hare Hare”. These spiritual practices helped me in de-stressing and guided me 
through a tough time during my PhD project by reiterating the real purpose of 
human life to go back home, to the spiritual world.   
Second, I would like to thank my supervisors: Prof. Darek Gorecki for finalising this 
enthusiastic project and helping me throughout its commencement; Dr Qian An and 
Dr Collin Sharpe for helping me better understand the project. I would like to thank 
the technical staff of the University for their help in day-to-day tasks. 
I would like to thank colleagues in the Department of Pharmacy and Biomedical 
sciences, specifically Dr Chung Fu Lien; Dr Chris Young; Dr Anthony Sinadinos; 
Mrs Rasha al-Khalidi; Ms Suzanne Edgar and Ms Natalia Chira. Without their help, 
it would be very hard to complete this big task. Also, the help provided by the 
students, Mr De-graft Koomson (BSc), Mr Ricky Lee Harris (BSc) and Mr Yao Wang 
(MSc) is of great significance. 
 
 
 
 
 
	 8	
 
 
 
 
 
 
 
 
 
Dedicated to patients of monogenetic diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 9	
 Title page................................................................................1 
 Abstract...................................................................................2 
 Hypothesis, aims, objectives..................................................5 
 Declaration………….……………………………………....…....6 
 Acknowledgement …………………………………………........7 
 Dedication…………………………………………………....…...8 
 Table of contents…………………………………………....…...9 
 List of tables ………………………………………………........13 
 List of figures…………………………………………………....14 
 List of abbreviations ……………………………………..….....17 
 
 Table of Contents 
 Chapter 1: General Introduction……………………….…......20 
1.1 Genetic Diseases…………………………….……….….....20 
1.2 Duchenne Muscular Dystrophy……………………...........21 
1.2.1 What is wrong in DMD………………….....….....21 
1.2.2 First signs of disease (symptoms)………….......21 
1.2.3 Diagnosis and screening for DMD.……….........23 
1.2.4 Dystrophin gene, transcript,  
         protein and its associated complex……….…....25 
1.2.5 Molecular mechanisms of the disease….…...…28 
1.2.6 The mdx mouse as the disease model…......….35 
1.2.7 Current Approaches to treat DMD……….......…35 
1.2.8 Exon Skipping………………………………....….38 
1.3 Gene Therapy…………………………………………........39 
1.3.1.1 Viral Vectors……………………………….....…39 
1.3.1.2 Applications of viral vectors……………….…..40 
1.3.2 Non-viral Vectors………………………….......….41 
         1.3.2.1 Transfection reagents……………….…..41 
         1.3.2.2 Nanoparticles………………………....….41 
         1.3.2.3 Prokaryotes…………………………....…41 
         1.3.2.4 Polyethene glycol derivatives………......41 
         1.3.2.5 Human ribosomal DNA……………....….42 
         1.3.2.6 Naked plasmid DNA………………….….42 
         1.3.2.7 Naked mRNA………………………….….42 
         1.3.2.8 Electroporation…………………….……..42 
         1.3.2.9 Ultrasound field……………………..…....43 
         1.3.2.10 TALEs and CRISPR/Cas9……….…....43 
         1.3.2.11 Applications of TALEN and 
                       CRISPR/Cas9 in genome editing….….46 
1.4 Tolerance Induction…………………………………..….....46 
           1.4.1 Mechanism of tolerance induction 
by the kynurenine pathway ……....…….….......47 
           1.4.2 Significance of tolerance induction………....…..50 
Chapter 2: Materials and methods……………………......…...51 
         2.1.4 Solutions and buffers……………………….........54 
2.2 Microbiological techniques…………………..……….........56 
         2.2.1 LB Broth & LB Agar preparation…………....…..56 
	 10	
         2.2.2 Transformation of bacteria………………….......57 
         2.2.3 Glycerol Stock preparation………………….......58 
2.3 Molecular Biology techniques………………………......…58 
           2.3.1 Small-scale preparation of plasmid DNA.....…..58 
           2.3.2 Large scale preparation of plasmid DNA….......60 
                    2.3.2.1 Ethanol precipitation of DNA……….......62 
           2.3.3 Analysis of concentration and purity  
            of nucleic acids using Nanodrop  
           spectrophotometer………………………………….......63 
 2.3.4 Genetic engineering of plasmid DNA……………….….63 
 2.3.5 Restriction digestion of plasmid DNAs..……………….64 
 2.3.6 Agarose gel electrophoresis………………………….....65 
 2.3.7 DNA extraction from agarose gels…………………......66 
 2.3.8 Dephosphorylation of vector arms…………………......67 
 2.3.9 DNA ligation...………………………………………….…67 
 2.3.10 PCR amplification of nucleic acids……………….......67 
 2.3.11 PCR product purification…………………………........68 
 2.3.12 PCR product cloning using pGEM-T  
                Easy Vector System…………………………….......69 
 2.3.13 DNA sequencing of plasmid constructs.…………......70 
 2.3.14 Extraction of RNA from cell lines and tissues…..…...71 
           2.3.14.1 Sample preparation from TA muscle…….....71 
           2.3.14.2 Sample preparation from cell lines……….....71 
           2.3.14.3 Extraction of RNA. …………………………....71 
           2.3.14.4 DNase treatment……………………………...73 
 2.3.15  Reverse transcription of RNA..…………………….....73 
           2.3.15.1 Annealing. ………………………………….....73 
           2.3.15.2 Extension. …………………………………......73 
 2.3.16  qPCR Setup using TaqMan  
                Gene Expression Assay ……………………….......74 
           2.3.16.1 Reaction Setup.…………………………….....74 
           2.3.16.2 Program Setup. ……………………………....75 
           2.3.16.3 Analysis of Results.…………………….….....75 
           2.3.16.4 qPCR setup using SYBR Green dye…….….76 
 2.3.17  Western Blotting…………………………………….….76 
           2.3.17.1 Sample preparation from TA muscle….........77 
           2.3.17.2 Sample preparation from cell lines…….........77 
           2.3.17.3 Protein estimation by BCA assay……...…....78 
           2.3.17.4 SDS-PAGE………………………………........79 
           2.3.17.5 Transfer setup. …………………………..…...81 
           2.3.17.6 Antibody incubation. …………………..……..82 
           2.3.17.7 Imaging and quantification of bands…..…....83 
 2.4 Tissue Culture………………………………………….......85 
           2.4.1 Counting of cells……............................….….....85 
           2.4.2 Culture of HEK 293 and  
                       RAW 264.7 cells…………………..…………....86 
           2.4.3 Culture of myoblast cells…………………..….....87 
           2.4.4 Transfection of cells…………………….….….....87 
	 11	
           2.4.5 Cryopreservation of cells. ………………….…....91 
           2.4.6 Confocal Microscopy of cells. ……………..…....91 
 2.5 Histology and Immunohistochemical analysis. …….......92 
           2.5.1 Cryo-sectioning of tibialis anterior muscle..…....92 
 2.5.2 Tissue staining…………………………………………....93 
           2.5.2.1 Haematoxylin and Eosin Staining…..…….…..93 
           2.5.2.2 DAB Staining……………………………...….....94 
                   2.5.2.2.1 Detection of dystrophin in muscle  
                              sections………………………………….....95 
                   2.5.2.2.2 Detection of IDO1 in dystrophic  
                             myoblast cells (SC5) ………………..….....95 
           2.5.2.3 VIP peroxidase staining. ………………….......96 
           2.5.2.4 X-gal staining. …………………………….........97 
 2.6 Intramuscular injection of mice……………………...........97 
           2.6.1   Injection calculations……………………...........98 
           2.6.2   Collection of TA muscle and blood……….......99 
 2.7 ELISA............…………………………………………........99 
           2.7.1 Dot-Blot technique to troubleshoot ELISA..…..100 
 2.8 Statistical analyses…………………………………….....102 
 2.9 Summary of results……………..………………………...102 
Chapter 3: Genetic engineering and analysis  
                 of expression vectors…………………………......104 
 3 Aims…………………………….………………………........104 
 3.1 Introduction…………………………….……………….....104 
 3.2 Cloning of dystrophin minigene into PX61MCK…….....105 
 3.3 Cloning of the dystrophin minigene into pcDNA3.........108 
 3.4 Cloning of CD11c promoter into IDO1,  
         IDO2 and TDO vectors……………………………....….110 
 3.5 Summary…………………………….………………….....114 
 3.6 Discussion………………………………………………....114 
Chapter 4 Analyses of transgene expression in vitro....…...116 
 4.0 Aims…………………………….……………………….....116 
 4.1 Introduction…………………………….……………...…..116 
 4.2 Analyses of pcDNA3.mini-dyst.Fwd expression…...….119 
 4.3 Analysis of pcS2+C Beta Galactosidase expression....127  
 4.4 Analyses of pcDNA3.IDO1 expression………………....128 
 4.5 Analyses of pcDNA3.IDO2 and  
           pcDNA3.TDO expression……...................................131 
 4.6 Analyses of pcDNA4.FOXO3WT expression……….....132 
 4.7 Analyses of pcDNA3.CD11c.IDO1 expression…….….133 
 4.8 Summary…………………………….………………….....134 
 4.9 Discussion………………………………………………....135 
4.9.1-mini-dystrophin plasmid……………………..….135 
4.9.2-in vitro expression……………………………....136 
4.9.3-Matrix metalloproteinases (MMPs)…………....136 
4.9.4-MicroRNAs inhibiting overexpression  
of mini-dystrophin…………………………………..….137 
	 12	
4.9.5-Methylation of pDNA………………………..…..137 
Chapter 5 Analyses of the effects of IDO1 expressing  
    plasmids on target gene expression in vivo….……….....140 
 5.0 Aims…………………………….…………………...….....140 
 5.1 Introduction…………………………….………….……....140 
 5.2 Analyses of mini-dystrophin expression………….........143 
 5.3 Analyses of pcS2+C Beta Galactosidase  
          expression……………................................................149 
 5.4 Analyses of pcDNA3.IDO1 expression……………...….159 
 5.5 Analyses of pcDNA3.CD11c.IDO1 expression….….....162 
 5.6 Analysis of pcDNA4.FOXO3WT expression…..……....163 
 5.7 Summary………………………………………….…........165 
 5.8 Discussion…………………………………………..….....167 
5.8.1- Lower uptake of plasmid being  
a common problem with naked plasmid injection.....167 
5.8.2-Absence of signal recognition particle sequence  
and similar signalling molecules in mini-dystrophi....169  
5.8.3-Degradation of plasmid DNA (pDNA)….……..171 
5.8.4-Immune responses against pDNA.…….…......172 
Chapter 6 Morphological and molecular analyses 
    of beta-galactosidase expressing muscle………..….......174 
 6.0 Aims…………………………….…………………............174 
 6.1 Introduction…………………………….…………............174 
 6.2 Morphological analyses of beta  
        galactosidase expressing muscles……………..……...177 
 6.3 Analysis of infiltrating immune cells……………..…......181 
 6.4 qPCR analyses……………………….……………..........183 
 6.5 ELISA…………………………….…………………..........185 
 6.6 Summary…………………………….……………............187 
 6.7.1 Discussion…………………………………………........190 
6.7.2 T-reg Cells………………………………….…....189 
6.7.3 IDO1……………………………………….……..191 
Chapter 7 Discussion…………………………….…….....…..192 
 7.1 General Discussion.......………………………...….…....192 
 7.2 Conclusion........................................…………….……..196 
 7.3 Future Work…………………………….……..…….........196 
 Chapter 8 References………………………………...…..…..198 
 Chapter 9Appendix…………………………….……………...251  
 9.1 Sequences and Maps of Plasmid Vectors…….…….....238 
 9.2 Ethical Approval………………….……………….……....273 
 9.3 Publication………………………………………………....274 
 
 
 
 
 
	 13	
LIST OF TABLES (numbering based on Section number) 
 
Chapter 1  
Table 1.2.2.1 Progression of symptoms of DMD disease. 22 
Table 1.2.5.1 Time-course of mdx muscle pathology. 31 
Table 1.2.7.1 Palliative care for DMD patients. 36 
Chapter 2 
Table 2.1.1 List of enzymes used. 51 
Table 2.1.2  List of antibodies used. 51 
Table 2.1.3 List of chemicals and kits used. 52 
Table 2.1.5 List of plasmids used. 54 
Table 2.1.6 List of bacterial strain used. 55 
Table 2.1.7 Description of PCR primers used. 55 
Table 2.1.8 List of qPCR probes used (Taqman, Thermo 
Fisher Scientific). 
56 
Table 2.3.2.0 Description of Low copy and High copy plasmid 
based on the origin of replication (adapted from 
Qiagen Endo-Free Mega Prep kit manual). 
60 
Table 2.3.4.1 Descriptions of plasmid modifications. 64 
Table 2.3.10 Description of PCR program for thermo-cycler. 68 
Table 
2.3.16.2.1 
Description of a qPCR program for qPCR 
thermocycler. 
75 
Table 
2.3.16.4.1 
Description of a qPCR program for qPCR 
thermocycler using a Sybr green master mix. 
76 
Table 2.3.17.4 Description of SDS-PAGE Gel composition. 80 
Table 2.3.17.6 Description of antibodies used in Western 
blotting. 
83 
Table 2.4.2.1 The composition of HEK 293 and RAW 264.7 
cell’s media. 
87 
Table 2.4.3.1 The composition of SC5 and IMO myoblasts 
media. 
87 
Table 2.4.3.2 The composition of SC5 and IMO myoblasts 
differentiation media. 
87 
Table 2.4.4 Description of working solution of various 
transfection reagents.   
89-
	 14	
90 
Table 2.4.6.1 Parameters of Zeiss LSM 510 META Confocal 
microscope. 
91-
92 
Table 2.5.2.3.1 Description of antibodies dilution used in the VIP 
staining 
96 
Table 2.6.1.1 Calculations for single plasmid injection in 0.9% 
saline. 
98 
Table 2.6.1.2 Calculation for two plasmid injection (co-injection) 
in 0.9% saline. 
98-
99 
Chapter 5 
Table 5.3.1 The combined Western blot and RT-PCR data for 
co-injected samples   
 
154 
 
LIST OF FIGURES (numbering based on section number) 
Chapter 1 
Figure 1.2.4.1 Schematic of the different isoforms of the 
dystrophin gene and protein structure showing 
various components.  
 
27 
Figure 1.2.4.2 Schematic of a dystrophin-associated protein 
complex (DAP) in skeletal muscle. 
28 
Figure 1.2.5.1   Summary of important pathways and their active 
molecules involved in muscle wasting in muscular 
dystrophy. 
 
34 
Figure 1.2.8.1 Schematics of exon skipping procedure.  
 
38 
Figure 
1.3.2.10.1  
Schematic of the mechanism of TALEN- and 
CRISPR/Cas9-mediated genome editing. 
 
44-
45 
Figure 1.4.1.1  Schematics of the L-tryptophan metabolism 
pathway 
48 
Chapter 2 
Figure 2.9 Flowchart describing the correlation between 
various result chapters. 
 
103 
Chapter 3 
Figure 3.2.1 Schematics of cloning of the dystrophin minigene 
(mini-dyst) into PX61MCK plasmid backbone. 
107 
	 15	
Figure 3.2.2 Agarose gel electrophoresis in 1% gel of 
PX61MCK.mini-dyst clones after restriction 
digestion. 
108 
Figure 3.3.1 Schematics of cloning of the dystrophin minigene 
(mini-dyst) into pcDNA3 plasmid backbone.  
109 
Figure 3.3.2 Agarose gel electrophoresis in 1% gel of 
pcDNA3.mini-dyst clones after restriction 
digestion. 
110 
Figure 3.4.1 Schematics of exchange of promoter CMV with 
the CD11c promoter in pcDNA3.IDO1/IDO2/TDO 
plasmids. 
112 
Figure 3.4.2 Agarose gel electrophoresis in 1% gel of 
pcDNA3.CD11c.IDO2 clones after restriction 
digestion. 
113 
Figure 3.4.3 Agarose gel electrophoresis in 1% gel of 
pcDNA3.CD11c.IDO1 and pcDNA3.CD11c.TDO 
after restriction digestion. 
113 
Figure3.4.4 Agarose gel electrophoresis in 2% gel of 
pcDNA3.CD11c.TDO clones after restriction 
digestion. 
114 
Chapter 4 
Figure 4.2.1 Analyses of pcDNA3.mini-dyst.Fwd expression in 
HEK 293 cells. 
120 
Figure 4.2.2 Confocal microscopy of SC5 myoblasts. 121 
Figure 4.2.3 Analyses of pcDNA3.mini-dyst.Fwd expression in 
SC5 and IMO myoblasts after doxycycline 
treatment. 
 
124 
Figure 4.2.4 Analyses of pcDNA3.mini-dyst.Fwd expression in 
SC5 and IMO myoblasts after transfection. 
 
126 
Figure 4.3.1  Western blot analyses of samples from the SC5 
myoblasts transiently transfected with pcS+C2 
Beta Galactosidase plasmid. 
 
128 
Figure 4.4 Analyses of pcDNA3.IDO1 expression. 130-
131 
	 16	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Analyses of pcDNA3.IDO2 and pcDNA3.TDO 
expression 
132 
Figure 4.6  Analyses of pcDNA4.FOXO3.WT expression. 133 
Figure 4.7  Analyses of pcDNA3.CD11c.IDO1 expression. 135 
Chapter 5 
Figure 5.2 Analyses of mini-dystrophin expression. 147-
149 
Figure 5.3.1 Analyses of pcS2+C Beta Galactosidase 
expression.  
151 
Figure 5.3.2 Analyses of pcS2+C Beta Galactosidase 
expression. 
155 
Figure 5.3.3 The plot of qPCR delta delta CT values for 
expression of b-gal (using Laz gene Taqman 
probe). 
156 
Figure 5.3.4 Densitometric analyses of compiled data of 
Western Blot analyses of b-gal. 
158-
159 
Figure 5.4  Analyses of pcDNA3.IDO1 expression. 161-
162 
Figure 5.5  Analyses of pcDNA3.CD11c.IDO1 expression. 163 
Figure 5.6   Analyses of pcDNA4.FOXO3WT expression. 165 
Chapter 6 
Figure 6.2.1  X-gal staining of muscle sections with 
Haematoxylin counterstain (low magnification). 
179 
Figure 6.2.2  X-gal staining of muscle sections with 
Haematoxylin counterstain (high magnification). 
180 
Figure 6.3.1 X-gal Stained co-injected sections with VIP 
peroxidase staining and haematoxylin.  
 
182 
Figure 6.4  
 
The plot of qPCR delta delta CT values for 
Immune markers expression. 
184-
185 
Figure 6.5.1  
 
Dot-Blot image of the membrane probed with anti-
b-gal antibody in different blocking solutions. 
186 
Figure 6.5.2 Co-expression of IDO1 reduces antibody 
response against b-gal . 
187 
	 17	
LIST OF ABBREVIATIONS 
APS Ammonium persulphate. 
bp   Base pairs. 
BMD Becker muscular dystrophy. 
BSA Bovine serum albumin. 
BCA Bicinchoninic acid assay. 
b-gal Beta galactosidase 
cDNA Complementary DNA. 
 
CMV Cytomegalovirus. 
DAB 3,3’-diaminobenzidine. 
DAPC Dystrophin-associated protein complex. 
DEPC  Diethyl pyrocarbonate. 
ddH20  Double distilled water (Milli-Q water). 
DMEM Dulbecco's Modified Eagle's medium. 
DMD Duchenne muscular dystrophy. 
DMSO Dimethylsulfoxide. 
DNA Deoxyribonucleic Acid. 
DNase Deoxyribonuclease. 
dNTP DeoxyNucleotide Tri Phosphate. 
E. coli  Escherichia coli. 
ELISA Enzyme-linked immunosorbent assay. 
 
EDTA  Ethylenediaminetetraacetic acid. 
FCS Fetal calf serum. 
FD Fast digest. 
g  gram. 
	 18	
GAPDH Glyceraldehyde 3-phosphate dehydrogenase. 
gDNA Genomic DNA. 
h  Hour. 
HRP Horse Radish Peroxidase. 
IgG Immunoglobulin G. 
IPTG Isopropyl-β-d-thiogalactopyranoside. 
IU International Units. 
KDa  Kilodalton. 
kb Kilobase. 
KO Knockout. 
LB Luria-Bertani. 
m Minutes. 
msec Millisecond.  
MCK Muscle creatine kinase. 
mRNA Messenger ribonucleic acid. 
MLC Myosin light chain. 
OD Optical Density. 
pM Picomole. 
PAGE Polyacrylamide Gel Electrophoresis. 
PBS Phosphate buffer saline. 
PCR Polymerase chain reaction. 
qPCR Quantitative real time polymerase chain reaction. 
PVDF  Polyvinyl di fluoride. 
RNA Ribonucleic acid. 
RT Reverse Transcription. 
	 19	
RT-PCR Reverse transcription polymerase chain reaction. 
s Second 
SEM  Standard error of mean. 
SDS Sodium Dodecyl Sulphate. 
SD Standard deviation. 
SOC Super Optimal Broth. 
TA tibialis anterior. 
TEMED Tetramethylethylenediamine. 
TMB Tetramethyl benzidine. 
TBS Tris-buffered saline. 
v/v volume/volume. 
w/v weight/volume. 
WT Wild type. 
X-gal 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside. 
    
 
   
 
 
 
 
 
 
 
 
 
 
 
 
	 20	
Chapter 1: General Introduction 
 
1.1 Genetic Diseases 
Genetic diseases occur due to mutations, most of these mutations are inherited 
from parents but some are spontaneous. The mutations are classified into gene 
mutation, which changes one-gene and chromosome mutations, which changes the 
number or structure of a chromosome (9). A mutation causes changes in the 
sequence of DNA in the genes coding for proteins that lead to the production of an 
abnormal protein or a total absence of a protein (9). Some studies confirmed that 
mutation in non-coding genes led to diseases (10, 11). The single gene mutations 
may lead to inborn errors of metabolism of early childhood. The examples are 
phenylketonuria due to the absence of phenylalanine hydroxylase, galactosemia 
due to the absence of galactose 1-phosphate uridyl transferase, Fabry’s disease 
due to the absence of alpha-galactosidase A etc. (12).  
The chromosome mutations are detected by chromosome banding to observe its 
structure under a microscope. The examples are Cri-du-chat syndrome due to 
deletion of short arm of chromosome 5, Down syndrome due to Trisomy (2n+1) of 
chromosome 21 etc. (9). 
The gene mutations are classified into base substitutions that change a single base 
(e.g transition: change of one kind of purine base to another purine base and 
transversion: change of purine to pyrimidine base); frame shift, that changes the 
open reading frame for protein synthesis (e.g insertion, deletion and duplication) 
and expanding trinucleotide repeats that contain repeats of nucleotides. The 
examples are myotonic dystrophy due to abnormal 44-3000 repeats of CTG 
sequence, Huntington disease due to abnormal 37-121 repeats of CAG sequence, 
Fragile X-syndrome due to abnormal 50-1500 repeats of CGG sequence etc. (9). 
The mutation in arginine and glycine amino acid residues together cause 30% of 
genetic diseases, while mutations in tryptophan and cysteine amino acids have the 
highest probability of causing genetic diseases (13).   
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1.2 Duchenne Muscular Dystrophy 
1.2.1 What is wrong in DMD  
Duchenne Muscular Dystrophy (DMD) is a hereditary disease caused by the loss 
of dystrophin gene that is located on the short arm of human X-chromosome (Xp12) 
and produces a 427 KDa cytoskeleton protein (14). The loss of dystrophin protein 
in DMD is due to mutations including deletions (60%), duplications (10%) and point 
mutations (30%) in the dystrophin gene (15).  This protein constitutes about 0.002% 
of total protein content of striated muscle and is also present in non-striated muscle 
(e.g. digestive track). The dystrophin glycoprotein complex (DGC) provide support 
between the cytoskeleton and extracellular matrix in sarcolemma membrane (3). It 
was named dystrophin due to its identification based on the Duchenne muscular 
dystrophy locus (Xp21) (14). DMD affects about 1 in 3,500 boys based on 1991 
data (16). The latest available data for the year 2010, evaluating six sites in the 
USA showed 1.38 per 10,000 males at the age of 5 to 24 were affected with 
Duchenne and Becker muscular dystrophy (17). Some other studies showed its 
prevalence about 1 in 5,000 boys.  
 
1.2.2 First signs of disease (symptoms) 
DMD causes progressive muscle wasting and weakness (18) that leads to 
myofibres atrophy, necrosis with fibrosis (2), which can be first observed at the ages 
of 2 to 5 years. The patients lose their gait ability at the age of about 9 years (18-
21). About 20% of patients have IQ lower than 70 (18). Table 1.2.2.1 shows the 
stages of disease progression with the corresponding symptoms.  
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Patients can move normally at early childhood but present with elevated serum 
levels of the muscle isoform of creatine kinase that can segregate Duchenne 
muscular dystrophy from Becker muscular dystrophy (a mild form of muscular 
dystrophy) patients (24). Later, these DMD patients restricted to use a wheelchair 
by the age of 12 and die in their twenties due to cardio- pulmonary complications 
(2, 25). Zhu et al (26) showed that the serum enzyme profile of susceptible subjects 
from muscle can detect the five different type of muscular dystrophy prior to genetic 
analyses, saving crucial time for early management of the disease. 
The patients with DMD have weakness of muscles involved in respiration (27) 
leading to 10-fold greater incidence of sleep disordered breathing than the general 
population. This chronic ventilatory failure in DMD patients could be mitigated using 
non-invasive ventilation using a nasal mask at the initial stage of DMD or negative 
pressure ventilation (NPV) using cuirass or jacket (poncho) type of negative 
pressure ventilator at a later stage of DMD (28-30). The respiratory infection due to 
inability to cough effectively poses a serious challenge to these patients and lung 
volume recruitment techniques could assist them (30).  
The less severe form of the disease is Becker muscular dystrophy (BMD) that 
occurs at the same locus has a much longer survival with patients dying at age of 
forty-fifty years (18). The deletion mutation in DMD patients leads to translation of 
a truncated and abnormal form of the protein, while, in BMD, the mutation leads to 
Table 1.2.2.1 Progression of symptoms of DMD disease (2, 22, 23) 
 
Stage Average age 
(years) 
Symptoms  
Pre-symptomatic  2 Elevated serum creatine kinase or 
positive family history 
Early ambulatory <5 Gower’s sign; waddling gait; they have 
toe walking, but patients are able to climb 
stairs 
Late ambulatory >5 Laboured gait; reduced ability to climb 
stairs and rising from a sitting position 
Early non-
ambulatory 
5-12 Able to maintain posture; able to self-
propel for short period; possibility of the 
development of scoliosis. 
Late non-
ambulatory 
>12 Limited postural maintenance and 
reduced upper limb functions.  
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translation of a shorter form of the protein having a semi-functional capability that 
results in a milder phenotype (31, 32).  
 
1.2.3 Diagnosis and screening for DMD 
The serum creatine kinase (CK) levels, electromyography, muscle histology, 
Immunohistochemistry and mutation analyses are the screening methods to detect 
DMD (18).  
CK levels indicate the level of muscle sarcolemma (membrane) damage and 
generally used in sports medicine to check the health of a muscle (33). CK levels 
were found to be 25 to 200 fold increased in DMD and BMD (33), due to leakage of 
CK from muscle fibres into blood (34). The neonatal levels of serum creatine kinase 
higher than 200 IU/L are used as an indicator of DMD (35-37) but are not used as 
a biomarker to check the progression of disease (34). The higher levels of serum 
creatine kinase are also observed later in life from age of 2 to 5 years (38). DMD 
patients have serum creatine kinase levels ranged from 1000 IU/L to 30,000 
IU/L(34).  
Electromyography indicates the neuromuscular fatigue during exercise (39) by 
analysing the motor unit potentials (MUPs). The presence of late component (LC) 
potential in DMD indicates the segmentation of existing muscle or muscle 
regeneration, which are absent in normal muscle (21, 40, 41). 
Muscle histology and immunohistochemical analyses indicate the level of fibrosis 
in muscle tissue. Fibrosis is an excessive accumulation of collagen in the 
extracellular matrix (ECM) that results in scar formation, the hallmark of DMD (42). 
Immune cells infiltrate rapidly into the injured muscle to remove necrotic tissue by 
secreting their respective soluble factors which further activates muscle satellite 
cells (43-45). These satellite cells secrete proinflammatory cytokines, IL-1, IL-6 and 
TNF-a, these allow immune cells to infiltrate and function (46, 47). The immune 
cells secrete growth factors, globular adiponectin, extracellular matrix components 
(ECM), these promote satellite cell proliferation and migration (48). In early stages 
of the disease, satellite cells compensate for muscle fibre loss but eventually, they 
become exhausted and that leads to accumulation of fatty connective tissue (49). 
This continuous degeneration of myofibres, independent of injury insult, releases 
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Th1 cytokine that signals to neutrophils and macrophages to sanitise the cell debris 
followed by secretion of Th2 cytokine that promotes muscle healing (50). 
The T-cells also play an active role in degeneration (51-53) although both MHC 
class I and class II has not been detected in healthy muscle (54) but the 
inflammatory milieu is shown to upregulate HLA-DR and co-stimulatory molecules 
(ICOS-L and CD40) that activate T-cells (55, 56). After an acute injury, T-cells are 
found in degenerating muscle, modulating the inflammatory milieu and function of 
other immune cells by secreting various cytokines and chemokines (57, 58). These 
T-cells have DMD specific T-cell receptor (TCR) rearrangement observed in various 
DMD patients (59) that differ from that in polymyositis (inflammatory myopathy) 
patients (60).  
The degeneration of various muscles in patient’s body is not uniform, although all 
muscles lack the dystrophin. Different degree of eccentric contraction during gait 
contributes to selective infiltration of fat (degeneration) in the muscle of lower limbs 
(61) 
Maunder et al (62) used muscle biopsy obtained from human subjects for detection 
of DMD carriers by quantitation of different proportion of fibre types, fibre diameters 
and several nuclei by histology. There was an increased proportion of type 1 fibres 
with changes in the mean diameter ratio of type 1: type 2 fibres ratio, an increase 
in the fibre diameter and number of nuclei in DMD carrier compared to controls. 
Using this approach, they confirmed that 71% of definite carriers, 86% of possible 
carriers with higher serum CK levels than in normal subjects and 78% of possible 
carriers with normal serum CK levels. This indicates the advantage of histological 
analyses over serum CK levels as a better method for the detection of carrier 
subjects.  
Kinali et al (63) confirmed MRI to be as reliable as histology for selection of specific 
muscles and recruitment of patients with DMD for clinical trials.  
Mutation analyses are being used to detect deletions, duplications, insertions etc., 
in patient’s samples to confirm the DMD.  
Bladen et al (64) developed the TREAT-NMD’s DMD global database 
(http://umd.be/TREAT_DMD/) to confirm the prevalence of the various types of 
genetic modifications leading to DMD. They studied 7149 DMD mutations available 
	 25	
in the database, the large mutations account for 79%, 68% were large deletions of 
1 or more than 1 exons, 11% were large duplication of 1 or more than 1 exons and 
the small mutations account for 21%, 5% were small deletion of 1 or less than 1 
exons, 2% were small insertion of 1 or less than 1 exons, 3% were splice sites of 
less than 10 bp from an exons, 11% were point mutations. 
Okubo et al (65) showed the use of Ion Torrent next-generation sequencing 
approach to detect 92% of patients with DMD/BMD while Yoo et al (66) used for 
single targeted massively paralleled sequencing of cell-free foetal DNA present in 
maternal plasma as a non-invasive prenatal diagnosis approach for DMD in 4 
families with a gestation of as early as 6 weeks and 5 days.  
 
1.2.4 Dystrophin gene, transcript, protein and its associated complex 
The dystrophin gene is about 2.5 Mb and has 79 exons (67), producing a 14kb 
mRNA for 7 different isoforms of protein that are expressed differently in specific 
tissues (2). The DMD transcript is made up of at least 60 exons that are mapped at 
various reference points of Xp21. Among these, the initial 33 exons covered nearly 
1000 kb region and the rest region was covered by 27 exons. The cDNA processed 
from the muscle biopsies of 104 DMD boys was tested for the presence of different 
type of mutations leading to DMD, among them 53 patients indicated the presence 
of deletion mutations which was located in the genomic region covering 2 kb (68). 
Figure 1.2.4.1 shows both the mRNA and protein structure, describing the various 
component involved. Dystrophin protein plays an important role in Dystrophin 
Associated Protein Complex (DAPC) and provides structural support to 
sarcolemmal membranes of muscle by binding to cytoplasmic complex and 
extracellular matrix (2). The Dystrophin interacting domains linking it with the 
dystrophin glycoprotein complex (DGC) consist of actin binding amino-terminus, 
central rod domain and terminal carboxyl-terminus. The DAPC consist of actin 
binding domain at amino-terminus, central rod domain and terminal cysteine-rich 
paired coiled-coil domain at the carboxyl-terminus. The actin binding domain shows 
homology with b-spectrin and a-actinin which are other actin binding proteins, this 
domain anchors dystrophin to the cytoskeletal side of the sarcolemmal membrane 
by g-actin filaments (69). The rod domain consists of 24 spectrin-like repeats, from 
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11 to 17 of these repeats form a second site for g-actin filament binding, this site 
differs in dystrophin homologue utrophin (70). The coiled-coil domain binds with 
beta-dystroglycan (βDG), sarcoglycan ((δ,γ,β,α,),sarcopan (ss) making 
sarcoglycan complex in the sarcolemmal membrane and syntrophins (syn) (71-73), 
alpha-dystrobrevin (αDB) in a cytoplasmic complex of sarcolemmal membrane. The 
beta-dystroglycan (βDG) binds to alpha-dystroglycan (αDG) of the extracellular 
matrix, which binds to laminin-2 (2). There are six sarcoglycans a,b,d,e,g and z, 
these are transmembrane-spanning glycoproteins. a and e are type I 
transmembrane proteins while all others are type II transmembrane proteins (74-
76). In DMD, the DAPC complex is not able to form and unable to give structural 
support to prevent muscle contraction induced damage (77, 78) that leads to 
sarcolemmal membrane leakiness with elevated levels of intracellular Ca2+ (79). 
Figure 1.2.4.2 shows the arrangement of a various component of this dystrophin-
associated complex.  
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Figure 1.2.4.1 Schematic of the different isoforms of dystrophin gene and 
protein structure showing various components.  
The DMD gene which has 2.5 Mb size producing 7 different protein 
isoforms. mRNA encodes a 427-kDa protein indicated by Dp, it also 
encodes small version. The Dp427(B) express in brain, Dp427(M) express 
in muscle, Dp427(P) express in Purkinje cells, Dp260(R) express in retina, 
Dp140(B3) express in brain, Dp116(S)express in Schwann cells, Dp71(G) 
express everywhere (red box). 
The protein structure has actin-binding domain (N-terminal end, red box), 
rod domain, WW, CYS (C-terminal end), CT binding domain. The WW 
domain, EF/ZZ domains of CYS domain, CC (paired coiled-coil) domain 
are cysteine-rich. The 1 to 4 proline-rich hinge regions. The binding sites 
are DG-dystroglycan, SYN-syntrophin, DFB-dystrophin family binding site. 
 
Adapted from (2, 3) 
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1.2.5 Molecular mechanisms of the disease  
The prevailing theory on the pathogenesis of DMD states that the absence of the 
dystrophin protein in myofibres causes muscle damage, inflammation and fibrosis. 
These results in continuous muscle degeneration and premature death of patients, 
usually in their late twenties (16). Dystrophin is a scaffolding protein linked to the 
cytoskeleton and anchoring a complex of dystrophin-associated proteins (DAPs), 
which includes a and b dystroglycan, sarcoglycans, dystrobrevin and syntrophins. 
Dystroglycan bind with the proteins of the extracellular matrix. The connection 
between cytoskeleton, the transmembrane dystroglycan and the extracellular 
matrix contributes to the stability of the muscle membrane. Loss of dystrophin 
results in the disruption of this complex and triggers membrane instability and 
Figure 1.2.4.2 Schematic of dystrophin-associated protein complex (DAP) 
in skeletal muscle. The NH2 terminus binds to cytoskeletal actin. The COOH 
terminus binds to beta dystroglycan (βDG), sarcoglycan ((δ,γ,β,α,), 
sarcopan (ss), in sarcolemma complex while in cytoplasmic complex (red 
box) it binds to syntrophins (syn), alpha dystrobrevin (αDB). The beta 
dystroglycan (βDG) binds to alpha dystroglycan (αDG) that present in 
extracellular matrix (red box), it binds to laminin-2.  
 
Adapted from (2, 3) 
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muscle damages (2, 3) (also discussed in section 1.2.4). This dystrophin absence 
causes increased in intracellular Ca2+ levels that affect the downstream pathways 
also causes increased levels of intracellular Ca2+, deregulation of mitochondrial 
activity, protease calpain-mediated necrosis and NF-κB activation that induces the 
production of inducible NOS (iNOS)-mediated inflammation in the myofibres (1, 80). 
iNOS mediated inflammation further activates Ca2+/calmodulin (CaM), CaM kinase 
II (CaMKII) and protein kinase A (PKA). These signalling molecules cause the 
hyper-phosphorylate of Ca2+ channels that increases the concentration of Ca2+ that 
further activates stretch-activated channels (SAC), Na+Ca2+exchanger (NCX) 
channels and voltage-gated Ca2+ channels (VGCC) (81). 
Furthermore, this increased cytoplasmic Ca2+ level activates 
sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), the ryanodine 
receptor (RyR) and the inositol 1,4,5-triphosphate (IP3) receptor (IP3R). The 
opening of these channels the further flow of Ca2+ and increases the intracellular 
Ca2+ concentration ([Ca2+]i) (81). 
The activation of stretch-activated channels (SAC) increases the membrane 
permeability via phospholipase A2 that causes leakage of creatine kinase (CK) from 
the myofibres. This process is further exacerbated by the presence of reactive 
oxygen species (ROS) causing the damage of membranes by peroxidation (82).   
Calcium concentration is tightly controlled in healthy cells. The ‘‘store-operated 
entry of Ca2+’’ causes the balance of Ca2+ stores after muscle fibre depolarization. 
This channel opens with a partial decrease in Ca2+ concentration in the 
sarcoplasmic reticulum (SR). This mechanism is however altered in dystrophic 
muscle cells (83). The uptake of the Ca2+ by mitochondria causes muscle relaxation 
and allows the supply of ATP to cope with the increase energy demand. The inositol 
1,4,5 triphosphate (IP3) receptors found in nuclear membranes support the 
movement of this Ca2+ waves to the neighbouring nucleus while the cytosolic Ca2+ 
buffers like parvalbumins modify the [Ca2+]i transiently and effect the mechanics of 
muscle in normal cells (84). Therefore, changes in Ca2+ homoeostasis in dystrophin 
muscles contribute to the chronic damage and fibre degeneration. 
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This continuous degeneration-regeneration in myofibres lead to the imbalance in 
matrix metalloproteinases, the release of fibrogenic cytokines i.e. TGF-β1 (85) and 
outpace the regeneration of new myofibres (86). This causes inflammatory cell 
infiltrations (sterile inflammation) and ultimately fibrosis. Rosenberg et al (87) 
reviewed the involvement of innate and adaptive immune systems in DMD. In 
neonates, the components of the innate immune system activate prior to the onset 
of clinical symptoms of DMD, due to the leakage of cytoplasmic components from 
the fragile myofibres that are recognised as danger-associated molecular patterns 
(DAMPs) by TLR forming inflammasomes (88). This causes altered signalling via 
Toll-like receptors (TLR4, TLR7), nuclear factor-kB (NF-kB) and activates major 
histocompatibility complex (MHC) class I molecules (normally it does not express 
on muscles) (87). That leads to the second stage of the immune cell infiltration (87). 
 
Macrophages, T cells and neutrophils are cell types that get activated in muscle 
cells at the second stage of inflammation. This is a continuous process in DMD 
patients and occurs at the ages of 2–4 weeks in mdx mouse model of DMD(89). 
Activated macrophages can be involved in phagocytosis of damaged myofibres and 
can further damage myofibres by the activation of nitric oxide (NO). Macrophages 
present in myofibres are two types, the M1 type of macrophages are 
proinflammatory in nature that activates nitric oxide production and other related 
cytokines, while the M2 type of macrophages are anti-inflammatory in nature (90) 
and a subpopulation of M2, the M2c type macrophages promote tissue repair. The 
presence of an M1 and M2c type of macrophages in situ influences the 
inflammatory process of myofibres. Interleukin-10 (IL-10) involves in the maturation 
of macrophages in vitro and its removal in mdx mice causes increased damage to 
muscle and reduced muscle strength (90).  The Table 1.2.5.1 indicates the time-
course pathology and role of M1-M2 macrophages in mdx mice.  
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Cytokines, i.e. tumour necrosis factor alpha (TNF-α), transforming growth factor 
beta (TGF-β), interferon gamma (INF-γ) and interleukin 6 (IL-6) etc., are involved 
in inflammation/fibrosis (80). Also, nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), eosinophils and T-cells are involved in the pathology of 
DMD. Also, the activity of NF-κB was found to be significantly upregulated in mdx 
myotubes compared to wild type myotubes (94, 95). 
TNF-α contributes to the early breakdown of dystrophic muscles. The blockage of 
TNF-α in mdx mice treated with anti-TNF-α antibody Remicade, in the acute phase 
of inflammation, delayed and reduced the breakdown of muscles (96).  
TGF-β superfamily includes TGF βs (TGFβ1, TGFβ2, TGFβ2), activins, inhibins 
bone morphogenetic proteins (BMP), growth and differentiation factors (GDF), 
Nodal and Mullerian inhibiting factor (AMH). These ligands bind to type I or II 
serine/threonine kinase receptors that activate specific intracellular receptors, 
Table 1.2.5.1 Time-course of mdx muscle pathology, adapted from Villalta et al 
(91) 
Stages Acute onset  
(3 to 4 weeks of 
age). 
Regenerative  
(6 to 12 weeks of 
age). 
Progressive  
(1 year and older). 
Muscle Injury of muscle 
fibre. 
Successful 
regeneration of 
muscle fibre. 
Failed regeneration; 
fibrosis of muscle 
fibre. 
Macrophages  M1 macrophages: 
A-
F4/80+/CD68+/CD
163-/CD206-
;cytolytic, pro-
inflammatory, 
iNOShigh, 
arginaselow 
M2 macrophages: 
A-
F4/80+/CD163+/CD
206+ 
B-F4/80+/CD163-/ 
CD206+, anti-
inflammatory, 
iNOSlow, 
arginaselow  
 M2 macrophages: 
A-F4/80+/CD163+/ 
CD206+,  
B-F4/80+/CD163-/ 
CD206+, anti-
inflammatory, 
iNOSlow, arginasehigh 
F4/80-cell surface marker expressed on most tissue macrophages, encoded by 
Emr1 gene; CD68- expressed on all M1 macrophages, encoded by Cd68 gene; 
CD163- expressed on most tissue M2 macrophages, encoded by Cd163; CD 206- 
present on macrophages and immature dendritic cells; arginase-enzyme involved 
in metabolism of arginine, iNOS-inducible nitric oxide synthase. Tissue damage 
within 1-2 days leads to conversion of arginine to citrulline by arginase, iNOS 
indicating the presence of M1 macrophages, while 3-15 days following tissue 
damage there is hydrolysis of arginine to ornithine and urea by arginase, 
indicating the presence of M2 macrophages (92, 93). 
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Smads (Signal transduction component of the canonical transforming growth factor-
β signalling pathway) (97, 98).  
TGFβ1 is a fibrogenic cytokine that peaked in its expression at 2 and 6 years of age 
in DMD patients. (99). 
INF-γ is a proinflammatory cytokine, secreted by Th1 cells and activated by M1 
macrophages. Inhibiting its expression led to reduced muscle damage by activation 
of M2 macrophages in mdx mice (Table 1.2.5.1) with an improved motor function 
(91).  
IL-6 is both pro-inflammatory and anti-inflammatory cytokine, secreted by T cells 
and macrophages (100, 101). Its blockade by neutralising monoclonal antibody 
tocilizumab has been approved in inflammatory diseases (100). The study was 
done by Kostek et al (101) in mdx mice showed no reduce inflammation, indicating 
towards the pleiotropic effect of cytokines in the inflammation.  
Similarly, NF-κB pathway is both pro-inflammatory and anti-inflammatory (102), it 
controls the transcription of DNA and production of cytokines. Acharyya et al(103) 
demonstrated improved muscle pathology and muscle following pharmacological 
inhibition of IKK. Messina et al(104) used genistein (isoflavone) which is an inhibitor 
of NF-κB, MAPK and TNF-α in 5-week old mdx mice and observed the increased 
strength of forelimb, reduced levels of serum CK, reduced expression of markers 
of oxidative stress and reduced muscle necrosis with enhanced regeneration. Also, 
Reay et al(105) confirmed decreased necrosis and increased regeneration in hind 
limbs and diaphragm of mdx mice by blocking NF-κB activation.  
Eosinophils are generally activated due to infection by parasites or allergic reactions 
and their differentiation is activated by IL-5 that is expressed by T cells (both CTL 
and Th cells). Eosinophilia (increased number of eosinophils) in mdx mice is 
promoted by the perforin-dependent activity of cytotoxic T lymphocyte cells that 
confirmed the role of CTL cells in mdx mice (106). 
The pre-existing T-cells immunity against dystrophin minigene was observed in 
DMD patients and that it increases with ageing of patients, while corticosteroid 
treatment modulates this T-cells response (107). The antibody-mediated depletion 
of CD4+ T-cell in mdx mice improved muscle pathology by 61% while antibody-
mediated depletion of CD8+ T-cell in mdx mice improved muscle pathology by 75% 
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confirming the active role of T-cells in DMD (57). The absence of B and T 
lymphocytes in scid/mdx mice correlates with the reduction of TGF- β1 with the loss 
of fibrosis further confirming the role of lymphocytes in DMD (51).  
 
miRNA is shown to modulate the DMD pathology. The microRNA (miRNA) are small 
RNA sequences that regulate gene expression post-transcriptionally and about 12 
microRNA were shown to be significantly expressed in BMD patients compared 
with controls. The BMD patients with 70–80% of dystrophin protein had high 
expression of miR-425 that is involved in myostatin signalling pathway, while BMD 
patients with 60-70% levels of dystrophin had up-regulation of miR-144 and miR-
451(108).  
 
Zucconi et al (109) confirmed the presence of Golden Retriever muscular dystrophy 
(GRMD) dogs having a normal lifespan with functional muscles in the absence of 
dystrophin, due to the expression of the Jagged1 gene (110) that is a regulator of 
Notch signalling pathway. This study indicates that using the upregulation of 
Jagged1 could constitute a novel therapy for DMD. Figure 1.2.5.1 shows the 
summary of important pathways and molecules involved in the disease mechanism. 
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Muscular Dystrophy 
Calcium Influx: 
TRPC Channels; Calpains; ERK1/2; AP-1; NF-kB; iNOS. 
 Calcium Influx: 
Calcineuring-NFAT; Calpastating. 
NF-kB Signalling: 
Canonical NF-kB pathway; E3 ubiquitin ligases; Inflammatory 
cytokines; Chemokines; Cell adhesion molecules; MMP-9. 
NF-kB Signalling: 
Non-canonical NF-kB pathway. 
Inflammatory response: 
Immune cells- M1 macrophages,T cells, neutrophils, mast cells and 
eosinophils; Inflammatory cytokines; Cell adhesion molecules. 
Inflammatory response: 
M2 macrophages; Anti-inflammatory cytokines; IL-4 and IL-10. 
Oxidative Stress: 
Oxidative species- Superoxide anion; Nitric oxide (NO); Hydroxyl 
radical (OH-); Peroxynitrite (ONOO-). 
Apoptosis: Bcl-2; Akt signaling 
Fibrosis: 
TGF-β1 pathway; Fibrinogen; Myostatin; OPN; MMPs, microRNA 21 
Apoptosis: BAX 
Autophagy: Low-protein diet; AMPK 
Autophagy: Akt-mTOR 
Figure 1.2.5.1 Summary of important pathways and their active 
molecules involved in muscle wasting in muscular dystrophy. 
Red boxes indicate activators or mediators of pathological response 
and green boxes indicate components that are activated to improve 
the dystrophic phenotype in muscular dystrophy.  
 
Adapted from Shin et al (1) 
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1.2.6 The mdx mouse as the disease model 
Generally, the X-linked muscular dystrophy (mdx) mouse is the preferred mouse 
model of DMD. It has a spontaneous point mutation in exon 23 causing the loss of 
the Dp427 isoform (111) in the C57BL/10ScSnJ mouse (112). This loss does not 
cause identical muscle degeneration in the whole body (e. g. hind limb muscles 
have a moderate dystrophic phenotype, while diaphragm muscle shows severe 
degeneration (113)). This makes this model suitable for studying the secondary 
effects of loss of Dp427 (114). A previous study has shown that restoration of 
dystrophin to >20% level in mdx mouse muscle protects it from exercise-induced 
damage (115). The cycle of degeneration-regeneration of myofibres starts at 2 
weeks, maximum at 12 months and continues until the death of mdx mice (113, 
116-119). A Recent study from our laboratory demonstrated that the pro-fibrotic 
phenotype is present in the mdx muscles from the very early stages of the 
disease(120).  
The mdx-β geo is another mouse model for DMD which has βgeo [encoding β-
galactosidase (β-gal)-neomycin phosphotransferase fusion protein] inserted 
downstream from dystrophin exon 63 using the gene trap vector ROSAβgeo. This 
mutation affects all isoforms of dystrophin protein (121), making it ideal for 
understanding gene replacement therapy for DMD with modulation of immunity by 
tolerogenic constructs (mentioned later in the text). Other animal models for DMD 
are summarised by Perkins et al (122).  
 
1.2.7 Current Approached to treat DMD  
The genetic cause of DMD has identified more than 30 years ago (14, 123) but 
effective treatments to fully correct the phenotype are still lacking. The one 
treatment was shown to mitigate the progression, albeit slightly, is with 
glucocorticoids (the group of corticosteroids) that have anti-inflammatory effects 
(124, 125). It has also been shown that corticosteroids are involved in the 
development of tolerogenic dendritic cells (DCs)(126) and so might influence this 
aspect of the disease.  
The palliative care is the main option to patients (127-133) as available therapies 
can only alleviate the symptoms. The early genetic screening (134) of membrane 
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form of serum creatine kinase (CK) enzyme activity (35, 37, 135, 136) and genetic 
counselling (137) provide tools to support patients. Strehle et al (34) summarised 
the palliative therapy options for DMD (as adapted in Table 1.2.7.1). 
 
Table 1.2.7.1 Palliative care for DMD patients, adapted from Strehle et al (34) 
Organ system Intervention 
Muscular  Assessment by health specialist to monitor the health, 
physiotherapy, administration of glucocorticoids (this led to 
short stature, delayed puberty and heavier weight (138, 
139)), orthoses, wheelchair, hoist, electric bed etc.  
Respiratory A regimen of respiratory tract infections, lung function 
monitoring, cough assistance, non-invasive ventilation, 
tracheostomy etc. 
Cardiovascular Assessments with echocardiography, electrocardiogram, 
blood pressure measurements, use of ACE inhibitors and β-
blockers for prevention of cardiomyopathy etc.  
Gastrointestinal Monitoring diet, swallowing, bowel function and weight gain, 
acid reducers etc. 
Skeletal Bone density tests using DXA (dual-energy x-ray 
absorptiometry), supplement capsules for calcium, vitamin 
D, bisphosphonates, surgery for scoliosis etc. 
Renal/urogenital Prevention of dehydration, myoglobinuria and 
enuresis etc. 
Nervous Speech and language assessment for providing learning 
and psychosocial support, pain and sleep control etc. 
 
Various approaches for DMD treatment currently in research phase have been 
summarised by Konieczny et al (8). These involve: viral vectors based gene therapy 
to deliver dystrophin cDNAs using lentiviral (140, 141), adenoviral (142-146) and 
adeno-associated(147-150) viral vectors; non-viral vectors for gene therapy 
involving delivery of plasmid DNA mixed with saline (naked plasmid) or other 
vehicle(151); changing mRNA splicing by antisense-mediated exon skipping 
(described in Section 1.2.8); forced read-through of a premature stop codon by 
treatment with Gentamicin(152, 153) or more specialised drug, Ataluren(154-156); 
cell-mediated therapies using stem cells (157)  involving myoblast (158-160), 
satellite cell transplantation (161-163) and systemic delivery of stem cells derived 
from: 1) bone marrow (164-166), 2) muscle-derived (167-170), 3) 
mesoangioblasts(171-173), 4) myoblasts from embryonic stem cells(174-177), 5) 
myoblasts from somatic cells(178-180). Some studies have also investigated gene 
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therapy/gene replacement by incorporating the functional region of dystrophin in a 
mini-gene form via packaging in different viral and non-viral vectors (8, 181, 182). 
Most of the new clinical trials are based on exon-skipping or regulating at the mRNA 
level (124, 183). Benedetti et al (184) summarised stem cell therapy-based clinical 
trials. Other therapeutic options involve using phosphodiesterase five inhibition, 
statins and glucocorticoids.  
The phosphodiesterase five (PDE5) inhibition was shown to increased lipid 
metabolism by up-regulation of PPARγ coactivator-1 (PGC-1 α) and increased 
protein synthesis efficiency. It also leads to a better actin’s Z-disk organisation 
(185). The human IgG was shown to diminish myopathic damage and inflammation 
in the early disease course of mdx mice (186). 
The Statins are cholesterol-lowering drugs that inhibit the processes involved in 
degradation of skeletal muscle in ischaemic diseases (187). Simvastatin is shown 
to reduce damage and enhanced muscle function in mdx mice (187). Long-term 
use of simvastatin in mdx was shown to improved overall muscle health, reducing 
plasma creatine kinase levels to near-normal and its shorter-term usages are 
shown to protect muscle against muscle fatigue with 40% increased force in 
hindlimb (187). Simvastatin is shown to inhibit the fibrosis, inflammation and 
oxidative stress by inhibiting NOX2 (NADPH oxidase 2) in mdx mice (188).  
Glucocorticoids (the group of corticosteroids) that have an anti-inflammatory effect 
(124, 125) and as mentioned before, it has been shown that corticosteroids are 
involved in the development of tolerogenic dendritic cells (DCs) (126).  
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1.2.8 Exon Skipping 
 
The most advanced approach, in terms of clinical trials, for the correction of the 
dystrophin deficit is by mRNA level exon skipping. The restoration of 20-30% of 
dystrophin protein in muscle fibres of mdx mice has been shown to alleviate the 
symptoms of muscular dystrophy (189-192).  
 
 
Several studies have indicated that the antisense-mediated exon skipping of the 
dystrophin mRNA, by removing the non-functional exons and merging the 
functional exons can lead to the production of semi-functional dystrophin protein 
(181, 183).  
Figure 1.2.8.1 shows the schematics of the exon skipping procedure using a 
mixture of Vivo morpholino (vPMO). The Phosphorodiamidate morpholino 
oligomers (PMO) are synthetic polymers used to increase exon skipping. The 
vPMO are made by conjugating PMO with dendrimeric octa guanidine (193). 
 Antisense oligonucleotides (AOs) with 2-O-methyl modifications were shown to 
ameliorate the dystrophic phenotype by exon skipping but it had issues with low 
Figure 1.2.8.1 Schematics of exon skipping procedure.  
The exons 45–55 skipping with a mixture of 10 Vivo morpholino (vPMOs) in 
mdx52 mouse that lacks exon 52 in the mRNA of the murine DMD gene that 
causes out-of-frame protein formation. The exons 45–55 (red box) skipping 
with mixture of Vivo morpholino [vPMOs] (indicated by the black line), 
restores the reading frame of DMD mRNA. 
  
Adapted from Aoki et al (6) 
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transduction efficiency that was increased by using polyethene glycol-polyethylene 
imine (PEG-PEI), (194). 
The cardiac muscle shows the prominent phenotype of muscular dystrophy both in 
animal models and in patients. The cardiac dysfunction involved in 90% patients 
and account for 40% of deaths. Antisense-mediated skipping of exon 51 was shown 
to restore dystrophin to 30% in human induced pluripotent stem cells (hiPSC) 
derived from cardiomyocytes having exon 47–50 or 48–50 deletions. Similarly, 
dystrophin minigene transferred to these cells with a deletion in exon 35 or exon 70 
restored the normal levels of dystrophin (195).  
 
1.3 Gene Therapy 
Gene therapy involves the transfer of missing genetic material using vector or non-
vector based approaches (described bellow). These vectors may be used to modify 
cells in vivo or ex vivo. For a historical review of gene therapy see Thomas et al 
(196). 
 
1.3.1.1 Viral Vectors 
Odom et al (197) summarised four types of viral vectors used to deliver dystrophin 
gene to ameliorate muscular dystrophy: 
The first and second generation of adenoviruses could carry double-stranded DNA 
(ds-DNA) with about 8.3 kb size of plasmid DNA (pDNA), did not integrate the pDNA 
in the genome of the host leading to short duration of expression with activation of 
cytotoxic T-lymphocytes (CTL) based immune responses and preexisting immunity 
was also observed leading to inflammatory reactions.  
The gutless adenoviruses could carry double-stranded DNA (ds-DNA) with about 
27 kb to 29 kb of size of pDNA, did not integrate the pDNA in the genome of the 
host leading to long duration of expression with activation of cytotoxic T-
lymphocytes (CTL) based immune responses and preexisting immunity was also 
observed leading to cytotoxic reactions.  
The adeno associated viruses (AAV) could carry single-stranded DNA (ss-DNA) 
with 
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about 4.8 kb size of pDNA, could integrate the pDNA in the genome of the host with 
variability in long-term expression with activation of cytotoxic T-lymphocytes (CTL) 
based immune responses and preexisting immunity was also observed.  
The lentivirus could carry RNA with about 7.5 kb to 9 kb size, had a long duration 
of expression with no activation of cytotoxic T-lymphocytes (CTL) based immune 
responses and no pre-existing immunity was observed (197). However, these 
vectors were shown to causing insertional mutations (197). 
 
1.3.1.2 Applications of viral vectors 
The clinical trial using mini-dystrophin gene enclosed in the modified adeno-
associated virus (AAV) involved biceps targeting in four patients. The results 
confirmed the activation of the immune response against the transgene protein 
(181). This indicates the limitation of viral based vectors.  
The adenoviral recombinants (AVR) were used for expression of a 6.3-kb partial 
dystrophin cDNA to the express truncated 200 kDa dystrophin protein for up to 10 
days in mdx muscles injected during the neonatal period, with a lesser degree of its 
expression in muscles injected in the young adult's age and in old animals. The 
total rejection of dystrophin positive fibres was observed after 60 days post-injection 
with the presence of CD8+ cytotoxic lymphocytes. Using the same vector in severe 
combined immunodeficiency (SCID) mice, the lack of both humoral and cellular 
immunity against transgene coincided with the expression for up to 30 days post-
injection (198). 
The safe and body-wide transduction of tyrosine-engineered adeno associated 
virus (AAV-9) reporter or micro-dystrophin (μDys) vectors with transient or 
sustained immunosuppression in dystrophic dogs leading to no adverse effect with 
improvements in muscle pathology were described (199). 
Similarly, tri-adeno associated virus vectors were used for the transfer of full length 
of human dystrophin ranging more than 11 kb with an expression of dystrophin up 
to 30 days, which indicated that an engineered adeno associated virus could be 
used for the delivery of up to 15 kb transgene (200).  
AAV micro-dystrophin was injected in immunocompetent mice leading to 
improvement in the histopathology (201). 
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1.3.2 Non-viral Vectors  
These are the chemicals that modify the permeability of the membrane to let 
plasmid DNA inside the cytoplasm. Also, the use of naked DNA plasmid leads to 
successful transgene expression. Recently, the use of TALEN and CRISPR/CAS9 
was shown to change gene expression. The details of various non-viral 
vectors/approaches are as follow: 
1.3.2.1 Transfection reagents 
Gebremedhin et al (202) used Glycofect, Metafectene, Metafectene Pro, 
Metafectene Easy and FuGENE HD transfection reagents, to enable suicide gene 
therapy of oral squamous cell carcinoma (OSCC) in HeLa cell lines.  
 
1.3.2.2 Nanoparticles  
Koirala et al (203) used DNA nanoparticles (NP) to rectify the mutation in retinal 
pigment epithelium (RPE) gene RPE65 and showed persistent, long-term 
improvements in the disease symptoms.  
 
1.3.2.3 Prokaryotes 
Elmer et al (204) suggested the use of a horizontal gene transfer technique that is 
prominent in prokaryotes. Certain vectors such as Agrobacterium tumefaciens used 
in plants for the horizontal gene delivery. Similarly, the use of intracellular parasites 
(i.e. Trypanosoma cruzi) for gene transfer can be explored with mitigating the 
related risk to the host. 
 
1.3.2.4 Polyethene glycol derivatives 
Raviv et al (205) used mannosylated polyion complexes (PICs) composed of 
cationic polyethyleneimine (PEI) and hydrophilic polyethene glycol (PEG) to 
effectively target CD11c (+) dendritic cells. They confirmed 2-3-fold higher 
expression efficiency in CD11c(+) DCs of the transgene in vivo (C57/BL6 mice). 
Similarly, Kodama et al (206) used polynucleotide complexes made up of plasmid 
DNA (pDNA) with polyethyleneimine (PEI). Polynucleotides are anionic 
macromolecules that complex with plasmid DNA and facilitate its transfer by 
receptor-mediated endocytosis. 
	 42	
1.3.2.5 Human ribosomal DNA 
Yang et al (207) used a human ribosomal DNA (hrDNA) vector to transfer mini 
dystrophin-GFP fusion gene into the hrDNA locus of HT1080 cells. They found the 
high efficiency of integration of the plasmid.  
 
1.3.2.6 Naked plasmid DNA  
The first experiment demonstrating the use of naked plasmid DNA in skeletal 
muscle was done by Wolff et al (151), demonstrating the special feature of muscle 
tissue. Later they described the probable mechanisms of uptake (208). Similarly, 
Budken et al (209) hypothesised various other factors influencing the uptake of 
naked DNA.  
 
1.3.2.7 Naked mRNA 
Phua et al (210) evaluated transfection efficiencies of mRNA delivered naked and 
in combination with nanoparticle in vitro and in vivo. They confirmed naked mRNA 
to be more efficient than nanoparticle encapsulated mRNA in subcutaneous 
delivery; nanoparticle-mRNA had a better efficiency when delivered intranasally 
and intravenously; the gene expression of intravenously injected nanoparticle-
mRNA was very short with a half-life at 1.5 hours and absence before 24 hours 
while when it was subcutaneously delivered it has a half-life of 18 hours and 
absence after 6 days. Marshall et al (211) used electroporation in cardiac muscles 
to deliver naked plasmid DNA expressing vascular endothelial growth factor 
(VEGF). The result indicated significantly increased VEGF expression in cardiac 
muscles via electroporation.  
 
1.3.2.8 Electroporation 
Similarly, Pringle et al (212) used electroporation enhanced gene transfer in the 
lungs of mice and sheep. Wang et al (213) summarised the optimal conditions for 
naked plasmid DNA transfer in skeletal muscle via electroporation. Liang et al (214) 
confirmed the restoration of dystrophin protein in both hind limbs of CD-1 mice, 
injected with naked plasmid DNA encoding the full-length dystrophin gene.  
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1.3.2.9 Ultrasound field  
Burke et al (215) used ultrasound (US) field in combination with polyethene glycol 
(PEG)/polyethylenimine (PEI) nano complex to target the naked DNA plasmid with 
transgenes in skeletal muscle transfection. 
 
1.3.2.10 TALEs and CRISPR/Cas9  
TALEs (transcription activator-like effectors) coding system and CRISPR (clusters 
of regularly interspaced short palindromic repeats) immune system in bacteria 
enabled the development of TALENs (transcription activator-like effector 
nucleases) and CRISPR/Cas9 (7). These two tools were shown to rapidly edit 
genomic DNA. These tools were used to develop disease models by target 
disruption of function gene up to 10 kb (216), mimicking the naturally occurring 
mutations. 
Figure 1.3.2.10.1 shows the mechanism of genome editing by these tools.  
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Figure 1.3.2.10.1 Schematic of mechanism of TALEN- and CRISPR/Cas9-mediated 
genome editing. 
A: a single TALEN consists of an nuclear localization signal (NLS) at amino-terminal, 
a central region of repeat domain (red box) having tandem TALE repeats which 
recognised specific DNA sequence and functional endonuclease (Fok I) domain at 
the carboxyl-terminal. The repeat domain consists of 34 amino acid unit that 
specifically differs at the position of 12th and 13th amino acids having NG 
(asparagine and glycine that recognise thymine base pair), NI (asparagine and 
isoleucine that recognise adenine base pair), HD (histidine and aspartic acid that 
recognise cytosine base pair) and NN ((asparagine and asparagine that recognise 
guanine base pair) according to the sequence of target DNA. 
B: After recognition of binding site by TALEN, the Fok I domain (red box) creates 
double-strand breaks (DSBs) in ds-DNA that are repaired either by non-homologous 
end-joining (NHEJ) mechanism creating insertions-deletions (indels) or by 
homologous recombination (HR) mechanism by the use of homologous donor 
templates.  
C: a CRISPR/Cas9 system made up of trans-activating crRNA (trancrRNA), a group 
of CRISPR-associated genes (Cas) (red box) and a CRISPR locus having an array 
of spacer sequences that has an average of 32 bp to recognise specific sequences 
in the target DNA The crRNA (CRISPR RNA) was produced by trans-activating 
crRNA (trancrRNA).  
D: the formation of ribonucleoprotein complex take place by binding of Cas9 (red 
box) protein to crRNA (orange strand) and tracrRNA (purple strand) in which crRNA 
guides the complex to the target DNA sequence leading the HNH and RuvC domains 
of Cas9 to create nick to make a double-strand break in the complementary and non-
complementary strands, respectively. The PAM stands for protospacer adjacent 
motif of NGG which is recognised by RuvC domain of Cas9 on non-complementary 
strand, NCC stands for is a complementary motif of the PAM motif which is 
recognized by HNH domain of Cas9 on complementary strand and gRNA stands for 
guiding RNA.Adapted from Wei et al (7, 8) 
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1.3.2.11 Applications of TALEN and CRISPR/Cas9 in genome editing  
Pu et al (217) did the comparative study of these two tools to confirm their efficiency 
and possibility of creating new disease models. Other examples of their use for 
genome editing in vivo are as follows: 
1-TALEN-Exon Skipping was used to develop an adult zebrafish model of collagen 
VI-related diseases such as Ullrich congenital muscular dystrophy (UCMD) and 
Bethlem myopathy (BM) (218). 
2-TALEN was used for the functional correction of X-linked chronic granulomatous 
disease in induced pluripotent cells (iPSC) derived from patients (219). 
3-TALEN-induced homologous recombination was used in goats to produce beta-
lactoglobulin-free, high-human lactoferrin milk. This indicates the commercial 
use/potential of TALEN in the modification of farm animals (220). 
4-CRISPR/Cas9 was used to edit the germ line of mdx mice to correct the 
dystrophin gene (Dmd) mutation (221).  
5-CRISPR/Cas9 was used to target the monkey dystrophin gene to create 
mutations in the rhesus monkey to create a disease model for DMD. This study 
confirmed the problem of mosaic mutation by using this tool and found up to 87% 
mosaic mutation in dystrophin alleles in the muscle of the rhesus monkey (222). 
6-CRISPR/Cas9 was used to restore the expression of the dystrophin in the 
patient’s myoblasts using single or multiplexed sgRNAs to target a mutational 
hotspot at exon 45-55 to restore the dystrophin reading frame (223).Cas9 protein 
was shown to be more efficient in homology-directed repair for genetic modification 
of rats and mice (224). 
 
1.4 Tolerance Induction  
Dystrophin was recognised to be an antigen by the presence of a T- cell-based 
immune responses (107, 225).  
It has been confirmed that restoring the normal dystrophin protein via gene 
replacement therapy in individuals not producing this protein causes an antigenic 
immune response. This response is a major issue in achieving DMD gene therapy 
(225). This response towards newly synthesised dystrophin in mdx mice is 
mediated by cytotoxic T-lymphocytes (125) that are activated by MHC class I-type 
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(major histocompatibility complex) molecules (226). This indicates the lack of innate 
tolerance towards dystrophin peptide in mdx mice.  
 T-cell receptor function depends on antigen presenting cells (227) i.e. the 
macrophages, dendritic cells and B-cells, these cells can present an antigenic 
peptide in the context of MHC molecules (226) either class I or II, based on the 
route of entry i.e. MHC class I for intracellular antigens and MHC class II for 
extracellular antigens. Dendritic cells can present extracellular antigens via 
alternative pathway (228-231) to MHC class I, this feature is called cross-
presentation (227, 232). Dendritic cells are also involved in tolerising T-cell to self-
antigens by anergy or deletion of naïve T-cells recognising self-antigens in the 
thymus (central tolerance) and lymphoid organs (peripheral tolerance) (226).   T 
cells also need a co-stimulatory signal from antigen presenting cells (233) to mature 
into cytotoxic T lymphocyte (CTL) or T-helper cells (226). The immature dendritic 
cells(234) can induce peripheral tolerance. When they circulate in peripheral 
lymphoid tissues they form an MHC-peptide complex in their steady state, in 
absence of additional maturation stimuli they induce naïve T cell activation that 
leads to T cell deletion (235) and unresponsiveness (236) towards antigen, the 
animal becomes tolerant (237-239). But when maturation stimulus (240, 241) is 
present, it leads the development of immunity against an antigen (242, 243).  
 
1.4.1 Mechanism of tolerance induction by the kynurenine pathway 
Tolerogenic dendritic cells express various molecules, TGF-β (transforming growth 
factor beta), IL-10 (interleukin 10), HLA-G (human leukocyte antigen G), LIF 
(leukaemia inhibitory factor), PD-L1 (non-secreted programmed cell death ligand 1) 
(244) and IDO (indoleamine 2,3-dioxygenase) (245, 246). Some of these molecules 
(i.e. IDO, IL-10) up-regulate the differentiation of dendritic cells into tolerogenic 
phenotype by various signalling pathways (247) and not into another form e.g. 
plasmacytoid dendritic cells. Plasmacytoid dendritic cells are activated by infection 
(i.e viral) and secrete type 1 interferons (248). 
It has been shown that a T-cell is tolerised or activated to become an effector cell 
depending on the activation status of the antigen presenting cells that interact with 
it (249) due to the requirement of co-stimulatory signals B7-1 and B7-2 (250).  
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Figure 1.4.1.1 shows a summary of tryptophan metabolism and the role of 
IDO1/TDO in the immune suppression. The catabolism of the rarest essential amino 
acid in the mammalian diet, the L-Tryptophan by indoleamine 2,3-dioxygenase 
(IDO1) and tryptophan 2,3-dioxygenase (TDO) produces kynurenines. These 
enzymes regulate innate and adaptive immune system and are essential for 
eukaryotic survival (251) by maintaining tolerance to self-antigen (252). The IDO1 
enzyme is encoded by the IDO1 gene that contains 10 exons and is present on 
chromosome 8p12-11 in humans (8A2 in mice). It is found in organisms as different 
as mammals and yeasts (251). TDO is present primarily in the liver and IDO2 is the 
Figure 1.4.1.1 Schematics of the L-tryptophan metabolism pathway.  
The 99% of the dietary tryptophan is metabolized by indoleamine 2,3 di-
oxygenase (IDO1, IDO2) and tryptophan 2,3-di oxygenase (TDO) (red box) 
to L-kynurenine and then to its derivatives. The immune suppression by the 
inhibition of pro-inflammatory T-cells (Th1, Th17) and induction of 
regulatory T-cells (red box) is mediated by Kynurenine aminotransferase 
(KAT), monoamine oxidase (MAO), quinolinic-acid phosphoribosyl 
transferase (QPRT) and 3-hydroxyanthranilic acid oxidase (HAO). In this 
way, IDO/TDO stimulate pathologies by causing either insufficient or 
excessive immune suppression.  
 
Adapted from Mbongue et al (5) 
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paralogue of IDO1. Tryptophan catabolism by these enzymes leads to tryptophan 
starvation and production of kynurenines (252). Tryptophan is essential for protein 
synthesis and cell division, therefore its absence causes the inhibition of allogeneic 
T-cell proliferation that leads to the tolerance induction (253). The expression of 
IDO1 is found highest in antigen-presenting cells (e.g. dendritic cells, macrophages 
and B-cells) and is induced by the normal response of type I IFN (IFN-α and IFN-
β) or by the elevated response of type II IFN (IFN-γ) (246, 251, 254). IDO was 
shown to suppress effector T-cell responses, promote regulatory T-cell (T-regs) and 
inhibit the IL-6 production by DCs (255). Dendritic cells control the activation of two 
types of T-regs, natural T-regs and induced T-regs. The natural T-regs express  
Foxp3+CD25+CD4+ and induced T-regs have Foxp3-CD4+ (256).  
IDO1 is expressed constitutively in the placenta and plays a key role in fetal-
maternal tolerance of alloantigens. It is also expressed in many tumours, where it 
contributes to tumoral resistance (246) to immune rejection (251). IDO1 has also 
been found to induce peripheral immune tolerance and the retro-control of immune 
responses (257). It was shown that TDO inhibition promotes tumour immune 
rejection (257). Both IDO and TDO were shown to function as local immune 
suppressive factors in protecting allogeneic fibroblasts and keratinocytes without 
using any immunosuppressive medication in an animal model of wound healing 
(258). The role of IDOs in dendritic cell tolerance had been summarised by Mellor 
et al (259).  
Theate et al (260) did immune profiling of human normal and tumour tissues for 
IDO1 expression. They used immunohistochemical analyses to detect the tissue-
specific expression of IDO and found the expression of IDO1 in normal tissues, 
endothelial cells of the placenta, lung and epithelial cells of the female genital tract.  
Similarly, In lymphoid tissues, i.e. bone marrow, thymus, spleen etc., IDO1 was 
expressed in mature dendritic cells that were not enriched in tumor-draining lymph 
nodes and were distinct from plasmacytoid dendritic cells. 58% of human tumours 
had IDO1 expressing tumour cells, endothelial cells, and stromal cells (260). 
Interestingly, Salmonella was shown to exhibit antitumour activity by lowering the 
levels of IDO (261).  
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1.4.2 Significance of tolerance induction 
It has been confirmed that suppression of immunity against transgene products 
prolongs and stabilises the expression of these products (262). Global 
immunosuppression of immunity has its own side-effects as it reduces the response 
to all antigens and might be life threatening due to resulting infections or cancer 
development (263). The alternative to immunosuppression is localised tolerance 
induction against transgene by co-injecting tolerance inducing plasmids with 
transgene expressing plasmids and this approach was tested in this study. 
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Chapter 2: Materials and Methods 
 
Table 2.1.1 List of enzymes used. 
Enzyme Supplier (product code) 
AatII Boehringer (Not Applicable-NA). 
AccI Boehringer (NA). 
Acc65I New England Biolabs (R0599S). 
ApaI (Fast Digest) Thermo Fisher Scientific (FD1414). 
AscI New England Biolabs (R0558S). 
Antarctic Phosphatase New England Biolabs (M0289S). 
BamHI (Fast Digest) Thermo Fisher Scientific (FD0054). 
BspEI New England Biolabs (R0540S). 
DraIII Boehringer (NA). 
DNA Ligase (Quick Ligation Kit) New England Biolabs (M2200S). 
DNA Ligase Master Mix New England Biolabs (M0370S). 
DNA polymerase (GoTaq) Promega (M8291). 
DNA polymerase:  
 GoTaq Green Master Mix Promega (M7123). 
 iProof High Fidelity Bio-Rad (1725301). 
EcoRI New England Biolabs (R0101T). 
EcoRI (Fast Digest) Thermo Fisher Scientific (FD0275). 
HindIII (Fast Digest) Thermo Fisher Scientific (FD0504). 
KpnI New England Biolabs (R0142S). 
MluI New England Biolabs (R0198S). 
MfeI New England Biolabs (R0589S). 
NarI New England Biolabs (R0191S). 
NaeI New England Biolabs (R0190S). 
NdeI New England Biolabs (R0111S). 
NgoMIV New England Biolabs (R0564S). 
NotI New England Biolabs (R0189S). 
NruI New England Biolabs (R0192S). 
NsiI New England Biolabs (R0127S). 
ScaI Sigma-Aldrich (10775266001). 
XbaI (Fast Digest) Thermo Fisher Scientific (FD0684). 
XhoI (Fast Digest) Thermo Fisher Scientific (FD0694). 
 
Table 2.1.2 List of antibodies used. 
Antibody Supplier (product code) 
Anti-mouse Actin, rabbit Sigma-Aldrich (A2066). 
Anti-GAPDH (V-18), goat Santa Cruz Biotech (sc-20357). 
Anti-mouse GAPDH, rabbit Sigma-Aldrich (G9545). 
Anti-β Tubulin, rabbit Novus, NB100-56459/Imgenex-IMG 
5810A) 
Anti-mouse IDO1 clone 10.1,mouse Merck Millipore (05-840). 
Anti-TDO, mouse polyclonal Abnova (H00006999-B01P). 
Anti-β Gal, rabbit ThermoFisher Scientific (A11132). 
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Anti-dystrophin C-terminus 
(MANDRA1), mouse 
DSHB, Iowa, USA (7A10). 
Anti-dystrophin C Terminus 
(2166AB), mouse 
Dr Derek  Blake, Cardiff University. 
Anti-FoxO3a (75D8), rabbit Cell Signalling Technology (2397). 
Anti-rabbit IgG, goat (HRP) Sigma-Aldrich (A0545). 
Anti-mouse IgG, goat (HRP) Sigma-Aldrich (A4416). 
Anti-Goat IgG, donkey (HRP) Promega (V8051). 
 
Table 2.1.3 List of chemicals and kits used. 
Chemical   Supplier (product code) 
Agarose electrophoresis grade Thermo Fisher Scientific 
(16500500). 
Ampicillin sodium salt Sigma-Aldrich (A0166-5G). 
Acrylamide/Bis Solution 30% (37.5:1) BioRad (1610158). 
Ammonium persulfate Sigma-Aldrich (A3678-25G). 
Bromophenol blue dye VWR (BDH7393-2). 
Bicinchoninic acid  Sigma-Aldrich (B9643-1L). 
β mercaptoethanol Sigma-Aldrich (M6250-100ML). 
Complete-M lysis buffer (Roche) Sigma-Aldrich (4719956001). 
Copper sulphate solution Sigma-Aldrich(C2284-25ML-D). 
Diethyl pyrocarbonate Sigma-Aldrich (D5758-5ML). 
DNase kit Thermo Fisher Scientific (AM1906). 
DNA ladder:  
 Quick Load, 1 kb New England Biolabs (N0552S). 
 Quick Load, 100 bp New England Biolabs (N0467S). 
DMEM (knockout) media Thermo Fisher Scientific (10829-
018). 
DMSO Sigma-Aldrich (D8418-250ML) 
EDTA Sigma-Aldrich (E9884-500G). 
Endo-free kit:  
 maxiprep  Qiagen (12362). 
 megaprep Qiagen (12381). 
Ethanol Fisher Scientific (10646134). 
Ethidium bromide Sigma-Aldrich (E1510-10ML). 
Eosin Y stain  Sigma-Aldrich (HT110316-500ML) 
Fetal Bovine Serum  Sigma-Aldrich (12306C-500ML) 
Glacial Acetic Acid Fisher Scientific	(10021123). 
Glycine Sigma-Aldrich (50046-1KG). 
Horse Serum  Sera Labs (GEM-100-508-S) 
HRP Western substrate:  
 Luminata Forte Millipore (WBLUF0100). 
 Luminata Crescendo Millipore (WBLUR0100). 
Haematoxylin stain Vector labs (H-3401) 
IPTG, Dioxane-Free Promega (V3951). 
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Interferon gamma (recombinant 
murine) 
Peprotech (315-05). 
Kanamycin Sigma-Aldrich (K4000-25G). 
L-Glutamine Sigma-Aldrich (G7513-100ML). 
LB Broth (miller) Sigma-Aldrich (L3152-1KG). 
LB Agar Sigma-Aldrich (L2897-1KG). 
Laemmli sample buffer (2X) BioRad (1610737). 
Miniprep kit (PureYield) Promega (A1222). 
Methanol Fisher Scientific (10785484). 
Protein standard, Bovine serum 
albumin (1mg/ml) 
Sigma-Aldrich (P0914-10AMP). 
PBS (1X) Thermo Fisher Scientific 
(10010031). 
PBS (-Ca2+/Mg2+)  Fisher Scientific (11540486). 
Penicillin/Streptomycin Sigma-Aldrich (P4458-100ML). 
PCR Purification kit:  
 GeneJet Thermo Fisher Scientific (K0692). 
 NucleoSpin Macherey Nagel (740609.250). 
Phosphatase inhibitor tablets (Roche) Sigma-Aldrich (4906845001). 
2-Propanol Sigma-Aldrich (I9516-25ML). 
Protein ladder:  
 Kleidoscope, 10-250 KDa Bio-Rad (1610375). 
 Pageruler, 10-250 KDa Thermo Fisher Scientific (26619). 
 Pageruler, 10-180 KDa Thermo Fisher Scientific (26616). 
Reverse Transcription Kit:  
 nano-Script 2 Primer Design (NA) 
 SuperScript VILO cDNA Synthesis 
kit 
Thermo Fisher Scientific 
(11754250). 
PrecisionPLUS 2x qPCR MasterMix 
 
Primerdesign (PrecisionPLUS-LR). 
Sodium Dodecyl Sulphate   Sigma-Aldrich (L3771-1KG). 
Tris-Base Sigma-Aldrich (93362-1KG). 
Trypan Blue  Sigma-Aldrich (T8154-20ML). 
Tryple Express Enzyme Thermo Fisher Scientific 
(12604013). 
Tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich (T7024-25ML). 
Transfection Reagents:  
 FuGene HD Promega (E2311). 
 GeneCellin Bulldog Bio (GC0500). 
 HappyFect Tecrea (NA). 
 K2 Biontex (T060-0.75). 
 Lipofectamine 3000 Thermo Fisher Scientific	(L3000001).	
 ScreenFect Wako (293-73201). 
 Viromer Red Lipocalyx (VR-01LB-00). 
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X-gal Promega (V3941). 
       
2.1.4 Solutions and buffers 
APS (10%): Ammonium persulfate-100 mg; H20-1ml. 
Buffer PI for Miniprep and Mega-prep (Resuspension buffer): 10 mM EDTA, 50 
mM Tris-HCl (pH 8.0) + 100 μg/ml RNAse A. 
Coomassie Brilliant blue staining solution: 10% (v/v) glacial acetic acid, 40% 
(v/v) Methanol, 0.1% (w/v) Coomassie Brilliant blue in dH2O. 
Destaining solution for Coomassie staining: 10% (v/v) glacial acetic acid, 10% 
(v/v) Methanol, in dH2O. 
Electrode (Running) Buffer (10X): Tris Base-0.250M; Glycine-1.918M; SDS-
0.034M; H20-1000ml; pH-8.3. 
Luria Broth (LB): 20 g of LB powder per 1 L of dH2O. 
LB-Agar: 3g of agar per 200ml of LB broth. 
TAE Buffer (50X): Tris Base-1.993M; Glacial Acetic Acid-57.1 ml; 0.5M EDTA 
(pH=8)-100ml; H20-1000ml; pH-8.4. To make 1X, add 20 ml buffer in 980 ml dH2O. 
TBS (10X): Tris-HCl-0.154M; NaCl-1.370M; H20-1000ml; pH-7.6. 
To make 1XTBST, add 100 ml of 10X TBS in 900 ml H20 and 500μl Tween20. 
Transfer Buffer (10X): Tris Base-0.250M; Glycine-1.918M; H20-1000ml; pH-8.3. 
To make 1X, add 100 ml of 10X transfer buffer in 900 ml H20 and 200 ml absolute 
methanol. 
 
 
Table 2.1.5 List of plasmids used. 
Vector Supplier 
PX61MCK In-house 
pcDNA3.1+C8 mini-dystrophin In-house 
pcDNA3.IDO1/IDO2/TDO Prof J. Golab, Warsaw Medical 
School, Poland 
pCS2+C beta-galactosidase (β-gal) 
 
Dr Colin Sharpe, University of 
Portsmouth. 
pcDNA4.myc-his.FoxO3.WT    
 
Dr. Anne Brunet, Stanford University, 
USA. 
pGEM-T EASY Vector System Promega. 
pBluescript.CD11c  Dr Thomas Brocker, LMU München, 
Germany 
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Table 2.1.6   List of bacterial strain used. 
Strain Supplier 
10-β Competent E.coli  New England Biolabs. 
      
Table 2.1.7 Description of PCR primers (Eurofins-MWG) used. 
Oligo Name Sequence Tm (based on 
Eurofins-MWG 
primer sheet) 
(Annealing 
temperature 
used)  
DystATGEco
R-FWD 
5’-TCAGAATTCCACCATGCTTTGG 
TGGGAAGAAGTAGAGGACTG-3’ 
73.3°C (62°C) 
1.5mM Mg2+ 
DysPolyAEc
oR-RC 
5’-TGAGAATTCGCCGGCATATGGCGC 
GCCCTTTCCGCCTCAGAA 
GCCATAGAGCC-3’ 
81.2°C (62°C) 
1.5mM Mg2+ 
CD11C-FWD 5’-AGTATTCTCTTGACCTTGGC-3’ 
 
55.2°C (47°C) 
1.5mM Mg2+ 
CD11C-RC 5’-GACTGGAGAACAGAAGCA-3’ 
 
53.7°C (47°C) 
1.5mM Mg2+ 
CD11cMfeIF
WD 
5’-TCAACGCGTCAATTGAGTATTCT 
CTTGACCTTGGCTGCC-3’ 
 
72.6°C (68°C) 
1.5mM Mg2+ 
CD11cAcc65
IRC 
5’-TGAGGTACCGACTGGAGAACA 
GAAGCAGGC-3’ 
 
70.9°C (68°C) 
1.5mM Mg2+ 
IDO1.Fwd1 5'-AGACCCAAGCTTGGTACCACCATG-3' 64.4°C (60°C) 
1.5mM Mg2+ 
IDO1.Fwd2 5'-GGAGACCCAAGCTTGGTACCACC-3' 66.0°C (60°C) 
1.5mM Mg2+ 
IDO1.RC1 5'-GCTCGAGCGGCCGCCTA-3' 62.4°C (60°C) 
1.5mM Mg2+ 
IDO1.RC2 5'-CATGCTCGAGCGGCCGC-3' 62.4°C (60°C) 
1.5mM Mg2+ 
Micro-
Dystrophin 
Hinge 
5’-ACCACCTCTGACCCTACACG-3’ 61.4°C (60°C) 
1.5mM Mg2+ 
Dystrophin 
Exon 65 
Reverse 
5’-GACCAGCCCATGGATATCCTGCAG-3’ 66.1°C (60°C) 
1.5mM Mg2+ 
IDO1.Exon10
.Fwd 
5’-GAGGCTGGCAAAGATCTCCTGC-3’ 64°C (60°C) 
1.5mM Mg2+ 
CD11c.IDO1.
Fwd 
5’-TGTTCTCCAGTCGGTACCACCATG-3’ 64.4°C (60°C) 
1.5mM Mg2+ 
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primer.5.fwd 
(minidystroph
in) 
5’-ACACGGAGCCCATTTCCTT-3’ 56.7°C (60°C) 
primer.5.rc 
(minidystroph
in) 
5’- CTCAGTATTGACCTCCTCAGCC-3’ 62.1°C (60°C) 
primer.7.fwd 
(minidystroph
in) 
5’- GCCCATTTCCTTCACAGCATT-3’ 58.4°C (60°C) 
primer.7.rc 
(minidystroph
in) 
5’- CCCACTCAGTATTGACCTCCTC-3’ 62.1°C (60°C) 
 
Table 2.1.8 List of qPCR probes used (Taqman, Thermo Fisher Scientific). 
Gene name and symbol  Assay ID  
CD4 antigen, Cd4 (mCG134308) Mm00442754_m1 
CD8 antigen alpha chain, Cd8a 
(mCG127285) 
Mm01182107_g1 
forkhead box P3, Foxp3 (mCG3948) Mm00475162_m1 
cytochrome c oxidase subunit II, COX2  Mm03294838_g1 
interleukin 10, Il10 (mCG2645) Mm00439614_m1 
interleukin 12A,Il12A (mCG15114) Mm00434169_m1 
glyceraldehyde-3-phosphate 
dehydrogenase, Gapdh (mCG1030816) 
Mm99999915_g1 
 
2.2 Microbiological techniques 
2.2.1-LB Broth & LB Agar preparation 
(i)-LB Broth- 20 g LB (Luria-Bertani) Broth was dissolved in 1000 ml or 4g in 200 ml 
of H20. The medium was mixed to make a homogeneous solution and aliquoted in 
small bottles. The media was sterilised by autoclaving and stored at 4°C. 
(ii)-LB Agar Plates- 35 g LB (Luria-Bertani) Agar was dissolved in 1000 ml or 3.5 g 
in 100 ml of H20. The medium was sterilised by autoclaving and cooled down to 
40°C. The antibiotic (Ampicillin or Kanamycin) was dispensed (see below) to 
medium, mixed by gentle swirling, poured into Petri dishes up to the half of its depth 
and let to cool down at room temperature. The lids were closed, the Petri dishes 
were kept at room temperature to let agar solidified as a gel, subsequently, dishes 
were stacked, wrapped with cling film and stored inverted to prevent the 
accumulation of moisture on the agar surface at 4°C. 
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(iii)-Ampicillin: The stock solution was made of 100 mg/ml. 100 μl was dispensed to 
100 ml LB Agar Media to obtain a final concentration of 100 μg/ml. 
(iv)-Kanamycin: The stock solution was 50 mg/ml. 100 μl was dispensed to 100 ml 
LB Agar media to obtain a final concentration of 50 μg/ml. 
 
2.2.2 Transformation of bacteria 
The 10-β competent E.coli cells had a transformation efficiency of 1 to 3 x 109 
CFU/μg pUC19 DNA. The transformation protocol was derived from the kit manual. 
The tube containing 50 μl of bacterial cells was transferred from the -80°C freezer 
to ice and incubated for 10 min to thaw the bacterial cells. The tube was gently 
flicked to check for the presence of ice crystals. If they were present, the tube was 
further incubated on ice to let them thaw. The plasmid DNA or ligation mixture (1pg 
to 100 ng concentration) was dispensed at a volume of up to 5 μl per tube of 
bacterial suspension. The tube was gently flicked to mix the content then incubated 
on ice for 30 min. The bacterial cells in the tube were heat shocked at 42°C for 30 
s and placed on ice for 5 min. Then 950 μl of SOC medium (at room temperature) 
was dispensed along the tube wall. The bacterial cells with SOC media were 
incubated at 37°C for 60 min with shaking at 250 rpm (HT INFORS, Minitron 
Shaker) to allow bacterial cells to express the antibiotic-resistance genes. 
The LB Agar plates that were earlier supplemented with ampicillin or kanamycin 
were removed from 4°C and kept in a 37°C incubator. Just before adding the 
bacterial culture (20-50 μl) to the dish, the IPTG 7 μl (stock of 0.1M) an inducer of 
the lac operon and X-gal 20 μl (stock of 50 mg/ml) substrate of β-gal enzyme were 
mixed together and spread over the surface of LB Agar in the Petri dish with the 
help of a spreader. The IPTG and X-gal on LB Agar plates were used when the 
plasmid DNA contained the lacZ gene (i.e. pGEM-T Easy Vector). When plasmid 
DNA did not contain the lacZ gene then the standard LB Agar plates supplemented 
with antibiotics were used without adding IPTG and X-gal. 
The bacterial suspension in SOC medium was mixed thoroughly by inverting the 
tube and 20 to 50 μl bacterial suspension was dispensed over the surface of the 
LB Agar plate. The spreader was used to spread the culture evenly on the surface 
of the LB Agar and the Petri dish was incubated in a 37°C incubator for 16 h. It was 
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analysed for the sign of bacterial colonies. The blue-white colonies were observed 
in the case of IPTG and X-gal supplemented agar, which indicated the positive 
clones expected to have plasmid DNA. Those plates that were not supplemented 
with IPTG and X-gal had all clones that appeared as white bacterial colonies. These 
were picked randomly but based on the size of the colonies. This was based on the 
assumption that the bigger colonies had a better ability to metabolise the antibiotics 
and hence more chance of having the plasmid. The individual, well-separated 
colonies were selected from the Petri dish with sterile toothpicks and added to 3 ml 
LB Broth supplemented with ampicillin or kanamycin in a 15 ml Falcon tube for mini-
prep preparations (described in Section 2.3.1). 
 
2.2.3 Glycerol stock preparation 
Glycerol stocks were made to preserve the positive clones for future use (i.e. re-
inoculation on Agar plates). Colonies of positive clones were selected and scaled 
up in LB Broth. The bacterial culture was selected for glycerol stock after confirming 
the presence of the plasmid by restriction digestion. 80% of Glycerol in a 150 ml 
Schott Duran bottle was prepared and autoclaved. 15 μl of culture from the original 
15 ml Falcon tube having residual bacterial growth after mini-prep preparation was 
taken and inoculated into 16 ml of LB media ampicillin or kanamycin (based on the 
presence of antibiotic resistance gene in plasmid following Section 2.2.1) in 50 ml 
Falcon tube. The culture was incubated at 37°C for 60 min with shaking at 250 rpm 
(HT INFORS, Minitron Shaker). 800 μl of bacterial growth was mixed with 200 μl of 
(80%) Glycerol and stored at -80°C. The rest of the culture was used as a starter 
culture for the maxi-prep preparation. 
 
2.3 Molecular biology techniques 
2.3.1 Small-scale preparation of plasmid DNA 
The small-scale plasmid preparation kit’s (Promega Pure Yield Plasmid Miniprep 
System) protocol was followed to detain the plasmid DNA to confirm the positive 
clones.  The positive clones were picked with a sterile toothpick and inoculated into 
3 ml LB broth supplemented with ampicillin or kanamycin in a 15 ml Falcon tube. 
The culture was incubated at 37°C for 60 min with shaking at 250 rpm (HT INFORS, 
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Minitron Shaker). The bacterial cells were harvested by obtaining a pellet through 
centrifugation at 16,200x g (Eppendorf, 5415D) for 3 min at room temperature in 
1.5 ml microcentrifuge tube and the pellet re-suspended into 700 μl ddH20. The 700 
μl bacterial culture was then transferred to a 1.5 ml microcentrifuge tube and 
centrifuged at 16,200 xg (Eppendorf, 5415D) for 30 s at room temperature. The 
pellet was recovered and the supernatant was discarded. These steps were 
repeated to harvest all the bacterial cells from the whole 3 ml LB broth. 600 μl of 
ddH20 was added to the bacterial cell pellets and tubes were vortexed to mix. 100 
μl of cell lysis buffer was dispensed and mixed by inverting the tube 6 times. This 
step would turn the opaque suspension to a blue colour. 350 μl of cold (4°C-8°C) 
neutralisation solution was dispensed and mixed by inverting the micro-centrifuge 
tubes until the blue coloured solution turned to yellow. The tubes were centrifuged 
at 16,200 xg (Eppendorf, 5415D) for 3 min at room temperature. The mini-column 
was assembled with the collection tube. The supernatant of about 900 μl was 
transferred to the mini-column with care not to disturb the pellet. The mini-column 
with the collection tube was centrifuged at 16,200 xg (Eppendorf, 5415D) for 15 s 
at room temperature. The flow-through was discarded. The column and the 
collection tube were re-assembled. The rest of the supernatant from 1.5 ml 
microcentrifuge tube was added to the column and centrifuged at 16,200 xg 
(Eppendorf, 5415D) for 15 s at room temperature. The flow-through was discarded. 
200 μl of the endotoxin removal wash solution was added to the mini-column and 
centrifuged at 16,200 xg (Eppendorf, 5415D) for 15 s at room temperature. The 
flow-through was discarded. 400 μl of wash solution was added to the mini-column 
and centrifuged at 16,200 xg (Eppendorf, 5415D) for 30 s at room temperature. The 
flow-through was discarded. The mini-column was transferred to a clean 1.5 ml 
micro-centrifuge tube. 30 μl of ddH20 was dispensed directly to the silica membrane 
of the column and incubated for 3 min at room temperature. The column with its 1.5 
ml tube was centrifuged at 16,200 xg (Eppendorf, 5415D) for 15 s at room 
temperature to elute plasmid DNA. The concentration and quality of plasmid DNA 
were analysed using Nanodrop spectrophotometer (ND-100, Biotech) (Section 
2.3.3) and the plasmid DNA was stored at -20°C.  The glycerol stock was made 
from the positive clones (as described in Section 2.2.3). 
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2.3.2 Large-scale preparation of plasmid DNA  
The large-scale endotoxin free plasmid preps were prepared by following the 
manufacturer’s (Endo Free Mega Prep Kit, Qiagen) protocol to obtain the 
endotoxin-free plasmid DNA suitable for cell transfection and muscle injection. For 
consistency with the results, the single batch plasmid DNA was used for both in 
vitro and in vivo studies as earlier done by Manthorpe et al(264). The protocol was 
based on a modified alkaline lysis method and plasmid DNA binding to an anion-
exchange resin. The plasmids were shortlisted into either high copy number or low 
copy number based on the presence of the origin of replication and analysed from 
the following Table 2.3.2.0: 
 
Table 2.3.2.0 Description of Low copy and High copy plasmid based on the 
origin of replication (adapted from Qiagen Endo-Free Mega Prep kit manual). 
DNA Plasmids Origin of 
replication 
Copy 
number 
Classification 
pUC vectors pMB1 related to 
ColE1 
500-700 high copy 
pBluescript vectors ColE1 300-500 high copy 
pGEM vectors pMB1 related to 
ColE1 
300-400 high copy 
pTZ vectors pMB1 related to 
ColE1 
>1000 high copy 
pBR322 and derivatives pMB1 related to 
ColE1 
15-12 low copy 
pACYC and derivatives p15A 10-12 low-copy 
pSC101 and derivatives pSC101 5 very low copy 
Cosmids    
SuperCos ColE1 10-20 low copy 
pWE15 ColE1 10-20 low copy 
 
The plasmid DNA with an origin of replication of high-copy number (derived from 
pUC vector) were pcDNA3.IDO1, pcDNA3.IDO2, pcDNA3.TDO, 
pcDNA3.cd11c.IDO1, pcDNA3.cd11c.IDO2, pcDNA3.cd11c.TDO, pcDNA3.mini-
dyst.Fwd, pcDNA3.mini-Dyst.RC, pcDNA4.FoxO3.WT, pcS2+C beta-galactosidase 
(β-gal). The plasmid DNA with an origin of replication of low copy number (derived 
from pBR322 vector) were PX61MCK.Dyst.Fwd and PX61MCK.Dyst.RC. A single 
E.coli colony was picked from a freshly streaked selective agar plate and inoculated 
into 5 ml of LB broth supplemented with ampicillin or kanamycin in a 50 ml Falcon 
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tube and incubated at 37°C for 8 h with shaking at 250 rpm (HT INFORS, Minitron 
Shaker). This culture was used as a starter culture. 1000 μl of starter culture was 
inoculated into either 500 ml LB broth supplemented with ampicillin or kanamycin 
in a 2.5 L flask for high copy number plasmid DNA or 2.5 L (5 x 500 ml) LB broth 
supplemented with ampicillin or kanamycin in 2.5 L flasks for low copy number 
plasmid DNA. The culture was incubated at 37°C for 18 h with shaking at 250 rpm 
(HT INFORS, Minitron Shaker) with aeration. 2.5 L flasks with bacterial culture were 
stored at 4°C to condense the bacterial suspension and prevent shearing of plasmid 
DNA during the extraction procedure. The bacterial cells were dispensed into 
multiple 50 ml Falcon tubes and pellets were harvested by centrifugation at 6000 x 
g (Jouan, MR1812) for 15 min at 4°C. The QIAfilter Mega cartridge was screwed 
onto a 45 mm neck of sterile Schott Duran 1000 ml glass bottle and connected to a 
vacuum source. The bacterial pellets in multiple 50 ml Falcon tubes were re-
suspended in a final volume of 50 ml of chilled buffer P1 by vortex and transferred 
to a sterile 500 ml Schott Duran bottle. 50 ml of buffer P2 was dispensed, mixed 
thoroughly by inverting vigorously 4-6 times and the lysate was incubated at room 
temperature for 5 min. 50 ml of chilled buffer P3 was dispensed and mixed 
thoroughly by inverting vigorously 4-6 times. The suspension was mixed until white, 
fluffy material formed and the lysate was no longer viscous. The suspension was 
poured into a QIAfilter Mega cartridge and incubated at room temperature for 10 
min to settle the suspension. The vacuum source was switched on until all liquid 
had been pulled through the filter into the sterile Schott Duran 1000 ml glass bottle. 
50 ml of buffer FWB2 was dispensed to QIAfilter cartridge and the precipitate gently 
stirred using a sterile inverted 1000 μl tip. The vacuum source was switched on until 
the liquid has been pulled through completely. 12.5 ml buffer ER was dispensed to 
the filtered lysate, mixed by inverting bottle about 10 times and incubated on ice for 
30 min. The Qiagen Tip 2500 was equilibrated by applying 35 ml buffer QBT and 
allowing it to an empty by gravity flow. When the Qiagen Tip 2500 was emptied, the 
filtered lysate was dispensed from a 1000 ml Schott Duran glass bottle to it. The 
total volume was filtered and the Qiagen Tip 2500 was washed with 200 ml of buffer 
QC. The plasmid DNA was eluted with 35 ml of buffer QN into a sterile 50 ml Falcon 
tube and precipitated by dispensing 24.5 ml of isopropanol. The tube was inverted 
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gently to mix, marked outside with permanent marker pen to trace the pellet and 
centrifuged at 5000 x g (Jouan, MR1812) for 60 min at 4°C. The pellet was 
recovered by gently discarding the supernatant. 7 ml of 70% ethanol in endotoxin 
free water was dispensed to pellet which was then resuspended and centrifuged at 
5000x g (Jouan, MR1812) for 60 min at 4°C. The pellet was recovered by gently 
discarding the supernatant with the help of a 1000 μl and 200 μl pipettes. The pellet 
was transferred to a 1.5 ml microcentrifuge tube with the help of a sterile 1000 μl 
tip and air-dried for 10 min. The pellet was re-suspended in 500 μl of ddH20 and 
incubated for 16 h at 4°C to dissolve the pellet. The concentration of plasmid DNA 
was assessed using Nanodrop spectrophotometer (ND-100, Biotech) (described in 
Section 2.3.3). The quality of plasmid DNA was evaluated by agarose gel 
electrophoresis (described in Section 2.3.6). 
 
2.3.2.1 Ethanol precipitation of DNA 
This protocol was used to precipitate plasmid DNA to increase the concentration 
and purity of diluted plasmid DNA preparations. The plasmid DNA was transferred 
to 50 ml Falcon tube. 37.5 μl of 3 M sodium acetate (chilled at 4°C) and 750 μl of 
absolute ethanol (chilled at -20°C) was added to 50 ml Falcon tube, mixed by 
inverting the tube and stored at -20°C for 1 h. The tube was centrifuged at 10,000 
x g (Jouan, MR1812) for 15 min at 4°C. The pellet was recovered by gently 
discarding the supernatant with the help of a 1000 μl pipette. The tube was further 
centrifuged at 10,000 x g (Jouan, MR1812) for 15 min at 4°C to separate the 
supernatant that was discarded with the help of 200 μl pipettes. 200 μl of 70% 
ethanol (chilled at -20°C) was added to the 50 ml Falcon tube which was then 
centrifuged at 10,000 x g (Jouan, MR1812) for 5 min at 4°C. The supernatant was 
discarded with the help of a 200 μl pipette. The tube with the pellet was air dried for 
5 min to evaporate the ethanol. The pellet was re-suspended in 200 μl of nuclease-
free water and kept for 16 h at 4°C to dissolve. The concentration of the preparation 
was analysed using a Nano-drop spectrophotometer (ND-100, Biotech) (described 
in Section 2.3.3) and the plasmid was stored at -80°C. 
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2.3.3 Analyses of concentration and purity of nucleic acids using Nanodrop 
spectrophotometer 
The Nanodrop spectrophotometer (ND-100, Biotech) was used to analyse the purity 
and concentration of DNA and RNA. The 260/280 nm ratio for pure DNA should be 
about 1.8 and for RNA should be about 2. The sensor point was cleaned with 1 μl 
of DEPC.H20 and wiped with a tissue wipe. 1 μl of DEPC.H20 was dispensed onto 
the sensor point and the nucleic acid (DNA/RNA) was selected from the menu of 
the software. The DEPC.H20 was wiped with a tissue wipe and 1 μl of the blank 
solution (a solution used to dissolve a nucleic acid in) was dispensed to establish 
the baseline (blank). The sensor was wiped and 1 μl of the nucleic acid solution 
was dispensed onto the sensor point and measurement was activated to record 
values. The sensor point was closed immediately after dispensing the solution to 
prevent air-drying of the samples. It was cleaned before and after the use, using 
DEPC.H20 to obtain rid of RNAase/DNAase contamination.  
2.3.4 Genetic engineering of plasmid DNA 
in silico maps of plasmids were made using Vector NTI-8 software by combining 
the insert DNA sequence (e.g. mini-dystrophin) with the vector DNA (e.g. pcDNA3 
plasmid) sequence. The resultant full plasmid sequences were analysed for the 
presence of various restriction enzyme sites using NEB Cutter 2.0 
(http://nc2.neb.com/NEBcutter2/) to facilitate restriction digestion of plasmids. 
These enzymes were shortlisted based on specific recognition sites in the plasmid, 
single-cutter enzymes were used to cut open the plasmid while two single-cutter 
and multiple-cutter enzymes were used to obtain predicted size bands in the 
agarose gel upon restriction digestion. Two sets of restriction enzymes were 
selected, first set to liberate the insert from the vector (e.g. EcoRI to liberate mini-
dyst in PX61MCK.mini-dyst.Fwd) to confirmed the proper ligation and the second 
set to cut the insert in the middle to confirm the orientation of the insert (e.g. Fwd 
or RC) that was ligated to vector (described in Section 3.2). The restriction digestion 
was setup by following the instructions of the manufacturer of the restriction 
enzyme. The digest was subjected to agarose gel electrophoresis and band sizes 
were determined by comparing with the DNA ladder that was loaded alongside the 
samples. The resultant positive clones were dispatched for DNA sequencing to re-
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confirm the sequence predicted in silico. The full sequences and maps of plasmid 
are presented in appendices (Section 9.1) and details are provided in Table 2.3.4.1. 
 
Table 2.3.4.1 Descriptions of plasmid modifications 
Original plasmid Restriction enzymes 
used for inserting the 
target gene, name of 
the target gene 
Designation of the 
resultant plasmid 
PX61MCK.human alpha  
galactosidase      [Lavigne 
et al(265)] 
EcoRI-EcoRI, mini-
dystrophin gene. 
PX61MCK.dyst.Fwd and 
PX61MCK.dyst.Rev 
pcDNA3.IDO1 EcoRI-EcoRI, mini-
dystrophin gene. 
pcDNA3.dyst.Fwd 
pcDNA3.IDO1 MfeI-Acc65I, promoter 
cd11c. 
pcDNA3.CD11c.IDO1 
pcDNA3.IDO2 MfeI-Acc65I, promoter 
cd11c. 
pcDNA3.CD11c.IDO2 
pcDNA3.TDO MfeI-Acc65I, promoter 
cd11c. 
pcDNA3.CD11c.TDO 
 
2.3.5 Restriction digestion of plasmid DNAs 
The restriction digestion involved the use of a restriction enzyme to cut the plasmid 
DNA at the specific recognition site to produced segments of plasmid DNA that 
were analysed using agarose gel electrophoresis. The single-cutter, two-cutter and 
multiple-cutter restriction enzymes were available from commercial suppliers. The 
NEB cutter 2.0 (http://nc2.neb.com/NEBcutter2/) was used to analyse the map of 
available restriction enzymes corresponding to the plasmid DNA base pair and a 
calculation was made to shortlist suitable enzymes. The single-cutter enzymes 
were used to check the total size of plasmid DNA as it cut at one site to open the 
covalently closed circular DNA (cccDNA) and linearised it (e.g. EcoRI was used for 
pcDNA3 plasmid). The two single-cutter enzymes (e.g MluI + Scal to liberate mini-
dystrophin from PX61MCK as described in Section 3.2) were used to liberate the 
insert from the plasmid backbone. The double-cutter enzyme was used to confirm 
the identity of plasmid DNA (e.g. FD-HindIII used to liberate mini-dystrophin from 
pcDNA3.mini-dyst.Fwd clones as described in Section 3.3). 500 ng to 1 μg of 
plasmid DNA was used for cloning experiments and 220 ng to 250 ng of plasmid 
DNA were used for restriction digestion. 
	 65	
2.3.6 Agarose gel electrophoresis 
The agarose gel was used to separate DNA molecules based on their molecular 
weight denoted in the form of base pairs. The greater the amount of agarose the 
smaller the pore size of the gel matrix that obstructs the electrophoretic movement 
of larger DNA molecules e.g. a 1% gel was used to separate the DNA bands for 
range of 1 kb to 10 kb and a 2% gel was used for the separation of lower base pair 
DNA bands (100 bp or less). The agarose powder and 1X TAE buffer were added 
to a 150 ml Schott Duran bottle according to the required volume (i.e based on the 
gel percentage). The suspension was carefully boiled in a microwave with repeated 
release of steam and mixing of the content. It was cooled to room temperature and 
ethidium bromide dye 1μl (stock of 10 mg/ml) in 50 ml tank buffer was dispensed 
and it was mixed with a gentle swirl. The gel was poured into the cast prefixed with 
combs. The gel solidified in about 1 h and this was analysed with the inverted 200 
μl pipette tip. The combs were removed gently from the cast and the gel was 
transferred to an electrophoretic tank. The nucleic acids migrate from the cathode 
to anode, so the wells were placed at the cathode side of the electrophoretic tank 
to load the samples. 1X TAE was dispensed to cover the gel and ethidium bromide 
dye (i.e 1μl in 50 ml) was dispensed toward the anode side (to compensate its loss 
from the gel during electrophoresis) in the tank buffer and it was mixed with gentle 
swirling with the help of the inverted 200 μl pipette tip. Nucleic acids samples were 
prepared for loading by mixing the 6X gel loading dye to obtain a 1X final 
concentration then loaded into the wells. The sequence of loading was DNA ladder 
(NEB Labs) in the left most well and then rest of samples were loaded. The lid was 
closed and the voltage was turned on from the panel. Initially, the voltage applied 
was low (25V) than it was increased to moderate (50V) and finally to high (100V) to 
enable good separation of bands. An initial image was taken using Gel Doc EZ 
(BioRad) to check the separation rate of bands with reference to the separation rate 
of the DNA ladder and the voltage was kept low (25V) to moderate (50V) for 
optimum resolution of bands. Electrophoresis was continued until the blue dye front 
reached the end of the gel slab. The electric current was stopped and the gel slab 
was gently transferred to a Gel Doc EZ (BioRad). The Image Lab software was 
activated on the computer. The image was captured, saved and subsequently 
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exported as a jpeg. 
 
2.3.7   DNA extraction from agarose gels 
DNA was extracted and purified using an extraction kit (Nucleo-spin kit by Machery-
Nagel). A clean scalpel was used to excise the DNA bands from agarose gel slabs. 
The weight was then determined and transferred to a 1.5 ml microcentrifuge tube. 
200 μl buffer NT1 was dispensed into the tube for gel weighing up to 100 mg and 
of gel concentration less than 2% while 400 μl buffer NTI was dispensed into the 
tube for gel weighing up to 100 mg and of gel concentration more than 2%. The 
sample was incubated for 5 to 10 min in a heat block at 50°C with a quick vortexing 
every 3 min until the gel slice was dissolved completely in the buffer. The column 
and the collection tube were assembled. 700 μl of the suspension was dispensed 
into the column and centrifuged at 11,000 x g (Eppendorf, 5415D) for 30 s at room 
temperature. The flow through was discarded from the collection tube and column 
was re-assembled with the collection tube. This step was repeated to cover the total 
volume of gel slab solution. 700 μl of buffer NT3 was then dispensed to the column, 
which was centrifuged at 11,000 x g (Eppendorf, 5415D) for 30 s at room 
temperature. The flow through was discarded and the column was re-assembled 
with the collection tube. This step was repeated to increase the purity. The column 
was centrifuged at 11,000 x g (Eppendorf, 5415D) for 1 min at room temperature to 
dry the silica membrane by removing any residual buffer NT3. The column was 
transferred to a new 1.5 ml microcentrifuge tube and incubated in a heat block at 
70°C for 5 min to evaporate any ethanol (a component of buffer NT3) from the silica 
membrane. 30 μl of ddH20 was dispensed directly to the membrane of the column 
which was incubated in the heat block at 70°C for 5 min with a 1.5 ml 
microcentrifuge tube. The column with the tube was then centrifuged at 11,000 x g 
(Eppendorf, 5415D) for 1 min at room temperature to elute the DNA. The eluted 
solution was reused to repeat the elution step to maximise the recovery and 
increase the concentration of eluted DNA. 
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2.3.8 Dephosphorylation of vector arms 
2 μl of 10X Antarctic Phosphatase Reaction buffer (NEB Labs) was added to a 1.5 
ml microcentrifuge tube containing 20 μl volume of plasmid DNA (in a range of 1 to 
5 μg concentration) following restriction digestion. 1 μl (5 units) of Antarctic 
Phosphatase enzyme (NEB Labs) was then added and mixed by repeated 
pipetting. The tube was incubated at 37°C for 60 min. The reaction was then 
stopped by inactivating the enzyme for 5 min at 65°C. The concentration of plasmid 
DNA was analysed using the Nanodrop spectrophotometer (ND-100, Biotech) 
(described in Section 2.3.3). 
 
2.3.9 DNA ligation 
The insert to vector molar ratio (3:1) calculation was performed to confirm the 
required volume of vector and insert based on their respective concentrations using 
the formula:-(ng of the vector x kb size of the insert)/ kb size of the vector x (insert: 
vector molar ratio) = ng of insert. Generally, a minimum concentration of 50 ng of 
vector and 150 ng of the insert in a volume up to 10 μl (adjusted with ddH20) was 
used. The vector and insert were dispensed into a 1.5 ml microcentrifuge tube. 10 
μl of 2X Quick Ligase buffer (NEB Labs) and 1 μl of Quick T4 DNA Ligase (NEB 
Labs) were added. The tube was centrifuged at 16,200 xg (Eppendorf, 5415D) for 
15 s at room temperature to mix its contents then incubated at room temperature 
(25°C) for 5 min. This ligation mixture was kept on the ice and was used for 
transformation (described in Section 2.2.2). 
 
2.3.10  PCR amplification of nucleic acids 
The polymerase chain reaction (PCR) was used to amplify the DNA molecules and 
the product size was analysed using agarose gel electrophoresis (described in 
Section 2.3.6). The two types of polymerase enzymes that were used in the project 
were iProof High-fidelity DNA polymerase (Bio-Rad) and GoTaq PCR Master mix 
(Promega). The iProof enzyme was used in all applications where base substitution 
had to be avoided (e.g. for subsequent cloning of expression cassettes), while Go-
Taq was used for all other routine and diagnostic PCR amplifications. The reaction 
was setup based on the instructions provided by the manufacturer (Bio-Rad or 
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Promega) of the respective enzymes. The primers were diluted to 20 pM 
concentration from the stock of 100 pM. The reaction was set up at 50 μl volume. 
The following Table 2.3.10 shows the details of PCR conditions used in a 
thermocycler (Peqlab, Primus 25 or MWG-AG Biotech, Primus 96 plus):  
 
Table 2.3.10 Description of PCR program for thermocycler. 
Initial denaturation 94°C, 3 min 
Loop of 35 cycle Denaturation 94 C, 1 min 
Annealing 45-60°C, 1 min [the annealing 
temperature was 5°C lower than the 
melting temperature of primers that was 
calculated from base-pair using the 
formula Tm=4(GC) + 2(AT) or provided in 
Eurofins-MWG data-sheets enclosed with 
primers] 
Extension 72°C, 1 min per 1 kb of amplified 
sequence 
Final extension 72°C, 1 min 
Storage 8°C 
 
2.3.11 PCR product purification 
PCR products were purified using a PCR clean up kit (Nucleo-spin kit by Machery-
Nagel) to remove primer dimers, salts, enzymes and other components of the PCR 
reaction. The volumes of the PCR samples were adjusted with nuclease-free water 
to obtain a final volume of 50 μl in a 1.5 ml microcentrifuge tube. 100 μl of buffer 
NTI was dispensed and mixed by repeated pipetting. The column was assembled 
with the collection tube. Up to 700 μl of the suspension was dispensed to the 
column. The column with the collection tube was centrifuged at 11,000 x g 
(Eppendorf, 5415D) for 30 s at room temperature. The flow-through was discarded 
from the collection tube and the column was re-assembled with the collection tube. 
700 μl of buffer NT3 was dispensed to the column and centrifuged at 11,000 x g 
(Eppendorf, 5415D) for 30 s at room temperature. The flow-through was discarded 
from the collection tube and the column was re-assembled with the collection tube. 
This step with buffer NT3 was repeated to minimise carry-over of the chaotropic salt 
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(i.e. guanidine hydrochloride and guanidinium thiocyanate that disrupt the water 
shell around nucleic acids, present in buffer NTI) and increase purity. The column 
with the collection tube was centrifuged at 11,000 x g (Eppendorf, 5415D) for 1 min 
at room temperature to remove the residual buffer NT3 from the silica membrane. 
The column was transferred to a new 1.5 ml microcentrifuge tube and incubated in 
a heat block at 70°C for 5 min to evaporate the residual ethanol (a component of 
buffer NT3) from the silica membrane. 30 μl of ddH20 was dispensed directly onto 
the silica membrane of the column and incubated for 3 min at room temperature. 
The column with the 1.5 ml tube was centrifuged at 11,000 x g (Eppendorf, 5415D) 
for 1 min at room temperature to elute the DNA. The eluted solution was reused to 
repeat the elution step to maximise the recovery and increase the concentration of 
eluted DNA. 
 
2.3.12 PCR product cloning using pGEM-T Easy vector system 
The purified PCR product (insert) was cloned into a pGEM-T Easy vector 
(Promega). This vector system has features of a blue/white selection of 
recombinant clones, T-overhangs for easy PCR cloning, rapid ligation and multiple 
cloning sites (MCS) with 19 restriction enzyme sites. Two steps were followed to 
obtain recombinant clones. The first step was tailing or addition of a single base A-
overhang to the PCR product that was amplified by the iProof High-fidelity DNA 
polymerase (Bio-Rad). The second step was ligation of the PCR product to bind 
with the single base T-overhangs (A=T) of the pGEM-T Easy vector to obtain a 
recombinant plasmid. This ligation mixture was used to transform the 10-β E.coli 
cells (NEB Labs) as described previously (Section 2.2.2). 
The tailing reaction was set up in a 10 μl volume in a PCR tube with 1 μl of GoTaq 
DNA polymerase, 2 μl of 5X colourless buffer, 0.6 μl of 25 mM MgCl2, 0.2 μl of 10 
mM dATP, X μl of purified PCR product based on its concentration and Y μl of 
nuclease-free water (the water was added to obtain total reaction volume of 10 μl). 
The reaction was incubated at 70°C for 30 min in a thermocycler machine (Peqlab, 
Primus 25 or MWG-AG Biotech, Primus 96 plus). The concentration of tailing 
product was analysed by Nanodrop spectrophotometer (ND-100, Biotech) (Section 
2.3.3) and stored on ice for setting up the ligation reaction. 
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The standard and background ligation reactions were set up following the pGEM-T 
Easy Vector System I kit’s user manual and the molar ratio of insert: vector was 
calculated [(ng of the vector x kb size of the insert)/ kb size of the vector x (insert: 
vector molar ratio) = ng of insert]. The standard reaction had 3 μl tailed PCR 
product, 5 μl of 2X Rapid ligation buffer, 1 μl pGEMT EASY vector (50 ng) and 1 μl 
of T4 DNA Ligase enzyme. The background reaction (control reaction) had no 
tailing product but 3 μl of nuclease-free water, 5 μl of 2X Rapid ligation buffer, 1 μl 
pGEMT EASY vector (50 ng) and 1 μl of T4 DNA Ligase enzyme. The tube of 
standard and background reaction was incubated at 4°C for 16 h to complete the 
ligation process. 
5 μl of this ligation mix from the standard and background reactions were added 
respectively to separate tubes of 10-β competent E.coli cells (NEB Labs) for the 
transformation (described in Section 2.2.2). Following transformation 20 μl of 
bacterial culture were spread on IPTG, X-gal, and ampicillin supplemented LB Agar 
plates. The plates were incubated at 37°C for 16 h and then stored at 4°C for 16 h 
to develop dark blue colour colonies. The population of blue and white colonies on 
the LB agar plate with the standard ligation reaction product was analysed against 
the LB agar plate of background ligation reaction to confirm the efficiency of 
transformation. White colonies (containing inserts) were picked with a toothpick for 
the mini-prep preparation (described in Section 2.3.1) and the presence of 
recombinant plasmids was confirmed by restriction digestion (described in Section 
2.3.5) of clones. 
 
2.3.13 DNA sequencing of plasmid constructs 
The plasmid clones were initially analysed by restriction digestion with different 
combinations of single cutter restriction enzymes (described in Section 2.3.5). The 
positive clones with the expected band size on agarose gel electrophoresis were 
shortlisted for DNA sequencing. These clones were mixed with specific forward and 
reverse primers and dispatched to Eurofins-MWG. After receiving the DNA 
sequencing results, the expected in silico sequences were aligned with the DNA 
sequencing results to rule out errors during the PCR, ligation and cloning. The T-
coffee and NCBI Blast web tools were used for the alignments. 
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2.3.14 Extraction of RNA from cell lines and tissues 
The RNeasy plus universal mini kit (Qiagen) was used to extract RNA from muscle 
tissues and cell lines. The procedure was adapted from kit’s user manual and run 
as follows: 
 
2.3.14.1 Sample preparation from TA muscles 
The TA (tibialis anterior) muscles were excised, transferred to pre-labelled 1.5 ml 
micro-centrifuge tubes and snap frozen in liquid nitrogen (-196°C). These were 
stored at -80°C. The frozen muscle samples were crushed using a chilled (dry ice) 
mortar and pestle. The powder was scooped into 1.5 ml micro-centrifuge tubes. 900 
μl of Qiazol Lysis Reagent (Qiagen) was dispensed and mixed by quick vortexing. 
The tubes were incubated on ice for 30 min and vortexed to homogenise the 
suspension. The suspension was further homogenised by passing it three times 
through a 27G needle attached to a syringe (if it got blocked then 18G and 21G 
needles were used). The tubes were vortexed every 3 min and then were stored on 
ice for 30 min. 
 
2.3.14.2 Sample preparation from cell lines 
The human embryonic kidney 293 cell line (HEK 293), dystrophic myoblasts (SC5) 
and wild-type myoblasts (IMO) were harvested (described in Section 2.4) to obtain 
pellets in separate 1.5 ml micro-centrifuge tubes. 900 μl of Qiazol Lysis Reagent 
was dispensed into the tubes and mixed by quick vortexing. The tubes were 
incubated on ice for 30 min and vortexed to homogenise the suspension. The 
suspension was further homogenised by passing it three times through a 27G 
needle attached to a syringe. The tubes were vortexed every 3 min and then were 
stored on ice for 30 min. 
 
2.3.14.3 Extraction of RNA 
The muscle and cell sample homogenates in Qiazol lysis reagent were transferred 
from ice to room temperature (15-25°C) for 5 min to promote the dissociation of 
nucleoprotein complexes. 100 μl of gDNA Eliminator Solution was dispensed into 
tubes and mixed by inverting the tubes vigorously for 15 s to reduce genomic DNA 
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contamination.180 μl of chloroform was dispensed to tubes and mixed by inverting 
the tubes vigorously for 15 s. The tubes were incubated at room temperature for 2 
to 3 min to enable phase separation. The tubes were centrifuged at 12,000 x g 
(Sanyo HARRIER 18/80) for 15 min at 4°C to obtain a three-phased layer. An upper 
colourless aqueous phase containing RNA, middle white interphase and lower red 
organic phases were observed. 600 μl upper aqueous layer was transferred to a 
new 1.5 ml micro-centrifuge tubes. 600 μl of 70% ethanol made in RNase-free water 
was dispensed to the 1.5 ml tubes and the contents mixed by inverting the tubes 
vigorously for 15 s. 700 μl of this solution was transferred to RNeasy Mini spin 
columns attached to the 2 ml collection tubes which were centrifuged at 9,300 x g 
(Eppendorf 5415 D) for 15 s at room temperature. The flow through was discarded 
from the collection tubes and these were re-assembled with their respective 
columns. This step was repeated with the rest of the 500 μl sample’s solution. 700 
μl buffer RWT was added to the RNeasy spin columns and centrifuged at 9,300 x 
g (Eppendorf 5415 D) for 15 s at room temperature. The flow through was discarded 
from the collection tubes and these were re-assembled with their respective 
columns. 500 μl buffer RPE was then added to the RNeasy spin columns and 
centrifuged at 9,300 x g (Eppendorf 5415 D) at room temperature for 15 s. The flow 
through was discarded from the collection tubes and these were re-assembled with 
their respective columns. 500 μl buffer RPE was added to the RNeasy spin columns 
and centrifuged at 9,300 x g (Eppendorf 5415 D) at room temperature for 2 min. 
The flow through was discarded from the collection tubes and these were re-
assembled with their respective columns. This long centrifugation was meant to 
remove ethanol (a component of buffer RPE) from the membrane of the columns. 
The RNeasy spin columns were transferred to a new 2 ml collection tubes and 
centrifuged at 9,300 x g (Eppendorf 5415 D) at room temperature for 1 min to 
remove any possible carryover of buffer RPE. The RNeasy spin columns were 
transferred to a new 1.5 ml micro-centrifuge tubes. 50 μl RNase-free water was 
added to the membrane of the spin column to elute the RNA and incubated at room 
temperature for 3 min. The spin columns with the collection tubes were centrifuged 
at 9,300 x g (Eppendorf 5415 D) for 1 min. The eluted RNA solution was collected 
from the 1.5 ml micro-centrifuge tubes and re-dispensed to respective RNeasy spin 
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columns to repeat the elution step to maximise the recovery and increase the 
concentration of RNA. These samples were subjected to DNase treatment. 
 
2.3.14.4 DNase treatment 
The DNase Kit (Ambion) was used to remove DNA contamination. 50 μl of RNA 
samples were transferred to PCR tubes and stored on ice. 5 μl of 10X Turbo DNase 
buffer with 1 μl of DNase were added to tubes and mixed by repeated pipetting. 
The tubes were incubated at 37°C for 30 min. 5 μl of DNase Inactivation Reagent 
was dispensed to tubes and mixed with repeated pipetting. The tubes were 
incubated for 5 min at room temperature. The tubes were centrifuged at 10,000 x g 
for 15 min at 4°C. The clear supernatant was transferred to a new 1.5 ml micro-
centrifuge tubes. The concentration and OD values of RNA were analysed using a 
Nano-drop spectrophotometer (ND-100, Biotech) (Section 2.3.3). The RNA 
samples were then stored at -80°C. 
 
2.3.15 Reverse transcription of RNA  
The reverse transcription reaction was setup using a nano-Script 2 Reverse 
Transcription Kit (Primer Design) and SuperScript VILO cDNA Synthesis kit 
(Thermo Fisher Scientific) to make cDNA from RNA. The protocol used was 
adapted from the kit as follows: 
 
2.3.15.1 Annealing step 
The Random primers were used to anneal to the RNA template. The RNA was used 
at 1000 ng concentration with the volume of up to 9 μl (adjusted with RNase-free 
water) and transferred to PCR tubes. Then 1 μl of random primers mix was 
dispensed and mixed by repeated pipetting. The tubes were incubated at 65°C for 
5 min in a thermocycler and then stored on ice. 
 
2.3.15.2 Extension step 
The master mix was prepared by calculating the number of samples. 10 μl of master 
mix for one sample had 5 μl of 4X RT buffer, 1μl of the dNTPs solution, 1μl of 
Reverse Transcriptase enzyme, 3 μl of water. The master mix was added to tubes 
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and mixed by repeated pipetting with centrifugation at 16,200 xg (Eppendorf 5415 
D) for 15 s at room temperature. The tubes were incubated in three continuous 
series of temperature at 25°C for 5 min; 55°C for 20 min and 75°C for 15 min in a 
thermocycler. These samples were stored on ice and were ready to setup normal 
PCR or qPCR. 
 
2.3.16 qPCR setup using TaqMan Gene Expression Assay 
The quantitative real-time polymerase chain reaction (qPCR) was set up using the 
TaqMan Gene Expression Assay (Applied Biosystems) for the relative 
quantification of the expression of genes β-gal (lacZ), IDO1, GAPDH, CD4, CD8A, 
FOXP3, COX2, IL-10 and IL-12 from β-gal + IDO1 plasmid injected and β-gal only 
injected (control) mdx mice. The protocol was adapted from the manual and run as 
follows: 
 
2.3.16.1 Reaction setup 
The qPCR experiments required 1 to 100 ng of cDNA per 20 μl reaction. The cDNA 
from the step 2.3.17.2 was used. The cDNAs for target genes (e.g. β-gal) were 
diluted 1:10 to obtain a 100 ng concentration. The cDNAs for housekeeping gene, 
GAPDH were diluted 1:20 to obtain a 50 ng concentration. The reaction was set up 
by preparing two sets of master mix, one for the target genes and another for the 
housekeeping gene. The composition of master mix for the target gene was 4 μl 
cDNA, 1 μl of TaqMan Gene Expression Assay Mix (20X), 10 μl TaqMan Universal 
PCR Master Mix with UNG (2X) and 5 μl of nuclease-free water. The composition 
of master mix for the housekeeping gene was 5 μl cDNA, 1 μl of TaqMan Gene 
Expression Assay Mix (20X), 10 μl TaqMan Universal PCR Master Mix with UNG 
(2X) and 4 μl of nuclease-free water. The master mix and cDNA for each sample 
were calculated to be sufficient for dispensing into three wells of a 96 well plate. All 
the components of the reaction mix were dispensed to 1.5 ml micro-centrifuge tube 
except cDNA. This tube was centrifuged for short duration to mix the components 
and stored on ice. RNase-free water was used as a negative control. The location 
of each sample was marked in the qPCR experiment planning sheet corresponding 
to a 96 well plate (MicroAmp Fast Optical 96-Well Reaction Plate). 16 μl/well of 
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master mix for the target gene and 15 μl/well of master mix for the housekeeping 
gene was dispensed in a 96 well plate. The cDNA was dispensed to the wells and 
the plate was sealed with adhesive film (MicroAmp Optical Adhesive Film). The 
plate was centrifuged to settle its contents. 
 
2.3.16.2 Program setup 
The plate was inserted into the Applied Biosystem ViiA 7 Real-Time PCR System 
by activating the eject button in its touch screen panel. The ViiA 7 Software was 
programmed to run the cycle: the Fast 96 well Block (0.1ml) plate was selected 
from the block type menu; Comparative CT (delta delta CT) was selected from the 
experiment menu; TaqMan Reagents was selected from reagent menu; Standard 
was selected from ramp speed menu. The targets (β-gal + IDO1), control (β-gal), 
housekeeping (GAPDH) and negative control (RNAase free water) were defined in 
the PCR machine software with FAM as reporter and NFQ-MGB as a quencher. 
The names of samples were fed to the sample column. The wells were selected 
and sample names were assigned to them, following the experiment planning 
sheet. The settings for the PCR reaction were obtained from the TaqMan Universal 
PCR Master Mix with UNG (2X) data-sheet and were described in Table 2.3.16.2.1: 
 
Table 2.3.16.2.1 Description of a qPCR program for qPCR thermocycler. 
System UNG 
incubation 
Polymerase 
activation 
PCR 
Cycles (40 cycles) 
Hold Hold Denature Anneal/ 
extend 
Temperature (°C) 50 95 95 60 
Time (mm:ss) 2:00 10:00 00:15 1:00 
Reaction volume 20 μl 
 
The settings were saved in the folder and the run was initiated.  
 
2.3.16.3 Analysis of results 
After the completion of the run, the data was saved by PCR software to the analysis 
file. The threshold value of the set was changed to 0.2 to remove multiple threshold 
lines. The data was exported to Excel sheets and saved as three tabs: sample set, 
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amplification data and results. The data from the results tab was copied to a new 
file, it had CT values of target and control genes as well as the negative control 
values. Individual samples were analysed in triplicate in the qPCR plate, so they 
had triple values that were traced by their respective name. The columns were 
marked with sample name, CT values of the gene of interest, of the housekeeping 
gene, delta CT values, delta delta CT values and 2^-(delta delta CT). The delta CT 
values were calculated by subtracting the CT value of the gene of interest with CT 
value of the housekeeping gene of a given sample. The average of delta CT values 
of the control group was obtained. The delta delta CT values were calculated by 
subtracting the delta CT values of each sample with the obtained average value of 
the control group. The delta delta CT values were placed in the formula: =2^-(Delta 
Delta CT) using the formula function of Excel and the obtained values were placed 
in the marked column. These values were copied to Minitab 17 software to perform 
statistical analyses. 
 
2.3.16.4 qPCR setup using SYBR Green dye 
All the steps were exactly same as described in TaqMan Gene Expression Assay 
setup except the PCR program using PrecisionPLUS 2x qPCR MasterMix, 10 pM 
of primers and set up in the machine, that is described in Table 2.3.16.4.1: 
 
Table 2.3.16.4.1 Description of a qPCR program for qPCR thermocycler 
using a Sybr green master mix. 
System Hold 
stage 
PCR stage Melting Curve stage 
Hold Denature Anneal/ 
extend 
Denature Anneal/ 
extend 
Temperature 
(°C) 
95 95 60 95 60 
Time (mm: 
ss) 
2:00 00:01 1:00 00:15 1:00 
Reaction 
volume 
20 μl  
 
2.3.17 Western blotting 
Western blotting was used to separate, identify and semi-quantitatively analyse the 
levels of the proteins of interest. The detailed procedure of preparing the protein 
sample, BCA estimation of protein concentration, SDS-PAGE, transfer of protein to 
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the membrane, incubation with the antibody (primary and secondary) and detection 
of bands were as follows: 
 
2.3.17.1 Sample preparation from TA muscle 
The TA (tibialis anterior) muscles were excised from the hind leg of mdx mice, 
transferred to pre-labelled 1.5 ml micro-centrifuge tubes and snap frozen in liquid 
nitrogen (-196°C). These were stored at -80°C. The frozen muscle samples were 
crushed using a chilled (dry ice) mortar and pestle. The powder was scoped into 
1.5 ml micro-centrifuge tubes. 200 μl of cOmplete Lysis-M buffer (Roche) 
[supplemented with cOmplete Protease Inhibitor Cocktail Tablets (Roche)] was 
dispensed to tubes. The tubes were incubated on ice for 30 min and vortexed to 
homogenise the suspension. The suspension was further homogenised by passing 
it three times through a 27G needle attached to a syringe (if the suspension blocked 
then 18G and 21G needles were used). The tubes were repeatedly vortexed to 
extract its content then stored on ice. The tubes were centrifuged at 16,200 xg 
(Eppendorf, 5415D) for 5 min at room temperature and the supernatant was 
transferred to a new 1.5 ml micro-centrifuge tube. The concentration of protein 
sample was measured using the BCA assay (Section 2.3.17.3). 
 
2.3.17.2 Sample preparation from cell lines 
The Human Embryonic Kidney 293 (HEK 293) cell line; SC5 (dystrophic myoblasts) 
and IMO (wild-type myoblasts) were harvested (described in Section 2.4.1) to 
obtain a pellet in separate 1.5 ml micro-centrifuge tubes. The pellet was re-
suspended in up to 1ml of 1XPBS (0.01M, pH=7.4). The tubes were centrifuged at 
300x g (Eppendorf 5415 D) for 5 min at room temperature. The pellet was recovered 
by gently discarding the supernatant with the help of a 1000 μl pipette. 200 μl of 
cOmplete Lysis Reagent (Roche) was dispensed to tubes. The tubes were 
incubated on ice for 30 min and vortexed to homogenise the suspension. The 
suspension was further homogenised by passing it three times through a 27G 
needle attached to a syringe (if it blocked then 18G and 21G needles were used). 
The tubes were repeatedly vortexed every 5 min to extract its content then stored 
on ice. The tubes were centrifuged at 16,200 xg (Eppendorf, 5415D) for 5 min at 
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room temperature and the supernatant was transferred to a new 1.5 ml micro-
centrifuge tube. The concentration of the protein sample was measured using the 
BCA assay. 
 
2.3.17.3 Protein estimation using the BCA Assay 
The concentration of protein in samples was analysed using the Bicinchoninic 
(BCA) Assay kit (Sigma-Aldrich). The assay required Bicinchoninic acid, copper 
sulphate solution, bovine serum albumin (BSA) (1 mg/ml) as a protein standard and 
a 96 well plate (Nunc). The Bicinchoninic acid assay (BCA) consisting of 
Bicinchoninic acid: copper (II) sulphate solution was mixed in a 50:1 ratio 
(10ml:200μl) and 190μl of this mixture were used to dispense in each well of the 
plate. The plate had marked columns with 1 to 12 numbers and marked rows with 
A to H. The top wells from column A to B and row 1 to 10 were used for making a 
standard curve by dispensing the BSA protein standard (1mg/ml) with 10-1serial 
dilution to obtain a final volume of 10 μl (adjusted with ddH2O).  
The last well had nuclease-free water as blank and rest of wells were allocated for 
dispensing the protein samples derived from muscle and cells. These were diluted 
half with ddH2O (final volume of 10 μl). The water was dispensed first to allocated 
wells for both the standard curve and protein samples. The BSA and protein 
samples were dispensed afterwards to their allocated wells.190 μl of BCA solution 
diluted with copper sulphate was dispensed to each well and the plate was 
incubated at 60°C for 15 min. The protein standard changed the colour from green 
to purple upon completion of the incubation based on the concentration of bovine 
serum albumin due to the formation of Cu2+ -protein complex under alkaline 
condition followed by reduction of the Cu2+ to Cu1+ .  The intensity of colour was 
analysed using a plate reader (optima by BMG-Labtech). The excitation wavelength 
was 544 nm and the emission wavelength was 540 nm. The values were plotted in 
Excel. The BSA values were averaged and subtracted from the blank. The values 
of protein samples were averaged and divided by the dilution factor. A two column 
table was made having BSA absorbance values and the amount of BSA, both 
columns were selected to plot a scatter-marked chart and a linear trend line was 
added to obtain the correlation coefficient. The option in trend line was selected to 
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show an intercept of zero, display equation on chart and display an R-squared value 
on chart. The R-square was the correlation coefficient. It was 0.98, close to the ideal 
value of 1. The value of the slope was recorded from the two-variable linear 
equation (y=mx+b, where x and y are variable, m was slope and b were intercept). 
The x-axis represented the protein concentration and the y-axis represented the 
optical density values. The protein concentration (x)= Optical density (y)/m in μg/μl, 
using this formula, the unknown concentrations of protein samples from 
muscles/cells were calculated. The volumes of protein samples were calculated to 
use 40 μg protein mixed with 2X Laemmli sample buffer (supplemented with β 
mercaptoethanol) in 1:1 ratio to obtain a final volume of 20-25 μl to load onto the 
SDS-PAGE gel. The 2X Laemmli sample buffer (supplemented with β 
mercaptoethanol) was dispensed into pre-labelled PCR tubes. The protein samples 
were dispensed into tubes and centrifuged at 16,200 xg (Eppendorf, 5415D) for 10 
at room temperature. The tubes were incubated at 95°C for 5 min to denature the 
protein samples in a thermocycler and stored on ice for loading onto SDS-PAGE 
gels. 
A diagnostic test was performed to check the variability of protein concentration 
when samples were diluted in water vs lysis buffer (Complete-M lysis buffer by 
Roche). The standard graph was made using respective diluents. The standard 
graph for water had an R-squared value of 0.99284, blank reading of 0.225 and 
protein concentration of 4.351 μg/ml while standard graph for lysis buffer had an R-
squared value of 0.98455, blank reading of 0.219. and protein concentration of 
4.336 μg/ml. The difference of protein concentration was 0.34% that was not 
significantly higher to confirm the use of water as inappropriate for the purpose of 
dilution. Also, taking in the account that R-squared values were different, this 0.34% 
would be much less if both the standard curve had same R-squared values.  
 
2.3.17.4 SDS-PAGE 
Sodium dodecyl sulphate, polyacrylamide gel electrophoresis (SDS-PAGE) was 
used to separate protein samples following discontinued Laemmli buffer system. It 
involves two gels, the top gel was a stacking and bottom was the resolving gel. 
The composition of the gels was as follows (Table 2.3.17.4): 
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Table 2.3.17.4 Description of the SDS-PAGE Gel composition. 
PAGE DDH20 30% Bis 
Acrylamide 
Gel buffer 10% SDS Total 
Resolving 
6% gel 
5.4 ml 2 ml 2.5 ml (1.5 M) 100 μl 10 ml 
Stacking 
4% Gel 
3.05 ml 650 μl 1.25 ml (0.5 M) 50 μl 5 ml 
 
The components of the resolving and stacking gels were added to respective 50 ml 
Falcon tubes and kept at room temperature. The gel cast was assembled using 
glass plates. The glass plates (1 mm spacer plate and short plate) were cleaned 
with soap, dried, wiped with 100% ethanol and secured in the gel-casting frame by 
aligning them evenly. The casting frame was secured in the casting stand and 
ddH20 was dispensed to check for any leak (if any indication of leakage then the 
gel casting frame was removed, glass plates were re-aligned and reassembled in 
the casting frame). The ddH20 was removed with the help of blotting paper. 50 μl 
of 10% ammonium persulphate (APS) was dispensed to the resolving gel and 25 
μl of 10% APS was dispensed to stacking gel. It was mixed by gently swirling. 10 
μl of TEMED was dispensed to the resolving gel, swirled gently to mix and poured 
into the gel cast. The ddH20 was dispensed into the top space to prevent 
evaporation and the assembly was kept at room temperature for 2 h. The ddH20 
was removed using blotting paper. 10 μl of TEMED was dispensed to the stacking 
gel, swirled gently to mix and poured into the gel cast. A 1 mm comb was inserted 
into the stacking gel and then kept at room temperature for 1 h. The gel plates were 
removed from the gel cast frame, combs were removed gently under a stream of 
water and the gel plates were secured to the electrode assembly. The electrode 
assembly was placed into the electrophoretic mini tank (BioRad) and filled with 1X 
electrode buffer. The denatured protein samples were loaded into the wells. The 
first and last wells were loaded with pre-stain protein ladder (Bio-Rad) and with the 
relevant positive control. The rest of the wells were loaded with protein samples. A 
constant voltage of 80V was applied until the blue dye front reached the bottom of 
the gel. The electrode buffer was discarded from the tank and the electrode 
assembly was opened to take the gel plates out. The gel plates were washed with 
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water and separated. The stacking gel was cut and removed and the resolving gel 
was transferred to a cold 1X transfer buffer in a tray. 
 
2.3.17.5 Transfer setup 
This step involves the transfer of the resolved proteins from the SDS-PAGE gel to 
a PVDF membrane. The resolving gel was transferred to 1X transfer buffer 
(supplemented with 20% methanol) in a tray and incubated for 8-10 min. The PVDF 
membranes were activated by dipping them in 100% methanol for 10 min and 
transferred into 1X transfer buffer. The sponges and filter papers were also 
transferred to the 1X transfer buffer tray. The resolving gel was placed onto filter 
paper. The transfer cassette was opened and black side of the cassette was kept 
down in the tray. The sandwich was made by placing the black sponge in the 
bottom, then filter paper with the resolving gel (dye front towards the inside of the 
cassette), activated PVDF membrane was laid on the gel, then filter paper on top 
of the membrane followed by a sponge. This sandwich was placed in the cassette. 
The roller tool was used to remove air bubbles from between the resolving gel and 
the PVDF membrane and then from between the whole assembly. The transfer 
cassette was closed and secured inside the Mini Trans-blot transfer unit (BioRad). 
An ice pack was placed inside the unit and it was filled with 1X transfer buffer. The 
magnetic stirrer was placed in the unit and it was connected to the power pack. A 
constant voltage of 40V was applied for 16-18 h at 4°C for optimum transfer. The 
cassettes were gently removed from the unit, opened to take the PVDF membrane 
out by cutting the edges that were not in contact with the resolving gel with the help 
of a scalpel. The PVDF membrane was separated from the gel, marked with a cut 
of a triangle mark on the left-hand side corner to remember the contact surface of 
the membrane with the gel and transferred to a tray filled with 1XTBST. The PVDF 
membrane was washed using 1XTBST three times for 10 min at room temperature 
on a shaking platform. The resolving gel from the transfer cassette was washed 
with distilled water and transferred to a staining tray. Coomassie Brilliant Blue dye 
was dispensed into the tray and the gel incubated for 5 min at room temperature. 
The resolving gel was destained by washing with distilled water for 16 h on a 
shaking platform. The blue bands were observed in the resolving gel and the image 
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was captured using Gel doc EZ (Bio-Rad). The intensity of the bands corresponds 
to the transfer efficiency of protein from resolving gel to the PVDF membrane. 
 
2.3.17.6 Antibody incubation 
The PVDF membrane was blocked with 5% skimmed milk powder dissolved in 1X 
TBST for 1 h on a shaking platform. The primary antibody was diluted as described 
in Table 2.3.17.6 in 2 ml 5% milk made in 1X TBST in a 40 ml glass tube and swirled 
to mix. The PVDF membrane was cut into strips by following the size of bands of 
the pre-stained protein ladder. The specificity of antibodies was analysed by 
matching the size of bands on the blot with the corresponding bands in the pre-
stained protein ladder and against the antibody’s data-sheet thus confirming the 
size of bands observed. Also, HEK293 cells were transfected with specific plasmid 
and after confirming the band size of protein this cell lysate was used as positive 
control.  Generally, the PVDF membrane was cut into two sets of strips, one 
corresponding to the target proteins (i.e. dystrophin, β-gal etc.) of higher molecular 
weights (427 KDa to 75 KDa range) and another strip corresponding to the 
housekeeping proteins (i.e. GAPDH, actin, tubulin etc.) of lower molecular weights 
(75 KDa to 10 KDa range). When the target protein (i.e. IDO1) was of low molecular 
weight then the whole PVDF membrane was incubated with antibody and no strips 
were made from it. These strips were inserted into the 40 ml glass tube having a 
primary antibody in 5% milk, the tubes were sealed and kept on a roller shaker for 
16 h incubation at 4°C. These strips were gently removed from the glass tube, 
transferred to an empty tray, half-filled with 1X TBST and washed three times, 10 
min each on a shaking platform. Strips were then incubated with a secondary 
antibody that was selected based on primary antibody and diluted in 5% skimmed 
milk powder dissolved in 1XTBST in 40 ml glass tube as mentioned in Table 
2.3.17.6. Strips were gently removed from the glass tube and washed three times, 
10 min each on a shaking platform. 
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Table 2.3.17.6 Description of antibodies used in Western blotting. 
Primary Antibody Secondary Antibody 
Anti-Dystrophin MANDRA1 clone 
7A10, mouse IgG1 antibody 
(DSHB), 1:50 dilution. 
Anti-Mouse IgG (whole molecule)-
Peroxidase antibody produced in 
goat (Sigma, A4416), 1:5000 
dilution 
Anti-β Gal, polyclonal rabbit 
antibody (Thermo Fisher Scientific, 
A11132), 1:500 dilution 
Anti-Rabbit IgG (whole molecule)- 
Peroxidase antibody produced in 
goat (Sigma, A0545), 1:5000 
dilution 
Anti-IDO1 clone 10.1, mouse 
monoclonal IgG antibody (Millipore, 
05-840), 1:500 dilution 
Anti-Mouse IgG (whole molecule)-
Peroxidase antibody produced in 
goat (Sigma, A4416), 1:5000 
dilution 
Anti-TDO, mouse polyclonal 
antibody (Abnova, H00006999-
B01P), 
Anti-Mouse IgG (whole molecule)-
Peroxidase antibody produced in 
goat (Sigma, A4416), 1:5000 
dilution 
Anti-FoxO3a (75D8), rabbit 
monoclonal antibody (Cell Signalling 
Technology, 2397), 1:500 dilution 
Anti-Rabbit IgG (whole molecule)- 
Peroxidase antibody produced in 
goat (Sigma, A0545), 1:5000 
dilution 
Anti-Actin, polyclonal rabbit antibody 
(Sigma,A2066), 1:500 dilution 
Anti-Rabbit IgG (whole molecule)- 
Peroxidase antibody produced in 
goat (Sigma, A0545), 1:5000 
dilution 
Anti-GAPDH, polyclonal rabbit 
antibody (Sigma, G9545), 1:500 
dilution 
Anti-Rabbit IgG (whole molecule)- 
Peroxidase antibody produced in 
goat (Sigma, A0545), 1:5000 
dilution 
Anti-GAPDH (V-18), goat polyclonal 
IgG (Santa Cruz Biotech, sc-20357), 
1:500 dilution 
Donkey Anti-Goat IgG (H+L) HRP 
(Promega, V8051), 1:5000 dilution 
Anti-β Tubulin, polyclonal rabbit 
antibody (Novus, NB100-56459/ 
Imgenex-IMG 5810A) 1:500 dilution 
Anti-Rabbit IgG (whole molecule)- 
Peroxidase antibody produced in 
goat (Sigma, A0545), 1:5000 
dilution 
 
2.3.17.7 Imaging and quantification of bands 
The Luminata Forte Western HRP substrate (Millipore) was used for 
chemiluminescent detection of protein bands on PVDF membrane strips. The 
substrate was added to the PVDF membrane strips to cover it, incubated for 3 min 
for target proteins (i.e. mini-dystrophin, β-gal, IDO1 etc.) and for 10 s for 
housekeeping proteins (i.e. GAPDH, actin, tubulin etc.). Strips were aligned to the 
	 84	
plastic tray and transferred to chemiluminescent gel doc machine (G-Box by 
Syngene). The Chemi-16X program was selected from the software, the white light 
was selected from the light option menu and an image of the membrane was 
captured at 10 msec scales. The light option was changed to no light, 15 images at 
every 2 min were captured for target proteins and 5 images at every 2 min for 
housekeeping proteins were captured. The multiple images provide the time scale 
to check the range of exposure of light for band intensities from low to medium to 
burnout (hollow bands indicates out of linear range and must be avoided). These 
analyses were used to calculate the optimum timescale to get the linear sensitive 
range to avoid overexposure. Once the optimum time was confirmed, it was applied 
to all Western blots. The images were inverted and exported in JEPG format. 
The open source Fiji software (compiled Image J) was used to quantify the band 
intensity of target and housekeeping proteins with the help of web tutorial 
(http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-with-
image-j/). This could also be done using software provided with the imaging 
machine (http://www.syngene.com/assets/doc/Technical-notes/Expression-
standards-57.pdf) but we used Fiji software as it is widely used by the scientific 
community for the quantification of Western blots. 
The image was opened in Fiji software. A rectangular box was drawn (overlay) 
around the first band on the left side of the image using the rectangular selection 
tool. The number 1 was given to this box. Then this rectangular box (overlay) was 
moved towards the right and aligned to the next band. The number 2 was given to 
this band. Similarly, this rectangular box (overlay) was moved to next band and 
number 2 was pressed, Fiji numbered the next band as 3 automatically. In this way, 
all the bands were marked. The number 3 was pressed to obtain the histogram (bell 
chart of the area covered). The straight-line tool was used to connect the troughs 
of the bell curve of the histogram to define the area of peaks of bands. In some 
samples bands were absent but they had the background. This background reading 
was obtained from these samples with the very small peak with very less area, this 
area of the peak was subtracted from the area of the bell curve of samples having 
bands to obtain the actual area of bands. The wand (tracing) tool was selected from 
the menu bar and inner area of bell curve was selected that represent the total area 
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of the band, it opened a new window with area and percentage values. These 
arbitrary values were copied to an Excel sheet and saved. The percentage values 
of the target protein and housekeeping protein were used.  
Relative densities of target protein were analysed by selecting an internal control 
(percentage value of optimum band in target protein) and dividing its percentage 
value with other samples of the target protein. Similarly, the relative densities of 
housekeeping protein were analysed.  
Adjusted densities were analysed by dividing relative densities of the target protein 
by relative densities of housekeeping protein.  
These adjusted densities of target protein were used for statistical analyses.   The 
statistic software, Minitab 17 was used to analyses significance using Student’s t-
test for two separate groups of samples and ANOVA for three or more sets of 
samples. 
 
2.4 Tissue culture 
Cell culture was used to test the expression of plasmid DNA in vitro. Human 
embryonic kidney (HEK293) cells were used primarily to check the plasmid DNA 
expression by transient transfection. The protein expression was confirmed by 
Western blotting and compared to pre-stained protein standards (Biorad). The 
expressed protein was stored and later used as positive control to compare against 
the band size of proteins isolated following expression in vivo. The muscle-specific 
cell lines: dystrophic myoblasts (SC5) and wild-type myoblasts (IMO) were used to 
check the muscle-specific expression of plasmid DNA. The neomycin analogue 
G418 was used to select the myoblasts for stable expression of plasmid DNA. 
 
2.4.1 Counting of cells 
T75 flasks with cells at about 80% confluence were used. The media was removed 
from the flask, warm 2 ml 1XPBS (0.01M, pH=7.4) was added and the flask was 
gently tilted on either side to give a quick wash. The 1XPBS was removed and 2 ml 
of modified trypsin solution (Tryple Express by Gibco) was dispensed to cover the 
cells and incubated at 37°C for a 15 min to detached them from the flask. The cells 
were observed under an inverted microscope (Zeiss Axiovert 40 C) to check the 
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efficiency of the treatment. 4 ml media was dispensed to the flask to stop the Tryple 
Express activity. The cell suspension was then transferred to 15 ml Falcon tube and 
centrifuged at 400 X g (Eppendorf 5416) for 5 min at room temperature. The pellet 
was recovered by gently discarding the supernatant. 1 ml of fresh media was added 
to cell pellet and cells were gently re-suspended in it. 10 μl of cell suspension was 
dispensed into a 1.5 ml microcentrifuge tube, 90 μl of Trypan blue dye was added 
and gently mixed. 10 μl suspension from this tube was added to haemocytometer 
from the edges. The suspension was allowed to fill the four big squares and the 
cells in these were counted under the light microscope. The cells with blue coloured 
cytoplasm had leaky plasma membranes that confirmed them as dead cells. These 
cells were excluded from counting. The number of cells counted in four big squares 
was used in the formula [Mean of cells x 104 x10 (dilution factor) = No. of cells/ ml] 
to calculate the number of cells in the given sample. 
 
2.4.2 Culture of HEK 293 and RAW 264.7 cells 
The human embryonic kidney cell line (HEK 293) and RAW 264.7 (macrophage-
like, Abelson leukaemia virus-transformed cell line derived from BALB/c mice) had 
the feature of being semi-adherent and fast growing. The RAW 264.7 cell line was 
cultured exactly as HEK293. The cryovial containing the HEK 293 cells was thawed 
to room temperature. 16 ml of HEK 293 cell media (Table 2.4.2.1) was dispensed 
into a T75 flask and the cells were gently added to it from the cryovial. The cells 
were grown at 37°C in a humidified carbon dioxide incubator (5% CO2 with 95% air) 
for 24 h. The media was discarded to remove the DMSO that was used during 
cryopreservation of the cells. The cells were gently washed with 1XPBS and fresh 
media was added to the flask. The cells were grown to approximately 80-90% 
confluence level and then passaged/split (i.e. lifting the cells from the vessel and 
re-plating in less amount to keep them in exponential phase) to allow their transfer 
into 35 mm dishes for transfection.  
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Table 2.4.2.1 The composition of HEK 293 and RAW 264.7 cell’s media. 
Fetal Bovine Serum (10%) 50 ml in 500 ml. 
Penicillin/Streptomycin 5 ml in 500 ml. 
DMEM media To make the volume up to 500 ml. 
L-Glutamine 5 ml in 500 ml. 
Temperature 37°C 
 
2.4.3 Culture of myoblasts  
The dystrophic (SC5) and wild type (IMO) myoblasts were used to study the 
expression of plasmid DNA intended for muscle specific expression (e.g. 
PX61MCK.mini-dyst.Fwd). The cell culture method was same as described in 
Section 2.4.2, but the difference was in the media composition and the temperature 
of cell culture (Table 2.4.3.1 and 2.4.3.2). The differentiation media was used to 
induce myoblast cells to form myotubes to check the expression of PX61MCK.mini-
dystrophin.Fwd plasmid that expressed only in differentiated myotubes. 
 
Table 2.4.3.1 The composition of SC5 and IMO myoblasts media. 
Fetal Bovine Serum (20%) 100 ml in 500 ml. 
Interferon gamma (20Unit/ml) 10 μl in 500 ml. 
Penicillin/Streptomycin 5 ml in 500 ml. 
Knockout DMEM media To make the volume up to 500 ml. 
L-Glutamine 5 ml in 500 ml. 
Temperature 33°C 
 
Table 2.4.3.2 The composition of SC5 and IMO myoblasts differentiation 
media. 
Horse Serum (5%) 10 ml in 500 ml. 
Penicillin/Streptomycin 5 ml in 500 ml. 
Knockout DMEM media To make the volume up to 500 ml 
L-Glutamine 5 ml in 500 ml. 
Temperature 37°C 
 
2.4.4 Transfection of cells  
Transiently transfected (plasmid present in the cytoplasm as autonomously 
replicating episomes) and stably transfected (integration of plasmid in the nucleus 
by homologous recombination) cell lines were developed using the various 
chemical transfection reagents (Table 2.4.4).  
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In transient transfection, cell lines were grown in T75 flasks to about the 80-90% 
confluence level, modified trypsin solution (Tryple Express by Gibco®) was used to 
detach cells from the flask as described in Section 2.4.1 and cells with media were 
transferred to 35 mm dishes (each dish had capacity of 2 ml media) to let the cells 
grow in the new vessel for plasmid DNA transfection. When cells reached the 80-
90% confluence level the transfection protocol was followed as described in Table 
2.4.4. The cells with transfection reagent were incubated for 24 h. The media was 
discarded and cells were washed gently with warm 1XPBS and fresh media was 
added to support their growth up to about the 90% confluence level. These cells 
were processed for protein extraction (described in Section 2.3.17.2) and RNA 
extraction (as described in Section 2.3.14.3).  
Stable transfection had similar steps to that of transient transfection, but the last 
step was different as cells were subjected to selection by addition of G418 
(neomycin analogue) to culture media. Those cells that had plasmid DNA with the 
neomycin resistance gene could metabolise the G418 and survive while other cells 
died. The cells were grown in 35 mm dishes, culture media with G418 (1.25 mg/ml 
final concentration) was dispensed and media was changed every third day for a 
period of 1 month to obtain about 90% confluence level of stably transfected cells. 
These cells were then transferred to T75 flasks to use for protein/RNA extraction 
and for cryo-preservation. 
The endotoxin-free plasmid DNA was prepared for transfection as described in 
Section 2.3.2. Various transfection reagents were used to enable successful 
transfection primarily in hard-to-transfect myoblast cells.  
Initially, the transfection efficiency was analysed by co-transfecting cells with the 
target plasmid (e.g. mini-dystrophin, β-gal etc.) mixed with eGFP expressing 
plasmid (pEGFP-C1) as described in section 2.4.6 and shown in Figure 4.2.2. The 
percentage of GFP-positive cells was used as transfection efficiency.  
In subsequent experiments when the selection was used, the transfection efficiency 
was calculated based on the percentage of cells that survived the G418 exposure. 
These efficiencies were same for all plasmids used in the project.  
 The working solutions used and their observed transfection rates are described in 
Table 2.4.4.  
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Table 2.4.4 Description of the working solutions of various transfection 
reagents.   
Vessel 
size 
Cell 
Conditions 
Transfection 
Reagent 
Incubation 
temperature 
(Observed 
transfection rate 
in cell lines) 
35 mm dish Freshly 
added 2 ml 
media to 
about 80% 
confluent 
cells 
2.5 μg plasmid 
DNA + 125 μl 
buffer + 7.5 μl 
HappyFect 
(Tecrea) 
20 min incubation at 
room temperature 
and then dispensed 
over the cells, mixed 
gently by swirling 
the dish. (about 
80% in HEK293; 
about 20% in 
myoblasts) 
35 mm dish Freshly 
added 2 ml 
media to 
about 80% 
confluent 
cells 
2 μg DNA + 8 μl 
GeneCellin 
(BioCellChallenge) 
+ 200 μl DMEM 
15 min incubation at 
37°C and then 
dispensed over the 
cells, mixed gently 
by swirling the dish. 
(about 80% in 
HEK293; about 
20% in myoblasts) 
35 mm dish Freshly 
added 2 ml 
media to 
about 80% 
confluent 
cells 
3 μg DNA + 6 μl 
Plus Reagent + 18 
μl Lipofectamine 
2000 LTX 
(ThermoFisher 
Scientific) + 300 μl 
DMEM 
15 min incubation at 
37°C and then 
dispensed over the 
cells, mixed gently 
by swirling the dish. 
(about 80% in 
HEK293; about 
20% in myoblasts) 
35 mm dish Freshly 
added 2 ml 
media to 
about 80% 
confluent 
cells 
2 μg DNA + 8 μl 
FuGene HD 
(Promega) + 200 
μl DMEM 
15 min incubation at 
37°C and then 
dispensed over the 
cells, mixed gently 
by swirling the dish. 
(about 80% in 
HEK293; about 
50% in myoblasts) 
35 mm dish Freshly 
added 2 ml 
media to 
about 80% 
confluent 
cells 
Two solutions 
were prepared: 
(i)-3.75 μl and 7.5 
μl Lipofectamine 
3000 
(ThermoFisher 
Scientific) was 
dispensed 
5 min incubation at 
37°C and then 
dispensed over the 
cells, mixed gently 
by swirling the dish. 
(about 80% in 
HEK293; about 
50% in myoblasts) 
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respectively in 125 
μl DMEM 
containing two 
tubes. 
(ii)-5 μg plasmid 
DNA was 
dispensed into 250 
μl of DMEM in two 
separate tubes 
and 10 μl of P3000 
reagent was 
added to them. 
The 125 μl of 
solution ii was 
added to tubes of 
solution I and 
incubated. 
Vessel 
size 
Cell 
Conditions 
Transfection 
Reagent 
Incubation 
temperature 
(Observed 
transfection rate 
in cell lines) 
35 mm dish Freshly 
added 2 ml 
media to 
about 80% 
confluent 
cells 
Two solutions 
were prepared: 
(i)-The plasmid 
DNA was diluted in 
100 μl buffer E to 
obtain 18 ng/μl in 
four separate 
tubes to obtain a 
total of 400 μl.  
(ii)-5 μl of viromer  
red (lipocalyx) 
solution was 
dispensed into 1.5 
ml tube and 120 μl 
buffer E was 
added to it and 
mixed by repeated 
pipetting. 
The 60 μl of 
solution ii were 
mixed with 340 μl 
of solution i.  
200 μl of this 
suspension was 
added to cells.  
15 min incubation at 
room temperature 
and dispensed over 
the cells, mixed 
gently by swirling 
the dish. (about 
80% in HEK293; 
about 20% in 
myoblasts) 
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2.4.5 Cryopreservation of cells 
The cell pellet was obtained as described in Section 2.4.1. The pellet was re-
suspended in 1 ml cryopreservation solution consisting of 10% DMSO in fetal calf 
serum. This suspension was transferred to sterile cryovials and stored at -80°C. 
The cryovials were transferred to a Dewar filled with liquid nitrogen for cryogenic 
storage. 
 
2.4.6 Confocal microscopy 
The SC5 myoblasts were transfected in multiple 35 mm dishes with pcDNA3.mini-
dyst.Fwd (9.8 kb) and pEGFP-C1 (4.7 kb) (enhanced green fluorescent protein-
EGFP) mixed at 6:1 ratio using GeneCellin, Lipofectamine and FuGENE HD. The 
cells were incubated with transfection reagent for 24 h and then fresh media was 
added after washing with 1XPBS. The cells were selected in G418 (described 
earlier in Section 2.4.4) and were incubated to an 80% confluence level. Earlier live-
cell imaging was used to detect the EGFP signal but it was very low and dispersed 
in media. So the Zeiss LSM 510 META confocal microscope was used to capture 
the EGFP signal that had excitation at 489 nm and emission at 509 nm.  
The parameters for the microscope to capture images were as follows (Table 
2.4.6.1): 
Table 2.4.6.1 Parameters of Zeiss LSM 510 META Confocal microscope. 
Control Panel  Settings used  
Argon laser, output 25%, green 
reflector, 40X objective 
450, 477,488, 514 nm 
Configuration control channel mode and single track 
Scan control Ch2 with pinhole of 260, detector gain 
874, amplifier offset 0.011, amplifier 
gain 1.5 
Scan control  frame, Achroplan 40x/0.8W, the frame 
size of 512 x 512, the scan speed of 8, 
pixel time 2.51 microsecond, the scan 
time of 1.57 s, data depth 8 bit, one 
direction scan 
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Control Panel  Settings used  
Mode frame 
Method Mean single number in number menu, 
single zoom in zoom menu and no 
rotation in rotation menu 
 
The dipping objective was used so that it can be inserted into the 1XPBS or media 
containing dish. The dish was kept on a heating stage to maintain the temperature. 
The cells were first analysed under an inverted microscope to confirm the 
confluence level. The media was removed and warm 1XPBS was added to the dish. 
The dish was transferred to the heating stage, the antireflective shield was used to 
prevent the reflection of the laser to eyes and image was captured. The protein was 
extracted from the cells for Western blotting (described in Section 2.3.17.2).  
 
2.5 Histology and immunohistochemical analyses 
2.5.1 Cryosectioning of tibialis anterior (TA) muscles 
The TA (tibialis anterior) muscles were used in this study, as it is the most active 
muscle of lower leg (266) with increased susceptibility to contraction-induced 
injuries (267). It has a high degree of resistance to fatigue during strenuous 
exercises (268). It is also easily accessible for injection and therefore was used in 
previous gene therapy studies (269-277). Proteomics confirmed the altered levels 
of 8 distinct proteins that could be used as a biomarker specific for TA (278). In 
myotonic dystrophy type 1 patients, TA muscle was shown to be sampled for 
histopathological and biomolecular evaluations using needle biopsy technique 
confirming its suitability for clinical trials (279). Furthermore, Sacco et al (280) 
compared the features of TA muscle of same aged mdx mice vs C57BL10 mice 
and confirmed that both muscles had the same rate of recovery of force after the 
exercise-induced loss of force.  
 
TA muscles were excised whole (tendon to tendon) and placed on aluminium foil 
cooled on ice. 100 ml plastic beaker was half filled with iso-pentane and chilled in 
liquid nitrogen until the ice crystals of iso-pentane formed in the solution. The 
	 93	
beaker was transferred to a small polystyrene box with liquid nitrogen. The TA 
muscles were picked from the distal tendon side and attached to a pre-labelled cork 
having a drop of embedding compound solution (CRYO-M-BED). The tissue with 
cork was immersed in the chilled isopentane solution for 2 min. These sections 
were then transferred to chilled pre-labelled 50 ml Falcon tubes and stored in a -
80°C freezer. The corks having muscle were transferred to a cryostat (LEICA CM 
3050S). The cork was attached to the specimen disk with the help of the embedding 
compound solution (CRYO-M-BED) and placed inside the chamber of the cryostat 
for 30 min to reach the -20°C temperature of the chamber. The specimen disk was 
fixed in the 90° Prism and secured by the lever. The knife was attached to its holder 
and secured by the lever. The sections were cut at 6-12 μ thickness. The individual 
sections had a polyanionic charge and were adsorbed to polycationic charged poly-
lysine glass slides (281). The sections were arranged into two-three rows 
depending on the size with each row having about six-ten sections.  These slides 
were air-dried overnight at room temperature and then stored at -80°C. 
 
2.5.2 Tissue staining 
2.5.2.1 Haematoxylin and Eosin staining 
The glass slides were air dried at room temperature for 30 min. The muscle sections 
were circled with a PAP pen. The sections were fixed using 4% paraformaldehyde 
(PFA) made in 1XPBS for 15 min on ice.  
The 4% paraformaldehyde was made by mixing it in 1XPBS at 50°C with constant 
mixing for 1 h in the chemical hood and then pH=7 was adjusted by addition of 1N 
NaOH. The solution was cooled to room temperature, aliquoted into 1.5 ml 
microcentrifuge tubes and stored at -20°C. 
4% PFA had decanted following the fixation onto tissue paper and disposed of in a 
biohazard bag. The slides were washed with 1XPBS for 3x 5 min on ice. 
Haematoxylin stain (Vector labs) was added to cover the muscle sections and 
incubated for 1 min at room temperature. The stain was decanted onto tissue paper 
and washed with alkaline tap water or 0.1M sodium hydroxide solution (pH=8). The 
Eosin stain (Sigma) was added to cover the sections and incubated for 1 min at 
room temperature. The stain was decanted to tissue paper and the slides were 
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washed with alkaline water. Permanent slides were made by treating them in 
increasing gradients of ethanol (70% ethanol >90% ethanol >95% ethanol >100% 
ethanol) to dehydrate for a min and finally in xylene for a min. The coverslip was 
mounted using DPX and slides were dried overnight at room temperature. 
 
2.5.2.2 DAB staining 
The ImmPACT DAB Peroxidase (HRP) substrate (VECTOR Laboratories) was 
used for immunohistochemical detection of antigens and chromogen had a brown 
colour. It was used for the detection of dystrophin in muscle sections and IDO1 in 
dystrophic myoblasts (SC5). 
The frozen (-80°C) poly-lysine coated glass slides with muscle sections were 
incubated at room temperature for 30 min to dry. The sections were circled with a 
PAP pen dividing them into two separate compartments, one acting as the positive 
and the other as negative. The positive compartment intended to be incubated with 
primary antibody and negative compartment intended to be incubated with serum 
only, as a negative control. The sections in both compartments were fixed using 4% 
PFA made in 1XPBS for 15 min on ice. 4% PFA was decanted following the fixation 
onto tissue paper and disposed of in biohazard bag. The slides were washed with 
1XPBS for 3x 5 min on ice. The endogenous peroxidases were quenched with 1% 
H202 made in 1XPBS for 30 min on ice. 1% H202 was discarded onto tissue paper 
and slides were washed with 1XPBS for 3X 5 min. The tissue sections were blocked 
using 5% horse serum (based on the animal used to raise secondary antibody) 
made in 1XPBS for 30 min on ice to prevent non-specific binding. The 5% horse 
serum was discarded from the positive compartment marked for primary antibody 
incubation, while the negative compartment was continuously incubated with 5% 
horse serum to act as a negative control. The primary antibody was added as 
described below (next page):  
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2.5.2.2.1 Detection of dystrophin in muscle sections 
The positive compartment was washed for 3x 5 min with 1XPBS. The primary 
antibody against dystrophin (2166) was diluted 1:500 in 5% horse serum made in 
1XPBS and added to the positive compartment of slides for 16-18 h incubation at 
4°C in a humid box. The slides were washed, including both compartments, with 
1xPBS for 3x 5 min on ice and incubated for 30 min with Anti-Rabbit IgG 
ImmPRESS reagent (VECTOR Laboratories) on the ice. The slides were washed 
with 1XPBS for 3x 5 min. 1 drop of ImmPACT DAB chromogen concentrate was 
added to 1 ml ImmPACT diluent solution and mixed by inverting the tubes. This 
DAB suspension was added to the sections and incubated for 2 to 5 min at room 
temperature. The slides were washed with 1XPBS for 3x 5 min, rinsed with alkaline 
tap water or 0.1M sodium hydroxide solution (pH=8) to stain with haematoxylin-
eosin and permanent slides were made, as described in Section 2.5.2.1. The image 
was captured using a light microscope.  
 
2.5.2.2.2 Detection of IDO1 in dystrophic myoblasts 
The dystrophic myoblasts (SC5) were stably transfected with pcDNA3.IDO1 
plasmid using two transfection reagents, Lipofectamine 3000 (ThermoFisher 
Scientific) and Genecillin (Biocellchallenge) by following the steps described in 
Section 2.4.4. These cells were cultured on square coverslips in 35 mm dishes to 
obtain 80-90% confluence level. The coverslips were gently detached from the 
surface of the dishes and the two coverslips were transferred to a glass slide. The 
PAP pen was used to mark the boundary around the coverslips. They were marked 
as positive (incubation with primary antibody) and negative (incubation with serum). 
The cells were fixed by using 4% PFA and the rest of steps described earlier in 
Section 2.5.2.2 and Section 2.5.2.2.1 was followed except the primary antibody 
used was anti-Indoleamine 2, 3-dioxygenase antibody clone 10.1(Merck Millipore) 
at a 1:500 dilution.  
DPX was added to coverslips and they were gently inverted after completion of the 
staining procedure with DAB, haematoxylin-eosin. The image was captured using 
an Ariol microscope (Leica).  
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2.5.2.3 VIP peroxidase staining 
The VIP peroxidase HRP kit (VECTOR Laboratories) was used for 
immunohistochemical detection of antigen in the tissue as an alternative to DAB 
staining. The chromogen had a purple colour.  The protocol was exactly the same 
as that for DAB staining (Section 2.5.2.2), with minor changes that are described 
below. The slides were fixed with 4% PFA made in 1XPBS for 15 min on ice and 
then washed with 1XTBST for 3X 10 min on ice. The slides were incubated in 1% 
H202 made in 1XTBST for 16 h at 4°C. The slides were then washed with 1XTBST 
for 3X 10 min on ice and blocked with 5% Goat serum made in 1XTBST for 30 min 
on ice. The slides were washed with 1XTBST for 3X 10 min on ice and incubated 
with primary antibody at a dilution described in Table 2.5.2.3.1. The primary 
antibody was added to the positive compartment, while 5% goat serum was added 
to the negative compartment and slides were kept in a moist chamber for 16 h at 
4°C.  The slides were washed with 1XTBST for 3X 10 min. The sections were 
incubated with anti-rat IgG ImmPRESS reagent (VECTOR Laboratories) diluted 
into 1XTBST in 1:1 ratio for 30 min on ice. The slides were washed with 1XTBST 
for 3X 10 min on ice. The VIP peroxidase HRP substrate (VECTOR Laboratories) 
was prepared by mixing 3 drops of reagent 1 with 3 drops of reagent 2 and 3 drops 
of hydrogen peroxide (30%) in 5 ml of 1XTBST. The substrate was added to the 
sections and incubated for 10 min at room temperature. The slides were 
counterstained with haematoxylin and permanent slides were made as described 
in Section 2.5.2.1. 
 
Table 2.5.2.3.1 Description of antibodies dilution used in the VIP staining 
Antibody Dilution 
Anti-mouse CD4 1:200 
Anti-mouse CD8A 1:200 
Anti-mouse CD68 1:200 
Anti-mouse CD34 1:200 
Anti-mouse P2X4 1:500 
Anti-mouse LY6G 1:200 
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2.5.2.4- X-gal staining 
The X-gal staining was used to detect the expression of β-gal in TA muscle injected 
with plasmid and the chromogen had a light blue colour. The DAB staining protocol 
(Section 2.5.2.2) was followed up by the fixation in 4% PFA. The fixed sections 
were washed with 1XPBS for 3X 10 min on ice and then transferred to a staining 
box filled with X-gal staining solution [500 μg/ml X-gal solution (Promega) + 5mM 
Potassium Ferricyanide (III) (Sigma-Aldrich) + 5mM Potassium Hexacyano Ferrate 
(II) (Sigma-Aldrich) + 2mM Magnesium chloride.6H20 (Sigma-Aldrich) +0.02% 
Nonidet P40 (Calbiochem) in 1XPBS (0.01M, pH=7.5)] and incubated at 37°C for 3 
days to develop the desired blue colour intensity. The sections were washed with 
1XTBST for 3X 10 min and counterstained with haematoxylin and eosin as 
described in Section 2.5.2.1. 
When there was a requirement to check the co-localisation of immune markers 
along with β-gal expression in muscle fibres, the section from the X-gal staining 
solution were transferred to 1XTBST and stored at 4°C. The VIP HRP substrate 
protocol (described in Section 2.5.2.3) was followed to detect immune markers. 
The images of muscle fibres were captured with a light microscope (Zeiss 
Axiophot). The axio-vision software was used and settings of exposure time for 40X 
were 480ms; 1:30 Cyan; 1:25 Magenta; 0:44 Yellow. 
 
2.6 Intramuscular injection of mice 
The TA muscles of mdx mice (male and female), mdx-β geo (male and female), 
C57BL10 (male and female) were used for the intramuscular injection of plasmid 
(151, 208, 264, 282-284). All procedures were performed according to the 
approvals of the institutional Ethical Review Board and the UK Home Office. 
Injections were carried out by Prof. Gorecki, animal killing by the staff of animal 
house and dissection by the candidate. The calculations were made for the volume 
of injection as described in Section 2.6.1. After mixing the volumes of plasmid DNA 
with normal saline, the solutions were kept on the ice and thawed to room 
temperature 15 min before injecting. The mice were maintained under general 
anaesthesia by isoflurane + oxygen mix, it also acts as analgesia with properties to 
relaxes the muscle. The area of the TA muscles was shaved and sterilised with 
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70% ethanol and the plasmid DNA dissolved in normal saline was injected using 
disposable 0.5 ml tuberculin syringe with 27G needle (Becton Dickinson). It was 
attached to a plastic collar to maintain the depth of needle constant in the muscle. 
The plasmid DNA was administered slowly and aseptically in both TA muscles with 
a volume of 25 to 50 µl/muscle. 
The mice were transferred to a warm cage and monitored until they were fully 
awakened and moving normally. They were then transferred to a standard cage 
and monitored for 7 to 14 days as required for the experimental setup. All animals 
were killed using a schedule 1 method in accordance with the UK Home Office 
guidelines. The TA muscles and blood serum were then collected. 
 
2.6.1- Injection calculations 
The representative calculations for plasmid DNA at a volume of 25 µl/muscle were 
as follows (Table 2.6.1.1 and Table 2.6.1.2): 
 
Table 2.6.1.1 Calculations for single plasmid injection in 0.9% saline. 
β-gal only=0.5 µg/µl for 25 µl/muscle; 10+1 muscles. 
Plasmid Volume 1µl of pDNA= 5868.6 ng/µl. 
0.170 µl pDNA=1000 ng/µl. 
0.0851 µl pDNA=500 ng/µl. 
1 Muscle required 25 µl: 25 x 0.0851=2.1275 µl. 
11 Muscles required: 11 x 2.1275 µl=23.40 µl. 
Injection Volume 25 µl x 11= 275 µl 
Saline Volume 275 x 0.05 µl of 18% NaCl= 13.75 µl of 18% NaCl 
23.40 µl β-gal plasmid + 13.75 µl of 18% NaCl + 237.85 µl H2O 
 
Table 2.6.1.2 Calculation for two plasmid injection (co-injection) in 0.9% saline. 
β-gal + IDO1= 1 µg/µl for 25 µl/muscle (12.5 µl of β-gal + 12.5 µl of IDO1); 10+1 
muscles. 
β-gal;1 µg/µl for 12.5 µl/muscle. 
Plasmid Volume 1µl of pDNA= 5868.6 ng/µl. 
0.170 µl pDNA=1000 ng/µl. 
1 Muscle required 12.5 µl: 12.5 x 0.170=2.125 µl. 
11 Muscles required: 11 x 2.125 µl=23.375 µl. 
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Injection Volume 12.5 µl x 11= 137.5 µl. 
Saline Volume 137.5 x 0.05 µl of 18% NaCl= 6.875 µl of 18% NaCl 
23.375 µl β-gal plasmid + 6.875 µl of 18% NaCl + 107.25 µl H2O. 
IDO1; 1 µg/µl for 12.5 µl/muscle. 
Plasmid Volume 1µl of pDNA= 4408.4 ng/µl. 
0.227 µl pDNA=1000 ng/µl. 
1 Muscle required 12.5 µl: 12.5 x 0.227=2.84 µl. 
11 Muscles required: 11 x 2.84 µl=31.24 µl. 
Injection Volume 12.5 µl x 11= 137.5 µl. 
Saline Volume 137.5 x 0.05 µl of 18% NaCl= 6.875 µl of 18% NaCl 
31.24 µl IDO1 plasmid + 6.875 µl 18% NaCl + 99.385 µl H2O. 
 
2.6.2- Collection of TA muscles and blood 
The TA muscle for protein/RNA extraction and blood for serum separation were 
collected immediately upon animal sacrifice. Mice were killed by asphyxiation in a 
CO2 chamber and their death was confirmed by cervical dislocation. The blood was 
taken immediately by cardiac puncture using a syringe with 18G needle and 
collected into 1.5 ml micro-centrifuge tubes for coagulation to separate the serum. 
The TA muscle was excised carefully by removing the upper skin layer, the lower 
layer of subcutaneous tissue, separated from rest of the muscles, excised from 
tendon to tendon with the help of forceps and scissors. The muscle was transferred 
to pre-labelled 1.5 ml micro-centrifuge tubes. The tubes were transferred to liquid 
nitrogen contained in a cryogenic Dewar flask and later stored at -80°C for 
protein/RNA extraction by crushing with the help of pestle-mortar. 
 
2.7 ELISA  
ELISA was used to analyse the relative levels of anti-β gal antibody in serum from 
the mice injected either with β-gal plasmid only or co-injected β-gal and IDO1 
plasmids.  
The tubes with fresh blood samples were stored at 37°C for 1 h and then transferred 
to 4°C for 1 h to allow the clot to shrink to facilitate the separation of the serum. The 
serum was transferred to a new 1.5 ml micro-centrifuge tube without disturbing the 
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blood clot and centrifuged at 800 x g (Eppendorf 5415D) for 10 min at room 
temperature to remove residual cellular debris. The clear supernatant (serum) was 
transferred to a new 1.5 ml microcentrifuge tube and stored at -80°C. 
The assay was designed based on (265, 285). Briefly, 96 well flat bottoms Maxisorp 
plates (Nunc, 10547781) were coated with 100 µl/well of β-gal antigen protein 
(Roche, 10745731001), diluted to 10 µg/ml in bicarbonate buffer (pH=9.6) and 
incubated overnight at 4°C. The plates were washed with 3x200 µl/well of wash 
buffer [0.05% Tween 20 (Fisher Scientific, 10419000) in PBS (-Ca2+/Mg2+) (Fisher 
Scientific, 11540486). Each sample was measured in triplicate. The plates were 
incubated at room temperature for 1 hour with 200 µl/well of blocking buffer 
containing 2% Tween 20 in PBS (-Ca2+/Mg2+) and washed with the wash buffer. 
100 µl/well of mouse monoclonal anti-β Gal antibody (Sigma, G8021-0.2ML) of 
known concentration was used for the standard curve at a range of 156.25 to 
10,000 pg/ml and serum samples in triplicate were diluted by a factor of 1:5000 and 
incubated at room temperature for 2 hours. The standard, mdx mouse sera and 
anti-β Gal antibody were diluted respectively in 300 μl PBS (-Ca2+/Mg2+) with 2% 
v/v Tween 20 and 100 μl/well was used. The wells were washed with washing buffer 
and incubated at room temperature for 2 hours with 100 µl/well of goat anti-mouse 
HRP antibody (Sigma, A4416-1ML) diluted in PBS (-Ca2+/Mg2+) with 2% v/v Tween 
20 to 200 ng/ml. The wells were washed with washing buffer and incubated at room 
temperature for approximately 10 min with 100 µl/well of TMB substrate (BD 
Biosciences, 555214). The reaction was stopped before colour saturation of the 
standards with 25 µl/well of 2M H2SO4  and the plates were read at OD 450/550nm in a 
plate reader (Dynex MRX TC II).The standard curve was made by the calculation 
of the optical density vs dilution of primary antibody and the concentration of anti-β 
Gal in serum was calculated.  
 
2.7.1 Dot-Blot technique to troubleshoot ELISA 
The protein samples were spotted onto a nitrocellulose membrane using a 96 well 
vacuum manifold apparatus. The membrane was cut to fit in the apparatus, marked 
with pencil and fixed in the apparatus. The apparatus has two parts, the upper part 
has pores and the bottom part has a tray. The bottom part was connected to the 
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vacuum source to create a vacuum. The membrane and filter paper were activated 
in 1XPBS for 5 min. They were placed in the middle region of apparatus and screws 
were tightened to assemble the whole unit. The outer wells of apparatus were not 
used for samples and filled with 1XPBS. 100 μl of 1XPBS was added to all wells 
and the vacuum was turned on. The protein samples (β-gal antigen-10745731001, 
Roche, dissolved in 1XPBS to obtain 10 μg/ml. Section 2.7 for details) at 10 μg/ml 
concentration were diluted 1:1 in 1XPBS for a 1400 μl volume, this was further 
diluted 1:1 and 100 μl of this solution was dispensed in triplicate into each marked 
wells. Afterwards, 100 μl of 1XPBS was dispensed into empty wells and outside 
wells. 200 μl pipette tips were used to remove any air bubbles that formed during 
the dispensing of the solutions. The vacuum was activated to pass the samples 
through the membrane. The apparatus was unscrewed to separate the upper part 
and bottom part to obtain the membrane out. The left-hand corner of the membrane 
was cut as an indicator of the surface that was in direct contact with the protein 
samples. The membrane was cut into strips and these were dried for 1 h at 37°C. 
The strips were blocked in blocking solutions (described below) for 1 h at room 
temperature on a shaking platform. Then three different blocking solutions were 
used to check their efficiency. They were 2%BSA made in 1XPBS+2% Tween 20 
(v/v), 2% Serum (Normal Rabbit Serum, Vector labs) made in 1XPBS+2% Tween 
20 (v/v) and 5% skimmed milk made in 1XPBS+2% Tween 20 (v/v). The strips were 
washed with 1XPBS+2% Tween 20 (v/v) for 3x 10 min. The strips were incubated 
with primary antibody (anti-β Gal polyclonal antibody rabbit, Life Technology) at 
1:500, 1:1000 and 1:5000 dilutions in 1XPBS+2% Tween 20 for 16 h at 4°C. The 
strips were washed with 1XPBS+2% Tween 20 (v/v) for 3x 10 min. The strips were 
incubated in the secondary antibody [anti-rabbit IgG (whole molecule) peroxidase 
antibody goat, Sigma] at 1:5000 dilutions in 1XPBS+2% Tween 20 for 1 h at room 
temperature on a shaking platform. The strips were washed with 1XPBS+2% 
Tween 20 (v/v) for 3x 10 min. The strips were incubated in HRP substrate for 3 min 
and the image was captured as described in Section 2.3.17.7. 
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2.8 Statistical analyses 
Statistical analyses were performed using Minitab software. The unpaired Student’s 
t-test (known as 2 sample T test in Minitab 17 software) was used when the means 
of two different groups were compared and the data was found normally distributed 
with equal variances. A One-way ANOVA with posthoc Tukey’s test was used for 
statistical analyses for more than two groups with parametric data sets. The data 
presented in the result sections were expressed as the mean ± standard errors of 
the mean (S.E.M.). P<0.05 was considered statistically significant. 
 
2.9 Summary of results 
Figure 2.9 shows the correlation and summary of result chapters.  
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Figure 2.9 Flowchart describing the correlation between various result chapters. 
	 104	
Chapter 3 Genetic engineering and analyses of expression vectors 
 
3 Aims and objectives 
Aims: To develop plasmid vectors with optimal properties for transgene 
expression.  
The objectives of this chapter were: 
• Genetic engineering of the mini-dystrophin transgene to include the specific 
restriction sites facilitating its insertion into PX61MCK and pcDNA3 
expression plasmids. 
• Genetic engineering of the CD11c minimal promoter for insertion into 
pcDNA3.IDO1/IDO2/TDO plasmids by replacing the CMV promoter.  
 
3.1 Introduction 
The project was based on the expression of two types of protein, the target protein 
and the tolerance-inducing protein by the expression from the respective type of 
vectors. Mini-dystrophin and bacterial beta galactosidase (b-gal) were the target 
proteins. These two target proteins were selected based on their structural 
properties, as mini-dystrophin is a structural protein and b-gal is a secretory protein 
and used here to study their respective expression profiles. Dystrophin is a part of 
the dystrophin-associated protein complex (DAPC)(2) in skeletal muscle but, due 
to size constraints of the dystrophin gene, the mini-dystrophin approach was 
developed: the mini-dystrophin lacks the rod domain but has the functional 
segments from the N-termini spliced “in-frame”. The mini-dystrophin construct used 
in our study (4) had a size of about 3.8 kb with a protein size of about 120 KDa.   
The bacterial b-gal has been widely used as model protein in life sciences. An active 
enzyme may be detected using X-gal, which is cleaved by b-gal and form an easy 
to detect and quantifiable blue product. This is commonly used in molecular biology 
as reporter marker to monitor gene expression (286-291). Moreover, being of 
bacterial origin it is an immunogenic protein with the advantage of easy detection.  
FOXO3 and IDO1/IDO2/TDO were the tolerance inducing proteins.  FOXO3 is 
encoded by the forkhead box O3 transcription factor and has been shown to 
modulate the function of dendritic cells (292). The indoleamine 2,3 dioxygenase 
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(IDO1 and IDO2) and tryptophan 2, 3 dioxygenases (TDO) enzymes mediate 
tryptophan catabolism and also modulate the function of dendritic cells (252) (258). 
The requirement for cell-specific expression of these was studied by incorporating 
the CD11c minimal promoter in their expression cassette, which enabled their 
specific expression in dendritic cells (293).  
The vectors for the expression of mini-dystrophin were pcDNA3.mini-dyst 
FWD/RC* and PX61MCK.mini-dyst FWD/RC* (*mini-gene was cloned with respect 
to the promoter in FWD-forward orientation to get the intended protein or in an RC-
reverse orientation not to get the protein and to be used as a negative control). The 
vector for the expression of the bacterial b-gal protein was pcS2+C Beta 
Galactosidase [courtesy of Dave Turner (294) and Ralph Rupp (295). Obtained 
from European Xenopus Resource Centre plasmid repository]. The tolerance 
inducing expression vectors were pcDNA3.IDO1, pcDNA3.IDO2, pcDNA3.TDO, 
pcDNA4.FOXO3.WT (WT-wild type), pcDNA3.CD11c.IDO1, pcDNA3.CD11c.IDO2 
and pcDNA3.CD11c.TDO. We received pcS2+C Beta Galactosidase, 
pcDNA4.FOXO3.WT, pcDNA3.IDO1/IDO2/TDO plasmids from collaborating 
laboratories (as indicated in chapter 2). The remaining plasmids were engineered 
under this project. 
 
3.2 Cloning of the dystrophin minigene into PX61MCK 
The mini-dystrophin gene (3872 bp) was PCR amplified from the plasmid 
pcDNA3.1+C8 using a set of primers designed with flanking restriction enzyme sites 
(AscI, NdeI, NgoMIV, NaeI, EcoRI) at their 3’ends in order to facilitate downstream 
cloning experiments and cloned into the pGEMT-T EASY vector using the TA-
cloning process. The positive clones were first identified by restriction digestion and 
then verified by DNA sequencing (Eurofins MWG company) to confirm the fidelity 
of the entire sequence. T-coffee and NCBI Blast were used for sequence alignment 
and the in-silico maps of plasmids were made using Vector NTI 8 software. The 
restriction enzymes were shortlisted using New England Biolabs (NEB) cutter 2.0 
(http://nc2.neb.com/NEBcutter2/) to identify suitable sites to clone the mini-
dystrophin into the plasmid PX61MCK.h-alpha galactosidase plasmid by replacing 
the human alpha-galactosidase (hAGA). 
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The PX61MCK.h-alpha galactosidase plasmid was previously used in our lab to 
express hAGA protein in the Fabry’s disease mouse model (265). This plasmid had 
a muscle creatine kinase (MCK) promoter (296) and myosin light chain enhancer 
(MLC 1/3 enhancer) (297) that made it a strong expression vector for muscle fibres. 
The details of these enhancers are discussed in the next chapter.  
 
The EcoRI-EcoRI restriction site was selected in the PX61MCK.h-AGA (vector) to 
replace the h-AGA it with the dystrophin minigene (insert) isolated from the pGEM-
T Easy.mini-dyst by the “shotgun” method (details described in Section 2.3.5). This 
approach produced plasmids with the mini-dystrophin cloned in forward orientation 
(Fwd) thus producing protein expression and in reverse orientation (RC) as a 
negative control. The positive clones were analysed by restriction with MluI+ScaI 
restriction enzymes to confirm the orientation of the insert.  
Figure 3.2.1 shows the vector maps to illustrate the cloning plan and the 
representative gel image in Figure 3.2.2 confirming the orientation of clones.  
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Figure 3.2.1- Schematics of cloning of the dystrophin minigene (mini-dyst) into the 
PX61MCK plasmid backbone. The mini-dyst gene was cloned into pGEM-T EASY to 
get pGEM-T EASY.mini-dyst and verified by sequencing. The mini-dyst excised from 
pGEM-T EASY was cloned into PX61MCK.h-alpha galactosidase by EcoRI 
restriction digestion and ligation. This resulted in PX61MCK.mini-dyst.Fwd and 
PX61MCK.mini-dyst.RC clones. Maps are just representation, not to scale. 
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3.3 Cloning of the dystrophin minigene into pcDNA3 
To test the fidelity of expression of the mini-dystrophin gene inserted into the 
PX61MCK plasmid, mini-dystrophin was also cloned into the pcDNA3 plasmid. This 
plasmid had a cyto-megalorvirus (CMV) promoter that enabled the expression of 
mini-dystrophin in most cells. The EcoRI-EcoRI restriction enzyme sites were 
selected and restriction digestion of PX61MCK.mini-dyst was performed to excise 
the mini-dystrophin insert. The same enzyme was used to digest the pcDNA3 
(vector) to create sticky ends and enable the ligation of the insert. The “shotgun” 
method was used for ligation, resulting in clones in forward (Fwd) and reverse 
orientation (RC). The clones with insert were analysed by HindIII restriction enzyme 
to confirm the orientation of the insert and these positive clones were verified by 
DNA sequencing (Eurofins MWG). Figure 3.3.1 shows the vector maps to illustrate 
the cloning plan and the Figure 3.3.2 shows a representative gel image to confirm 
the orientation of the clones. 
Figure 3.2.2- Agarose gel electrophoresis in 1% gel of PX61MCK.mini-
dyst clones after restriction digestion.  
The 9478 bp plasmid had mini-dystrophin gene cloned either in the 
forward or in the reverse orientation. The clones were digested with MluI 
+ ScaI restriction enzymes to confirm the orientation of the insert. The 
clones with forward-oriented mini-dyst had two bands of 1754 bp and 
7733 bp. The clones with reverse-oriented mini-dyst had two bands of 
5472 bp and 4006 bp.  The clones A and F had mini-dystrophin in the 
forward orientation and clones B, C, D, E, F had mini-dystrophin in the 
reverse orientation. The 10 kb band (top) corresponds to the linearised 
plasmid due to incomplete digestion (single cut). The NEB 1KB quick load 
DNA ladder was used for band size verification.   
A B C D E F 
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Figure 3.3.1- Schematics of cloning of the dystrophin minigene (mini-dyst) into the 
pcDNA3 plasmid backbone. The mini-dyst gene was excised from PX61MCK.mini-
dyst.Fwd plasmid using EcoRI restriction enzyme and ligated into pcDNA3 plasmid. 
This resulted in pcDNA3.mini-dyst.Fwd and pcDNA3.mini-dyst.RC clones. Maps are 
just representation, not to scale. 
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3.4 Cloning of CD11c promoter into IDO1, IDO2 and TDO vectors 
We received the pBluescript.CD11c (5.3 KB) from Dr Thomas Brocker’s lab, 
Germany. The primers were designed to amplify the minimal functional 700 bp 
regions of CD11c from the 5.3 KB full CD11c using sequences from the literature 
(293, 298) and NCBI blast. The PCR was done in two phases; the first phase was 
to get a 733 bp amplicon and the second phase was to add restriction enzyme site 
for downstream cloning to get a 760 bp amplicon.  
Figure 3.4.1 shows the experimental plan. The primer sets for the first phase PCRs 
were CD11c-FWD and CD11c-RC. The primer sets for the second round of PCR 
were CD11cMfeIFWD and CD11cAcc65IRC designed to add MfeI and Acc65I 
restriction enzyme sites to get 760 bp PCR amplicon. This was cloned into a pGEM-
T EASY vector. The clones were confirmed by restriction digestion and then sent 
for DNA sequencing. After confirming the sequence of the 760 bp CD11c minimal 
promoter region with MfeI and Acc65I, the CMV promoter in pcDNA3-
IDO1/IDO2/TDO was replaced with it. 
 
Figure 3.3.2- Agarose gel electrophoresis in 1% gel of pcDNA3.mini-dyst 
clones after restriction digestion.  
The 9363 bp plasmid had the mini-dystrophin gene cloned either in the 
forward or in the reverse orientation. The clones were digested with HindIII 
restriction enzyme to confirm the orientation of the insert. The clones with 
forward-oriented mini-dyst had two bands of 1410 bp and 7953 bp. The 
clones with reverse-oriented mini-dyst had two bands of 2605 bp and 6758 
bp.  The clones B, C, D and E had mini-dystrophin in forward orientation and 
clones F and G had mini-dystrophin in reversed orientation. The clone A had 
pcDNA3 plasmid without any insert and it linearized thus confirming its size 
of 5.4 kb. The NEB 1KB quick load DNA ladder was used for band size 
verification. 
 
A B C D E F G 
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Figure 3.4.2 shows the pcDNA3.CD11c.IDO2 clones after restriction digestion with 
NruI and Acc65I. The NruI had a recognition site at 208 bp in CMV promoter and 
no recognition site in CD11c, while Acc65I had recognition sites at 896 bp in CMV 
promoter and 901 bp in CD11c. Therefore, in pcDNA3.CD11c.IDO2 (6656 bp) 
Acc65I linearized the plasmid resulting in a single band of 6656 bp as confirmed in 
clones no. 6 and 8. In pcDNA3.CMV.IDO2 (6647 bp) it excised CMV promoter 
region (654 bp) to get a band size of 5993 bp as confirmed in sample D. Sample D 
was run alongside the clones no. 6 and 8 to confirm the difference of 663 bp in 1% 
agarose gel. The clone no. 8 was selected for DNA sequencing and for the 
preparation of a glycerol stock. The sequencing results confirmed the presence of 
CD11c in IDO2 clone no.8.  
 
Figure 3.4.3 shows the pcDNA3.CD11c.TDO and pcDNA3.CD11c.IDO1 clones. 
The EcoRI and MfeI restriction enzymes were used to confirm the 
pcDND3.CD11c.TDO clones, while MfeI and Acc65I were used to confirm the 
pcDNA3.CD11c.IDO1 clones. This restriction enzyme combination was used to 
excise the CD11c promoter (760 bp) from the plasmid and to confirm clone identity 
by releasing the band of about 800 bp as seen in 1% agarose gel electrophoresis. 
The TDO clone had some incomplete digestion so the restriction digestion was 
repeated (shown in Figure 3.4.4). The TDO clone no.1 and IDO1 clone no. 2 (batch 
b clones) were selected to send for DNA sequencing and for the preparation of 
glycerol stocks. The sequencing results confirmed the presence of the CD11c 
promoter in TDO clone no.1 and IDO1 clone no. 2.  
 
Figure 3.4.4 shows the pcDNA3.CD11c.TDO clones digested with EcoRI and MfeI 
restriction enzymes to liberate 760 bp CD11c promoter. The band of about 800 bp 
in the 2% agarose gel confirmed the presence of CD11c. 
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PCR using CD11c.FWD + CD11c.RC primers=733 bp 
pBluescript.CD11c.Beta Globin Ova I plasmid (5.3 kb) 
5.3 kb CD11c cloned using NotI+PstI 
PCR of 733 bp product using CD11c.MfeI.FWD + 
CD11c.Acc65I.RC primers=760 bp 
Figure 3.4.1- Schematics of the exchange of the CMV promoter with 
the CD11c promoter in pcDNA3.IDO1/IDO2/TDO plasmids. 
Swap of CMV with CD11c using MfeI and Acc65I in pcDNA3 
backbone 
	
Swap was confirmed by MfeI +Acc65I restriction for IDO1; 
NruI + Acc65I for IDO2; 
EcoRI + MfeI for TDO. 
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Figure 3.4.2- Agarose gel electrophoresis in 1% gel of 
pcDNA3.CD11c.IDO2 clones after restriction digestion.  
The lane A is pcDNA3.CMV.IDO2 as positive control. The lane B and C had 
clones of pcDNA3.CD11c.IDO2 plasmid (6656 bp). These clones are >6 kb 
which confirmed the presence of CD11c. The clone C was selected to send 
for DNA sequencing. The NEB 1 kb quick load DNA ladder was used for 
band size verification. 
A B C 
Figure 3.4.3- Agarose gel electrophoresis in 1% gel of 
pcDNA3.CD11c.IDO1 and pcDNA3.CD11c.TDO clones after restriction 
digestion.   
The TDO clones A, B and C were digested with EcoRI + MfeI restriction 
enzymes and IDO1 clones D, E, F, G, H, I, J and K were digested with MfeI 
+ Acc65I restriction enzymes to excise the CD11c promoter of 760 bp. All of 
these clones had bands close to 800 bp that confirmed the presence of 
CD11c. The TDO clones had additional band that indicated the incomplete 
digestion with restriction enzymes (repeat in Figure 3.4.4). The clone A of 
TDO and clone I of IDO1 were selected for DNA sequencing. The NEB 100 
bp quick load DNA ladder was used for band size verification. 
TDO.CD11c-
760 bp clones 
IDO1.CD11c-760 bp Clones 
A B C D E F G H I J K 
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3.5 Summary 
The cloning experiments resulted in the insertion of the mini-dystrophin cDNA into 
PX61MCK to get PX61MCK.mini-dyst.Fwd and PX61MCK.mini-dyst.RC plasmids 
for skeletal muscle-specific transgene expression as well as into pcDNA3 to get 
pcDNA3.mini-dyst.Fwd and pcDNA3.mini-dyst.RC for general expression. 
Moreover, the CD11c minimal promoter region was used to replace the ubiquitously 
active CMV promoter in pcDNA3.IDO1/IDO2/TDO to obtain 
pcDNA3.CD11c.IDO1/IDO2/TDO vectors driving the expression of tolerance-
inducing genes specifically in dendritic cells. The next step was to analyses the 
expression of these plasmids in vitro and in vivo. 
	
3.6 Discussion 
The modification of plasmids and cloning was performed as planned. Initially, there 
was a problem with ligation of the vector and insert segments. It was due to the 
damage caused to DNA ends by the prolonged exposure to UV-light (299) on 
transilluminator during the cutting of the gel slab containing the desired DNA 
Figure 3.4.4 Agarose gel electrophoresis in 2% agarose gel of 
pcDNA3.CD11c.TDO clones after restriction digestion.  
The clones A, B and C of pcDNA3.CD11c.TDO plasmid of 6636 bp size were 
digested with EcoRI + MfeI restriction enzymes to excise the CD11c promoter 
of 760 bp. The band of about 800 bp confirmed the presence of CD11c. The 
clone A was selected for DNA sequencing. The NEB 100 bp quick load DNA 
ladder was used (right) and 1 kb quick load DNA ladder were used (left) for 
band size verification. 
TDO.CD11c 760 bp 
Clones 
A	 B	 C	
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fragments of DNA obtained after the restriction digestion of plasmids. This problem 
was resolved by applying the “shotgun” cloning method (300) that involved no 
manipulations (e.g. agarose electrophoresis and band excision) after restriction 
digestion of vector and insert segments, which were then ligated as per standard 
protocol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 116	
Chapter 4 Analyses of transgene expression in vitro 
 
4.0 Aims and objectives 
Aims: To check the transgene expression in cells in vitro.  
The objectives of this chapter were: 
• Analyse the expression of plasmid-driven mini-dystrophin, b galactosidase, 
IDO1 and FOXO3 in cell lines by Western blotting and RT-PCR.  
 
4.1 Introduction 
The in vitro approach has been used to establish whether the plasmids engineered 
in the previous step were fully functional and capable of driving expressions of their 
respective genes.  The expression efficiencies of plasmid vectors were analysed 
following their transfection into Human Embryonic Kidney cells (HEK 293), 
dystrophic myoblast cells (SC5) and wild-type myoblast cells (IMO). The features 
of these cells were as follows: 
 
Human embryonic kidney cells (HEK 293)  
The original HEK 293 cells were derived from the kidney of an aborted human 
embryo and transformed with sheared Adenovirus 5 DNA (301). The development 
of the embryonic kidney is adjacent to the adrenal gland that contains neural crest 
cells of ectodermal origin (301), so these cells have the capability to express some 
genes of neuronal origin, genes of ligand-gated channels, genes of G-protein 
coupled voltage-gated channels and another diverse group of genes as described 
by Thomas et al (302). 
The HEK 293 cell lines that overexpress SV40 T protein (303) are designated as 
HEK 293T (HEK 293 in our text) (301). These are semi-adherent and fast growing 
cells. The transfection of HEK 293 cells was used to analyse the protein produced 
by plasmids to confirm their expression levels and size by Western blotting. The 
RNA was also isolated to complete RT-PCR as an alternative to Western blotting.  
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Dystrophic myoblasts (SC5) and wild-type myoblasts (IMO) 
The Immortalised H2Kb-tsA58 (wild type myoblasts-IMO) and H2Kb-tsA58/mdx 
(dystrophic myoblasts-SC5) (304, 305) were present in our lab’s central repository 
and were originally obtained from Prof. Hanns Lochmüller (University of 
Newcastle). 
These cell lines were derived from an H-2Kb-tsA58 immortomouse generated in 
1991 by Jat et al (304). This transgenic mouse contains the temperature-sensitive 
variant (tsA58, ts-temperature sensitive, A58 strain of simian virus) of simian virus 
40 (SV40) large tumour (T) antigen (TAg) that was shown to immortalise cell lines 
driven by mouse major histocompatibility complex (MHC) class I inducible promoter 
(H-2Kb). The transcriptional activity of the SV40 T-antigen was under the control of 
inducible promoter H-2Kb that activates at a temperature of 33°C and the presence 
of interferon gamma in the media to maintain myoblast characteristics. This feature 
can be changed to induce differentiation (305) of myoblasts into myotubes by 
removing the interferon gamma from the media and changing the temperature to 
37°C (as described in Section 2.4.3).   
The SC5 myoblasts (304) were used to analyse the expression of plasmids in the 
dystrophic myoblast cellular environment and their expression profile was an 
indicator for the plasmid’s expression in the muscles of mdx mice. Similarly, IMO 
myoblasts (304) were used to analyse the expression of the plasmid in a wild-type 
myoblast cellular environment, used as an indicator of the plasmid’s expression in 
the wild-type muscles. Due to the known difficulties in transfecting myoblasts, a 
variety of transfection reagents (described in Section 2.4.5) were tested to 
maximise the efficacy of transfection and samples were labelled with the name of 
respective transfection reagent to help repeat the experiment with the same 
reagent.  
The transfection reagents were categorised into three groups based on their mode 
of action: Nanoparticle-based e.g. FuGene HD, HappyFect and Genecellin; 
Cationic lipid based e.g. Lipofectamine 2000 LTX and Lipofectamine 3000 and 
Cationic polymers e.g polyethyleneimine (PEI) polyplex, Viromer Red polyplex 
(alkylated and carboxy alkylated branched PEI)(306).  
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The synthetic nanoparticle-based reagent work by making positively charged 
complexes with plasmid DNA (pDNA), these positive surfaces bind to negatively 
charged cell membranes, enter the cell through endocytosis, transferred their load 
to the cytoplasm and nucleus, typically resulting in the episomal expression (307).  
The cationic lipid-based reagents bind to DNA molecules to form lipoplexes (308) 
that fuse with the cell’s plasma membrane, transferring the DNA to the cytoplasm 
and nucleus of the cell for expression.  
The cationic polymer based reagent complexes with pDNA to form polyplexes (307) 
and reach the cytoplasm by endocytosis and release the pDNA into the cytoplasm 
where it is transported to the nucleus by trafficking through the nuclear envelope 
(309) involved in active transport mechanisms (310). The PEI based polymer use 
Clathrin-mediated endocytosis for their transport (310). 
 
The target gene vectors were PX61MCK.mini-dyst Fwd, pcDNA3.mini-dyst.Fwd 
and pcS2+C Beta Galactosidase. The mini-dyst in PX61MCK.mini-dyst.Fwd was 
driven by the muscle creatine kinase-MCK and myosin light chain enhancer-MLC, 
muscle specific promoter and enhancer combinations. Therefore, It could only be 
analysed in differentiated myotubes in vitro or in muscles in vivo.  
The pcDNA3.mini-dyst.Fwd driven by the CMV promoter was analysed in HEK 293, 
SC5 and IMO myoblasts.  
Likewise, the pcS2+C Beta Galactosidase was transfected into HEK 293 cells and 
SC5 myoblasts.  
 
The tolerance-inducing vectors generated in the previous step, the pcDNA3.IDO1, 
pcDNA4.FOXO3.WT and pcDNA3.CD11c.IDO1 were tested for their expression in 
vitro. The pcDNA3.IDO1 and pcDNA4.FOXO3.WT were analysed in HEK 293 and 
SC5 myoblasts while the pcDNA3.CD11c.IDO1 was analysed in HEK 293 cells and 
RAW 264.7 (macrophage-like, Abelson leukaemia virus-transformed cell line 
derived from BALB/c mice).  
 
Western blotting was used for the analyses of protein expression. When the 
expression of a protein product was very low and not detectable through Western 
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blotting, RT-PCR method was then used to analyse the mRNA expression levels. 
Given that Crawford et al (311) identified the downregulation of endogenous 
dystrophin protein with normal expression of mRNA, RT-PCR was also performed 
to compare the expression at the protein and mRNA levels.  
 
The cell lysates obtained from transfected HEK 293 cells were preserved and used 
as a positive control upon confirming the expression of the respective plasmids in 
Western blot.  
 
4.2 Analyses of pcDNA3.mini-dyst.Fwd expression 
The mini-dystrophin used in our project was the D2: 24w57 version (Figure 4.2.1.A), 
the same construct was used by Jorgensen et al (4) with an m3 label in Figure 1 of 
their article. The D2: 24w57 contains the N-terminal domain, H1-H4 hinge regions 
as well as the cysteine and C-terminal domains.  
The HEK cells were transiently transfected with pcDNA3.mini-dyst.Fwd using 
transfection reagents described in Figure 4.2.1.B. The protein was extracted. This 
lysate was used for Western blotting and, upon confirmation of 125 KDa mini-
dystrophin expression, used as positive control for mini-dystrophin. Figure 4.2.1.B 
shows a representative Western blot. The band of 125 KDa in the GC-Fwd sample 
corresponding to the positive control confirmed the expression of pcDNA3.mini-
dyst.Fwd. This result confirmed that the plasmid is driving expression of the correct 
protein, but this did not give any information about its expression in the muscle 
environment. So, plasmid transfection was done in myoblasts.  
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Figure 4.2.1 Analyses of pcDNA3.mini-dyst.Fwd expression in HEK 293 cells: 
 
A-Diagram representing the various regions of the full-length dystrophin protein 
(top) and the four mini-gene constructs with in-frame deletions of various parts. 
The dark blue discs represent individual spectrin-like repeats of the rod domain; 
H-hinge regions. The mini-dystrophin gene used in this project was the D2: 24W57 
with 125 KDa size.  Figure adapted from an image received from Dr. Rolf Stucka 
and Prof. Hanns Lochmuller (received in personal communication) and published 
in (4). 
 
B- Western blot analyses of HEK 293 cells transiently transfected with mini-dyst 
plasmid. 
A- Happy Fect (HF) transfection reagent was used to transfect cells with 
pcDNA3.mini-dyst.Fwd plasmid; B-HEK 293 untransfected cells as negative 
control; C- HF reagent  was used to transfect cells with pcDNA3.mini-dyst.RC 
plasmid; D-Genecelline (GC) reagent was used to transfect cells with 
pcDNA3.mini-dyst.Fwd plasmid; E-HEK 293 untransfected cells as negative 
control; F-GC reagent was used to transfect cells with pcDNA3.mini-dyst.RC 
plasmid. Beta-actin (cytoskeletal) was used as the protein loading control. Bio-Rad 
Precision Plus Protein Kaleidoscope standards were used in all Western blots to 
access band size.  
 
A 
A B C D E F 
Dystrophin  125 KDa  
b-Actin 42 KDa 
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Transfections in SC5 and IMO myoblasts were carried out in five stages that show 
the evolution of this experiment. All transfection experiments were done in 35 mm 
dishes with variability in transfection efficiencies observed (Section 2.4.4). These 
stages are as follows: 
The first stage was to transfect SC5 myoblasts with pcDNA3.mini-dyst.Fwd for 24 
h and the expression was analysed by Western blotting. This stage was repeated 
six times with an absence of detectable bands in Western blotting in each attempt. 
This stage pointed to two problems, either transfection was sub-optimal or 
expression of the plasmid was sub-optimal to give protein levels detectable in 
Western blot. So, in the second stage, we used a GFP plasmid co-transfection to 
confirm the levels of transfection and modify the protocol to increase its efficiency. 
To analyse the transfection efficiency of the pcDNA3.mini-dyst.Fwd plasmid, it was 
co-transfected with the pEGFP-C1 (Enhanced Green Fluorescent Protein) plasmid 
by mixed at a 6:1 ratio respectively. Initially, live-cell imaging was used to capture 
the signal of GFP but it was very low and not detectable clearly. Therefore, the 
confocal microscope with dipping objective was used to capture the images. The 
cells were cultured in 35 mm dishes that were easy to handle and fit in the heated 
stage of the confocal microscope (Figure 4.2.2). 
 
 
 
Figure 4.2.2 Confocal microscopy of SC5 myoblasts:  
Images (A and B) of SC5 dystrophic myoblasts co-transfected with 
pcDNA3.mini-dyst.Fwd and pEGFP-C1. Some cells were expressing the 
more GFP signal indicative of better uptake of plasmid (B) while in others 
having less cells expressing the GFP signal indicative of poor uptake of the 
plasmid (A). The scale bar is 50 μm.	
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The second stage experimented with SC5 myoblasts co-transfected with 
pcDNA3.mini-dyst.Fwd and pEGFP-C1 plasmids confirmed the presence of GFP’s 
green signal with a variability in transfection efficiency (Figure 4.2.2) in each of four 
attempts undertaken. The image was captured by confocal microscopy (Zeiss LSM 
510 META) and Laser capture microdissection (Veritas Microdissection). Laser 
capture microdissection instrument was used with an aim to isolate the expressing 
cells. Although it could show the wider distribution of GFP signal to analyse the 
transfection efficiency, the cell isolation was not carried out. Nevertheless, this 
stage confirmed that transfection was reasonably successful and therefore, the 
problem was in the detection of the mini-dystrophin protein.  
However, one additional consideration was the difference in size of the two 
plasmids used for co-transfection, the pEGFP-C1 had a size of 4.7 kb and 
pcDNA3.mini-dyst.Fwd had a size of 9.8 kb. Generally, the small plasmids were 
easy to transfect (312) compared to big plasmids, so the presence of the GFP signal 
does not guarantee the presence of the mini-dystrophin plasmid in the cells.  
 
The third stage was to select the pcDNA3.mini-dyst.Fwd transfected SC5 
myoblasts in the presence of G418 in the culture medium for 4-6 weeks and analyse 
the expression by Western blotting and RT-PCR. This stage was repeated seven 
times with no success in the detection of mini-dystrophin by Western blotting. 
However, the specific mini-dystrophin bands were identified by RT-PCR. This 
motivated us to use a timeline for the selection of transfected SC5 myoblasts. 
 
The fourth stage was to follow a timeline of day 1, day 3, day 5 and day 7 after the 
transfection with pcDNA3.mini-dyst.Fwd and culture in the presence of G418. The 
idea behind this stage was to rule out that long-term incubation of cells in G418 
induced cells to mutations leading to the ability to metabolise G418 and thus able 
to survive in the absence of the plasmid. This stage was done only once with no 
bands observed by Western blotting. The next step was to use PX61MCK.mini-
dyst.Fwd plasmid with the aim of analysing mini-dystrophin expression in myotubes 
driven by muscle specific promoter/enhancer elements.  
PX61MCK.mini-dyst.Fwd plasmid was used to transfect SC5 myoblasts, which 
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were then kept in differentiation medium, as this plasmid has a promoter that 
activates following differentiation of myoblast into myotubes. The cells were plated 
sparsely to enable efficient transfection with plasmid, to derive these clones from 
expanding into myotube by preventing initial dense contact as it would initiate very 
early myotube formation among them having cells without plasmid. This stage was 
repeated six times with no bands observed by Western blotting. The next step was 
to use doxycycline to improve the transfection efficiency of the pcDNA3.mini-
dyst.Fwd plasmid.  
 
The fifth stage was to use doxycycline (313, 314) to inhibit matrix metalloproteinase 
(MMP)-9 (315) that were thought to be inhibiting the mini-dystrophin expression. 
Doxycycline treatment (50 μM) was applied after transfecting the cells with plasmid, 
to SC5 (Figure 4.2.3-A) and IMO myoblasts (Figure 4.2.3-B) with or without G418 
selection and analyses of the pcDNA3.mini-dyst.Fwd expression in transfected SC5 
myoblasts was performed after 24 h and IMO myoblasts after 24 h or 48 h by 
Western blotting. Figure 4.2.3-B shows some very faint bands that were not aligned 
to the positive control. This stage was repeated twice with no detection of mini-
dystrophin by Western blot analyses. Therefore, the doxycycline treatment did not 
lead to increase expression.  
 
Following this pcDNA3.mini-dyst.Fwd transfected SC5 and IMO myoblasts in G418 
were selected after 4-6 weeks and scaling up of the cells from a 35 mm dish to a 
T75 flask. This enabled the few SC5 and IMO myoblasts having mini-dystrophin to 
expand into a large population and enable low expression of the mini-dystrophin to 
be detected by the Western blot. The representative images of successful 
experiments are shown in Figure 4.2.3-A and Figure 4.2.3-B.  
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Subsequently, the wild-type myoblasts (IMO) were transiently transfected using 
transfection reagents described in Figure 4.2.4-A, which shows a representative 
Western blot. The very faint band of about 125 KDa in A, C, D samples 
corresponding to the positive control confirmed the expression of mini-dystrophin in 
IMO myoblasts. The lower band observed in blot is presumably non-specific. The 
dystrophic myoblasts (SC5) were stably transfected using transfection reagents 
described in Figure 4.2.4-B, which shows a representative Western blot. The very 
faint band of about 125 KDa in C sample corresponding to the positive control 
confirmed the expression of mini-dystrophin in SC5 myoblasts. The positive control 
sample F was loaded minimally with about 5 μg of protein to prevent over saturation 
of its signal (a dense band in the blot incubated with anti-dystrophin antibody). This 
A 
Dystrophin 125KDa β-Actin 
42KDa 
B 24h 48h 
125KDa Dystrophin 
A B C D F E G 
A B C A C B 
β-Actin 
D E 
42KDa 
Figure 4.2.3 Analyses of pcDNA3.mini-dyst.Fwd expression in SC5 and IMO 
myoblasts after doxycycline treatment: 
 
A- Western blot analyses of samples from the SC5 cells treated with 50µM 
doxycyclin. A-P17 (SC5 untransfected myoblasts) as negative control; B- 
Doxycyclin treated (SC5 untransfected myoblasts) as negative control; C-
Lipofectamine 3000; D-Genecelline; E-K2_Biontex; F-FuGene HD 
transfection reagents used respectively and G-HEK 293 cells transfected with 
pcDNA3.mini-dyst.Fwd plasmid used as positive control. Beta-actin 
(cytoskeletal) was used as the protein loading control.  
 
B-Western blot analyses of samples from the IMO myoblasts treated with 
50µM doxycycline for 24 and 48 h. A-Lipofectamine 3000; B-Genecelline; C-
FuGene HD transfection reagents used respectively; D-P17 (IMO 
untransfected myoblasts) as negative control and E-HEK 293 cells 
transfected with pcDNA3.mini-dyst.Fwd plasmid used as positive control. 
Beta-actin (cytoskeletal) was used as the protein loading control. 	
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low protein leads to the absence of the actin band in this lane in the loading control 
blot. The repeat of the transfection in wild-type myoblasts (IMO) was also shown in 
Figure 4.2.4-B and the very faint band in E-sample confirmed the expression of the 
plasmid. The untransfected A and D samples were loaded as a negative control to 
confirm the absence of the 125KDa mini-dystrophin in these cells. This confirmed 
that mini-dystrophin is expressed in myoblast cells but its expression levels were 
very low compared to HEK 293 cells. 
 
Furthermore, the expression of mini-dystrophin was analysed at the RNA level 
using an RT-PCR approach. The RNA was extracted from SC5 myoblasts 
transfected by pcDNA3.mini-dyst.Fwd using various transfection reagents that are 
described in Figure 4.2.4-C. The PCR was set up using Micro-dystrophin Hinge 
Fwd primer and Dystrophin Exon 65 Reverse primer set (described in Table 2.1.7) 
to detect a mini-dystrophin specific amplicon of 805 bp. Figure 4.2.4-C shows the 
image of the RT-PCR product following agarose gel electrophoresis using a 2% 
agarose gel to analyse the RT-PCR product.  
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Figure 4.2.4 Analyses of pcDNA3.mini-dyst.Fwd expression in SC5 
and IMO myoblasts after transfection: 
 
A- Western blot analyses of samples from the IMO myoblasts.  
A-Lipofectamine 3000; B-GeneCellin reagent; C-K2-Biontex; D-
FuGene HD transfection reagents used respectively and E-HEK 293 
cell transfected with pcDNA3.mini-dyst.Fwd used as positive control. 
GAPDH was used as the protein loading control 
 
B- Western blot analyses of samples from the SC5 and IMO myoblasts.  
A-SC5 untransfected myoblasts as negative control; B-empty well in 
the gel; C-SC5 myoblasts transfected with pcDNA3.mini-dyst.Fwd 
plasmid; D-IMO untransfected myoblasts as negative control; E-IMO 
myoblasts transfected with mini-dystrophin plasmid using FuGene 
transfection reagent; F-HEK 293 cells transfected with pcDNA3.mini-
dyst.Fwd plasmid used as positive control. Beta-actin(cytoskeletal) was 
used as the protein loading control. 
 
C-Agarose gel electrophoresis in 2% gel of RT-PCR products. 
A-H20 only; B-RNA from untransfected SC5 myoblasts; C-RNA from 
HEK 293 untransfected cells; D-RNA from SC5 myoblasts transfected 
with pcDNA3.mini-dyst.Fwd; E-cDNA from untransfected SC5 
myoblasts; Sample A-E were all used as negative controls; F-cDNA 
from SC5 myoblasts transfected with pcDNA3.mini-dyst.Fwd test 
sample and G-cDNA from HEK 293 cells transfected with 
pcDNA3.mini-dyst.Fwd used as positive control. NEB quick load 100 
bp DNA ladder was used for band size verification. 
 
Dystrophin 
A 
125KDa 
A 
GAPDH 35KDa 
B 
Dystrophin 125 KDa 
B C D E 
A B C D B B E F 
b-Actin 42 KDa 
C A B C D E G F 
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Five different types of negative controls were used to rule out false positive results 
and their details are as follows: i) the nuclease free water was used to confirm 
contamination-free PCR reaction; ii) RNA from untransfected SC5 myoblasts was 
used to confirm that SC5 did not have any detectable traces of genomic DNA with 
mini-dystrophin resulting from spontaneous corrective somatic mutations 
(analogous to those occurring in revertant fibres) (311, 316-319); iii) RNA from 
untransfected HEK 293 cells was used to confirm that HEK 293 did not have any 
detectable trace of mini-dystrophin; iv) RNA from SC5 myoblasts transfected with 
pcDNA3.mini-dyst.Fwd was used to confirm the absence of any plasmid DNA and 
proper DNase treatment; v) cDNA made from untransfected SC5 myoblasts was 
used to confirm that SC5 did not have any detectable traces of mini-dystrophin and 
proper cDNA preparation.  
The cDNA from SC5.Dyst.Fwd.LF/FU cells confirmed expression of mini-dystrophin 
by the presence of an approximate 800 bp band in agarose gel electrophoresis. 
The cDNA from HEK 293.Dyst.Fwd.GC cells used as positive control. Since PCR 
of housekeeping genes (i.e. GAPDH) was not run alongside the above PCR for 
detection of mini-dystrophin, this result does not show the relative levels of 
expression of mini-dystrophin in SC5 compared to HEK 293 cells. This result only 
confirms that expression of the mini-dystrophin transcript from pcDNA3.min-
dyst.Fwd is detectable in SC5 myoblasts.  
 
4.3 Analyses of pcS2+C Beta Galactosidase expression 
The pcS2+C Beta Galactosidase (β-gal) plasmid was obtained from the in-house 
plasmid repository. The CMV promoter drives its expression to express 120KDa of 
bacterial (E.coli) b-gal. The HEK 293 cells were transiently transfected (Section 
2.4.4) with the β-gal plasmid and upon confirming its expression by Western 
blotting, the cell lysate was saved to use as a positive control for Western blotting. 
The SC5 dystrophic myoblasts were transiently transfected with the β-gal plasmid 
using a range of transfection reagents described in Figure 4.3.1, which shows a 
representative Western blot and presence of bands at about 120 KDa in GC1, GC2 
and FU samples. This band size corresponded with the positive control confirming 
the expression of β-gal in SC5 myoblasts. This result confirmed the expression of 
	 128	
β-gal in dystrophic myoblasts albeit with a similar pattern of low expression when 
compared to HEK 293 cells.  
 
 
4.4 Analyses of pcDNA3.IDO1 expression 
The HEK 293 cells were transiently transfected (Section 2.4.4) with the 
pcDNA3.IDO1 plasmid and upon confirmation of its expression by Western blotting, 
the cell lysate was saved to use as a positive control.  
The wild-type myoblasts (IMO) were stably transfected with pcDNA3.IDO1 using a 
range of transfection reagents described in Figure 4.4-A, which shows a 
representative Western blot. The presence of bands at about 42 KDa in the B 
sample, with the size corresponding to the positive control, confirmed the 
expression of IDO1 in IMO myoblasts.  
Similarly, dystrophic myoblasts (SC5) were stably transfected with the plasmid. 
Figure 4.4-B shows a representative Western blot and presence of bands at about 
42 KDa in A and B samples confirming the expression of IDO1 in SC5 myoblasts.  
To confirm the expression levels of IDO1 in SC5 myoblasts resulted from the 
transfected plasmid rather than being endogenous, an RT-PCR approach was 
used. The RNA was extracted from SC5 myoblasts and HEK 293 cells that were 
stably transfected with the IDO1 plasmid and IDO1.Fwd1 +IDO1.RC1 primers were 
used to detect the specific amplicon of 1200 bp. These primers were specifically 
Figure 4.3.1 Western blot analyses of samples from the SC5 myoblasts 
transiently transfected with pcS+C2 Beta Galactosidase plasmid. 
A-HEK 293 cells transfected with β-gal used as positive control; B-blank, 
empty well to prevent crossover; C-D are duplicate of GeneCelline; E-
K2_Biontex; F-FuGene HD reagents were used for transfection respectively. 
Beta-actin (cytoskeletal) was used as the protein loading control. The 
absence of actin band in positive control (sample A) was due to low amount 
of the control protein being loaded in gel to avoid oversaturation as 
explained in text of Figure 4.2.4-B.  
 
	A 	B 	C D 	E 	F 
β-gal 
β-Actin 
120KDa 
 42KDa 
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designed to detect plasmid-encoded IDO1 and not endogenously expressed IDO1 
by the presence of different sequences upstream of the start codon (Figure 4.4-C). 
Figure 4.4-D shows the image of the RT-PCR product resolved in 1% agarose gel. 
The reaction was set up with five negative controls, the nuclease free water was 
used confirm contamination free PCR reaction and minus RT to confirm the proper 
DNAase treatment. The presence of specific 1200 bp band in lane B, C, F and G 
confirmed the expression of IDO1 in HEK 293 cells and in SC5 myoblasts. The 
levels of housekeeping genes (i.e. GAPDH) were not analysed alongside this RT-
PCR, so these results were not used to confirm the relative expression levels of 
IDO1 in cells but only confirmed the exogenous IDO1 detection.  
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A B C D 
42KDa 
42KDa 
IDO1 
b-Actin 
A 
A B C 
IDO1 
GAPDH 
42KDa 
35KDa 
B 
IDO1 mRNA-                     5’-GGAGTAGACAGCAATGGCAC-3’ 
IDO1.FW1 Primer-     5’-AGACCCAAGCTTGGTACCACCATGGCAC-3’ 
cd11c.IDO1.Fwd Primer- 5’-CTGTTCTCCAGTCGGTACCACCATGGCAC-3’ 
 
 
IDO1 mRNA-                5’-GCCTTAGTGTAGCAAGCTCCA-3’ 
IDO1.RC1 Primer region-      5’-GCCTTAGGCGGCCGCTCGAGC-3’ 
cd11c.IDO1.RC Primer region- 5’-GCCTTAGGCGGCCGCTCGAGCATGC-3’ 
 
ATG- Start codon;TAG- Stop codon; GGTACC-KpnI restriction 
site; GCGGCCGC- NotI restriction site.  
 
C 
A B C D E F G H I J D 
Figure 4.4 Analyses of pcDNA3.IDO1 expression: 
A-Western blot analyses of samples from the IMO myoblasts. A-HEK 293 cells 
transfected with pcDNA3.IDO1, used as positive control; B-FuGene HD, C-Screen 
Fect reagents were used for transfection respectively; D-P17 (untransfected IMO 
myoblasts) used as negative control. Beta-actin (cytoskeletal) was used as the 
protein loading control.  
 
B-Western blot analyses of samples from the SC5 myoblasts. A-Lipofectamine 3000, 
B- GeneCellin reagents were used for transfection respectively; C-HEK 293 cells 
transfected with pcDNA3.IDO1, used as positive control. GAPDH was used as the 
protein loading control. 
(see next page) 
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C-Regions of native and plasmid-driven IDO1 sequences used for 
primer design.  
 
D-Agarose gel electrophoresis in 1% gel of the RT-PCR product.  
A-H20 as negative control; B-cDNA of HEK 293 transfected with 
K2_Biontex and C-transfected with GeneCellin, used as positive 
controls; D, E- RNA of HEK 293 transfected with K2_Biontex (D) or 
with GeneCellin (E) transfection reagents respectively, treated 
without reverse transcriptase enzyme (minus RT) used as negative 
controls; F-cDNA of SC5 myoblasts transfected with GeneCellin 
and G-transfected with FuGene HD reagents respectively; H,I-RNA 
of SC5 transfected with GeneCellin (H) or with FuGene HD (I) 
transfection reagents respectively, treated without reverse 
transcriptase enzyme (minus RT) used as negative control; J-2 µl 
of PCR product obtained from the amplification of pcDNA3.IDO1, 
used as positive control. NEB quick load 100 bp DNA ladder was 
used for band size verification.  
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4.5 Analyses of pcDNA3.IDO2 and pcDNA3.TDO expression 
The HEK 293 cells were transfected with pcDNA3.IDO2 using transfection reagents 
described in Figure 4.5-A, which shows a representative Western blot. The 
presence of 72 KDa in all samples confirmed the expression of IDO2. The sample 
D (HEK 293) positive control for IDO1 was also run alongside the samples for band 
detection and to rule out any cross contamination.  Similarly, the HEK 293 cells 
were transfected with pcDNA3.TDO using Lipofectamine (LF) transfection reagent. 
Figure 4.5-B shows a representative Western blot. The presence of a 45 KDa band 
confirmed the expression of TDO but there were two bands in close proximity, 
presumably one being a non-specific. The result confirmed that the TDO plasmid 
was working properly.  
 
 
IDO2 
IDO1 
A 
GAPDH 
42KDa 
A 
72KDa 
35KDa 
45KDa TDO 
β-Actin 42KDa 
B 
Figure 4.5 Analyses of pcDNA3.IDO2 and pcDNA3.TDO expression: 
A-Western blot analyses of samples from the HEK 293 cells transfected with 
pcDNA3.IDO2. A-Lipofectamine, B-Genecelline, C-ScreenFect A reagents were 
used for transfection respectively; D-HEK 293 cells transfected with pcDNA3.IDO1, 
used as positive control showing the expected 42KDa band. GAPDH was used as 
the protein loading control.  
 
B- Western blot analyses of samples from the HEK 293 cells transfected with 
pcDNA3.TDO using Lipofectamine reagent. Beta-actin (cytoskeletal) was used as 
the protein loading control.  
 
B C D 
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4.6 Analyses of pcDNA4.FOXO3WT expression 
The HEK 293 cells were transiently transfected (Section 2.4.4) with 
pcDNA4.FOXO3WT using transfection reagents shown in Figure 4.6-A. The band 
at about 80 KDa in both A and B samples confirmed the expression of FOXO3WT 
(Figure 4.6-A). Similarly, the SC5 myoblasts were transiently transfected with this 
plasmid (Figure 4.6-B). The band at about 80 KDa in both B and C samples, 
corresponding to the positive control sample D confirmed the expression of 
FOXO3WT in SC5 myoblasts (Figure 4.6-B). The similar band in the SC5 
myoblast’s lysate at passage 13 in sample A indicated the presence of endogenous 
FOXO3. The bands in Figure 4.6-B look to be a larger size compared to the positive 
control, presumably due to the slanting position of the membrane while the image 
was captured and or different post-translational modifications in SC5 myoblasts and 
HEK 293 cells.  
 
Figure 4.6 Analyses of pcDNA4.FOXO3.WT expression:  
A- Western blot analyses of samples from the HEK 293 cells. A-GeneCellin 
and B-K2_Biontex reagents used for transfection respectively. Beta-actin 
(cytoskeletal) was used as the protein loading control. 
  
B- Western blot analyses of samples from the SC5 myoblasts. A-P13 
(untransfected SC5 myoblasts) used as negative control; B-GeneCellin 
reagent; C-K2_Biontex reagent used for transfection respectively; D-HEK 293 
cells transfected with pcDNA4.FOXO3WT used as positive control. Beta-actin 
(cytoskeletal) was used as the protein loading control.  
 
 
β-Actin 
FOXO3 
A 
	
 B 
80KDa 
42KDa 
	
A 
80KDa 
42KDa 
FOXO3 
b-Actin 
B A 	 B 	 C 	 D 	
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4.7 Analyses of pcDNA3.CD11c.IDO1 expression 
The HEK 293 cells were transiently transfected (Section 2.4.4) with 
pcDNA3.CD11c.IDO1 using transfection reagents described in Figure 4.7-A. The 
band at about 42 KDa in the B and C samples corresponding to the positive control 
band size confirmed the expression of pcDNA3.CD11c.IDO1 in HEK 293 cells 
(Figure 4.7-A). This confirmed that the plasmid was functional but also that HEK 
293 cells (sample D) could activate the minimal CD11c promoter. Nevertheless, as 
these are not specific for CD11c, so RAW 264.7 macrophage cells were used (293, 
298). These cells were transfected with plasmid using Lipofectamine transfection 
reagent and Figure 4.7-B shows a representative Western blot. The very faint bands 
at about 42KDa in samples B-E corresponding to the positive control band 
confirmed the expression of IDO1 driven by CD11c. There was a strong non-
specific band, bigger than 42KDa, which was also present in the negative control. 
This experiment confirmed that CD11c.IDO1 is functional but its expression levels 
were not high.  
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4.8 Summary 
The in vitro expression analyses performed by Western blotting confirmed the 
expression of pcDNA3.mini-dyst.Fwd, pcS2+C Beta Galactosidase, pcDNA3.IDO1, 
pcDNA3.IDO2, pcDNA3.TDO, pcDNA4.FOXO3WT, pcDNA3.CD11c.IDO1 in a 
range of cells including HEK 293, SC5 myoblasts, IMO myoblasts, and RAW 264.7 
macrophage. The RT-PCR confirmed the expression of pcDNA3.mini-dyst.Fwd and 
pcDNA3.IDO1 in SC5 myoblasts. Considering the transfection efficiency, the 
FuGene HD reagent (320) was found to be the best reagent among the 
nanoparticle-based reagents for myoblast transfection. Moreover, although, it has 
been shown in various studies that cationic lipids can inhibit the expression of pDNA 
(309, 321), Lipofectamine 3000 gave best myoblast transfection efficiency in our 
study.  
Figure 4.7 Analyses of pcDNA3.CD11c.IDO1 expression: 
A- Western blot analyses of samples from the HEK 293 cells. A-P17 
(untransfected HEK 293 cells) used as negative control; B-Lipofectamine, C-
Genecelline reagents were used for transfection respectively; D-HEK 293 cells 
transfected with pcDNA3.IDO1 used as a positive control for 42KDa band. 
GAPDH was used as the protein loading control. 
 
B- Western blot analyses of samples from the RAW 264.7 cells transfected with 
Lipofectamine transfection reagent. A-P5 (untransfected RAW 264.7 cells) used 
as negative control; B-C-RAW 264.7 cells with G418 for 24 h; D-E-RAW 264.7 
cells without G418; F-HEK 293 cells transfected with pcDNA3.IDO1 used as a 
positive control for 42KDa band. Beta-actin (cytoskeletal) was used as the protein 
loading control. 
 
42KDa 
A D E 
42KDa β-Actin 
IDO1 
42 KDa 
35 KDa 
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GAPDH 
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The next step was to analyse the plasmid expression and functional efficacy in-
vivo. 
 
4.9 Discussion  
The low expression of mini-dystrophin plasmid might be due to various reasons 
such as microRNA regulations (322-325)inhibiting the over-expression of mini-
dystrophin in myoblasts, lower uptake of a plasmid which is a common problem with 
myoblasts and degradation of protein by the proteasome (326, 327) etc.  
The details of mini-plasmid plasmid, in-vitro expression, Matrix metalloproteinases 
and other factors are described as follows: 
 
4.9.1-mini-dystrophin plasmid: Jorgensen et al (4) previously studied the 
dystrophin minigene used in our study. The four different versions of mini-
dystrophin were characterised by variable in-frame large deletions of the spectrin-
like domain with the preservation of a few rod-domains repeats and intact C and N-
terminal regions (4).  
Several DMD patients with Becker muscular dystrophy (milder type muscular 
dystrophy) had in-frame deletions of these rod domains for up to two-thirds of the 
total region (328, 329). These studies indicated the non-essential role of the full-
length rod domains that was truncated to construct the mini-gene.  
However, other studies indicated that the rod domains of the dystrophin minigene 
have an important role in enabling binding of the sarcolemma bilayer and actin 
through electrostatic interactions (330, 331). The minigene used in out project had 
69% of the repeated hinge region deleted. This region consists of 24 nucleotides 
from 1011bp to 8796bp. The remaining dystrophin cDNA is of 3696 bp encoding 
with 125 KDa protein (4).  
The above mini-dystrophin gene was cloned into the plasmid PX61MCK.h-alpha 
galactosidase (265) by replacing the human alpha-galactosidase (hAGA) with the 
mini-dystrophin. The vector had muscle specific promoter/enhancer elements 
(MCK- muscle creatine kinase promoter and MLC-myosin light chain enhancer). 
Various studies showed that use of these elements increased expression of the 
transgene specifically in skeletal muscles (296, 297, 332). The presence of these 
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promoter/enhancer elements restricts the expression of this plasmid to 
differentiating myotubes (in vitro) and to muscle fibres (in vivo). The same mini-
dystrophin was cloned from this vector into a CMV promoter-driven vector (i.e. 
pcDNA3) to enable its expression profile in various cell lines (in vitro) and in the 
muscle fibres of mdx mouse (in vivo).  
 
The high expression of the CMV-driven plasmid was detected in HEK 293 cells (in 
vitro) but its expression was very low in myoblast cells. This confirmed the 
functionality of this plasmid. The in vitro transfection for expression of this plasmid 
was performed using several commercially available transfection reagents. The 
HEK 293 cells were transfected efficiently with most of the reagents but dystrophic 
myoblasts (SC5) and wild-type myoblasts (IMO) were transfected with two reagents 
only, the FuGene HD and the Lipofectamine 3000. Interestingly, these two reagents 
represent the two different types of transfection methods, FuGene HD belongs to 
the group of nanoparticles and Lipofectamine 3000 belongs to the group of cationic 
lipids.   
 
4.9.2-in vitro expression: The poor in vitro expression efficiency of the CMV-
driven mini-dystrophin plasmid in myoblasts compared to its high expression 
following the same plasmid transfection into HEK 293 cells might have been due to 
poor transfection efficiency. The similar pattern of very low to no expression of both 
CMV-driven mini-dystrophin and MCK/MLC driven mini-dystrophin plasmids was 
later confirmed in the expression profile of in vivo following their injection into TA 
muscle of mdx mice (described in next chapter). This indicates the contribution of 
factors other than transfection efficiency towards this very low expression of mini-
dystrophin in myoblasts and muscles.  
 
4.9.3-Matrix metalloproteinases (MMPs): regulate the remodelling of the extra-
cellular matrix (ECM)(333) and have therapeutic roles in Duchenne muscular 
dystrophy (334). MMP-2 was shown to induce for proteolysis of dystrophin in 
ischemia and the use of doxycycline to inhibit MMP-2 before ischemia was shown 
to prevent this dystrophin degradation (335). Moreover, doxycycline was shown to 
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inhibit inflammation (313), reduce the levels of matrix metalloproteinase-9 (315) and 
tumour necrosis factor alpha in mdx mice (314). Therefore, we used doxycycline to 
prevent the mini-dystrophin degradation in vitro but there was no significant 
improvement of expression efficiency with doxycycline. Miyazaki et al (336) showed 
that MMP-2 had no critical effect on the degradation of the dystrophin-associated 
protein complex and its essential role in regenerating muscle fibres, thus supporting 
our observations. 
 
4.9.4-MicroRNAs inhibiting overexpression of mini-dystrophin 
MicroRNAs (miRNAs) are 21-23 nucleotide long noncoding RNAs (337) that 
regulate the transcription of mRNA in a tissue-specific manner (338) by guiding the 
RNA-induced silencing complex (RISC) to degrade or inhibit mRNA. In this way, 
miRNA negatively regulate the gene expression at post-transcriptional level. They 
have been shown to inhibit transgene expression in hematopoietic cells (322), 
regulate myogenic differentiation (339), regulate the development of all subtypes of 
the CD4 T cell lineage (340) and miR-142 is shown to promote immunological 
tolerance towards antigen-specific regulatory T cells when delivered in vivo (341). 
These studies indicate the important role of miRNA in successful transgene 
expression in vivo. In our study, we did not analyse the supposed miRNAs 
regulating the transgene expression of mini-dystrophin, but this will be an 
interesting possibility to study in the future work.  
 
4.9.5-Methylation of pDNA 
 The addition of a methyl group to a cytosine base pair in DNA that precedes to a 
guanine base-pair is known as methylation of cytosine (CpG). This modification is 
known as an epigenetic modification and regulates gene expression. It was 
confirmed that this methylation and its role in the regulation of expression was 
different in identical cells (342). The presence of immunostimulatory, unmethylated 
CpG sequences in bacterial DNA that form the plasmid’s backbone (343) induces 
an inflammatory reaction that promotes the development of B cell and T cell-specific 
immune responses against the cloned transgene product (344). It was confirmed 
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that the expression of the transgene in transgenic mice is inversely proportional to 
the level of methylation of the transgene (342, 345).  
Collas et al (345) used two inhibitors to inhibit DNA methylation of pDNA (luciferase 
used as a transgene) to increase its expression in zebrafish embryos. They used 
5-azacytidine (5-AzaC), the specific inhibitor of cytosine methyltransferase that 
blocks methylation and sodium butyrate, the inhibitor of histone deacetylation that 
regulates heterochromatin formation. They confirmed that plasmid demethylation is 
a passive repair mechanism and independent of DNA replication in vivo. The use 
of inhibitors enabled significant inhibition of plasmid methylation and promoted 
demethylation of methylated DNA in vivo. The intensity of luciferase was not 
increased by 5-AzaC but butyrate prolonged the duration of expression for two days 
post injection. Using both inhibitors led to a moderate level of luciferase expression 
that was absent in control embryos.  
Hong et al (346) used 5-azacytidine (5-AzaC) to increase the expression of a 
transgene (GFP) in C3A human hepatoblastoma cells. They confirmed that 5-AzaC 
significantly increased the number of cells having the transgene with higher levels 
of expression and the level of transgene methylation was inversely proportional to 
the levels of its expression. A review article by Jones et al (347) summarised the 
different mechanisms involved in methylation. 
Yew et al (348) used plasmid vector with 80% depleted CpG motifs and observed 
sustained expression of the transgene for 49 days in lungs and liver of 
immunocompetent BALB/c mice compared to control plasmid having un-depleted 
CpG motifs that produced transient expression only.  
Hodges et al (349) showed that the use of supercoiled CpG-reduced pDNA led to 
increased levels and duration of the transgene (human alpha-galactosidase A for 
lysosomal storage disease and Factor IX for haemophilia) compared to linear CpG-
replete pDNA in C57Bl/6, BALB/c, and CD1 mice monitored for 6 months.  
Reyes-Sandoval et al (344) used CpG-methylated pDNA for expressing highly 
immunogenic transgenes (glycoprotein of rabies virus) in C3H/He mice. They 
confirmed that CpG methylation of pDNA leads to an absence of an immune 
response against the transgene product without reducing its expression levels, but 
led to a strong immune response when the pDNA was enclosed in a viral vector. 
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Chen et al (343) confirmed that minicircle DNA vectors made by removing the 
plasmid bacterial backbone were persistent in their expression in liver compared to 
traditional pDNA that was silenced in the liver. The presence or absence of 
methylation of CpG in traditional pDNA had no significant effect on transcriptional 
silencing. The use of two tandem copies of chicken cHS4 insulator at each end of 
the traditional pDNA was shown to partially inhibit the transgene transcriptional 
silencing. The formation of repressive heterochromatin on the traditional pDNA 
backbone leads to inactivation of the transgene in the liver. A study by De wolf et 
al (350) also confirmed that the absence of CpG motifs improves the degree and 
duration of the transgene (tumour gene) expression when pDNA is mixed with PEI 
(polyethyleneimine). A similar study confirmed the presence of 20 CpG motifs in the 
cDNA of an interferon gamma transgene leads to its sustained expression at a 
therapeutic concentration leading to an inhibitory effect on pulmonary metastases 
of the tumour (351). 
Lesina et al(352) confirmed an important point that the absence of CpG motifs leads 
to increased expression while the long duration of expression of pDNA required 
CpG motifs to facilitate the normal degradation of pDNA.  
In our study, we did not change the CpG contents of plasmids to facilitate their 
expression for a long duration but this possibility should be explored in further 
studies.  
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Chapter 5 Analyses of the effects of IDO1 expressing plasmids on transgene 
expression in vivo.  
 
5.0 Aims and objectives 
Aims: To study the transgene expression following plasmid targeting into the 
muscle of mdx mouse.  
The objectives of this chapter were: 
• Analyse the expression following injection of mini-dystrophin, b-gal, IDO1 
and FOXO3 plasmids in mdx mice by Western blotting, RT-PCR, qPCR and 
immunohistochemistry. 
• Analyse the efficiency of the vehicle used to formulate the plasmid for 
injection (Pluronic SP1017-2 vs normal saline) to produce increased 
expression. 
• Analyse the expression of b-gal following plasmid co-injection with IDO1 and 
with CD11c.IDO1 by Western blotting, RT-PCR and qPCR.  
 
5.1 Introduction 
The expression of both target gene plasmids and tolerance-inducing gene plasmids 
were detectable in vitro (Chapter 4) confirming that plasmid modifications 
(described in Chapter 3) resulted in the generation of functional plasmids. This 
Chapter describes the testing of the expression of target gene plasmids and 
tolerance-inducing plasmids in vivo by intramuscular (i.m) injection of naked 
plasmid DNA (151) into the tibialis anterior (TA) muscle of mdx mice. There are 
other approaches (i.e. viral vectors) to introduce plasmid DNA but i.m. injection of 
naked pDNA was selected as this approach is less immunogenic and therefore 
better for the analyses of the immune response to transgene transfer in the skeletal 
muscle(353). Different parameters for intramuscular injection were studied in detail 
by Manthorpe et al (264) and were adopted here i.e. using endotoxin-free plasmid 
DNA made in a single batch to avoid variability (described in Section 2.3.2).   
Two types of mice were used in the project, the mdx (X-linked muscular dystrophy) 
mouse (354) and the mdx-β geo mouse (121). These are the disease models for 
Duchenne muscular dystrophy (DMD).  
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The mdx mouse (112) is the most commonly used mouse model of DMD. It has a 
spontaneous nonsense mutation in exon 23 causing the loss of the Dp427 isoform 
(2) of the dystrophin protein but it expresses the shorter isoforms (355). The effect 
of the loss of dystrophin in mdx mice is more prominent in the diaphragm (113, 356) 
than in the limb muscles, with extensive replacement of muscle fibres with fibrous 
connective tissue in mdx mice. The female mdx mice show less pathology (357). 
Similarly, mdx males had faster muscles with higher maximum power output than 
from females. The mdx female muscles are more fatigue resistant, recover faster 
with less mechanical damage (358) due to the presence of the oestrogen receptor-
beta. Therefore, we used female mice to optimise our calculation of the plasmid 
injection and initial expression profile for some plasmids. Later, we moved to using 
mdx male mice of 4 weeks of age, when they present with the pathology identical 
to that found in human DMD patients  (118) and this data was used for all analyses 
in this thesis.  
The mdx-β geo mouse has promoter less ROSAβgeo construct [encoding (β-gal)-
neomycin phosphotransferase fusion protein], inserted downstream from the 
dystrophin exon 63 and thus disrupting expression of all seven isoforms of 
dystrophin protein(2, 121). The mdxβgeo, being a true null Dmd mutant due to the 
absence of all isoforms of dystrophin protein compared to mdx, is likely to mount a 
more potent immune response against dystrophin (mini-dystrophin) compared to 
mdx.  
 
The pcDNA3.mini-dyst.Fwd and PX61MCK.mini-dyst.Fwd plasmids were analysed 
for their respective expression in mice by Western blotting. To increase the 
expression levels of these plasmids, they were formulated with Pluronic SP1017-2, 
a non-ionic carrier that was shown to increase the level and duration of transgene 
expression in muscle (359), also used in our lab for similar studies (265).  
Moreover, the expression of pcS2+C Beta Galactosidase (b-gal) was analysed by 
Western blotting. The co-injection of the pcS2+C Beta Galactosidase plasmid with 
pcDNA3.IDO1 and pcDNA3.CD11c.IDO1 was performed to analyse the effects of 
tolerance-inducing plasmids on the expression profile of b-gal in terms of increasing 
the expression levels in muscle as detected by the presence of expression in 
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Western blotting 21 days post-injection or increasing the number of muscle samples 
expressing the b-gal as detected by Western blotting 14 days post-injection. The 
expression was analysed by Western blotting, RT-PCR and qPCR.   
 
As described earlier, tolerance-inducing plasmids were used to induce specific 
natural tolerance against the newly synthesised transgene (b-gal) by minimising the 
immune activation of T-cells against it. Similarly, the expressions of tolerance-
inducing plasmids were also analysed by Western blotting, RT-PCR and qPCR to 
confirm that they were expressed in vivo and that their presence influenced on the 
expression profile of b-gal. 
 
All injection experiments were performed using single doses of plasmid delivered 
as an i.m. injection into the tibialis anterior (TA) muscle of mice followed by 
expression period of 5 to 21 days in the muscle. All Western blot experiments were 
performed using 40 µg of total protein loaded onto SDS-PAGE gels that were 
increased to 60 µg of total protein to detect very low expression levels as described 
in the respective Figure legends.  
 
5.2 Analyses of mini-dystrophin expression 
The expression of pcDNA3.mini-dyst.Fwd plasmid was initially analysed by 
injecting four mdx-β geo female mice at age five months at the time of injection 
(plasmid dilutions were calculated as described in Section 2.6.1). This experiment 
was performed in mdx-β geo female mice primarily to test the efficiency of the 
plasmid expression for optimisation. The mice were killed 7 days post-injection and 
Western blot analyses were performed with 60 µg of total protein. Figure 5.2-A 
shows a representative blot. The very faint bands at an approximately 125 KDa in 
samples A-E with a size corresponding to the positive control, confirmed the 
expression of pcDNA3.mini-dyst.Fwd in mdx-β geo female mice.  
The repeat of this experiment was performed using three mdx male mice. The mice 
were killed 7 days post-injection and TA muscles were analysed by Western 
blotting. Figure 5.2-B shows a representative blot. The absence of a 125KDa band 
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in samples A-F corresponding to the positive control showed no detectable 
expression of mini-dystrophin by pcDNA3.mini-dyst.Fwd plasmid.  
 
This experiment was further repeated by optimising the injection parameters as 
follows: i) the injection volume was increased to 50µl; ii) using C57BL10 female 
mice as they express full-length dystrophin (427KDa) and therefore allowed 
exclusion of immune mechanisms that could be leading to the very low to no 
expression of mini-dystrophin in mdx mice; iii) formulating the plasmid with Pluronic 
SP1017-2 polymer to increase the efficiency of plasmid uptake in mdx mice and iv) 
increasing the injection volume to 50µl of plasmids formulated with Pluronic 
SP1017-2 in normal saline in mdx mice.  
No expression of pcDNA3.mini-dyst.Fwd was detected in any of these experiments 
by Western blotting, but there was a detectable expression of its transcript by RT-
PCR in the 50µl pluronic samples (Figure 5.2-C).  
 
Next, the RT-PCR and immunohistochemistry were used as alternative techniques 
to detect mini-dystrophin expression. The expression of the dystrophin minigene at 
the RNA level was analysed by RT-PCR in five mdx male mice. They were injected 
with three combinations: i) Saline only (as a control); ii) pcDNA3.mini-dyst.Fwd 
Plasmid DNA in saline and iii) pcDNA3.mini-dyst.Fwd plasmid DNA formulated with 
pluronic SP1017-2 in normal saline. The TA were excised from the mice 7 days 
post-injection, frozen and crushed under liquid nitrogen. The tissue powder was 
divided into two equal parts; one part was used for protein extraction for Western 
blotting and another for RNA extraction. The RT-PCR was set up using the Micro-
dystrophin Hinge Fwd primer and Dystrophin Exon 65 Reverse primer set 
(described in Table 2.1.7) to detect a mini-dystrophin specific amplicon of 805 bp. 
The same primer sets were used to detect mini-dystrophin in cell lines (Figure 4.2.4-
C). 
Figure 5.2-C shows a representative image of RT-PCR products following 
electrophoresis in 2% agarose gel. The sample 1 and 2 (cDNA from the animal no.3 
right and left TA muscle) were from the animal injected with plasmid DNA in saline 
with pluronic SP1017-2. Sample 4 and 5 were from the animal injected with plasmid 
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DNA in saline.  The presence of mini-dystrophin specific amplicon of 805 bp bands 
in samples 4 and 5 (cDNA from an animal no. 4 right and left TA muscle) 
corresponding to the positive control (cDNA from HEK-T 293 cells transfected with 
pcDNA3.mini-dyst in lane 3) confirmed the expression of the mini-dystrophin 
plasmid.  
The immunodetection of dystrophin (Section 2.5.2.2.1) was performed in the TA 
muscle samples obtained from the mdx-β geo female mice injected previously. This 
experiment was performed to analyse the distribution pattern of plasmid-expressing 
fibres. These were expected to present in and around the injection needle track 
(more expression of plasmid near the site of the needle than far away from it). The 
sections were observed under the light microscope but no dystrophin-specific 
staining pattern was found. In fact, of all the muscle sections studied (approx. 200 
sections), only one had some signal and this could have been a false positive (as 
there should be more than one fibre with the signal in serial sections) rather than 
the positive mini-dystrophin expression. It further confirmed the very low expression 
of pcDNA3.mini-dyst.Fwd either due to a low uptake or due to degradation of the 
plasmid by cellular machinery or other regulatory mechanisms that inhibit its 
expression. The details of various mechanisms are discussed in Section 5.8.  
The plasmid PX61MCK.mini-dyst.Fwd has the muscle creatine kinase promoter 
(MCK) with myosin light chain enhancer (MLC) driving the expression of mini-
dystrophin. These elements were used for the specific and enhanced targeting of 
mini-dystrophin in muscle compared to pcDNA3.mini-dyst. The expression of 
PX61MCK.mini-dyst.Fwd was initially analysed by injecting five mdx male mice. 
The mice were killed 7 days post-injection and TA samples were obtained for 
Western blot analyses was completed. Figure 5.2-D shows a representative blot. 
The very faint bands at an approximately 125 KDa, corresponding to the positive 
control, confirmed the expression of PX61MCK.mini-dystrophin.Fwd.  
The repeat of this experiment was performed using five mdx male mice and two 
mdx male mice with the same injection parameters as used above except they were 
killed 5 days and 9 days post-injection to obtain TA muscles for Western blotting. 
To analyse early expression levels and expression levels beyond the routine 7 days 
respectively. Western blot analyses for the detection of mini-dystrophin was 
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completed using 60 µg of total protein. Figure 5.2-E shows a representative blot for 
the TA muscle samples obtained from the mice killed 5 days post-injection. There 
was no detectable expression of the 125KDa band corresponding to the positive 
control in any of the samples analysed. Similar, Western blot results were obtained 
from the TA muscle samples obtained from the mice killed 9 days post-injection 
(data not shown). 
It is not clear why the first attempt showed the signal and why it was not detected 
on repeating the experiment.  
The qPCR was used to detect the expression levels of mini-dystrophin in co-
injected samples using a Sybr green master mix with two primer sets, primer set 5 
(fwd and rc) and primer set 7 (fwd and rc) respectively (Table 2.1.7). The expression 
levels between co-injected samples and control were not significant (primer set 
5,p=0.353 and primer set 7, p=0.4161) (data not shown). 
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Figure 5.2 Analyses of mini-dystrophin expression: 
A-Western blot of samples from mdx-β geo female mice, injected with 1 µg/leg 
of pcDNA3.mini-dyst.Fwd plasmid, 7 days post-injection, 60μg of total protein 
loaded.  A, B-animal no.1, right and left legs respectively; C, D-animal no.2 right 
and left legs respectively: E- animal no. 3, right leg; F- HEK-T 293 cells 
transfected with pcDNA3.mini-dyst.Fwd used as a positive control for the 125 
KDa mini-dystrophin band (5 μg of protein used to avoid overexposure as seen 
in blot D, therefore no actin bands in loading control are visible); G- C57BL10 
mouse leg muscle sample used as a positive control for the 427 KDa dystrophin 
band. Beta-actin (cytoskeletal) was used as the protein loading control. Bio-
Rad’s Precision Plus kaleidoscope protein standards were used in all Western 
blots to access band sizes. 
 
B-Western blot of samples from mdx male mice injected with 1.8 µg/leg of 
pcDNA3.mini-dyst.Fwd plasmid, 7 days post-injection.  A- animal no.1, right leg, 
saline injected; B- animal no.1, left leg, plasmid injected; C-animal no.2, right 
leg, saline injected; D-animal no.2, left leg, plasmid injected; E- animal no.3, 
right leg, saline injected; F-animal no.3, left leg, plasmid injected; H- HEK-T 293 
cells transfected with pcDNA3.mini-dyst.Fwd used as a positive control for 
the125 KDa mini-dystrophin band; C+= C57BL10 mouse leg muscle sample as 
positive control for the 427 KDa dystrophin band. Beta-actin (cytoskeletal)  was 
used as the protein loading control.  
 
C-Agarose gel electrophoresis in a 2% agarose gel of the RT-PCR product in 
muscle samples from mice injected with pcDNA3.mini-dyst.Fwd in pluronic 
SP1017-2 solution. B-H20 as negative control; 1-3R mice cDNA (animal no.3, 
right leg); 2-3L mice cDNA (animal no.3, left leg), animal no. 3 was injected with 
plasmid DNA in saline with pluronic SP1017-2; 3-HEK-T.Dyst.cDNA (cDNA 
from HEK-T cells transfected with pcDNA3.mini-dyst.Fwd), used as a positive 
control. 4-4R mice cDNA (animal no. 4, right leg); 5-4L mice cDNA (animal no. 
4, left leg), animal no. 4 is injected with plasmid DNA in saline only. NEB 100 
bp quick load DNA ladder was used.  
 
D- Western blot of samples from mdx male mice injected with 1 µg/leg for (50µl) 
PX61MCK.Dyst.Fwd plasmid, 7 days post-injection. A-animal no.1, right leg; B-
animal no.1, left leg; C-animal no.2, right leg; D-animal no.2, left leg; E-animal 
no.3, right leg; F-animal no.3, left leg; G-animal no.5, right leg; I-animal no.5, 
left leg; H-HEK-T 293 cells transfected with pcDNA3.mini-dyst.Fwd used as a 
positive control for the 125 KDa mini-dystrophin band. Beta-actin (cytoskeletal) 
was used as the protein loading control.  
(see next page) 
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5.3 Analyses of pcS2+C Beta Galactosidase expression 
This section concerns the expression profile of pcS2+C Beta Galactosidase (β-gal), 
injected alone or with tolerance inducing plasmids. Initially, the experimental details 
about the b-gal only injection are given and later about the co-injection of two 
plasmid combinations are described.  
The expression of pcS2+C Beta Galactosidase was initially analysed by performing 
a single i.m. injection in three mdx female mice. The mice were killed 7 days post-
injection and TA muscle samples were obtained for Western blot analyses. Figure 
5.3.1-A shows a representative blot and bands at an approximately 120 KDa 
corresponding to the positive control confirmed the expression of pcS2+C Beta 
Galactosidase in all samples, with a faint band in sample no. E. This initial analysis 
was performed in female mice due to unavailability of male mdx mice and this 
represents the optimisation phase.  
The next step was to analyse the expression of the plasmid in male mice and to 
analyse the efficiency of vehicles used for injection, i.e. saline injected vs Pluronic 
formulations.   
The six male mdx mice used were divided into three separate batches: i) the first 
batch had three mice that received 1µg/leg of pcS2+C Beta Galactosidase mixed 
with normal saline; ii) the second batch had two mice that received 1µg/leg of 
plasmid formulated with Pluronic SP1017-2 in normal saline and iii) the third batch 
had mice injected with normal saline only, used as a negative control. Figure 5.3.1-
B shows a representative blot. The bands at an approximately 120 KDa 
corresponding to the positive control in all samples confirmed the expression of the 
plasmid with sample no. C having a very faint band, also there were non-specific 
bands of molecular weight higher than 120 KDa, present in all samples. The 
comparison of samples A, B, C (plasmid dissolved in pluronic + saline) and samples 
E- Western blot of samples from mdx male mice injected with 1 µg/leg of (50µl) 
PX61MCK.Dyst.Fwd plasmid, 5 days post-injection, 60 µg of total protein 
loaded. H+= HEK-T 293 cells transfected with pcDNA3.mini-dyst.Fwd used as 
a positive control for the125 KDa mini-dystrophin band; A, B-animal no.1, right 
and left legs respectively ; C, D-animal no.2, right and left legs respectively ; 
E,F-animal no.3, right and left legs respectively; G-animal no.4, left leg; I-
animal no.5, right leg; J-saline only injected mice sample as negative control. 
Beta-actin was used as the protein loading control.  
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D-G (plasmid dissolved in saline only) showed that Pluronic did not increase the 
expression efficiency. Therefore, it was not used in subsequent experiments.  
The next step was to establish the expression timeline and to optimise the plasmid 
injection parameters. Eight mdx male mice were analysed 14 days after the injection 
and Figure 5.3.2-A shows a representative blot with bands at about 120 KDa 
corresponding to the positive control confirmed the expression of pcS2+C Beta 
Galactosidase in samples E and F. 
The next step was to study the expression of the plasmid 21 days post-injection in 
three mdx male mice and Figure 5.3.1-C shows a representative blot. The absence 
of a 120 KDa bands corresponding to the positive control confirmed that there was 
no expression of the plasmid 21 days post-injection. The band lower than 120 KDa 
present in all samples seemed to be non-specific. 
Therefore, these experiments confirmed the expression of b-gal in samples for 7 
days and 14 days and absence of expression 21 days post-injection. The next step 
was to co-inject b-gal with IDO1 and CD11c.IDO1 plasmids to confirm the 
tolerogenic role of IDO1 by increasing the expression of b-gal. After confirming the 
expression profile of b-gal only injection, the co-injection of b-gal with IDO1 would 
confirm whether IDO1 is increasing/inhibiting the expression of b-gal 14 days post-
injection.  
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Next, the co-injection of pcS2+C Beta Galactosidase with pcDNA3.IDO1 and with 
pcDNA3.CD11c.IDO1 was performed to analyse the impact of IDO1 in terms of 
prolonging the b-gal expression. The injections of pcS2+C Beta Galactosidase 
β-gal 
E B C D A F H 
120KDa 
β-Tubulin 55KDa 
A 
β-gal 120KDa 
β-Actin 42KDa 
E B C D A F G H I B
Figure 5.3.1 Analyses of pcS2+C Beta Galactosidase expression: 
A- Western blot of samples from three mdx female mice injected with 1µg/leg 
of pcS2+C Beta Galactosidase plasmid, 7 days post-injection. A, B-animal 
no.1, right and left legs respectively; C, D-animal no.2, right and left legs 
respectively; E, F-animal no.3, right and left legs respectively; H- HEK-T 293 
cells transfected with pcS2+C Beta Galactosidase used as a positive control 
for 120 KDa Beta Galactosidase. Beta-tubulin (cytoskeletal) was used as the 
protein loading control.  
 
B- Western blot of samples from six mdx male mice injected with 1µg/leg 
with Pluronic SP1017-2 in normal saline with pcS2+C Beta Galactosidase 
plasmid, 7 days post-injection. A-Pluronic + Saline + pDNA (2R-animal no. 
2, right leg); B-Pluronic + Saline + pDNA (2L-animal no.2, left leg); C- 
Pluronic + Saline +pDNA (3R- animal no. 3, right leg); D-Saline + pDNA (4R-
animal no. 4, right leg); E-Saline + pDNA (4L-animal no. 4, left leg); F-Saline 
+ pDNA (5R-animal no. 5, right leg); G-Saline + pDNA (5L-animal no. 5, left 
leg); I-Saline + pDNA (6R-animal no. 6, right leg); H-HEK-T 293 cells 
transfected with pcS2+C Beta Galactosidase used as a positive control for 
120 KDa b-gal. Beta-actin (cytoskeletal) was used as the protein loading 
control.  
 
C- Western blot of samples from three mdx male mice injected with 1µg/leg 
of pcS2+C Beta Galactosidase plasmid, 21 days post-injection. A-animal 
no.1, right leg; B-animal no.1, left leg; C-animal no.2, right leg; D-animal 
no.2, left leg; E-animal no.3, right leg; F-animal no.3, left leg; H-HEK-T 293 
cells transfected with pcS2+C Beta Galactosidase used as apositive control 
for 120 KDa b-gal. Beta-actin (cytoskeletal) was used as the protein loading 
control.  
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plasmid only were used to establish the baseline (control) levels of b-gal expression 
and these were compared with co-injected samples of pcDNA3.IDO1 and 
pcDNA3.CD11c.IDO1.  
All co-injection experiments were performed as a single i.m. injection of two 
plasmids. The mice were killed 14 days post-injection and TA muscles were 
excised, frozen, crushed to obtain the tissue powder which was divided into two 
equal parts, one part for the extraction of RNA and the other part for protein 
analyses (as described in Sections 2.3.14.3 and 2.3.17.1). Each protein sample 
was subjected to seven repeats of Western blotting to obtain consistent results. Fiji 
software was used for densitometric analyses of Western blots data (as described 
in Section 2.3.17.7). The obtained arbitrary values obtained were normalised to 
actin/GAPDH bands and with an internal control (sample expressing band with a 
perfect shape). These values were analysed with a Student’s t-test (Minitab 17 
software) to analyse the statistical significance level and the plot was shown as 
mean+SEM.  
The baseline injections were performed using eight mdx male mice and Western 
blot analyses were performed for all 16 muscle samples. The samples were 
analysed on separate blots and One example blot is shown in Figure 5.3.2-A, the 
120 KDa bands in sample 6R (E) and 6L (F) correspond to the positive control 
confirmed the expression of pcS2+C Beta Galactosidase in animal samples 3L, 6R 
(E), 6L (F) and 7L. The bands lower than the positive control were seems to be non-
specific bands and appeared in all Western blots. These analyses showed that out 
of 16 muscle samples only 4 were still expressing b-gal 14 days after plasmid 
injection. 
The co-injections of pcS2+C Beta Galactosidase + pcDNA3.IDO1 were performed 
by using eight mdx male mice and Western blot analyses were performed for all 16 
muscle samples. One example blot is shown in Figure 5.3.2-B, the 120KDa bands 
in samples 12L (A), 14R (B), 14L (C), 15R (D), 15L (E), 16R (F) and 16L (G) 
corresponding to the positive control confirmed the expression of pcS2+C Beta 
Galactosidase in animal samples 10L, 11R, 11L, 12L (A), 14R (B), 14L (C), 15R 
(D), 15L (E), 16R (F) and 16L (G). These analyses showed that out of 16 muscle 
samples only 7 were expressing b-gal 14 days after plasmid co-injection. The 
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arbitrary values obtained from densitometric analyses and using a Student’s t-test. 
A p-value of 0.510 indicates that it was not significant (plot not shown).   
The co-injections of pcS2+C Beta Galactosidase + pcDNA3.CD11c.IDO1 were 
performed by using six mdx male mice and Western blot analyses were performed 
for all 12 muscle samples. One example blot is shown in Figure 5.3.2-C, the 
120KDa bands in samples 5R (C), 5L (D) and 6L (F) corresponding to the positive 
control confirmed the expression of pcS2+C Beta Galactosidase in animal samples 
3R, 3L, 5R (C), 5L (D) and 6L (F). These analyses showed that out of 12 muscle 
samples only 5 were expressing b-gal 14 days after plasmid co-injection. The 
arbitrary values obtained from densitometry analyses were further analysed with a 
Student’s t-test. A p-value of 0.239 indicates that it was not significant (plot not 
shown).   
The RT-PCR and qPCR experiments had repeated a minimum of twice to a 
maximum of five times. Every qPCR experiment was performed using triplicates of 
each mouse sample to minimise error in handling, pipetting etc., that affect the 
values obtained on completion of the assay.  
The Table 5.3.1 gives the summary of the results of the IDO1 RT-PCR, compiled 
with the Western blotting expression profile of b-gal to correlate the effect of IDO1 
in samples expressing b-gal. 
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The qPCR was used to quantify the relative expression of b-gal in samples injected 
with pcS2+C Beta Galactosidase (N=5; 4R, 4L, 5R, 5L and 6R) and pcS2+C Beta 
Galactosidase + pcDNA3.IDO1 (N=5; 10L, 11L, 14R, 16R and 16L) using LacZ 
gene Taqman probe (Life Technologies). These were the selection of samples that 
were earlier analysed for the protein expression by Western blotting (Figure 5.3.2-
A and Figure 5.3.2-B respectively) and RT-PCR (Table 5.3.1). The aim of this 
experiment was to study whether there was any correlation between Western blot, 
RT-PCR and qPCR data. The Student’s t-test was used to analyse the statistical 
Table 5.3.1 The combined Western blot and RT-PCR data for co-injected 
samples   
 
Samples Western blot 
for detection 
of b-gal 
PCR detection of 
pcDNA3.IDO1 in 
injected samples 
PCR detection of 
pcDNA3.CD11c.IDO1in 
injected samples  
9R 0 + NA 
9L 0 + NA 
10R 0 + NA 
10L + + NA 
11R + + NA 
11L + + NA 
12L + + NA 
13R + + NA 
13L + + NA 
14R + + NA 
14L + + NA 
15R + + NA 
15L + + NA 
16R + + NA 
16L + + NA 
3Rc + NA + 
3Lc + NA 0 
4Rc 0 NA + 
4Lc + NA 0 
5Rc + NA 0 
5Lc + NA 0 
6Lc + NA 0 
The symbols used in the table:  0 denotes no expression; + denotes confirmed 
expression; NA=not applicable, i.e. not used in these samples. The RT-PCR 
detected expression of IDO1 in samples 9R, 9L and 10R with no detectable b-
gal in Western blots. CD11c.IDO1 samples 3Rc and 4Rc were confirmed by 
RT-PCR for detectable level of expression of CD11c.IDO1, but majority 
expressed b-gal in Western blots.  
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significance. A p=0.011 was found to be significant and the plot is shown in Figure 
5.3.3.  
 
A B C D E F H 
β-gal 120 KDa 
GAPDH 35KDa 
A 
Figure 5.3.2 Analyses of pcS2+C Beta Galactosidase expression: 
A- Western blot of samples from mdx male mice injected with 0.5 µg/leg of 
pcS2+C Beta Galactosidase plasmid, 14 days post-injection. A, B-animal no. 
4, right and left legs respectively; C, D-animal no.5, right and left legs 
respectively; E, F-animal no.6, right and left legs respectively; H- HEK-T 293 
cells transfected with pcS2+C Beta Galactosidase used as a positive control 
for the 120 KDa Beta Galactosidase. GAPDH was used as the protein 
loading control.  
 
B- Western blot of samples from mdx mice injected with 1 µg/leg of pcS2+C 
Beta Galactosidase + pcDNA3.IDO1 plasmid, 14 days post-injection. A-
animal no. 12, left leg); B-animal no.14, right leg; C-animal no.14, left leg; D-
animal no.15, right leg; E-animal no.15, left leg; F-animal no.16, right leg; G-
animal no.16, left leg; H- HEK-T 293 cells transfected with pcS2+C Beta 
Galactosidase used as a positive control for the 120 KDa Beta 
Galactosidase. GAPDH was used as the protein loading control. 
  
C- Western blot of samples from mdx mice injected with 1 µg/leg of pcS2+C 
Beta Galactosidase + pcDNA3.CD11c.IDO1 plasmid, 14 days post-injection. 
A, B-animal no. 4, right and left legs respectively; C, D-animal no.5, right and 
left legs respectively; E, F-animal no.6, right and left legs respectively; H- 
HEK-T 293 cells transfected with pcS2+C Beta Galactosidase used as a 
positive control for the 120 KDa b-gal. GAPDH was used as the protein 
loading control.  
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Moreover, a one-way ANOVA analysis with Tukey post-hoc test was performed on 
the Western blot densitometric data (arbitrary unit) only for samples that had clear 
bands. This exercise was performed to compile data of all Western blot analyses 
performed using b-gal only, b-gal +CMV.IDO1 and b-gal +CD11c.IDO1 plasmids to 
obtain a broad view of the results. The samples with their values were: b-gal only, 
N=4 (3L, 6R, 6L and 7L); b-gal + pcDNA3.CD11c.IDO1, N=5 (3Rc, 3Lc, 5Rc, 5Lc, 
6Lc) and b-gal + pcDNA3.IDO1, N=11 (10L, 11R, 11L, 12L, 13R, 14R, 14L, 15R, 
15L, 16R and 16L). These analyses confirmed that there was no statistically 
significant difference among the groups, p= 0.25.  
However, it also revealed an important difference, upon combining the data from all 
experiments it becomes obvious that in animals injected with b-gal, only 25% 
muscles expressed b-gal 14 days after injection. In contrast, the number of 
expressing muscles increased to 41.67% b-gal was co-expressed with IDO1 driven 
Figure 5.3.3 The plot of qPCR delta delta CT values for expression of b-
gal (using Laz gene Taqman probe). 
The plot between b-gal (BG, N=5, 5x3=15 data points) and b-gal co-
injected with pcDNA3.IDO1 (BG+IDO1, N=5, 5x3=15 data points). 
Samples were run in triplicates so Nx3, their individual values were used. 
The p=0.011 (**) by Student’s t-test. The mean+SEM is shown in the plot.  
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by the CD11c promoter and to 68.75% in the group with the ubiquitously expressed 
IDO1 driven by CMV promoter. The 68.75% increased expression in presence of 
CMV-driven IDO1 meant that eleven out of 16 muscles sustained the (Figure 5.3.4-
A and Figure 5.3-B).  
The double amount of the b-gal was injected in control (BG) samples that resulted 
in significantly (p=0.008) lower expression of the transgene in these samples 
compared to co-injected samples that indicate the specific immunosuppressive role 
of IDO1 in co-injected samples (Figure 5.3.4.C). This data was used only once in 
the thesis to avoid confusion in Figure 5.3.4.C. 
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Figure 5.3.4 Densitometric analyses of compiled data of Western Blots data 
of b-gal expression.  
A-The plot between BG=b-gal only (N=8); BG+CD11c.IDO1= b-gal co-
injected with pcDNA3.CD11c.IDO1 (N=6) and BG+IDO1= b-gal co-injected 
with pcDNA3.IDO1 (N=8).  
The Y-axis represents Western blot band intensity values from Fiji software. 
The p=0.261 by one-way ANOVA analysis with Tukey’s post-hoc test. The 
mean+SEM is shown in the plot. 
B-The expression was detected in BG=4 muscles out of 16; 
BG+CD11c.IDO1=5 muscles out of 12; BG+IDO1=11 muscles out of 16. 
 
 
BG+IDO1BG + CD11c.IDO1BG
2.5
2.0
1.5
1.0
0.5
0.0
Re
la
tiv
e 
pr
ot
ei
n 
ex
pr
es
sio
n 
(A
rb
itr
ar
y 
un
it)
p= 0.261
A 
B 
	 159	
 
5.4 Analyses of pcDNA3.IDO1 expression 
The expression of pcDNA3.IDO1 was analysed using four mdx male mice injected 
with IDO1 and one mouse injected with saline only as negative control. The mice 
were killed 7 days post-injection and TA muscle samples were obtained for Western 
blotting and RT-PCR analyses.  
Figure 5.4-A shows a representative blot. The absence of a 42 KDa band 
corresponding to the positive control in all samples showed there was no detectable 
expression of IDO1. There were bands of molecular weight higher than 42 KDa 
present in most samples presumably non-specific.  
The RT-PCR was used to analysed pcDNA3.IDO1 expression at the transcript 
level. The RNA was extracted from muscle samples 5R and 5L and cDNAs were 
made (as described in Section 2.3.15). The IDO1.Fwd1+ IDO1.RC1 primers were 
used to detect an IDO1 specific amplicon of 1200 bp PCR amplicon. Figure 5.4-B 
Figure 5.3.4 (continued) 
C-Densitometric analyses of Western Blots data of double 
amount of b-gal plasmid in control samples (BG).  
The plot between BG=b-gal only (N=14); BG+IDO1= b-gal co-
injected with pcDNA3.IDO1 (N=14).  
The Y-axis represents Western blot band intensity values from 
Fiji software. The p=0.008 by one-way ANOVA analysis with 
Tukey’s post-hoc test. The mean+SEM is shown in the plot. 
	
P=0.008 
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shows a gel image. The presence of faint bands of an IDO1 specific amplicon of 
1200 bp in sample B and C corresponding to the positive control confirmed the 
expression of the IDO1 plasmid.  
This experiment was a pilot one, performed to confirm the feasibility of using the 
RT-PCR procedure for the detection of IDO1as these primers were not designed to 
specifically detect plasmid encoded IDO1 from endogenously produced IDO1. So, 
the next step was to design new primers and to confirm their specificity.  
The new primers were designed to anneal to the sequence present only in the 
transcript expressed from plasmid but not in the endogenous IDO1. The RT-PCR 
was set up with this new set of primers in samples from eight mice that were co-
injected with pcS2+C Beta Galactosidase + pcDNA3.IDO1 (these animal samples 
were described in Section 5.3 for co-injection). The IDO1.Exon10.Fwd1 primer and 
IDO1.RC1 primer set was used to detect plasmid encoded IDO1 specific amplicon 
of 382 bp. The forward primer was designed based on the internal sequence of 
IDO1 mRNA at exon 10 and the reverse primer based on the sequence flanking the 
pcDNA3 vector as shown in Figure 4.4-C. Figure 5.4-C shows a representative gel 
image with six samples, others were loaded in separated gels (data not shown). 
The presence of IDO1 specific amplicon of 382 bp bands in animal samples 9R, 
9L, 10R, 10L, 11R, 11L, 12L, 13R, 13L, 14R (B), 14L (C), 15R (D), 15L (E), 16R 
(F), and 16L (G) confirmed the expression of plasmid-driven IDO1. The RT-PCR of 
RNA samples without reverse transcriptase were used as negative controls and no 
amplification was detected in 2% agarose gel, as expected (data not shown).  
The results of the IDO1 RT-PCR were compiled with the Western blotting 
expression profile of b-gal in Table 5.3.1. This was done to correlate the effect of 
IDO1 in samples expressing b-gal. 
The qPCR was used to quantify the relative expression of the IDO1 gene (using 
Taqman Probes) in pcS2+C Beta Galactosidase (N=5) and pcS2+C Beta 
Galactosidase + pcDNA3.IDO1 (N=5) injected animals. The Student’s t-test was 
used to analyse the differences and at p=0.000 (Figure 5.4-D), it was found to be 
statistically significant. This revealed that IDO1 expression was very significantly 
increased in muscle samples co-injected with pcDNA3.IDO1 (Table 5.3.1). 
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5.5 Analyses of pcDNA3.CD11c.IDO1 expression 
The pcDNA.CD11c.IDO1 expression was analysed by RT-PCR due to the 
presence of a very faint band of pcDNA3.CD11c.IDO1 (Figure 4.7) in cell lines and 
the absence of pcDNA3.IDO1 expression in Western blot in animal samples (Figure 
5.4.A). 
Six mdx male mice were co-injected with pcS2+C Beta Galactosidase + 
pcDNA3.CD11c.IDO1. These are the same mice that were used in Figure 5.3.4-A 
Figure 5.4 Analyses of pcDNA3.IDO1 expression: 
A-Western blot of samples from mdx mice injected with 1µg/leg of 
pcDNA3.IDO1 plasmid and 60 µg of total protein loaded in gel.  
A, B-mice no.1, right and left legs respectively, saline only used as 
negative control; C, D-mice no.2, right and left legs respectively; E, F-mice 
no.3, right and left legs respectively; G, I-mice no.4, right and left legs 
respectively; H-HEK-T 293 cells transfected with pcDNA3.IDO1 used as a 
positive control for the 42 KDa IDO1 band. GAPDH was used as the 
protein loading control.  
 
B- Agarose gel electrophoresis in 1% agarose gel of the RT-PCR product 
of pcDNA3.IDO1.cDNA.   
A-H20 as negative control; B, C-cDNA from animal no.5, right and left legs 
respectively; D-cDNA made by minus RT (no reverse transcriptase 
enzyme added) of animal no.5 right leg, used as negative control; E-cDNA 
made by minus RT of animal no.5 left leg; F-diluted pcDNA3.IDO1 plasmid 
as positive control; G-2 µl of PCR product from previous PCR, that was 
run to analyse the efficiency of primers using diluted pcDNA3.IDO1, used 
as positive control. NEB 100 bp quick DNA load ladder was used. Bands 
of about 1200 bp in samples B and C confirmed the expression. 
 
C- Agarose gel electrophoresis in 2% agarose gel of RT-PCR product of 
pcDNA3.IDO1.cDNA.  
A-H20 as negative control; B, C-animal no.14, right and left legs 
respectively; D, E-animal no.15, right and left legs respectively; F, G-
animal no.16, right and left legs respectively; H-cDNA from animal no.8, 
left leg, used as negative control as not injected with pcDNA3.IDO1. NEB 
100 bp quick load DNA ladder was used. Bands of about 400 bp in samples 
B to G confirmed the expression.  
 
D- Plot of qPCR delta delta CT values for expression of IDO1. 
The plot between b-gal (BG, N=5, 5x3=15 data points) and b-gal co-
injected with pcDNA3.IDO1 (BG+IDO1, N=5, 5x3=15 data points). 
Samples were run in triplicates so Nx3, their individual values were used. 
The p=0.000 (****) by Student’s t-test. The mean+SEM shown in the plot. 
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for b-gal Western blotting. The mice were killed 14 days post-injection and TA 
muscles were crushed for RNA extraction (as described in Section 5.3). The PCR 
was set up using IDO1.Exon10.Fwd1 and IDO1.RC1 primer sets to detect an IDO1 
specific amplicon of 382 bp (as described in Section 5.4). The presence of very faint 
bands in Figure 5.5 of an IDO1 specific amplicon of 382 bp in animal samples G 
(3Rc) and I (4Rc) confirmed the expression of CD11c.IDO1. The RNA samples 
without reverse transcriptase were used as negative controls and no amplification 
was detected as expected (data not shown). 
The absence of 382 bp bands in other samples could be due to multiple factors 
including: 1) low level of CD11c.IDO1 expression at the transcript (RNA) level or 
efficient targeting of this construct to dendritic cells causing modulation of dendritic 
cells leading to increased expression of the transgene (b-gal), hence absence of its 
transcript; 2) degradation of pDNA (described in Section 5.8.3); 3) in-efficient 
primers to fully amplify the very few transcripts.  
  
 
5.6 Analyses of pcDNA4.FOXO3WT expression 
The expression of pcDNA4.FOXO3WT was analysed using five mdx male mice, 
killed 7 days post-injection and TA muscle samples were obtained for Western blot 
analyses. Figure 5.6-A shows a representative Western blot. The presence of a 
Figure 5.5 Analyses of pcDNA3.CD11c.IDO1 expression.  
Agarose gel electrophoresis in 2% gel of RT-PCR product of samples 
injected with pcS2+C Beta Galactosidase +pcDNA3.CD11c.IDO1.cDNA. 
A-H20 as negative control; B-animal no. 8, left leg used as negative control 
as not injected with pcDNA3.CD11c.IDO1/pcDNA3.IDO1; C, D-animal no.1, 
right and left legs respectively; E-animal no. 2, right and left legs respectively; 
G, H-animal no. 3, right and left legs respectively; I, J-animal no. 4, right and 
left legs respectively; K-animal no. 5, right leg.  
NEB 100 bp quick load DNA ladder was used. Bands of about 400 bp in 
samples G and I confirmed the expression. 
A B C D E F G H I J K 
*	 *	
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very faint band of 80 KDa corresponding to the positive control in all samples 
confirmed expression of pcDNA4.FOXO3WT. Sample-B was the HEK 293 
untransfected cell lysate used as a negative control which shows lower band 
relative to the positive control (sample no. A). This might indicate the presence of 
endogenous FOXO3 expression. Since all animal samples are aligned to the 
positive control, they confirmed the expression of FOXO3WT.  
 
The experiment was repeated with six mdx male mice, killed 7 days post-injection. 
The Western blot was completed as shown in Figure 5.6-B that indicates the 
absence of 80 KDa band corresponding to the positive control confirmed the 
absence of FOXO3WT expression.  
RT-PCR and immunohistochemistry were used to analyse further the expression. 
RT-PCR was not able to detect specific FOXO3 PCR amplicon (data not shown) 
and Haematoxylin-Eosin staining of mdx mice muscle did not confirm any structural 
improvement compared to a saline injected sample (used as negative control, data 
not shown). Therefore, the FOXO3WT plasmid was not used in further experiments.  
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5.7 Summary 
The single plasmid expression experiment with pcDNA3.mini-dyst.Fwd revealed 
highly variable protein expression by Western blotting. RT-PCR analyses confirmed 
its expression while immunohistochemistry was inconclusive. Expression of 
PX61MCK.mini-dyst.Fwd was confirmed by Western blotting. However, there was 
no significant difference in expression of mini-dystrophin driven by CMV compared 
to that driven by the muscle-specific MCK promoter/MLC enhancer combination in 
PX61MCK.mini-dyst.Fwd. The use of Pluronic SP1017-2 did not have any 
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Figure 5.6 Analyses of pcDNA4.FOXO3WT expression: 
A- Western blot of samples from mdx mice injected with 1µg/leg of 
pcDNA4.FOXO3WT plasmid, 60 µg of total protein loaded.  
A- HEK-T 293 cells transfected with pcDNA4.FOXO3WT was used as the 
positive control for 80 KDa FoxO3WT; B-HEK-T 293 un-transfected cell 
lysate used as the negative control; C, D-animal no.1, right and left legs 
respectively; E, F-animal no.2, right and left legs respectively; G, H-animal 
no.3, right and left legs respectively; I, J-animal no.4, right and left legs 
respectively, saline only injected sample used as a negative control. GAPDH 
was used as the protein loading control.  
 
B-Western blot of samples from mdx mice injected with 1µg/leg of  
pcDNA4.FOXO3WT plasmid, 60 µg of total protein. A- HEK-T 293 cells 
transfected with pcDNA4.FOXO3WT was used as the positive control for 80 
KDa FoxO3WT; B, C-animal no.1, right and left legs respectively, saline only; 
D, E-animal no.2, right and left legs respectively; F, G-animal no.3, right and 
left legs respectively; H, I-animal no.4, right and left legs respectively; J- 
animal no.5, right leg. Beta-actin (cytoskeletal) was used as the protein 
loading control.  
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significant effects on the expression levels of plasmids as compared to the standard 
saline formulation.  
The low-level and ill-reproducible expression of dystrophin minigene was not 
suitable as a model to study the impact of the co-expression of the tolerance-
inducing IDO1 gene. Therefore, the immunogenic b-gal reporter was used instead. 
The timeline of its expression was established, it was found to be expressed at 7 
days post-injection in all samples, still expressed at 14 days post-injection in some 
and absent at 21 days post-injection.  
The expression of IDO1 in the injected muscles was not detectable at the protein 
level but clearly present when the specific, plasmid-driven transcript expression 
was analysed by RT-PCR. 
Co-injection of pcS2+C Beta Galactosidase with IDO1 driven by CMV promoter 
resulted in significantly prolonged expression of this reporter protein. It was found 
in nearly 70% of muscles co-injected with the two plasmids while it was found in 
25% of beta gal only samples. However, the average expression levels were not 
significantly different, mostly due to the high expression variability in individual 
samples. Moreover, IDO1 expression targeted to dendritic cells by using CD11c 
promoter also resulted in a larger number of a reporter gene (b-gal) expressing 
muscles (<50%) but it has higher intensities of bands in Western blotting compared 
to CMV-driven IDO1.  
The data compiled from RT-PCR with Western blot for expression of pcDNA3.IDO1 
and pcDNA3.CD11c.IDO1 in Table 5.3.1 also confirmed some important points. It 
showed that the RT-PCR approach could detect bands for pcDNA3.IDO1 in 
samples 9R, 9L and 10R that were not expressing b-gal in Western blot, similarly 
4Rc (I) sample was detected for pcDNA3.CD11c.IDO1. The expression levels of 
CD11c.IDO1 need greater optimisation to detect its expression by RT-PCR as it 
could detect only two samples 3Rc (G) and 4Rc (I). This indicates that the plasmid 
did not degrade so it might be that its expression was used by dendritic cells causing 
tolerance induction that leads to higher intensities of b-gal bands in Western 
blotting, albeit in fewer muscle samples. The Table 5.3.1 also indicates that 
CD11c.IDO1 while able to increase the b-gal expression, it was not as effective as 
the ubiquitously expressed, CMV-driven, IDO1. This is an important observation as 
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it demonstrated that there is no need for cell-specific targeting of this tolerance 
inducing gene, which makes such an approach more universally applicable. 
The qPCR data confirmed a significantly increased expression of b-gal and IDO1 
in co-injected samples (pcS2+C Beta Galactosidase+ pcDNA3.IDO1) compared to 
control samples (pcS2+C Beta Galactosidase).  
These results indicated that the co-expression of the tolerance inducing gene 
(IDO1) can sustain the expression of an immunogenic transgene (b-gal) 
 
5.8 Discussion 
The reason for these observations:  
5.8.1- Lower uptake of plasmid being a common problem with naked plasmid 
injection. 
5.8.2-Absence of signal recognition particle sequence and similar signalling 
molecules in mini-dystrophin.  
5.8.3-Degradation of plasmid DNA (pDNA).  
5.8.4-Immune responses against pDNA. 
 
5.8.1-Lower uptake of plasmid being a common problem with naked plasmid 
injection 
Wolff et al (151) first showed successful expression of E.coli b-gal by injection of 
100 μg naked plasmid in the quadriceps muscle of BALB/c mice. Interestingly, the 
paper shows just a few myofibres expressing b-gal, which was a very similar pattern 
to our muscle sections injected with β-gal and stained using X-gal staining. 
However, we only used 12.5 μg of plasmid DNA following previous work perform in 
our lab (360) compared to 100 μg used by Wolff et al in their study.  
The review article by Budker et al (209) discussed the mechanisms of naked pDNA 
uptake compiled from different publications to support the various hypotheses 
related to pDNA uptake, e.g: large membrane disruption; transient large membrane 
pores, transient small membrane pores, an active uptake process, adsorptive vs 
fluid phase endocytosis, plasma membrane receptors for oligo-nucleic acids, 
plasma membrane receptors for large double-stranded DNA, the role of scavenger 
receptors in DNA uptake, and the effect of excess polyanions and the role of high 
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pressure. These studies were performed in a variety of different types of tissue to 
give an overview of the wider mechanism but did not give a clear and specific 
understanding of plasmid uptake in the skeletal muscles of mdx mice to further 
improve the pDNA uptake efficiency. 
The study by Andre et al (361) showed that by increasing the speed of injection 
from 2 μl/s to 25 μl/s significantly increased (an approximate 280 times) gene 
expression in skeletal muscles. This study indicates a relation between the 
variability of the speed of injection towards the variability of pDNA expression often 
found among the muscle samples obtained from the same animal. In our study, the 
injection speed was kept to slow, at about 5 μl/s to prevent blowback of pDNA 
leading to its spillage that might increase variability among the pDNA expression in 
muscle samples. The high-speed injection could be used to test its abilities to 
increase the efficiency of pDNA uptake in the future work.  
A study by Kawase et al(362) indicated that the total accumulation of pDNA in other 
tissues (devoid of direct injection) was less than 2% of the amount injected at the 
injection site; pDNA from the quadriceps muscle was taken up directly by the blood 
circulation or indirectly by the lymphatic system from the site of injection within 10 
m of injection but 20 μg of plasmid was sufficient for high expression of luciferase 
(>108 relative light units) despite this rapid clearance from the injection site. These 
values are like those used in this study.  
A study by Taniyama et al (363) showed a 10-fold significant increase of naked 
pDNA in skeletal muscle by using ultrasound irradiation with echo contrast 
microbubble (Optison) compared to naked pDNA. Ultrasound was shown to 
increase cell permeability and facilitate the quick and easy migration of pDNA from 
outside to the cytoplasm of a cell. Similarly, a study by Li et al (364) employed both 
electroporation (electric pulses using a syringe electrode) and ultrasound 
(Ultrasound field using syringe focused ultrasound device) methods to increase 
transfection efficiency of naked pDNA by increasing the cell permeability. They 
used a syringe electrode with pulses of alternating current sine-waves (365) with a 
frequency of 60 Hz to apply a lower field strength to reduce the muscle damage 
compared to the calliper electrode’s direct current square-wave pulses that were 
used most often in this type of study. This study reported the detection of the 
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expression of 1 μg pDNA after 6 h of injection with gene expression efficiency of 8 
fold in the liver and 10 fold in the skin. Moreover, the application of a syringe focused 
ultrasound device on delivering naked pDNA for the expression of human neprilysin 
in mouse hindlimb skeletal muscles was shown to last for two months with minor 
tissue damage, while pDNA injected without ultrasound failed to show any 
detectable levels of plasmid expression (366). 
The mini-dystrophin construct used in our study was expressed using an 
approximate 30 μg of pDNA in the TA muscle of 6-week old mdx mice by an 
electroporation procedure (4). However, in our study, we used an approximate 12 
μg pDNA. Also, we used TA muscle of 4 week old mdx mice without using 
electroporation procedure but simple naked i.m. injection. Electroporation requires 
specialised, expensive equipment and it was shown to cause tissue damage. 
Moreover, we did not aim for a high level of transgene expression in TA muscle as 
our study aimed to confirm the influence of tolerogenic plasmids on increasing the 
expression of the transgene. Therefore, it was thought that we could rely on the 
natural mechanisms of plasmid uptake by skeletal muscle as confirmed in previous 
work perform in our laboratory using CMV and MCK/MLC driven plasmids 
expressing human alpha-galactosidase (secretory protein) generating sufficient 
levels of plasmid expression followed by naked pDNA injection in Fabry mice (a 
mouse model of X-linked inherited metabolic disorder called Anderson-Fabry 
disease that is caused by a deficiency of α-galactosidase A) (265). In our study, 
mini-dystrophin is a structural protein while b-gal is a secretory protein, so it seems 
that pDNA expression of the secretory protein is more efficient in its consistent 
expression profile both in vitro and in vivo.  
 
5.8.2-Absence of signal recognition particle sequence and similar signalling 
molecules in mini-dystrophin  
 It is proposed that the mini-dystrophin, being a structural protein, needs a 
membrane targeting sequence to enable its localisation in the sarcolemma 
membrane, to prevent its degradation by the proteasome and similar other proteins 
engineering to increase its stabilisation and localisation in the membrane. 
The integral membrane proteins are co-translated into the endoplasmic reticulum 
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(ER) mediated by ER translocon (367). This process of integration of the membrane 
protein in the lipid layer is multistep process completed by the transmembrane (TM) 
sequence, Sec61 alpha, TRAM and other accessory molecules (368-370). 
Von et al (371) indicated the important role of the bacterial and mammalian signal 
recognition particle (SRP), that are a universally conserved protein targeting 
machine, co-translated with protein and which control the membrane localisation of 
nascent proteins. Similarly, the integral membrane proteins were shown to contain 
very hydrophobic amino acids, due to the presence of 50% uracil in their mRNA 
(372). The uracil sequence could be added to the protein sequence to enable 
targeting of the membrane protein without depending on the co-translational 
mechanism of a signal recognition particle. Those proteins that are misfolded or not 
localised to their destined location were degraded by either autophagy or the 
ubiquitin–proteasome system. Kraft et al (373) showed that a cross-talk link exists 
between these two pathways. The addition of a glycosyl-phosphatidyl inositol (GPI) 
signal to the transgene was shown to localise an expressed intracellular protein to 
the extracellular leaflet of the plasma membrane in neurons and polarised epithelial 
cells (374). The use of RhoAV14, an active form of the Rho family of small GTPase 
signalling molecules was shown to induce transcriptional activation of the utrophin 
promoter, post-translational stabilisation and increased localisation of utrophin in 
the plasma membrane (375). The overexpression of a full-length utrophin was 
shown to prevent muscular dystrophy characteristics in mdx mice (376). Similarly, 
the use of truncated utrophin was shown to improve mechanical performance and 
intracellular calcium homoeostasis (377). The 26S proteasome is a large ATP-
dependent protein complex that degrades non-functional and potentially toxic 
proteins (378). Similarly, the process of SUMOylation of proteins was shown to 
degrade misfolded protein by using PML/TIM19, SUMO-dependent ubiquitin ligase 
and ubiquitin-dependent RNF4, the SUMOylated proteins were recognised by 
ubiquitinated RNF4 and degraded by the proteasome complex to prevent 
neurodegeneration (379). 
 The use of the proteasome inhibitor MG-132 was shown to recover expression of 
dystrophin, beta-dystroglycan, alpha-dystroglycan, and alpha-sarcoglycan  
(components of Dystrophin-associated protein complex) in skeletal muscle fibres 
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from mdx mice (326) confirming the active role of the protein degradation 
mechanism.  
 
5.8.3-Degradation of plasmid DNA (pDNA)  
The naked pDNA starts being degraded by cytosolic nucleases immediately after 
injection. Bureau et al (380) used radiolabeled plasmid DNA delivered by 
electroporation and showed that, after injection, the pDNA was partitioned into two 
compartments. In the first compartment, pDNA was rapidly degraded by cytosolic 
nucleases while the second compartment, generated by electroporation, contained 
a small amount of the pDNA that remained safe from the cytosolic nucleases. 
Autoradiography confirmed the distribution of most pDNA into the interfibrillar space 
that makes a large proportion of skeletal muscle, having the DNAses. The 
degradation of pDNA starts after 5 minutes and remains active up to 3 hours post-
injection. The initial 5 minutes causes the loss of an approximate 70% of the pDNA 
injected. The actual expression of pDNA was correlated to a small amount of pDNA 
preserved from this degradation. Pollard et al (381) used cDNA plasmids 
microinjected in mammalian cells and its detection by fluorescent in-situ 
hybridization (FISH) confirmed that the naked cDNA was rapidly degraded in the 
cytosolic fraction of mammalian cells due to the presence of cytosolic nucleases, 
leaving only 50% pDNA intact after 2 hours of post-injection. In contrast, the pDNA 
transferred to the nuclear fraction did not show this rapid degradation. The use of 
cytosolic nucleases inhibitors (i.e. aurin tricarboxylic acid and Zn2+) prevented 
cDNA degradation when tested in vitro using the cytosolic fraction isolated from 
cells. Moreover, the mixing of pDNA with either Polyethylenimine (PEI) or the 
addition of oligonucleotide to pDNA inhibited the in vitro degradation of cDNA. PEI 
was shown to increase transgene expression in mammalian cells (309) and in ddY 
mice (382). Lechardeur et al (383) confirmed that the naked pDNA (both the single 
circular and double circular) entering the cytoplasm of HeLa and COS cells is 
unstable due to the presence of cytosolic nucleases that degrade it by 50% within 
the range of 50 to 90 m post-injection. This degradation was not seen upon pDNA 
encapsulation in stabilised plasmid-lipid particles (SPLP) that are phospholipid 
vesicles or cells depleted of cytosol with selective permeabilization with digitonin or 
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if protein synthesis was inhibited using cycloheximide. This degradation was not 
due to cell division or apoptotic nucleases or lysosomal nucleases. Rattan et al 
(384) used high-throughput sequencing to locate the degradation site for the S1 
and cytosolic nucleases in a polyplex treated cell cytosol for luciferase pDNA. The 
cytosolic nucleases cut the pDNA at multiple sites, at the poly (A) region of the beta-
lactamase gene to the cytomegalovirus promoter (CMV), at the 5’ end of the beta-
lactamase gene and at additional sites of the OriC region, SV40 poly (A) region and 
luciferase gene. The S1 nuclease cut at the region of bovine growth hormone 
polyadenylation signal (BGH poly A), this was also confirmed by Riberio et al (385) 
and both nucleases were shown to have a higher affinity for degrading supercoiled 
pDNA than linear pDNA. The use of the proteasome Inhibitor (MG-132) in mdx mice 
by Bonuccelli et al(326) confirmed there is less damage to muscle and a reduction 
in the histopathological signs of muscular dystrophy in mice. Similarly, use of the 
proteasome inhibitor was shown to result in a gain of muscle mass (327) and has 
a potential that needs to be explored to increase the expression of pDNA 
expressing mini-dystrophin. 
 
5.8.4-Immune responses against pDNA 
The study by Mendell et al (125) transferring the functional dystrophin transgene to 
the skeletal muscle of six patients suffering from Duchenne muscular dystrophy 
confirmed the presence of dystrophin-specific T-cells and also detected circulatory 
dystrophin-specific T-cells prior to the treatment indicating the activation of a T-cell 
mediated immune response.  
The transplantation study by Ohtsuka et al (225) of myoblast cells from C57BL10 
to mdx confirmed the role of dystrophin as an antigen in dystrophin-deficient mice 
by detection of CD8 dominant cytotoxic T lymphocytes (CTL) restricted to H-2Kb, 
which is a peptide-binding site of the murine MHC class I (386).  The study by 
Eghtesad et al (387) used irradiation of the mdx mice to remove all the components 
of the central and peripheral immune system followed by intramuscular injection of 
high-capacity adenoviral vectors (HD-Ad) containing murine full-length dystrophin 
cDNA driven by the muscle creatine kinase promoter (MCK) which led to a reduced 
or absent humoral response against the dystrophin protein. This significantly 
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delayed the development of an anti-dystrophin antibody response in low-dose and 
high-dose irradiated muscles of mdx mice after reconstitution with bone marrow 
derived from wild type C57BL10 mice, which have immune cells naturally tolerant 
to dystrophin. The absence of T-cells in irradiated vector injected muscle samples 
of mdx mice and in untreated muscle samples of mdx mice was contrasted with 
their presence in the muscle samples of non-irradiated vector injected mdx mice. 
The presence of higher levels of Foxp3+ T- reg cells in irradiated vector injected 
muscles confirmed tolerance induction against dystrophin as these cells were 
native of C57BL10 mice derived by bone marrow transfer. The use of rapamycin 
containing poly-lactic-co-glycolic acid (PLGA) microparticles was shown to reduce 
immunity against vector-mediated dystrophin protein (388). Similarly, the 
suppression of Natural killer cells (NK) cells by localised expression of T-reg cells 
was shown to improve the efficiency of DNA vaccines (389).  
The use of recombinant adeno-associated virus (AAV) was shown to express b-gal, 
the neoantigen transgenic products in TA muscle fibres of C57BL6 mice without 
activation of cellular and humoral immunity (390, 391). It was also confirmed that 
the use of the muscle creatine kinase (MCK) promoter with b-gal in AAV delayed 
the immune response (391). These studies confirmed the role of tolerance induction 
by targeting Foxp3+ T-cells that was applied in our study.  
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Chapter 6 Morphological and molecular analyses of b-gal expressing 
muscles  
 
6.0 Aims and objectives  
Aims: To study the expression of immune markers to confirm tolerance induction. 
The objectives of this Chapter were to: 
• Analyse the distribution pattern of b-gal in injected muscles by X-gal 
staining.  
• Analyse the presence of specific immune markers (CD4, CD8, CD34, 
CD68, LY6G) in muscle sections by immunohistochemistry.  
• Analyse the expression of specific immune markers (CD4, CD8a, 
FOXOP3, COX2, IL-10, IL-12a) using qPCR.  
• Analyse the serum titre of antibodies against b-gal in single-injected vs co-
injected mice by ELISA.  
 
6.1 Introduction 
X-gal staining was performed to analyse the distribution of pcS2+C Beta 
Galactosidase in TA muscle. The staining was performed for both types of 
injections, the single plasmid injected with pcS2+C Beta Galactosidase and co-
injected pcS2+C Beta Galactosidase + pcDNA3.IDO1. The single injected and co-
injected samples were analysed for the presence of immune markers in the 
proximity of the fibres expressing b-gal. This was performed to obtain relative 
analyses of these makers between single and co-injected samples to correlate it 
with the effect of IDO1 expression.  We selected these immune markers for their 
following features:  
CD4/CD8: Morrison et al (52) confirmed the presence of more activated T-
lymphocytes in mdx mice compared to wild type and their presence up to 24 weeks. 
These T-cells were shown to be responsible for the fibrosis in mdx mice (53) and in 
promoting the muscle pathology (57).  The binding of CD4 with major 
histocompatibility complex II (MHC-II) activates CD4+ T- cells (T-helper cell). The 
blockade of this binding of CD4 (392) leads to tolerance induction. Similarly, the 
binding of CD8 with MHC-I activates CD8+ T-cells (cytotoxic T-cells) also known as 
cytotoxic T-lymphocytes (CTL). The depletion of CD4 by non-cytotoxic antibody in 
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vivo in mdx mice leads to a reduction of 61% in muscle pathology and a similar 
depletion of CD8 leads to a reduction of 75% in muscle pathology (57). This 
indicates the importance of CD4 and CD8 T cells in determining muscle pathology. 
The presence of CD44 high, which is an indicator of T cell activation, further confirms 
the activated state of these cells. CD44 high was shown to present more in muscle 
cells compared to lymphoid tissues (57). The mdx mice had 17 times more CD44 
high CD4 T cells and 18 times more CD44 High CD8 T cells compared to C57B/L10 
mice in muscle (57). This activation depends on antigen presentation to the antigen 
presenting cells (APC), MHC-I and MHC-II. Carpentier et al (393) confirmed that 
the expression of the transgene in APC cells could be avoided by manipulating 
subcellular localisation of the transgene, they used ovalbumin that lacks strong 
MHC-II epitope hence evades CD8+ T cells. The immune markers used in our study 
to confirm the region of inflammation around the b-gal expressing fibre to quantify 
whether single injected or co-injected has more of these markers.  
CD34: CD34 is a marker for haematopoietic stem cells and for quiescent muscle 
satellite cells (394). CD34 with α7 integrin was used to select and purify satellite 
cells (395). Therefore, this marker was used to study the region of active 
regeneration in muscle (396).  
CD68: CD68 is an M1 type of macrophage marker and important for their functions. 
It is also known as macrosialine (397) and binds to oxidised low-density lipoproteins 
(398) to process them for phagocytosis. This marker was selected to detect M1 
macrophages in the section to study the regions of active endocytosis of cellular 
content.  
Ly6G: Ly6G is a marker of neutrophil migration (399) (400). The study by Pizza et 
al. (401) showed that a neutrophil’s endocytic activity causes breakdown of 
membranes in myotubes cultured in vitro. A similar study by Hodgetts et al. (402) 
showed that the depletion of neutrophils reduces the necrosis in mdx mice. This 
marker was therefore selected to locate neutrophils in the regions around the b-gal 
expressing fibres.  
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The qPCR method was used to detect the relative expression of CD4, CD8a, 
FOXOP3, COX2, IL-10, IL-12a in co-injected muscle samples to confirm the effect 
of IDO1 expression. We selected these immune markers for their following features:  
CD4/CD8: The details of the feature of CD4 and CD8 marker were described in 
above sentences.  
FOXP3: The FOXP3 (forkhead box P3) is a transcription factor that regulates the 
development and function of T-reg (T-regulatory) cells (403). T-reg cells suppress 
the immune response and are also shown to repair muscle (404) (405). The use of 
IDO1 was to target DCs to induce tolerance via T-reg cells.  
COX2: COX (cyclooxygenase) is an enzyme involved in the synthesis of 
prostaglandins. The COX-2 expression is induced by pro-inflammatory cytokines 
(406) and its inhibition by using the non-steroidal anti-inflammatory drug (NSAIDs) 
(i.e Asprin) relieves the inflammation. So, its presence is indicative of an 
inflammatory state.  
IL-10: IL-10 (interleukin 10) is an anti-inflammatory cytokine (407) which plays an 
important role in maintaining inflammation and immune regulation (408) and it is 
required for normal muscle regeneration (409). IL-10 is produced by Th2 cells (410).  
IL-12: Similarly IL-12 (interleukin 12) is involved in the development of CD4+ Th1 
cells (411). It also activates natural killer (NK) cells, that cause inflammation (412). 
Dendritic cells secrete IL-12 to regulate the Th1 pathway (413, 414) to initiate cell-
mediated immunity against intracellular pathogens (415) and lead to the lytic 
function of cytotoxic T-lymphocyte (CTL) that is not dependent on the reduction of 
interferon-gamma (INF-γ) and tumour necrosis factor alpha (TNF-α) (416). These 
dendritic cells were shown to exhibits a growth stimulating activity for T cells(417).  
Felzmann et al (418) confirmed the presence of two types of dendritic cells: sm-
DC1, the semi-mature IL-12 secreting type 1 dendritic cells and fm-DC1, the fully-
mature DC1 cells that lose their ability to secrete IL-12. The sm-DC1 activates 
cytolysis by T-cells. The combination of IL-1β, IL-6, TNF-α, and prostaglandin E2 
convert sm-DC1 to DC2. The DC2 lose both their ability to secrete IL-12 and 
activate T-cells. Thus, IL-12-secreting sm-DC1 play an essential role in activating 
CTL response against the exogenously provided antigen. IL-12 has been shown to 
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reduce allergic lung inflammation by targeting Th17 cells (419). This marker was 
selected to confirm the presence of dendritic cells and its accessory Th1 cells  
 
6.2 Morphological analyses of b-gal expressing muscles 
Five mice were co-injected with pcS2+C Beta Galactosidase + pcDNA3.IDO1 or 
injected with pcS2+C Beta Galactosidase alone. One animal from each batch was 
used for the immunohistochemistry analyses.  
The X-gal staining (described in Section 2.5.2.4) was used to analyse the 
distribution of the plasmid-encoded E.coli b-gal in the TA muscle of mdx mice by 
using staining solution at pH 7.5 it was possible to avoid the detection of 
endogenous b-gal (420). The light microscope analyses (Figure 6.2.1) revealed 
very few fibres expressing b-gal (on average, 3-4 fibres per section). This 
corresponded with the observed low-level expression found in Western blots.  
The blue coloured areas in the images are the X-gal stained fibres confirming the 
presence of b-gal. The dark purple coloured areas are the haematoxylin stained 
nucleus and the presence of multiple nuclei near to b-gal fibres confirm the 
infiltration of cells.  These cells might be immune cells or might be nuclei of muscle 
fibres showing a central nucleation pattern (421), which is characteristic of mdx 
mouse inflammation.  There was no obvious difference between the infiltrations in 
b-gal only injected muscles (Figure 6.2.2 A and B) and the co-injected samples 
(Figure 6.2.2 C-H). In fact, some highly-expressing fibres were surrounded by 
mononuclear cells while others were not.  
Figure 6.2.1 shows a low-resolution image of the X-gal stained sections of the 
muscle injected with b-gal +IDO1 and presents the distribution of very few fibres 
expressing b-gal, some of these being high expressors (dark blue stained fibres in 
section A) while others are low expressors (light blue stained fibres in section B).  
Figure 6.2.2 shows high-resolution images of infiltrating cells near the fibres 
expressing b-gal. Section A and B that are injected with b-gal only, used as a control 
and rest sections are co-injected with b-gal + IDO1. The b-gal injected section A 
has about 11 infiltrating cells compared to section B has about 89 infiltrating cells. 
Similarly, the co-injected section C has about 70 infiltrating cells, section D has 
about 29 infiltrating cells, section E has about 39 infiltrating cells, section F has 
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about 75 infiltrating cells, section G has about 22 infiltrating cells and section H has 
about 41 infiltrating cells.   
The next step was to study the identity of the infiltrating cells by detecting the 
presence of specific immune markers on the cells near the b-gal expressing fibres.  
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Figure 6.2.1 X-Gal staining of muscle sections with Haematoxylin 
counterstain (low magnification). The blue colour represents X-gal staining 
and dark purple colour is haematoxylin staining. Section A has few dark blue 
stained fibres at the edge, section B has few light blue stained fibres in the 
centre. 
A 
B 
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Figure 6.2.2 X-Gal staining of muscle sections with Haematoxylin 
counterstain (high magnification). A-B: b-gal injected. C-H: b-gal + IDO1 
injected. The blue colour is X-gal staining and dark purple colour is 
haematoxylin staining. Section A=about 11 infiltrating cells, section B=about 
89 (39+50) cells, section C=about 70 cells, section D=about 29 (10+12+7) 
cells, section E=about 39 cells, section F=about 75 cells, section G=about 
22 cells, section H=about 41 infiltrating cells. The scale bar is 70 μm. 
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6.3 Analyses of infiltrating immune cells 
To analyse specific immune cell markers, the X-gal stained sections were probed 
with the respective antibodies and VIP peroxidase HRP staining (using a kit from 
Vector labs, UK) was performed (described in Section 2.5.2.3) with counterstaining 
using haematoxylin. The markers selected were CD4, CD8, CD34, CD68 and LY6G 
as these are prominent inflammatory markers. Figure 6.3.1 shows representative 
images of co-injected sections. The sections A-B were incubated with serum in 
place of primary antibody to act as a negative control. The sections C-H were 
incubated with different primary antibodies as indicated in the figure legend. The 
negative controls should be without stain while other sections should be stained, 
indicating the presence of a specific marker. The presence of a stain in the negative 
controls confirmed the non-specific binding of stain and indicates the failure of this 
experiment. This experiment was repeated four times, initially twice using DAB 
staining by changing the H202 incubation from 30 m to a 1 h incubation period and 
later twice with VIP peroxidase staining by changing the primary antibody, 
secondary antibody incubation period. These modifications did not solve the 
problem of non-specific binding in the negative control. This experiment was 
performed to analyse the presence of immune markers in single-injected vs co-
injected muscle samples and find its correlation with the effect of IDO1. But since 
the experiment gave us non-specific signals, we cannot draw any conclusion from 
these results. The infiltration of immune cells in myoblast fibres is a characteristic 
feature of mdx mice.  
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Figure 6.3.1 X-Gal Stained co-injected sections with VIP peroxidase 
staining and haematoxylin.  
A-B: Negative control, no primary antibody. C:CD4; D:CD8; E:CD34; 
F:CD68; G-H:Ly6G. The blue colour is X-gal staining and dark purple colour 
is haematoxylin staining.  The scale bar is 70 μm.  
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6.4 qPCR analyses 
qPCR analyses were used to evaluate the expression of CD4 (T-helper cell), CD8a 
(T-cytotoxic cells), FOXP3 (T-regulatory cells), COX2 (level of inflammation), IL-10 
(level of anti-inflammation) and IL-12a (level of presence of dendritic cells) using 
Taqman Probes (Life Technology) for relative gene expression. Figure 6.5.1 shows 
the plot of the qPCR result obtained. 
The samples used for qPCR analyses were pcS2+C Beta Galactosidase (N=4: 4R, 
4L, 5R and 5L) and pcS2+C Beta Galactosidase + pcDNA3.IDO1 injected 
(N=4:10L, 11L, 14R and 16R) from the animals described in Section 5.3 for Western 
blotting experiments and were chosen based on the presence of b-gal expression 
in Western blotting. The results (Figure 6.4.1) were as follow: 
CD4/CD8-The statistically significant higher expressions of CD4/CD8 markers 
suggested the presence of more T-helper and CTL cells in co-injected samples. 
FoxP3-The statistically significant higher expression of FoxP3 in co-injected 
samples indicates the presence of induced T-reg cells which might be suppressing 
the immune response against b-gal.  
COX2-The statistically significant higher expression of COX2 in co-injected 
samples indicates a higher level of inflammation. The plot in Figure 6.4.1 creates 
confusion as most of the co-injected samples show a lower value and only one 
sample has a very high value compared to the single injected samples, which are 
all higher than co-injected samples, indicating that single-injection produces a 
higher level of COX2. 
IL-10- It has been shown by Metghalchi et al. (422) that IDO1 represses IL-10. This 
supports our findings of a statistically significant lower expression of IL-10 in co-
injected samples.  
IL-12a- The absence of IL-12a in co-injected samples indicates the absence of 
dendritic cell and its accessory Th1 cells in these samples. It indicates that IDO1 
signalled to the dendritic cell to suppress the CTL pathway against the transgene 
and induce tolerance against it, while the presence of higher levels of IL-12 in 
single-plasmid-injected muscle samples indicates greater activation of the CTL 
pathway. This does not, however, correlates with lower levels of CD4/CD8 in these 
samples.   
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Figure 6.4.1 The plot of qPCR delta delta CT values for immune marker expression. 
The difference in immune marker expression between b-gal (BG, N=4, 4x3=12 data 
points) and b-gal co-injected with pcDNA3.IDO1 (BG+IDO1; N=4, 4x3-12 data 
points). Samples were run in triplicates so Nx3, their individual values were used. 
The significance was confirmed by the Student’s t-test. The mean+SEM is shown in 
the plot. CD4 (N=4x3=12) expression with p=0.000 (***), CD8a (N=4x3=12) 
expression with p=0.000 (***), (next page) 
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6.5 ELISA 
The ELISA test was used to analyse the serum titre of antibodies against b-gal in 
single-plasmid injected vs co-injected mice. In the absence of suitable commercial 
kit, there was a need for extensive optimisation of the method using ELISA plates 
coated with the antigen.  
The anti-b-gal antibody produced in rabbit was used as a positive control to make 
a standard curve so that levels of antibody present in serum derived from the blood 
of injected mice could be determined. The antibody was serially diluted in the range 
between 1/100 to 1/100,000 and the protocol was followed as described in Section 
2.7. The experiment was repeated fifteen times using various dilutions of the 
primary antibody, changing the buffer used for dissolving the antigen from 1XPBS 
to 1X Bicarbonate, changing the blocking agent from 2% rabbit serum to 2% BSA 
and increasing the time of primary antibody incubation from 1.5 h at 37°C to 
overnight at 4°C.  
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Figure 6.4.1 (continued)  
FOXP3 (N=4x3=12) expression with p=0.000 (***), COX2 (N=4x3=12) 
expression with p=0.008 (**), IL-10 (N=6x3=18) expression with p=0.005 
(**), IL-12 (N=4x3=12) expression with p=0.006 (**). 
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The protocol did not work initially as the chromogenic detection readings did not 
correspond with the primary antibody dilution. Subsequently, by using the dot-blot 
technique (described in Section 2.7.1) the problem was traced to the inefficient 
blocking by the rabbit serum. Figure 6.5.1 shows the image of the membrane 
spotted with dilutions of b-gal antigen dissolved in 1X bicarbonate buffer. The 
membrane showed less non-specific binding (background) when probed with the 
secondary antibody only in 2% BSA and 5% skimmed milk compared to 2% rabbit 
serum. Hence, bovine serum albumin was used for blocking in subsequent ELISA 
experiments. Figure 6.5.2 shows the ELISA test results that confirmed the 
statistically significant (p=0.023) lower anti-b-gal antibody titers in co-injected 
samples.  
 
 
Figure 6.5.1 Dot-Blot image of the membrane probed with anti-b-gal 
antibody in different blocking solutions. The blocking agents were 
2% BSA= 2% solution of bovine serum albumin in 1X PBS; 2% 
Rabbit serum in 1XPBS; 5% skimmed milk dissolved in 1XPBS+ 2% 
(v/v) Tween 20 and the dilution factors for anti- b-gal antibody were 
1:500,1:1000, 1:5000.  
2%BSA 
2% Rabbit 
Serum 
5%Milk +1x PBS, 
2% Tween 20  
1:500 
1:1000 
1:5000 
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6.6 Summary 
X-gal staining confirmed the expression of b-gal in a very few fibre, which correlates 
with the Western blot data (Section 5.3) and confirmed the low efficiency of naked 
plasmid uptake by skeletal muscles. Nevertheless, the presence of b-gal in these 
fibres permits the analyses of the immune cell subpopulations infiltrating individual 
fibres. Unfortunately, the antibody stainings used to study these immune cells were 
not successful.  
qPCR showed the statistically significant higher expression of CD4, CD8a, FoxP3 
and COX2 in co-injected samples. The higher expression of FoxP3 could suggest 
that the increased CD4 numbers were associated with a switch to T-reg phenotype. 
However, the statistically significant higher IL-10 and IL12a expression in b-gal only 
injected samples do not indicate a global decrease in inflammation in IDO1 injected 
samples, albeit some of these results correspond with the finding in the literature. 
The ELISA test to quantify the antibody titre showed statistically significant lower 
Figure 6.5.2 Co-expression of IDO1 reduces antibody response against 
beta-galactosidase. The levels of anti-β-gal antibodies 14 days post-
injection were significantly lower in sera from mice co-expressing the CMV-
driven IDO1 plasmid (P=0.023, ANOVA with Tukey’s post-hoc test).  
β-gal, n=7; βgal+CD11c.mIDO1, n=5; β-gal+CMV.mIDO1, n=6. The 
mean+SEM is shown in the plot 
P=0.023 
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titers of anti-b-gal antibody in co-injected samples, indicating the tolerogenic effect 
of IDO1 expression.  
 
6.7 Discussion 
Our observations confirmed the earlier study perform by Doh et al (423) of the 
expression pattern of b-gal in the skeletal muscle of female Balb/c mice. In that 
study, 1) the expression of the b-gal plasmid was not accordingly to the expected 
pattern of injection that is of having more expression of plasmid near the site of 
injection and less expression of plasmid further away from the injection site (deep 
inside the muscle tissue),we also observed this random distribution of plasmid; 2) 
individual myofibres stained with X-gal next to un-stained myofibres, we also 
observed this in muscle sections; 3) use of cytoplasmic targeted and nuclear-
targeted vectors expressing b-gal with single dose of 50 μg b-gal plasmid, we used 
cytoplasmically targeted vector with single dose of 12.5 μg (0.5 μg x 25 μl =12.5 
μg) total pDNA injected per mdx male mouse that was very low compared to the 
study. In general, we observed that fibres highly expressing the b-gal (intensely 
stained) were dispersed between non-expressing (unstained) fibres and that the 
expression of plasmid was not always clearly associated with the vicinity of the 
injection’s needle track. Similar observations were by Doh et al (423) in mice and 
Maeda et al (283) in dogs.  
Maeda et al (283) used normal canines injected using 500 μg b-gal plasmid also 
confirmed a low efficiency of plasmid expression at 7 days by PCR and absence of 
expression at 14 days. In our study, we were able to detect b-gal expression 14 
days post-injection in Western blot. It indicates that our procedure is more efficient 
in mdx mice than that conducted by Maeda et al (283).  To confirm the presence of 
T-reg cells and to identify other immune markers, a qPCR approach was used. 
qPCR confirmed the significantly higher expression of CD4, CD8a, FoxP3 and 
COX2 in co-injected samples, while expression of IL-10 and IL-12a were 
significantly higher in b-gal only injected samples (details described in Section 6.4). 
The presence of higher Foxp3 in CMV.IDO1 co-injected samples indicated the 
presence of T-reg cells and activation of immune tolerance. 
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X-gal staining was performed to analyse the distribution of transgene (b-gal) 
expression in TA muscle sections 14 days post injection and very few fibres were 
confirmed to express b-gal. This correlates with the low-intensity band observed in 
Western blotting experiments. The identification of various immune markers in 
muscle sections of co-injected samples was performed by comparing non-injected 
(control) muscle sections using immunohistochemistry procedure. This staining 
procedure did not work, as it was not possible to discern between control and co-
injected samples. 
However, following extensive standardisation of the ELISA test to quantify the 
antibody titre generated against the transgene b-gal transgene, the significantly 
lower titer was found in co-injected samples, supporting the effect of IDO1 co-
expression. 
Tolerance induction has multiple components: T-regs, dendritic cells and also the 
role of IDO1. The detailed mechanism of tolerance induction was discussed in 
Chapter 1 so here a discussion of the correlation of results with the properties of T-
regs and IDO1 is presented. 
 
6.7.1 T-reg Cells 
T-reg cells (T-regs) are of two types: naturally arising CD25+CD4+ T-reg cells in 
which the activation of the transcription factor forkhead box p3 (Foxp3) took place 
in the thymus and the second are induced T-reg cells (iT-regs), having Foxp3 
activated in peripheral lymphoid organs after interacting with antigen. Both types of 
these cells work in maintaining immunological self-tolerance and immune 
homoeostasis (424-426).  
The antigen-specific iT-regs which secrete IL-10 (427) are called as Tr1, while those 
iT-regs that secrete TGFβ are called Th3 cells (428). IL-10 was also shown to 
activate naïve dendritic cells towards tolerogenic dendritic cells that activate iT-regs 
(429-432). The increased levels of Foxp3 correlate with increased levels of iT-regs 
(433). The presence of significantly higher levels of Foxp3 expression in the co-
injected muscle samples in our study indicated the presence of iT-regs cells and 
induction of tolerance toward the b-gal.  
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The CD25+CD4+ T-reg cells induce tolerance by suppressing cytotoxic T 
lymphocytes and antibody responses to the transgene product (389, 434, 435). 
These CD4+CD25+ Tregs cells can suppress immune responses against self-
antigens and against foreign antigens. They suppress these responses by providing 
a negative feedback for the effector T cell immune responses (389). This 
suppression by CD25+CD4+ T-reg was shown to be independent of IL-10 (436) and 
dependent on transforming growth factor beta (TGF-β)(389).  
In a condition of the low level of inflammation, the activation of T-regs was based 
on activated effector CD4+T cells (Teff) in combination with TNF, OX40L, and 
plasmacytoid dendritic cells, whereas in a high level of inflammation, the activation 
of T-regs involves TNF and IL-2 (437). IFN-alpha/beta receptor (IFNAR) signalling 
supports the growth of T-regs in the thymus, survival in peripheral lymphoid organs 
and is required for maintaining homoeostasis (438). CD5 was shown to direct the 
development of peripheral self-reactive T cells towards iT-regs cells (439). The 
development of engineered antigen-specific iT-regs cells shows that CD25+CD4+ 
T-regs cells are non-specific and can be used for global immunosuppression (440).  
 
CD25+CD4+ T-regs present in necrotic lesions expressed increased levels of IL-10 
in the dystrophic mouse muscle but IL-10 was absent in the muscles of wild-type 
mice and normal humans. The use of IL-2 and anti-IL-2 was shown to reduced 
cyclooxygenase 2 (COX-2) expression leading to reduce myofibres injury with 
increased levels of interleukin-10 and CD25+CD4+ T-regs. Low levels of 
CD25+CD4+ T-regs were shown to increase interferon gamma (IFN-ϒ) and 
activation of M1 macrophages leading to increased muscle inflammation (441).  
When evaluating the data obtained in this programme of work a significantly higher 
expression of IL-10 was found in b-gal only injected samples, which confirms the 
presence of CD25+CD4+ T-regs cells.  
The study by Burzyn et al (404) demonstrated the presence of populations of 
specific iT-regs cells that localise in acutely injured skeletal muscles showing the 
expression of the growth factor amphiregulin that act, in vitro on muscle satellite 
cells and in vivo, in mdx mice, by improving muscle repair. The satellite cells derived 
from the mice deficient in these iT-regs cells had a decreased colony-forming 
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capacity in satellite cells, in vitro and less regenerative potential in skeletal muscle, 
in vivo.    
 
6.7.2 IDO1 
The overexpression of Indoleamine 2,3-dioxygenase (IDO) was used to induce 
immune suppression to b-gal protein. In our study, we used two types of plasmids, 
one controlled by the ubiquitous CMV promoter to drive widespread expression of 
IDO1 and the other, a minimal CD11c promoter, to drive expression of IDO1 in 
dendritic cells.  
IDO is an enzyme that catalyses the rate limiting oxidative cleavage of the indole 
ring of the essential amino acid tryptophan (442).  The increased tryptophan 
catabolism leads to the suppression of T-cell proliferation and induces apoptosis of 
activated T cells (443, 444). Curti et al (445) showed that conversion of CD4+CD25- 
T cells to CD4+CD25+T cells is IDO-dependent. Liu et al (446) showed that memory 
CD8+ T cells are susceptible to tryptophan catabolism mediated by IDO.  
On the basis of these observations, this study explored the hypothesis that co-
expression of IDO1 with antigenic transgene may prevent/minimise immune 
response development against b-gal, transgene. This should result in increased 
levels of expression or sustained expression in more muscle samples in mdx mice. 
Our results confirmed this hypothesis. The mdx mice receiving the co-injection of 
murine IDO1 and bacterial b-gal had significantly higher expression of b-gal than 
the mice receiving the b-gal gene alone. The mechanism of increased transgene 
expression in the present study involved the immunosuppressive feature of IDO1. 
Interestingly, specific targeting of IDO1 to dendritic cells (CD11c.IDO1) to develop 
iT-regs did not improve the outcome and the ubiquitous expression is driven by the 
CMV was sufficient. This is an important finding as the IDO does not need to be 
targeted to specific cells, which makes the application of this approach significantly 
easier. Indeed, the same approach can be used to induce tolerance to transplanted 
organs, thus reducing need for immunosuppressive treatments (447). 
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Chapter 7 Discussion 
7.1 General Discussion 
This study investigated the efficacy of immunomodulatory factors such as IDO 
(Indoleamine 2,3-dioxygenase) and TDO (tryptophan 2,3-dioxygenase) in 
prolonging expression of transgenes encoding antigenic proteins in dystrophic 
mice. One of the most studied approaches to the treatment of Duchenne muscular 
dystrophy is the re-expression of dystrophin either through the gene replacement 
therapy (8, 181, 182), exon skipping (6, 181, 183) or nonsense mutation read-
through (153-156). Numerous treatments in both animal models and in clinical trials 
were not successful because dystrophin is being recognised as an antigen (107, 
225) upon re-expression in dystrophic muscles and initiates a strong immune 
response, which lead to loss or no expression of this protein (125, 448). This 
happens because there is no endogenous expression of dystrophin or because of 
sequence differences between the re-expressed product (dystrophin minigene) and 
the endogenous mutant gene product. Therefore, such a protein becomes a 
standard neo-antigen and the expressing cells also become the immune response 
target. This, sooner or later, leads to the cessation of the therapeutic effect (125).  
While this transgene immunogenicity is a common problem in the development of 
gene therapy for any inherited disorder requiring a long-term expression of a 
therapeutic protein, it gets exacerbated when targeting skeletal muscle and 
especially in dystrophic one. The skeletal muscle itself is a location with an 
immunogenic potential but in DMD it is also affected by a chronic inflammation (89, 
449, 450), which worsens this highly unfavourable environment. 
It had been shown that the presence of pre-existing T-cells responding to dystrophin 
was responsible for this effect and immunosuppressive drug treatments resulted in 
a longer-term expression of dystrophin(451).  
Therefore, this study exploited the properties of IDO and TDO, which are the rate-
limiting enzymes of the tryptophan catabolism pathway that regulate the production 
of kynurenines (5). This mechanism is known to increase the survival of grafts (433, 
452) in transplantation by targeting antigen presenting cells (APCs), which play an 
important role in the T-cell activation. 
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Many factors affect the immunogenicity of therapeutic proteins. Therefore, to 
minimise the often opposing immunising and immunomodulatory effects of viral 
vector proteins, plasmid vectors expressing antigenic transgene alone or co-
expressed with mouse IDO1 were used. 
Moreover, the choice of the promoter and enhancer combination controlling the 
transgene expression can seriously affect its immunogenicity. The ubiquitously-
active control elements (such as CMV) trigger immune responses because 
transgenes become expressed directly in the APCs, which results in increased 
antigen presentation (298) and rapid recruitment of cytotoxic T cells (CTLs). Tissue-
specific promoter/enhancer control can improve the duration of transgene 
expression.  Nevertheless, for many transgenes, immune responses (although of a 
lower magnitude and delayed in comparison with the CMV-driven construct) are still 
being triggered because proteins released from cells are processed and presented 
by APCs, which causes activation of T-helper cells and ultimately the response. In 
this study, the aim was to maximise the immunogenic effect and therefore the CMV 
promoter was used. For tolerance induction two mouse IDO1-expressing plasmids: 
pcDNA3.CMV.mIDO1 and pcDNA3.CD11c.mIDO1 were generated. The first one 
was driven by the same ubiquitously-active CMV while in the 
pcDNA3.CD11c.mIDO1 the IDO expression was controlled by the minimal CD11c 
promoter active primarily in dendritic cells and macrophages (293, 298, 453). 
 
When injected into Tibialis anterior muscles of 4-week old male mdx mice, the 
dystrophic mouse muscle has all the hallmarks of the disease with its highly 
inflammatory environment. Unfortunately, the reproducibility of expression using 
the mini-dystrophin plasmid was an extremely poor while b-gal from the same 
plasmid produced a reliable expression. Attempts to increase the expression levels 
of the mini-dystrophin plasmids formulated with Pluronic SP1017-2 were also 
unsuccessful despite the fact that this carrier was shown to increase the level and 
duration of transgene expression in muscle (359), also when used in our lab in 
similar studies (265).  
Therefore, the study continued using the b-gal as a model antigen, which was 
expressed alone or co-injected with one of the IDO1-expressing plasmids and b-
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gal expression was analysed at 14 days post injection. The overall low expression 
from the naked plasmid vector was confirmed by staining muscle sections with X-
gal and was in agreement with previous studies (423). 
Analysis of proteins and RNA from muscle extracts revealed that only 25% of 
muscles injected with b-gal plasmid alone had detectable expression. In contrast, 
69% of muscles co-injected with the pcDNA3.CMV.mIDO1 and 42% co-injection 
with pcDNA3.CD11c.mIDO1 plasmid (targeting IDO1 to APCs) showed detectable 
b-gal expression. Therefore, IDO1 does not need targeting to APCs to have an 
effect, while it is the elevated expression of this enzyme in CD11C (+) dendritic 
cells, which promotes the development of tolerogenic Treg cells. However, IDO1 
expressed by other cell types depletes tryptophan, which blocks the growth of T 
cells and causes immunomodulation. This second effect is exploited by many 
different tumours to protect against immune cell attack and it is clearly effective in 
modulating responses against transgenes, which also makes the co-targeting 
approach much more feasible.  
 
Injection of double the amount of b-gal plasmid in the control group resulted in 
statistically significant reduction rather than an increase of this protein expression. 
This experiment confirmed that higher b-gal expression in co-injected muscles was 
due to the IDO1 immunomodulation as the higher plasmid load should trigger more 
expression but it was lost because of the immune response.   
Indeed. IDO1 expression changed the inflammatory profile of injected muscles, with 
several key marker genes for different T cell subsets showing a statistically 
significant change in expression. Specifically, increased Cd4, Cd8 and the forkhead 
box P3 (Foxp3) genes in muscles co-injected with IDO1 plasmids is interesting as 
the increased expression of lymphocyte markers was concomitant with higher 
levels of Foxp3, which is a transcription factor regulating the development and 
function of T-regulatory (T-reg) cells (403). Therefore, overexpression of IDO1 
appears to prolong antigen expression via the induction of T-regs. The significantly 
higher expressions of Cd4/Cd8 markers in our study suggested the presence of 
more T-helper and CTL cells in co-injected samples. These T-cells were shown to 
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be responsible for the fibrosis in mdx mice (53) and promoting the muscle pathology 
(57). However, significantly higher expression of FoxP3 in co-injected samples 
indicates the presence of induced T-reg cells, which might be suppressing the 
immune response against b-gal. As mentioned, the FOXP3 is a transcription factor 
that regulates the T-reg cells (403), which suppress the immune response and have 
been shown to contribute to muscle repair (404) (405). 
 
The levels of interleukin 10 (Il10) and Il12a expression showed statistically 
significant differences in this study, which agrees with the previously demonstrated 
regulatory interactions between IDO1, IL-10 and IL-12 in antigen presenting cells 
(454, 455).. Specifically, IDO1 is known to suppress the IL-10, as kynurenic acid 
reduces IL-10 production (422). Likewise, IL-12, which is involved in the 
development of Th1 CD4+ T cells that leads to cytotoxic T-lymphocyte activation 
(411) and also activate natural killer (NK) cells (412) was reduced in IDO1-injected 
muscles. On the other hand IL-12, like FOXP3, is considered important in the 
development of Treg cells (456). Therefore, the IL-10/IL-12 regulatory interplay may 
have some role although subtle changes in expression of these interleukins may 
not be easily detected when analysed globally in the already strongly inflammatory 
environment of the dystrophic muscle.  
 
The ELISA performed to quantify the serum anti-b-gal antibody titre showed a 
significantly lower response in animals co-administered with the IDO1 plasmid. This 
finding is consistent with the studies in haemophilic mouse models, which revealed 
that kynurenine prevented generation of anti-FVIII antibodies and suppressed FVIII-
specific B cells by a mechanism involving the IDO1-dependent induction of T-regs 
(457). Interestingly, a recent study indicates a novel role for IDO1, which is intrinsic 
to B cells, where it acts as a regulator of humoral immunity (458).  
 
Together, these findings suggest that IDO1 strategies for preventing immunisation 
in gene therapy approaches should be explored while further studies are needed to 
help our understanding of the exact mechanisms involved.  
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7.2 Conclusions 
In summary, this proof-of-principle study demonstrated that local expression of 
strong non-self antigens in immunogenic tissue such as skeletal muscle and even 
one affected by the pre-existing inflammation can be prolonged using enzymes 
modulating kynurenine pathways. These data indicate this to be a viable strategy 
for preventing transgene loss in various gene targeting settings. Recently, this 
approach was used to induce tolerance to transplanted organs, thus reducing need 
for immunosuppressive treatments (459). Therefore, it could be re-purposed for 
gene therapy of muscular dystrophy and also in other diseases where skeletal 
muscle can be used as the expression site of therapeutic but potentially 
immunogenic proteins. 
 
7.3 Future Work  
It would be of great interest to analyse the miRNA regulation towards the transgene 
expression specifically for low expression of mini-dystrophin in vitro and in vivo as 
miRNA were shown to inhibit transgene expression in hematopoietic cells (322), 
regulate myogenic differentiation (339), regulate the development of all subtypes of 
the CD4 T cell lineage (340) and miR-142 is shown to promote immunological 
tolerance towards antigen-specific regulatory T cells when delivered in vivo (341). 
 
The modification of the mini-dystrophin plasmid to insert membrane translocation 
sequence to enable the transfer and integration of mini-dystrophin protein from the 
cytoplasm to the membrane. As integral membrane proteins are co-translated into 
the endoplasmic reticulum (ER) mediated by ER translocon (367). This process of 
integration of membrane protein in lipid layer is multistep process completes by the 
transmembrane (TM) sequence, Sec61 alpha, TRAM and other accessory 
molecules (368-370). Similarly, Von et al (371) indicate the towards the important 
role of bacterial and mammalian signal recognition particle (SRP), that is universally 
conserved protein targeting machine, co-translated with protein and control the 
membrane localisation of the nascent protein. The use of nuclear localisation 
sequence derived from adeno-associated viruses to enable targeting of mini-
dystrophin in the nucleus to increase pDNA uptake (390, 391). 
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We used 5 μl/s of injection speed in our experiments. The use of high-speed 
injection to increase the efficiency of pDNA uptake was shown by Andre et al (361) 
indicating that increasing the speed of injection from 2 μl/s to 25 μl/s significantly 
increases (about 280 times) the gene expression in skeletal muscles.   
The use of electroporation procedure to increase the plasmid uptake by skeletal 
muscle. The mini-dystrophin construct used in our study was expressed using about 
30 μg of pDNA in TA muscle of 6-week old mdx mice by electroporation procedure 
by Jorgensen et al (4). Similarly, the use of nanoparticles (203), stabilised plasmid-
lipid particles (SPLP)(383), AAV (390, 391) and other related methods to increase 
plasmid uptake and expression of pDNA in muscle.  
Furthermore, the repeat of immunohistochemistry experiments to detect specific 
immune markers in muscle fibre expressing mini-dystrophin and the T-reg specific 
tests to confirm the Foxp3+ T-regs cells following the current literature and 
collaborate with expert immunologist currently working on T-regs cells to obtain 
access to expertise, equipment etc.  
Finally, as IDO1 expression does not need to be targeted to specific cells, it would 
be interesting to test the efficacy of immunomodulation of a transgene co-expressed 
with IDO1 from the same, bi-cistronic vector. This would guarantee that expression 
of a transgene in a particular cell would coincide with the expression of the 
immunomodulatory factor in the same cell.  If proved effective, such a vector could 
be used for multiple applications, where only the transgene would need replacing. 
 
 
 
 
 
 
 
 
 
 
	 198	
Chapter 8 
References 
 
1. Shin J, Tajrishi MM, Ogura Y, Kumar A. Wasting mechanisms in muscular 
dystrophy. Int J Biochem Cell Biol. 2013 Oct;45(10):2266-79. PubMed PMID: 
23669245.  doi: http://dx.doi.org/10.1016/j.biocel.2013.05.001 
2. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of 
dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002 
Apr;82(2):291-329. PubMed PMID: 11917091.  doi: 
http://dx.doi.org/10.1152/physrev.00028.2001 
3. Lapidos KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex: 
signaling strength and integrity for the sarcolemma. Circ Res. 2004 Apr 
30;94(8):1023-31. PubMed PMID: 15117830.  doi: 
http://dx.doi.org/10.1161/01.RES.0000126574.61061.25 
4. Jorgensen LH, Larochelle N, Orlopp K, Dunant P, Dudley RW, Stucka R, et 
al. Efficient and fast functional screening of microdystrophin constructs in vivo and 
in vitro for therapy of duchenne muscular dystrophy. Hum Gene Ther. 2009 
Jun;20(6):641-50. PubMed PMID: 19239382.  doi: 
http://dx.doi.org/10.1089/hum.2008.162 
5. Mbongue JC, Nicholas DA, Torrez TW, Kim NS, Firek AF, Langridge WH. 
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and 
Autoimmunity. Vaccines (Basel). 2015;3(3):703-29. PubMed PMID: 26378585. 
PMCID: PMC4586474.  doi: http://dx.doi.org/10.3390/vaccines3030703 
6. Aoki Y, Yokota T, Wood MJ. Development of multiexon skipping antisense 
oligonucleotide therapy for Duchenne muscular dystrophy. Biomed Res Int. 
2013;2013:402369. PubMed PMID: 23984357. PMCID: PMC3747431.  doi: 
http://dx.doi.org/10.1155/2013/402369 
7. Wei C, Liu J, Yu Z, Zhang B, Gao G, Jiao R. TALEN or Cas9 - rapid, 
efficient and specific choices for genome modifications. J Genet Genomics. 2013 
Jun 20;40(6):281-9. PubMed PMID: 23790627.  doi: 
http://dx.doi.org/10.1016/j.jgg.2013.03.013 
8. Konieczny P, Swiderski K, Chamberlain JS. Gene and cell-mediated 
therapies for muscular dystrophy. Muscle Nerve. 2013 May;47(5):649-63. 
PubMed PMID: 23553671. PMCID: PMC4077844.  doi: 
http://dx.doi.org/10.1002/mus.23738 
9. Pierce BA. Genetics: A Conceptual Approach: W.H. Freeman and Co; 
2003. 736 p. 1572591609 
10. Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W. Genome-wide 
analysis of noncoding regulatory mutations in cancer. Nat Genet. 2014 
Nov;46(11):1160-5. PubMed PMID: 25261935. PMCID: PMC4217527.  doi: 
http://dx.doi.org/10.1038/ng.3101 
11. Hrdlickova B, de Almeida RC, Borek Z, Withoff S. Genetic variation in the 
non-coding genome: Involvement of micro-RNAs and long non-coding RNAs in 
disease. Biochim Biophys Acta. 2014 Oct;1842(10):1910-22. PubMed PMID: 
24667321.  doi: http://dx.doi.org/10.1016/j.bbadis.2014.03.011 
	 199	
12. Raghuveer TS, Garg U, Graf WD. Inborn errors of metabolism in infancy 
and early childhood: an update. Am Fam Physician. 2006 Jun 1;73(11):1981-90. 
PubMed PMID: 16770930.   
13. Vitkup D, Sander C, Church GM. The amino-acid mutational spectrum of 
human genetic disease. Genome Biol. 2003;4(11):R72. PubMed PMID: 
14611658. PMCID: PMC329120.  doi: http://dx.doi.org/10.1186/gb-2003-4-11-r72 
14. Hoffman EP, Brown RH, Jr., Kunkel LM. Dystrophin: the protein product of 
the Duchenne muscular dystrophy locus. Cell. 1987 Dec 24;51(6):919-28. 
PubMed PMID: 3319190.  doi: http://dx.doi.org/10.1016/0092-8674(87)90579-4 
15. Zimowski J, Fidzianska E, Holding M, Zaremba J. Two mutations in one 
dystrophin gene. Neurol Neurochir Pol. 2013;47(2):131-7. PubMed PMID: 
23650001.  doi: http://dx.doi.org/10.5114/ninp.2013.34586 
16. Emery AE. Population frequencies of inherited neuromuscular diseases--a 
world survey. Neuromuscul Disord. 1991;1(1):19-29. PubMed PMID: 1822774. 
Epub 1991/01/01. eng.   
17. Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GK, et 
al. Prevalence of Duchenne and Becker muscular dystrophies in the United 
States. Pediatrics. 2015 Mar;135(3):513-21. PubMed PMID: 25687144. PMCID: 
PMC4477633.  doi: http://dx.doi.org/10.1542/peds.2014-2044 
18. Emery AE. The muscular dystrophies. Lancet. 2002 Feb 23;359(9307):687-
95. PubMed PMID: 11879882. Epub 2002/03/07. eng.  doi: 
http://dx.doi.org/10.1016/s0140-6736(02)07815-7 
19. Vuillerot C, Girardot F, Payan C, Fermanian J, Iwaz J, De Lattre C, et al. 
Monitoring changes and predicting loss of ambulation in Duchenne muscular 
dystrophy with the Motor Function Measure. Dev Med Child Neurol. 2010 
Jan;52(1):60-5. PubMed PMID: 19453691.  doi: http://dx.doi.org/10.1111/j.1469-
8749.2009.03316.x 
20. Humbertclaude V, Hamroun D, Bezzou K, Berard C, Boespflug-Tanguy O, 
Bommelaer C, et al. Motor and respiratory heterogeneity in Duchenne patients: 
implication for clinical trials. Eur J Paediatr Neurol. 2012 Mar;16(2):149-60. 
PubMed PMID: 21920787.  doi: http://dx.doi.org/10.1016/j.ejpn.2011.07.001 
21. Melkonian GJ, Cristofaro RL, Perry J, Hsu JD. Dynamic gait 
electromyography study in Duchenne muscular dystrophy (DMD) patients. Foot 
Ankle. 1980 Sep;1(2):78-83. PubMed PMID: 7274902. Epub 1980/09/01. eng.   
22. Ciafaloni E, Kumar A, Liu K, Pandya S, Westfield C, Fox DJ, et al. Age at 
onset of first signs or symptoms predicts age at loss of ambulation in Duchenne 
and Becker Muscular Dystrophy: Data from the MD STARnet. J Pediatr Rehabil 
Med. 2016 Feb 27;9(1):5-11. PubMed PMID: 26966795.  doi: 
http://dx.doi.org/10.3233/PRM-160361 
23. Bushby K, Finkel R, Birnkrant D, Case L, Clemens P, Cripe L, et al. 
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, 
and pharmacological and psychosocial management. Lancet Neurol. 
2010;9(1):77-93.  doi: http://dx.doi.org/10.1016/S1474-4422(09)70271-6 
24. Zhang H, Zhu Y, Sun Y, Liang Y, Li Y, Zhang Y, et al. Serum creatinine 
level: a supplemental index to distinguish Duchenne muscular dystrophy from 
Becker muscular dystrophy. Dis Markers. 2015;2015:141856. PubMed PMID: 
25852218. PMCID: PMC4380093.  doi: http://dx.doi.org/10.1155/2015/141856 
	 200	
25. Segura LG, Lorenz JD, Weingarten TN, Scavonetto F, Bojanic K, Selcen D, 
et al. Anesthesia and Duchenne or Becker muscular dystrophy: review of 117 
anesthetic exposures. Paediatr Anaesth. 2013 Sep;23(9):855-64. PubMed PMID: 
23919455.  doi: http://dx.doi.org/10.1111/pan.12248 
26. Zhu Y, Zhang H, Sun Y, Li Y, Deng L, Wen X, et al. Serum Enzyme 
Profiles Differentiate Five Types of Muscular Dystrophy. Dis Markers. 
2015;2015:543282. PubMed PMID: 26063958. PMCID: PMC4429213.  doi: 
http://dx.doi.org/10.1155/2015/543282 
27. Perrin C, Unterborn JN, Ambrosio CD, Hill NS. Pulmonary complications of 
chronic neuromuscular diseases and their management. Muscle Nerve. 2004 
Jan;29(1):5-27. PubMed PMID: 14694494. Epub 2003/12/25. eng.  doi: 
http://dx.doi.org/10.1002/mus.10487 
28. Braun SR, Sufit RL, Giovannoni R, O'Connor M, Peters H. Intermittent 
negative pressure ventilation in the treatment of respiratory failure in progressive 
neuromuscular disease. Neurology. 1987 Dec;37(12):1874-5. PubMed PMID: 
3683880. Epub 1987/12/01. eng.   
29. Shneerson JM, Simonds AK. Noninvasive ventilation for chest wall and 
neuromuscular disorders. Eur Respir J. 2002;20(2):480-7.  doi: 
http://dx.doi.org/10.1183/09031936.02.00404002 
30. Katz SL, McKim D, Hoey L, Barrowman N, Kherani T, Kovesi T, et al. 
Respiratory management strategies for Duchenne muscular dystrophy: practice 
variation amongst Canadian sub-specialists. Pediatr Pulmonol. 2013 
Jan;48(1):59-66. PubMed PMID: 22451223.  doi: 
http://dx.doi.org/10.1002/ppul.22548 
31. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An 
Explanation for the Phenotypic Differences between Patients Bearing Partial 
Deletions of the DMD Locus. Genomics. 1988 Jan;2(1):90-5. PubMed PMID: 
WOS:000208529200012. English.  doi: http://dx.doi.org/10.1016/0888-
7543(88)90113-9 
32. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, et al. 
The molecular basis for Duchenne versus Becker muscular dystrophy: correlation 
of severity with type of deletion. Am J Hum Genet. 1989 Oct;45(4):498-506. 
PubMed PMID: 2491009. PMCID: PMC1683519.   
33. Brancaccio P, Maffulli N, Limongelli FM. Creatine kinase monitoring in 
sport medicine. Br Med Bull. 2007;81-82:209-30. PubMed PMID: 17569697.  doi: 
http://dx.doi.org/10.1093/bmb/ldm014 
34. Strehle EM, Straub V. Recent advances in the management of Duchenne 
muscular dystrophy. Arch Dis Child. 2015 Jul 7. PubMed PMID: 26153505.  doi: 
http://dx.doi.org/10.1136/archdischild-2014-307962 
35. Greenberg CR, Rohringer M, Jacobs HK, Averill N, Nylen E, van Ommen 
GJ, et al. Gene studies in newborn males with Duchenne muscular dystrophy 
detected by neonatal screening. Lancet. 1988 Aug 20;2(8608):425-7. PubMed 
PMID: 2900355.   
36. Dellamonica C, Robert JM, Cotte J, Plauchu H, Dorche C. [Systematic 
neonatal screening for Duchenne muscular dystrophy]. Nouv Presse Med. 1979 
Apr 21;8(18):1491-3. PubMed PMID: 471723. Depistage neonatal systematique 
de la myopathie de Duchenne de Boulogne (author's transl)].   
	 201	
37. Edwards RJ, Watts DC, Watts RL, Rodeck CH. Creatine kinase estimation 
in pure fetal blood samples for the prenatal diagnosis of Duchenne muscular 
dystrophy. Prenat Diagn. 1984 Jul-Aug;4(4):267-77. PubMed PMID: 6483787.   
38. Zatz M, Rapaport D, Vainzof M, Passos-Bueno MR, Bortolini ER, 
Pavanello Rde C, et al. Serum creatine-kinase (CK) and pyruvate-kinase (PK) 
activities in Duchenne (DMD) as compared with Becker (BMD) muscular 
dystrophy. J Neurol Sci. 1991 Apr;102(2):190-6. PubMed PMID: 2072118. Epub 
1991/04/01. eng.   
39. Hanon C, Thepaut-Mathieu C, Hausswirth C, Le Chevalier JM. 
Electromyogram as an indicator of neuromuscular fatigue during incremental 
exercise. Eur J Appl Physiol Occup Physiol. 1998 Sep;78(4):315-23. PubMed 
PMID: WOS:000075834200006. English.  doi: http://dx.doi.org/DOI 
10.1007/s004210050426 
40. Desmedt JE, Borenstein S. Regeneration in duchenne muscular dystrophy: 
Electromyographic evidence. Arch Neurol. 1976;33(9):642-50.  doi: 
http://dx.doi.org/10.1001/archneur.1976.00500090048010 
41. Frascarelli M, Rocchi L, Feola I. EMG computerized analysis of localized 
fatigue in duchenne muscular dystrophy. Muscle Nerve. 1988;11(7):757-61.  doi: 
http://dx.doi.org/10.1002/mus.880110712 
42. Pessina P, Cabrera D, Morales MG, Riquelme CA, Gutierrez J, Serrano 
AL, et al. Novel and optimized strategies for inducing fibrosis in vivo: focus on 
Duchenne Muscular Dystrophy. Skelet Muscle. 2014;4:7. PubMed PMID: 
25157321. PMCID: PMC4142391.  doi: http://dx.doi.org/10.1186/2044-5040-4-7 
43. Saclier M, Cuvellier S, Magnan M, Mounier R, Chazaud B. 
Monocyte/macrophage interactions with myogenic precursor cells during skeletal 
muscle regeneration. FEBS J. 2013 Sep;280(17):4118-30. PubMed PMID: 
23384231.  doi: http://dx.doi.org/10.1111/febs.12166 
44. Seale P, Ishibashi J, Scime A, Rudnicki MA. Pax7 is necessary and 
sufficient for the myogenic specification of CD45+:Sca1+ stem cells from injured 
muscle. PLoS Biol. 2004 May;2(5):E130. PubMed PMID: 15138500. PMCID: 
PMC406392.  doi: http://dx.doi.org/10.1371/journal.pbio.0020130 
45. Mauro A. Satellite Cell of Skeletal Muscle Fibers. The Journal of Cell 
Biology. 1961;9(2):493-5.  doi: http://dx.doi.org/10.1083/jcb.9.2.493 
46. Palacios D, Mozzetta C, Consalvi S, Caretti G, Saccone V, Proserpio V, et 
al. TNF/p38alpha/polycomb signaling to Pax7 locus in satellite cells links 
inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell. 
2010 Oct 08;7(4):455-69. PubMed PMID: 20887952. PMCID: PMC2951277.  doi: 
http://dx.doi.org/10.1016/j.stem.2010.08.013 
47. Serrano AL, Baeza-Raja B, Perdiguero E, Jardi M, Munoz-Canoves P. 
Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle 
hypertrophy. Cell Metab. 2008 Jan;7(1):33-44. PubMed PMID: 18177723.  doi: 
http://dx.doi.org/10.1016/j.cmet.2007.11.011 
48. Kuang S, Gillespie MA, Rudnicki MA. Niche regulation of muscle satellite 
cell self-renewal and differentiation. Cell Stem Cell. 2008 Jan 10;2(1):22-31. 
PubMed PMID: 18371418.  doi: http://dx.doi.org/10.1016/j.stem.2007.12.012 
49. Sacco A, Mourkioti F, Tran R, Choi J, Llewellyn M, Kraft P, et al. Short 
telomeres and stem cell exhaustion model Duchenne muscular dystrophy in 
	 202	
mdx/mTR mice. Cell. 2010 Dec 23;143(7):1059-71. PubMed PMID: 21145579. 
PMCID: PMC3025608.  doi: http://dx.doi.org/10.1016/j.cell.2010.11.039 
50. Heredia JE, Mukundan L, Chen FM, Mueller AA, Deo RC, Locksley RM, et 
al. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle 
regeneration. Cell. 2013 Apr 11;153(2):376-88. PubMed PMID: 23582327. 
PMCID: PMC3663598.  doi: http://dx.doi.org/10.1016/j.cell.2013.02.053 
51. Farini A, Meregalli M, Belicchi M, Battistelli M, Parolini D, D'Antona G, et al. 
T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic 
skeletal muscles in the scid/mdx mouse. J Pathol. 2007 Oct;213(2):229-38. 
PubMed PMID: 17668421.  doi: http://dx.doi.org/10.1002/path.2213 
52. Morrison J, Palmer DB, Cobbold S, Partridge T, Bou-Gharios G. Effects of 
T-Lymphocyte Depletion on Muscle Fibrosis in the mdx Mouse. The American 
Journal of Pathology. 2005;166(6):1701-10.  doi: http://dx.doi.org/10.1016/s0002-
9440(10)62480-7 
53. Morrison J, Lu QL, Pastoret C, Partridge T, Bou-Gharios G. T-cell-
dependent fibrosis in the mdx dystrophic mouse. Lab Invest. 2000 Jun;80(6):881-
91. PubMed PMID: 10879739.   
54. Choi JH, Park YE, Kim SI, Kim JI, Lee CH, Park KH, et al. Differential 
immunohistological features of inflammatory myopathies and dysferlinopathy. J 
Korean Med Sci. 2009 Dec;24(6):1015-23. PubMed PMID: 19949654. PMCID: 
PMC2775846.  doi: http://dx.doi.org/10.3346/jkms.2009.24.6.1015 
55. Marino M, Scuderi F, Mazzarelli P, Mannella F, Provenzano C, Bartoccioni 
E. Constitutive and cytokine-induced expression of MHC and intercellular 
adhesion molecule-1 (ICAM-1) on human myoblasts. J Neuroimmunol. 
2001;116(1):94-101.  doi: http://dx.doi.org/10.1016/s0165-5728(01)00287-9 
56. Schmidt J, Rakocevic G, Raju R, Dalakas MC. Upregulated inducible co-
stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance 
for CD8+ T cell cytotoxicity. Brain. 2004 May;127(Pt 5):1182-90. PubMed PMID: 
15047591.  doi: http://dx.doi.org/10.1093/brain/awh148 
57. Spencer MJ, Montecino-Rodriguez E, Dorshkind K, Tidball JG. Helper 
(CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-
deficient muscle. Clin Immunol. 2001 Feb;98(2):235-43. PubMed PMID: 
11161980.  doi: http://dx.doi.org/10.1006/clim.2000.4966 
58. Eghtesad S, Jhunjhunwala S, Little SR, Clemens PR. Rapamycin 
ameliorates dystrophic phenotype in mdx mouse skeletal muscle. Mol Med. 2011 
Sep-Oct;17(9-10):917-24. PubMed PMID: 21607286. PMCID: PMC3188871.  doi: 
http://dx.doi.org/10.2119/molmed.2010.00256 
59. Gussoni E, Pavlath GK, Miller RG, Panzara MA, Powell M, Blau HM, et al. 
Specific T cell receptor gene rearrangements at the site of muscle degeneration in 
Duchenne muscular dystrophy. J Immunol. 1994 Nov 15;153(10):4798-805. 
PubMed PMID: 7963545. Epub 1994/11/15. eng.   
60. Mantegazza R, Andreetta F, Bernasconi P, Baggi F, Oksenberg JR, 
Simoncini O, et al. Analysis of T cell receptor repertoire of muscle-infiltrating T 
lymphocytes in polymyositis. Restricted Vα/β rearrangements may indicate 
antigen-driven selection. J Clin Invest. 1993;91(6):2880-6.   
61. Hu X, Blemker SS. Musculoskeletal simulation can help explain selective 
muscle degeneration in Duchenne muscular dystrophy. Muscle Nerve. 2015 
	 203	
Aug;52(2):174-82. PubMed PMID: 25704785.  doi: 
http://dx.doi.org/10.1002/mus.24607 
62. Maunder-Sewry CA, Dubowitz V. Needle muscle biopsy for carrier 
detection in Duchenne muscular dystrophy. Part 1. Light microscopy--histology, 
histochemistry and quantitation. J Neurol Sci. 1981 Feb;49(2):305-24. PubMed 
PMID: 6452514.   
63. Kinali M, Arechavala-Gomeza V, Cirak S, Glover A, Guglieri M, Feng L, et 
al. Muscle histology vs MRI in Duchenne muscular dystrophy. Neurology. 2011 
Jan 25;76(4):346-53. PubMed PMID: 21263136. PMCID: PMC3034418.  doi: 
http://dx.doi.org/10.1212/WNL.0b013e318208811f 
64. Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, et 
al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 
Duchenne muscular dystrophy mutations. Hum Mutat. 2015 Apr;36(4):395-402. 
PubMed PMID: 25604253. PMCID: PMC4405042.  doi: 
http://dx.doi.org/10.1002/humu.22758 
65. Okubo M, Minami N, Goto K, Goto Y, Noguchi S, Mitsuhashi S, et al. 
Genetic diagnosis of Duchenne/Becker muscular dystrophy using next-generation 
sequencing: validation analysis of DMD mutations. J Hum Genet. 2016 Feb 25. 
PubMed PMID: 26911353.  doi: http://dx.doi.org/10.1038/jhg.2016.7 
66. Yoo SK, Lim BC, Byeun J, Hwang H, Kim KJ, Hwang YS, et al. 
Noninvasive prenatal diagnosis of duchenne muscular dystrophy: comprehensive 
genetic diagnosis in carrier, proband, and fetus. Clin Chem. 2015 Jun;61(6):829-
37. PubMed PMID: 25847990.  doi: http://dx.doi.org/10.1373/clinchem.2014.236380 
67. Kota J, Handy CR, Haidet AM, Montgomery CL, Eagle A, Rodino-Klapac 
LR, et al. Follistatin gene delivery enhances muscle growth and strength in 
nonhuman primates. Sci Transl Med. 2009 Nov 11;1(6):6ra15. PubMed PMID: 
20368179. PMCID: 2852878. Epub 2010/04/07.  doi: 
http://dx.doi.org/10.1126/scitranslmed.3000112 
68. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. 
Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and 
preliminary genomic organization of the DMD gene in normal and affected 
individuals. Cell. 1987 Jul 31;50(3):509-17. PubMed PMID: 3607877. Epub 
1987/07/31. eng.   
69. Rybakova IN, Patel JR, Ervasti JM. The Dystrophin Complex Forms a 
Mechanically Strong Link between the Sarcolemma and Costameric Actin. The 
Journal of Cell Biology. 2000 06/12/received 
07/17/rev-request 
07/17/accepted;150(5):1209-14. PubMed PMID: PMC2175263.   
70. Rybakova IN, Patel JR, Davies KE, Yurchenco PD, Ervasti JM. Utrophin 
binds laterally along actin filaments and can couple costameric actin with 
sarcolemma when overexpressed in dystrophin-deficient muscle. Mol Biol Cell. 
2002 May;13(5):1512-21. PubMed PMID: 12006649. PMCID: PMC111123.  doi: 
http://dx.doi.org/10.1091/mbc.01-09-0446 
71. Ahn AH. Syntrophin binds to an alternatively spliced exon of dystrophin. 
The Journal of Cell Biology. 1995;128(3):363-71.  doi: 
http://dx.doi.org/10.1083/jcb.128.3.363 
	 204	
72. Suzuki A, Yoshida M, Ozawa E. Mammalian alpha 1- and beta 1-
syntrophin bind to the alternative splice-prone region of the dystrophin COOH 
terminus. The Journal of Cell Biology. 1995;128(3):373.   
73. Crosbie RH, Heighway J, Venzke DP, Lee JC, Campbell KP. Sarcospan, 
the 25-kDa Transmembrane Component of the Dystrophin-Glycoprotein Complex. 
J Biol Chem. 1997;272(50):31221-4.  doi: 
http://dx.doi.org/10.1074/jbc.272.50.31221 
74. Hack AA, Ly CT, Jiang F, Clendenin CJ, Sigrist KS, Wollmann RL, et al. γ-
Sarcoglycan Deficiency Leads to Muscle Membrane Defects and Apoptosis 
Independent of Dystrophin. The Journal of Cell Biology. 1998 05/20/received 
07/31/revised;142(5):1279-87. PubMed PMID: PMC2149352.   
75. Coral-Vazquez R, Cohn RD, Moore SA, Hill JA, Weiss RM, Davisson RL, 
et al. Disruption of the sarcoglycan-sarcospan complex in vascular smooth 
muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell. 
1999 Aug 20;98(4):465-74. PubMed PMID: 10481911. Epub 1999/09/11. eng.   
76. Hack AA, Lam MY, Cordier L, Shoturma DI, Ly CT, Hadhazy MA, et al. 
Differential requirement for individual sarcoglycans and dystrophin in the 
assembly and function of the dystrophin-glycoprotein complex. J Cell Sci. 2000 
Jul;113 ( Pt 14):2535-44. PubMed PMID: 10862711. Epub 2000/06/23. eng.   
77. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin 
protects the sarcolemma from stresses developed during muscle contraction. 
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3710-4. PubMed PMID: 8475120. 
PMCID: PMC46371. Epub 1993/04/15. eng.   
78. Danialou G, Comtois AS, Dudley R, Karpati G, Vincent G, Des Rosiers C, 
et al. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to 
mechanical stress-induced contractile failure and injury. FASEB J. 2001 
Jul;15(9):1655-7. PubMed PMID: 11427517. Epub 2001/06/28. eng.   
79. Gillis JM. Understanding dystrophinopathies: an inventory of the structural 
and functional consequences of the absence of dystrophin in muscles of the mdx 
mouse. J Muscle Res Cell Motil. 1999 1999//;20(7):605-25.  doi: 
http://dx.doi.org/10.1023/A:1005545325254 
80. Altamirano F, Lopez JR, Henriquez C, Molinski T, Allen PD, Jaimovich E. 
Increased resting intracellular calcium modulates NF-kappaB-dependent inducible 
nitric-oxide synthase gene expression in dystrophic mdx skeletal myotubes. J Biol 
Chem. 2012 Jun 15;287(25):20876-87. PubMed PMID: 22549782. PMCID: 
PMC3375511.  doi: http://dx.doi.org/10.1074/jbc.M112.344929 
81. van Westering TL, Betts CA, Wood MJ. Current understanding of molecular 
pathology and treatment of cardiomyopathy in duchenne muscular dystrophy. 
Molecules. 2015;20(5):8823-55. PubMed PMID: 25988613.  doi: 
http://dx.doi.org/10.3390/molecules20058823 
82. Allen DG, Whitehead NP. Duchenne muscular dystrophy--what causes the 
increased membrane permeability in skeletal muscle? Int J Biochem Cell Biol. 
2011 Mar;43(3):290-4. PubMed PMID: 21084059.  doi: 
http://dx.doi.org/10.1016/j.biocel.2010.11.005 
83. Onopiuk M, Brutkowski W, Young C, Krasowska E, Rog J, Ritso M, et al. 
Store-operated calcium entry contributes to abnormal Ca(2)(+) signalling in 
dystrophic mdx mouse myoblasts. Arch Biochem Biophys. 2015 Mar 01;569:1-9. 
PubMed PMID: 25659883.  doi: http://dx.doi.org/10.1016/j.abb.2015.01.025 
	 205	
84. Gailly P. New aspects of calcium signaling in skeletal muscle cells: 
implications in Duchenne muscular dystrophy. Biochimica et Biophysica Acta 
(BBA) - Proteins and Proteomics. 2002;1600(1-2):38-44.  doi: 
http://dx.doi.org/10.1016/s1570-9639(02)00442-9 
85. Zanotti S, Gibertini S, Mora M. Altered production of extra-cellular matrix 
components by muscle-derived Duchenne muscular dystrophy fibroblasts before 
and after TGF-beta1 treatment. Cell Tissue Res. 2010 Feb;339(2):397-410. 
PubMed PMID: 19902258.  doi: http://dx.doi.org/10.1007/s00441-009-0889-4 
86. Zanotti S, Bragato C, Zucchella A, Maggi L, Mantegazza R, Morandi L, et 
al. Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne 
muscular dystrophy patients. Life Sci. 2016 Jan 15;145:127-36. PubMed PMID: 
26679108.  doi: http://dx.doi.org/10.1016/j.lfs.2015.12.015 
87. Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao VA, et 
al. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med. 
2015 Aug 5;7(299):299rv4. PubMed PMID: 26246170.  doi: 
http://dx.doi.org/10.1126/scitranslmed.aaa7322 
88. Petrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: a danger 
sensing complex triggering innate immunity. Curr Opin Immunol. 2007 
Dec;19(6):615-22. PubMed PMID: 17977705.  doi: 
http://dx.doi.org/10.1016/j.coi.2007.09.002 
89. Evans NP, Misyak SA, Robertson JL, Bassaganya-Riera J, Grange RW. 
Immune-mediated mechanisms potentially regulate the disease time-course of 
duchenne muscular dystrophy and provide targets for therapeutic intervention. PM 
R. 2009 Aug;1(8):755-68. PubMed PMID: 19695529. PMCID: PMC2779711.  doi: 
http://dx.doi.org/10.1016/j.pmrj.2009.04.010 
90. Villalta SA, Rinaldi C, Deng B, Liu G, Fedor B, Tidball JG. Interleukin-10 
reduces the pathology of mdx muscular dystrophy by deactivating M1 
macrophages and modulating macrophage phenotype. Hum Mol Genet. 2011 Feb 
15;20(4):790-805. PubMed PMID: 21118895. PMCID: PMC3024048.  doi: 
http://dx.doi.org/10.1093/hmg/ddq523 
91. Villalta SA, Deng B, Rinaldi C, Wehling-Henricks M, Tidball JG. IFN-
gamma promotes muscle damage in the mdx mouse model of Duchenne 
muscular dystrophy by suppressing M2 macrophage activation and inhibiting 
muscle cell proliferation. J Immunol. 2011 Nov 15;187(10):5419-28. PubMed 
PMID: 22013114. PMCID: PMC3208069.  doi: 
http://dx.doi.org/10.4049/jimmunol.1101267 
92. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage 
subsets. Nat Rev Immunol. 2011 Nov;11(11):723-37. PubMed PMID: 21997792. 
PMCID: PMC3422549.  doi: http://dx.doi.org/10.1038/nri3073 
93. Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG. Shifts in macrophage 
phenotypes and macrophage competition for arginine metabolism affect the 
severity of muscle pathology in muscular dystrophy. Hum Mol Genet. 2009 11/07 
07/23/received 
11/05/accepted;18(3):482-96. PubMed PMID: PMC2638796.  doi: 
http://dx.doi.org/10.1093/hmg/ddn376 
94. Messina S, Vita GL, Aguennouz M, Sframeli M, Romeo S, Rodolico C, et 
al. Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to 
	 206	
age. Acta Myol. 2011 Jun;30(1):16-23. PubMed PMID: 21842588. PMCID: 
PMC3185832. Epub 2011/08/17. eng.   
95. Li H, Malhotra S, Kumar A. Nuclear factor-kappa B signaling in skeletal 
muscle atrophy. J Mol Med (Berl). 2008 Oct;86(10):1113-26. PubMed PMID: 
18574572. PMCID: PMC2597184.  doi: http://dx.doi.org/10.1007/s00109-008-0373-
8 
96. Grounds MD, Torrisi J. Anti-TNFalpha (Remicade) therapy protects 
dystrophic skeletal muscle from necrosis. FASEB J. 2004 Apr;18(6):676-82. 
PubMed PMID: 15054089.  doi: http://dx.doi.org/10.1096/fj.03-1024com 
97. Soderberg SS, Karlsson G, Karlsson S. Complex and context dependent 
regulation of hematopoiesis by TGF-beta superfamily signaling. Ann N Y Acad 
Sci. 2009 Sep;1176:55-69. PubMed PMID: 19796233.  doi: 
http://dx.doi.org/10.1111/j.1749-6632.2009.04569.x 
98. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. 
Nat Rev Drug Discov. 2012 Oct;11(10):790-811. PubMed PMID: 23000686. 
PMCID: PMC3520610.  doi: http://dx.doi.org/10.1038/nrd3810 
99. Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora M, 
et al. Expression of transforming growth factor-beta 1 in dystrophic patient 
muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin 
Invest. 1995 Aug;96(2):1137-44. PubMed PMID: 7635950. PMCID: PMC185304.  
doi: http://dx.doi.org/10.1172/JCI118101 
100. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-
inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011 
May;1813(5):878-88. PubMed PMID: 21296109.  doi: 
http://dx.doi.org/10.1016/j.bbamcr.2011.01.034 
101. Kostek MC, Nagaraju K, Pistilli E, Sali A, Lai SH, Gordon B, et al. IL-6 
signaling blockade increases inflammation but does not affect muscle function in 
the mdx mouse. BMC Musculoskelet Disord. 2012;13:106. PubMed PMID: 
22716658. PMCID: PMC3522537.  doi: http://dx.doi.org/10.1186/1471-2474-13-106 
102. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold 
Spring Harb Perspect Biol. 2009 Dec;1(6):a001651. PubMed PMID: 20457564. 
PMCID: PMC2882124.  doi: http://dx.doi.org/10.1101/cshperspect.a001651 
103. Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers 
M, et al. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers 
promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest. 
2007 Apr;117(4):889-901. PubMed PMID: 17380205. PMCID: PMC1821069. 
Epub 2007/03/24. eng.  doi: http://dx.doi.org/10.1172/jci30556 
104. Messina S, Bitto A, Aguennouz M, Vita GL, Polito F, Irrera N, et al. The soy 
isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-alpha 
activation and ameliorates muscle function and morphology in mdx mice. 
Neuromuscul Disord. 2011 Aug;21(8):579-89. PubMed PMID: 21658942.  doi: 
http://dx.doi.org/10.1016/j.nmd.2011.04.014 
105. Reay DP, Yang M, Watchko JF, Daood M, O'Day TL, Rehman KK, et al. 
Systemic delivery of NEMO binding domain/IKKgamma inhibitory peptide to 
young mdx mice improves dystrophic skeletal muscle histopathology. Neurobiol 
Dis. 2011 Sep;43(3):598-608. PubMed PMID: 21624467. PMCID: PMC3145633.  
doi: http://dx.doi.org/10.1016/j.nbd.2011.05.008 
	 207	
106. Cai B, Spencer MJ, Nakamura G, Tseng-Ong L, Tidball JG. Eosinophilia of 
Dystrophin-Deficient Muscle Is Promoted by Perforin-Mediated Cytotoxicity by T 
Cell Effectors. The American Journal of Pathology. 2000 
01/24/accepted;156(5):1789-96. PubMed PMID: PMC1876906.   
107. Flanigan KM, Campbell K, Viollet L, Wang W, Gomez AM, Walker CM, et 
al. Anti-Dystrophin T Cell Responses in Duchenne Muscular Dystrophy: 
Prevalence and a Glucocorticoid Treatment Effect. Hum Gene Ther Methods. 
2013 Aug 9. PubMed PMID: 23805800.  doi: 
http://dx.doi.org/10.1089/hgtb.2013.092 
108. Zaharieva I, Cirak S, Anthony K, Feng L, Tasca G, Ferlini A, et al. Micro 
RNA profile associated with the dystrophin level in Becker muscular dystrophy. 
Neuromuscul Disord. 2015 Oct;25:S255-S. PubMed PMID: 
WOS:000362925400249. English.  doi: http://dx.doi.org/10.1016/j.nmd.2015.06.253 
109. Zucconi E, Valadares MC, Vieira NM, Bueno CR, Jr., Secco M, Jazedje T, 
et al. Ringo: discordance between the molecular and clinical manifestation in a 
golden retriever muscular dystrophy dog. Neuromuscul Disord. 2010 
Jan;20(1):64-70. PubMed PMID: 19944604.  doi: 
http://dx.doi.org/10.1016/j.nmd.2009.10.011 
110. Vieira NM, Elvers I, Alexander MS, Moreira YB, Eran A, Gomes JP, et al. 
Jagged 1 Rescues the Duchenne Muscular Dystrophy Phenotype. Cell. 2015 Nov 
11. PubMed PMID: 26582133.  doi: http://dx.doi.org/10.1016/j.cell.2015.10.049 
111. Arechavala-Gomeza V, Kinali M, Feng L, Guglieri M, Edge G, Main M, et 
al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: 
implication for clinical trials. Neuromuscul Disord. 2010 May;20(5):295-301. 
PubMed PMID: 20395141.  doi: http://dx.doi.org/10.1016/j.nmd.2010.03.007 
112. Bulfield G, Siller W, Wight P, Moore K. X chromosome-linked muscular 
dystrophy (mdx) in the mouse. PNAS. 1984 February 1;81(4):1189–92.   
113. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof 
B, et al. The mdx mouse diaphragm reproduces the degenerative changes of 
Duchenne muscular dystrophy. Nature. 1991 Aug 08;352(6335):536-9. PubMed 
PMID: 1865908. Epub 1991/08/08. eng.  doi: http://dx.doi.org/10.1038/352536a0 
114. Carberry S, Brinkmeier H, Zhang Y, Winkler CK, Ohlendieck K. 
Comparative proteomic profiling of soleus, extensor digitorum longus, flexor 
digitorum brevis and interosseus muscles from the mdx mouse model of 
Duchenne muscular dystrophy. Int J Mol Med. 2013 Sep;32(3):544-56. PubMed 
PMID: 23828267. English.  doi: http://dx.doi.org/10.3892/ijmm.2013.1429 
115. van Putten M, Hulsker M, Nadarajah VD, van Heiningen SH, van Huizen E, 
van Iterson M, et al. The effects of low levels of dystrophin on mouse muscle 
function and pathology. PLoS One. 2012;7(2):e31937. PubMed PMID: 22359642. 
PMCID: 3281102.  doi: http://dx.doi.org/10.1371/journal.pone.0031937 
116. Gosselin LE, Williams JE. Pentoxifylline fails to attenuate fibrosis in 
dystrophic (mdx) diaphragm muscle. Muscle Nerve. 2006 Jun;33(6):820-3. 
PubMed PMID: 16502423. Epub 2006/02/28. eng.  doi: 
http://dx.doi.org/10.1002/mus.20523 
117. Huang P, Zhao XS, Fields M, Ransohoff RM, Zhou L. Imatinib attenuates 
skeletal muscle dystrophy in mdx mice. FASEB J. 2009 Aug;23(8):2539-48. 
PubMed PMID: 19289603. PMCID: PMC2717779. Epub 2009/03/18. eng.  doi: 
http://dx.doi.org/10.1096/fj.09-129833 
	 208	
118. Manning J, O'Malley D. What has the mdx mouse model of Duchenne 
muscular dystrophy contributed to our understanding of this disease? J Muscle 
Res Cell Motil. 2015 Apr;36(2):155-67. PubMed PMID: 25669899.  doi: 
http://dx.doi.org/10.1007/s10974-015-9406-4 
119. Madaro L, Bouche M. From innate to adaptive immune response in 
muscular dystrophies and skeletal muscle regeneration: the role of lymphocytes. 
Biomed Res Int. 2014;2014:438675. PubMed PMID: 25028653. PMCID: 
PMC4083765.  doi: http://dx.doi.org/10.1155/2014/438675 
120. Sinadinos A, Young CN, Al-Khalidi R, Teti A, Kalinski P, Mohamad S, et al. 
P2RX7 Purinoceptor: A Therapeutic Target for Ameliorating the Symptoms of 
Duchenne Muscular Dystrophy. PLoS Med. 2015 Oct;12(10):e1001888. PubMed 
PMID: 26461208.  doi: http://dx.doi.org/10.1371/journal.pmed.1001888 
121. Wertz K, Füchtbauer E-M. Dmdmdx-βgeo: A new allele for the mouse 
dystrophin gene. Dev Dyn. 1998;212(2):229-41.  doi: 
http://dx.doi.org/10.1002/(sici)1097-0177(199806)212:2<229::aid-aja7>3.0.co;2-j 
122. Kelly J Perkins, Davies KE. Recent advances in Duchenne muscular 
dystrophy. Degener Neurol Neuromuscul Dis. 2012;2:141-64.  doi: 
http://dx.doi.org/10.2147/DNND.S26637 
123. Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin 
predicts a rod-shaped cytoskeletal protein. Cell. 1988 Apr 22;53(2):219-28. 
PubMed PMID: 3282674.  doi: http://dx.doi.org/10.1016/0092-8674(88)90383-2 
124. Michela Guglieri, Bushby K. Recent developments in the management of 
Duchenne muscular dystrophy. Paediatr Child Health. 2011;21(11):501-9.  doi: 
http://dx.doi.org/10.1016/j.paed.2011.06.007 
125. Mendell J, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, et 
al. Transient Expression of a Therapeutic Dystrophin Transgene in Duchenne 
Muscular Dystrophy Revealed by T Cell Mediated Immunity. Neurology. 2010 Mar 
2;74(9):A111-A. PubMed PMID: WOS:000275274000424. English.   
126. de Jong EC, Vieira PL, Kalinski P, Kapsenberg ML. Corticosteroids inhibit 
the production of inflammatory mediators in immature monocyte-derived DC and 
induce the development of tolerogenic DC3. J Leukoc Biol. 1999 Aug;66(2):201-4. 
PubMed PMID: 10449154.   
127. Fraser LK, Aldridge J, Manning S, O'Leary S, Miller M, McCulloch R, et al. 
Hospice provision and usage amongst young people with neuromuscular disease 
in the United Kingdom. Eur J Paediatr Neurol. 2011 Jul;15(4):326-30. PubMed 
PMID: 21371919.  doi: http://dx.doi.org/10.1016/j.ejpn.2011.02.003 
128. Arias R, Andrews J, Pandya S, Pettit K, Trout C, Apkon S, et al. Palliative 
care services in families of males with Duchenne muscular dystrophy. Muscle 
Nerve. 2011 Jul;44(1):93-101. PubMed PMID: 21674523.  doi: 
http://dx.doi.org/10.1002/mus.22005 
129. Birnkrant DJ, Noritz GH. Is there a role for palliative care in progressive 
pediatric neuromuscular diseases? The answer is "Yes! J Palliat Care. 2008 
Winter;24(4):265-9. PubMed PMID: 19227018.   
130. Bonnard C, de Courtivron B, Bricout JM, Toutain A, Glorion B. [Palliative 
treatment of myopathies. Contribution of surgical treatments]. Ann Pediatr (Paris). 
1993 Apr;40(4):242-52. PubMed PMID: 7686731. Traitement palliatif des 
myopathies. Apport des traitements chirurgicaux.   
	 209	
131. Carter GT, Joyce NC, Abresch AL, Smith AE, VandeKeift GK. Using 
palliative care in progressive neuromuscular disease to maximize quality of life. 
Phys Med Rehabil Clin N Am. 2012 Nov;23(4):903-9. PubMed PMID: 23137745.  
doi: http://dx.doi.org/10.1016/j.pmr.2012.08.002 
132. Ciafaloni E, Moxley RT. Treatment options for Duchenne muscular 
dystrophy. Curr Treat Options Neurol. 2008 Mar;10(2):86-93. PubMed PMID: 
18334131.   
133. Tidball JG, Wehling-Henricks M. Evolving therapeutic strategies for 
Duchenne muscular dystrophy: targeting downstream events. Pediatr Res. 2004 
Dec;56(6):831-41. PubMed PMID: 15531741.  doi: 
http://dx.doi.org/10.1203/01.PDR.0000145578.01985.D0 
134. Plauchu H, Dellamonica C, Cotte J, Robert JM. Duchenne muscular 
dystrophy: systematic neonatal screening and earlier detection of carriers. J 
Genet Hum. 1980 Dec;28(4):65-82. PubMed PMID: 7205199.   
135. Greenberg CR, Jacobs HK, Halliday W, Wrogemann K. Three years' 
experience with neonatal screening for Duchenne/Becker muscular dystrophy: 
gene analysis, gene expression, and phenotype prediction. Am J Med Genet. 
1991 Apr 1;39(1):68-75. PubMed PMID: 1867267.  doi: 
http://dx.doi.org/10.1002/ajmg.1320390115 
136. Beckmann R, Scheuerbrandt G. [Screening for elevated creatine kinase 
activities for the early diagnosis of Duchenne muscular dystrophy]. Fortschr Med. 
1979 Oct 18;97(39):1733-6. PubMed PMID: 511067. Screening auf erhohte 
Kreatinkinase-Aktivitaten zur Fruherkennung der Duchenne-Muskeldystrophie.   
137. Hildes E, Jacobs HK, Cameron A, Seshia SS, Booth F, Evans JA, et al. 
Impact of genetic counselling after neonatal screening for Duchenne muscular 
dystrophy. J Med Genet. 1993 Aug;30(8):670-4. PubMed PMID: 8411054. 
PMCID: PMC1016496.   
138. Lamb MM, West NA, Ouyang L, Yang M, Weitzenkamp D, James K, et al. 
Corticosteroid Treatment and Growth Patterns in Ambulatory Males with 
Duchenne Muscular Dystrophy. J Pediatr. 2016 Jun;173:207-13 e3. PubMed 
PMID: 27039228.  doi: http://dx.doi.org/10.1016/j.jpeds.2016.02.067 
139. Wood CL, Straub V, Guglieri M, Bushby K, Cheetham T. Short stature and 
pubertal delay in Duchenne muscular dystrophy. Arch Dis Child. 2016 
Jan;101(1):101-6. PubMed PMID: 26141541.  doi: 
http://dx.doi.org/10.1136/archdischild-2015-308654 
140. Dunckley MG, Wells DJ, Walsh FS, Dickson G. Direct retroviral-mediated 
transfer of a dystrophin minigene into mdx mouse muscle in vivo. Hum Mol Genet. 
1993;2(6):717-23.   
141. Kimura E, Li S, Gregorevic P, Fall BM, Chamberlain JS. Dystrophin 
delivery to muscles of mdx mice using lentiviral vectors leads to myogenic 
progenitor targeting and stable gene expression. Mol Ther. 2010 Jan;18(1):206-
13. PubMed PMID: 19888194. PMCID: PMC2839215. Epub 2009/11/06. eng.  
doi: http://dx.doi.org/10.1038/mt.2009.253 
142. Smith AE. Viral vectors in gene therapy. Annu Rev Microbiol. 1995;49:807-
38. PubMed PMID: 8561480.  doi: 
http://dx.doi.org/10.1146/annurev.mi.49.100195.004111 
	 210	
143. Verma IM, Somia N. Gene therapy -- promises, problems and prospects. 
Nature. 1997 Sep 18;389(6648):239-42. PubMed PMID: 9305836. Epub 
1997/09/26. eng.  doi: http://dx.doi.org/10.1038/38410 
144. Moullier P, Friedlander G, Calise D, Ronco P, Perricaudet M, Ferry N. 
Adenoviral-mediated gene transfer to renal tubular cells in vivo. Kidney Int. 
1994;45(4):1220-5.  doi: http://dx.doi.org/10.1038/ki.1994.162 
145. Ragot T, Vincent N, Chafey P, Vigne E, Gilgenkrantz H, Couton D, et al. 
Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal 
muscle of mdx mice. Nature. 1993 Feb 18;361(6413):647-50. PubMed PMID: 
8437625.  doi: http://dx.doi.org/10.1038/361647a0 
146. Morral N, O'Neal W, Rice K, Leland M, Kaplan J, Piedra PA, et al. 
Administration of helper-dependent adenoviral vectors and sequential delivery of 
different vector serotype for long-term liver-directed gene transfer in baboons. 
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12816-21. PubMed PMID: 
10536005. PMCID: PMC23112. Epub 1999/10/27. eng.   
147. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, et al. 
Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med. 
1997 Mar;3(3):306-12. PubMed PMID: 9055858. Epub 1997/03/01. eng.   
148. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle 
tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996 
Nov;70(11):8098-108. PubMed PMID: 8892935. PMCID: PMC190884. Epub 
1996/11/01. eng.   
149. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS, et al. 
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational 
optimized AAV vector. Mol Ther. 2012 Feb;20(2):443-55. PubMed PMID: 
22068425. PMCID: PMC3277234. Epub 2011/11/10. eng.  doi: 
http://dx.doi.org/10.1038/mt.2011.237 
150. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, et al. 
CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 
2007 Apr;13(4):419-22. PubMed PMID: 17369837. Epub 2007/03/21. eng.  doi: 
http://dx.doi.org/10.1038/nm1549 
151. Wolff J, Malone R, Williams P, Chong W, Acsadi G, Jani A, et al. Direct 
Gene Transfer into Mouse Muscle in Vivo. Science. 1990 23 Mar;247(4949 Pt 
1):1465-8.   
152. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. 
Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx 
mice. J Clin Invest. 1999 Aug 15;104(4):375-81. PubMed PMID: 10449429. 
PMCID: PMC481050. eng.   
153. Malik V, Rodino-Klapac LR, Viollet L, Wall C, King W, Al-Dahhak R, et al. 
Gentamicin-induced readthrough of stop codons in Duchenne muscular 
dystrophy. Ann Neurol. 2010 Jun;67(6):771-80. PubMed PMID: 20517938. Epub 
2010/06/03. eng.  doi: http://dx.doi.org/10.1002/ana.22024 
154. Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda 
S, et al. Current status of pharmaceutical and genetic therapeutic approaches to 
treat DMD. Mol Ther. 2011 May;19(5):830-40. PubMed PMID: 21468001. PMCID: 
PMC3098643. Epub 2011/04/07. eng.  doi: http://dx.doi.org/10.1038/mt.2011.59 
155. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, et al. 
PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007 
	 211	
May 03;447(7140):87-91. PubMed PMID: 17450125. Epub 2007/04/24. eng.  doi: 
http://dx.doi.org/10.1038/nature05756 
156. Finkel RS. Read-through strategies for suppression of nonsense mutations 
in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren 
(PTC124). J Child Neurol. 2010 Sep;25(9):1158-64. PubMed PMID: 20519671. 
PMCID: PMC3674569. Epub 2010/06/04. eng.  doi: 
http://dx.doi.org/10.1177/0883073810371129 
157. Vilquin JT, Catelain C, Vauchez K. Cell therapy for muscular dystrophies: 
advances and challenges. Current opinion in organ transplantation. 2011 
Dec;16(6):640-9. PubMed PMID: 22001714. Epub 2011/10/18. eng.  doi: 
http://dx.doi.org/10.1097/MOT.0b013e32834cfb70 
158. Skuk D, Roy B, Goulet M, Chapdelaine P, Bouchard JP, Roy R, et al. 
Dystrophin expression in myofibers of Duchenne muscular dystrophy patients 
following intramuscular injections of normal myogenic cells. Mol Ther. 2004 
Mar;9(3):475-82. PubMed PMID: 15038390. Epub 2004/03/25. eng.   
159. Skuk D, Goulet M, Roy B, Piette V, Cote CH, Chapdelaine P, et al. First 
test of a "high-density injection" protocol for myogenic cell transplantation 
throughout large volumes of muscles in a Duchenne muscular dystrophy patient: 
eighteen months follow-up. Neuromuscul Disord. 2007 Jan;17(1):38-46. PubMed 
PMID: 17142039. Epub 2006/12/05. eng.  doi: 
http://dx.doi.org/10.1016/j.nmd.2006.10.003 
160. Skuk D, Goulet M, Roy B, Chapdelaine P, Bouchard JP, Roy R, et al. 
Dystrophin expression in muscles of duchenne muscular dystrophy patients after 
high-density injections of normal myogenic cells. J Neuropathol Exp Neurol. 2006 
Apr;65(4):371-86. PubMed PMID: 16691118. Epub 2006/05/13. eng.  doi: 
http://dx.doi.org/10.1097/01.jnen.0000218443.45782.81 
161. Cerletti M, Jurga S, Witczak CA, Hirshman MF, Shadrach JL, Goodyear LJ, 
et al. Highly efficient, functional engraftment of skeletal muscle stem cells in 
dystrophic muscles. Cell. 2008 Jul 11;134(1):37-47. PubMed PMID: 18614009. 
PMCID: PMC3665268. Epub 2008/07/11. eng.  doi: 
http://dx.doi.org/10.1016/j.cell.2008.05.049 
162. Sacco A, Doyonnas R, Kraft P, Vitorovic S, Blau HM. Self-renewal and 
expansion of single transplanted muscle stem cells. Nature. 2008 Nov 
27;456(7221):502-6. PubMed PMID: 18806774. PMCID: PMC2919355. Epub 
2008/09/23. eng.  doi: http://dx.doi.org/10.1038/nature07384 
163. Gilbert PM, Havenstrite KL, Magnusson KE, Sacco A, Leonardi NA, Kraft 
P, et al. Substrate elasticity regulates skeletal muscle stem cell self-renewal in 
culture. Science. 2010 Aug 27;329(5995):1078-81. PubMed PMID: 20647425. 
PMCID: PMC2929271. Epub 2010/07/22. eng.  doi: 
http://dx.doi.org/10.1126/science.1191035 
164. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, 
Cossu G, et al. Muscle regeneration by bone marrow-derived myogenic 
progenitors. Science. 1998 Mar 06;279(5356):1528-30. PubMed PMID: 9488650. 
Epub 1998/03/21. eng.   
165. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and 
functional properties of murine hematopoietic stem cells that are replicating in 
vivo. J Exp Med. 1996 Apr 01;183(4):1797-806. PubMed PMID: 8666936. PMCID: 
PMC2192511. Epub 1996/04/01. eng.   
	 212	
166. Montanaro F, Liadaki K, Schienda J, Flint A, Gussoni E, Kunkel LM. 
Demystifying SP cell purification: viability, yield, and phenotype are defined by 
isolation parameters. Exp Cell Res. 2004 Aug 01;298(1):144-54. PubMed PMID: 
15242769. Epub 2004/07/10. eng.  doi: 
http://dx.doi.org/10.1016/j.yexcr.2004.04.010 
167. Bachrach E, Perez AL, Choi YH, Illigens BM, Jun SJ, del Nido P, et al. 
Muscle engraftment of myogenic progenitor cells following intraarterial 
transplantation. Muscle Nerve. 2006 Jul;34(1):44-52. PubMed PMID: 16634061. 
Epub 2006/04/25. eng.  doi: http://dx.doi.org/10.1002/mus.20560 
168. Bachrach E, Li S, Perez AL, Schienda J, Liadaki K, Volinski J, et al. 
Systemic delivery of human microdystrophin to regenerating mouse dystrophic 
muscle by muscle progenitor cells. Proc Natl Acad Sci U S A. 2004 Mar 
09;101(10):3581-6. PubMed PMID: 14993597. PMCID: PMC373505. Epub 
2004/03/03. eng.  doi: http://dx.doi.org/10.1073/pnas.0400373101 
169. Dezawa M, Ishikawa H, Itokazu Y, Yoshihara T, Hoshino M, Takeda S, et 
al. Bone marrow stromal cells generate muscle cells and repair muscle 
degeneration. Science. 2005 Jul 08;309(5732):314-7. PubMed PMID: 16002622. 
Epub 2005/07/09. eng.  doi: http://dx.doi.org/10.1126/science.1110364 
170. Torrente Y, Belicchi M, Marchesi C, D'Antona G, Cogiamanian F, Pisati F, 
et al. Autologous transplantation of muscle-derived CD133+ stem cells in 
Duchenne muscle patients. Cell Transplant. 2007;16(6):563-77. PubMed PMID: 
17912948. Epub 2007/10/05. eng.   
171. Sampaolesi M, Torrente Y, Innocenzi A, Tonlorenzi R, D'Antona G, 
Pellegrino MA, et al. Cell therapy of alpha-sarcoglycan null dystrophic mice 
through intra-arterial delivery of mesoangioblasts. Science. 2003 Jul 
25;301(5632):487-92. PubMed PMID: 12855815. Epub 2003/07/12. eng.  doi: 
http://dx.doi.org/10.1126/science.1082254 
172. Sampaolesi M, Blot S, D'Antona G, Granger N, Tonlorenzi R, Innocenzi A, 
et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. 
Nature. 2006 Nov 30;444(7119):574-9. PubMed PMID: 17108972.  doi: 
http://dx.doi.org/10.1038/nature05282 
173. Tedesco FS, Hoshiya H, D'Antona G, Gerli MF, Messina G, Antonini S, et 
al. Stem cell-mediated transfer of a human artificial chromosome ameliorates 
muscular dystrophy. Sci Transl Med. 2011 Aug 17;3(96):96ra78. PubMed PMID: 
21849666. Epub 2011/08/19. eng.  doi: 
http://dx.doi.org/10.1126/scitranslmed.3002342 
174. Barberi T, Willis LM, Socci ND, Studer L. Derivation of Multipotent 
Mesenchymal Precursors from Human Embryonic Stem Cells. PLoS Med. 2005 
Jun;2(6). PubMed PMID: 15971941. PMCID: PMC1160574. eng.  doi: 
http://dx.doi.org/10.1371/journal.pmed.0020161 
175. Kodama H, Nose M, Niida S, Nishikawa S, Nishikawa S. Involvement of the 
c-kit receptor in the adhesion of hematopoietic stem cells to stromal cells. Exp 
Hematol. 1994 Sep;22(10):979-84. PubMed PMID: 7522185. Epub 1994/09/01. 
eng.   
176. Nakano T, Kodama H, Honjo T. Generation of lymphohematopoietic cells 
from embryonic stem cells in culture. Science. 1994 Aug 19;265(5175):1098-101. 
PubMed PMID: 8066449. Epub 1994/08/19. eng.   
	 213	
177. Darabi R, Arpke RW, Irion S, Dimos JT, Grskovic M, Kyba M, et al. Human 
ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and improve 
contractility upon transplantation in dystrophic mice. Cell Stem Cell. 2012 May 
04;10(5):610-9. PubMed PMID: 22560081. PMCID: PMC3348507. Epub 
2012/05/09. eng.  doi: http://dx.doi.org/10.1016/j.stem.2012.02.015 
178. Huard C, Moisset PA, Dicaire A, Merly F, Tardif F, Asselin I, et al. 
Transplantation of dermal fibroblasts expressing MyoD1 in mouse muscles. 
Biochem Biophys Res Commun. 1998 Jul 30;248(3):648-54. PubMed PMID: 
9703980. Epub 1998/08/15. eng.  doi: http://dx.doi.org/10.1006/bbrc.1998.8995 
179. Kimura E, Han JJ, Li S, Fall B, Ra J, Haraguchi M, et al. Cell-lineage 
regulated myogenesis for dystrophin replacement: a novel therapeutic approach 
for treatment of muscular dystrophy. Hum Mol Genet. 2008 Aug 15;17(16):2507-
17. PubMed PMID: 18511457. PMCID: PMC2574879. Epub 2008/05/31. eng.  
doi: http://dx.doi.org/10.1093/hmg/ddn151 
180. Lattanzi L, Salvatori G, Coletta M, Sonnino C, Cusella De Angelis MG, 
Gioglio L, et al. High efficiency myogenic conversion of human fibroblasts by 
adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex 
vivo gene therapy of primary myopathies. J Clin Invest. 1998 May 
15;101(10):2119-28. PubMed PMID: 9593768. PMCID: PMC508800. Epub 
1998/05/29. eng.  doi: http://dx.doi.org/10.1172/jci1505 
181. Mendell JR, Rodino-Klapac L, Sahenk Z, Malik V, Kaspar BK, Walker CM, 
et al. Gene therapy for muscular dystrophy: lessons learned and path forward. 
Neurosci Lett. 2012 Oct 11;527(2):90-9. PubMed PMID: 22609847. PMCID: 
3492936.  doi: http://dx.doi.org/10.1016/j.neulet.2012.04.078 
182. Goyenvalle A, Seto JT, Davies KE, Chamberlain J. Therapeutic 
approaches to muscular dystrophy. Hum Mol Genet. 2011 Apr 15;20(R1):R69-78. 
PubMed PMID: 21436158. PMCID: 3095062.  doi: 
http://dx.doi.org/10.1093/hmg/ddr105 
183. Opar A. Exon-skipping drug pulls ahead in muscular dystrophy field. Nat 
Med. 2012 Sep;18(9):1314. PubMed PMID: 22961147.  doi: 
http://dx.doi.org/10.1038/nm0912-1314 
184. Benedetti S, Hoshiya H, Tedesco FS. Repair or replace? Exploiting novel 
gene and cell therapy strategies for muscular dystrophies. FEBS J. 2013 
Sep;280(17):4263-80. PubMed PMID: 23387802.  doi: 
http://dx.doi.org/10.1111/febs.12178 
185. De Arcangelis V, Strimpakos G, Gabanella F, Corbi N, Luvisetto S, Magrelli 
A, et al. Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular 
Dystrophy. J Cell Physiol. 2016 Jan;231(1):224-32. PubMed PMID: 26097015.  
doi: http://dx.doi.org/10.1002/jcp.25075 
186. Zschuntzsch J, Zhang Y, Klinker F, Makosch G, Klinge L, Malzahn D, et al. 
Treatment with human immunoglobulin G improves the early disease course in a 
mouse model of Duchenne muscular dystrophy. J Neurochem. 2015 Jul 31. 
PubMed PMID: 26230042.  doi: http://dx.doi.org/10.1111/jnc.13269 
187. Whitehead NP, Kim MJ, Bible KL, Adams ME, Froehner SC. A new 
therapeutic effect of simvastatin revealed by functional improvement in muscular 
dystrophy. Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12864-9. PubMed 
PMID: 26417069. PMCID: PMC4611601.  doi: 
http://dx.doi.org/10.1073/pnas.1509536112 
	 214	
188. Whitehead NP, Kim MJ, Bible KL, Adams ME, Froehner SC. Simvastatin 
offers new prospects for the treatment of Duchenne muscular dystrophy. Rare 
Dis. 2016;4(1):e1156286. PubMed PMID: 27141415. PMCID: PMC4838314.  doi: 
http://dx.doi.org/10.1080/21675511.2016.1156286 
189. Neri M, Torelli S, Brown S, Ugo I, Sabatelli P, Merlini L, et al. Dystrophin 
levels as low as 30% are sufficient to avoid muscular dystrophy in the human. 
Neuromuscul Disord. 2007 Dec;17(11-12):913-8. PubMed PMID: 17826093. Epub 
2007/09/11. eng.  doi: http://dx.doi.org/10.1016/j.nmd.2007.07.005 
190. Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA, et al. 
Expression of full-length and truncated dystrophin mini-genes in transgenic mdx 
mice. Hum Mol Genet. 1995 Aug;4(8):1251-8. PubMed PMID: 7581361. Epub 
1995/08/01. eng.   
191. Rafael JA, Sunada Y, Cole NM, Campbell KP, Faulkner JA, Chamberlain 
JS. Prevention of dystrophic pathology in mdx mice by a truncated dystrophin 
isoform. Hum Mol Genet. 1994 Oct;3(10):1725-33. PubMed PMID: 7849695. 
Epub 1994/10/01. eng.   
192. Wells DJ, Wells KE, Asante EA, Turner G, Sunada Y, Campbell KP, et al. 
Expression of human full-length and minidystrophin in transgenic mdx mice: 
implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Genet. 
1995 Aug;4(8):1245-50. PubMed PMID: 7581360. Epub 1995/08/01. eng.   
193. Wu B, Li Y, Morcos PA, Doran TJ, Lu P, Lu QL. Octa-guanidine morpholino 
restores dystrophin expression in cardiac and skeletal muscles and ameliorates 
pathology in dystrophic mdx mice. Mol Ther. 2009 May;17(5):864-71. PubMed 
PMID: 19277018. PMCID: 2835139.  doi: http://dx.doi.org/10.1038/mt.2009.38 
194. Williams JH, Sirsi SR, Latta DR, Lutz GJ. Induction of dystrophin 
expression by exon skipping in mdx mice following intramuscular injection of 
antisense oligonucleotides complexed with PEG-PEI copolymers. Mol Ther. 2006 
Jul;14(1):88-96. PubMed PMID: 16488666.  doi: 
http://dx.doi.org/10.1016/j.ymthe.2005.11.025 
195. Dick E, Kalra S, Anderson D, George V, Ritso M, Laval SH, et al. Exon 
Skipping and Gene Transfer Restore Dystrophin Expression in Human Induced 
Pluripotent Stem Cells-Cardiomyocytes Harboring DMD Mutations. Stem Cells 
Dev. 2013 Oct 15;22(20):2714-24. PubMed PMID: 23829870. PMCID: 3787465.  
doi: http://dx.doi.org/10.1089/scd.2013.0135 
196. Wirth T, Parker N, Yla-Herttuala S. History of gene therapy. Gene. 2013 
Aug 10;525(2):162-9. PubMed PMID: 23618815.  doi: 
http://dx.doi.org/10.1016/j.gene.2013.03.137 
197. Odom GL, Gregorevic P, Chamberlain JS. Viral-mediated gene therapy for 
the muscular dystrophies: Successes, limitations and recent advances. Biochim 
Biophys Acta. 2007 Feb;1772(2):243-62. PubMed PMID: 17064882. PMCID: 
Pmc1894910. eng.  doi: http://dx.doi.org/10.1016/j.bbadis.2006.09.007 
198. Acsadi G, Lochmuller H, Jani A, Huard J, Massie B, Prescott S, et al. 
Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo 
gene transfer. Hum Gene Ther. 1996 Jan 20;7(2):129-40. PubMed PMID: 
8788164. Epub 1996/01/20. eng.  doi: http://dx.doi.org/10.1089/hum.1996.7.2-129 
199. Yue Y, Pan X, Hakim CH, Kodippili K, Zhang K, Shin JH, et al. Safe and 
bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs 
with adeno-associated virus. Hum Mol Genet. 2015 Oct 15;24(20):5880-90. 
	 215	
PubMed PMID: 26264580. PMCID: PMC4581611.  doi: 
http://dx.doi.org/10.1093/hmg/ddv310 
200. Lostal W, Kodippili K, Yue Y, Duan D. Full-length dystrophin reconstitution 
with adeno-associated viral vectors. Hum Gene Ther. 2014 Jun;25(6):552-62. 
PubMed PMID: 24580018. PMCID: PMC4064726.  doi: 
http://dx.doi.org/10.1089/hum.2013.210 
201. Scott Q. harper hM, Christiana dellorusso, Dongsheng duan, R.W. 
crawford, S.F. phelps, H.A. harper, A.S. robinson,J.F. engelhardt, S.V. brooks,  
J.S. chamberlain. Modular flexibility of dystrophin: Implications for gene therapy of 
Duchenne muscular dystrophy. Nat Med. 2002;8(3):253-61.   
202. Gebremedhin S, Singh A, Koons S, Bernt W, Konopka K, Duzgunes N. 
Gene Delivery to Carcinoma Cells via Novel Non-Viral Vectors: Nanoparticle 
Tracking Analysis and Suicide Gene Therapy. Eur J Pharm Sci. 2014 Apr 18. 
PubMed PMID: 24751674.  doi: http://dx.doi.org/10.1016/j.ejps.2014.03.003 
203. Koirala A, Conley SM, Makkia R, Liu Z, Cooper MJ, Sparrow JR, et al. 
Persistence of non-viral vector mediated RPE65 expression: Case for viability as 
a gene transfer therapy for RPE-based diseases. J Control Release. 2013 Sep 
11. PubMed PMID: 24035979.  doi: http://dx.doi.org/10.1016/j.jconrel.2013.08.299 
204. Elmer JJ, Christensen MD, Rege K. Applying horizontal gene transfer 
phenomena to enhance efficacy of non-viral gene therapy. J Control Release. 
2013 Aug 30. PubMed PMID: 23994344.  doi: 
http://dx.doi.org/10.1016/j.jconrel.2013.08.025 
205. Raviv L, Jaron-Mendelson M, David A. Mannosylated polyion complexes 
for in vivo gene delivery into CD11c(+) dendritic cells. Mol Pharm. 2015 Feb 
2;12(2):453-62. PubMed PMID: 25531245.  doi: 
http://dx.doi.org/10.1021/mp5005492 
206. Kodama Y, Ohkubo C, Kurosaki T, Egashira K, Sato K, Fumoto S, et al. 
Secure and effective gene delivery system of plasmid DNA coated by 
polynucleotide. J Drug Target. 2015 Jan;23(1):43-51. PubMed PMID: 25148610.  
doi: http://dx.doi.org/10.3109/1061186X.2014.950665 
207. Yang J, Liu X, Yu J, Sheng L, Shi Y, Li Z, et al. A non-viral vector for 
potential DMD gene therapy study by targeting a minidystrophin-GFP fusion gene 
into the hrDNA locus. Acta Biochim Biophys Sin (Shanghai). 2009 
Dec;41(12):1053-60. PubMed PMID: 20011980.   
208. Wolff JA, Budker V. The Mechanism of Naked DNA Uptake and 
Expression. Non-Viral Vectors for Gene Therapy, Second Edition: Part 2. 
2005;54:3-20. PubMed PMID: WOS:000280571400002. English.  doi: 
http://dx.doi.org/10.1016/S0065-2660(05)54001-X 
209. Budker V, Budker T, Zhang GF, Subbotin V, Loomis A, Wolff JA. 
Hypothesis: naked plasmid DNA is taken up by cells in vivo by a receptor-
mediated process. J Gene Med. 2000 Mar-Apr;2(2):76-88. PubMed PMID: 
WOS:000086828200001. English.  doi: http://dx.doi.org/10.1002/(Sici)1521-
2254(200003/04)2:2<76::Aid-Jgm97>3.0.Co;2-4 
210. Phua KK, Leong KW, Nair SK. Transfection efficiency and transgene 
expression kinetics of mRNA delivered in naked and nanoparticle format. J 
Control Release. 2013 Mar 28;166(3):227-33. PubMed PMID: 23306021. PMCID: 
PMC3594075.  doi: http://dx.doi.org/10.1016/j.jconrel.2012.12.029 
	 216	
211. Marshall WG, Jr., Boone BA, Burgos JD, Gografe SI, Baldwin MK, 
Danielson ML, et al. Electroporation-mediated delivery of a naked DNA plasmid 
expressing VEGF to the porcine heart enhances protein expression. Gene Ther. 
2010 Mar;17(3):419-23. PubMed PMID: 19956270. PMCID: PMC3138211.  doi: 
http://dx.doi.org/10.1038/gt.2009.153 
212. Pringle IA, McLachlan G, Collie DD, Sumner-Jones SG, Lawton AE, 
Tennant P, et al. Electroporation enhances reporter gene expression following 
delivery of naked plasmid DNA to the lung. J Gene Med. 2007 May;9(5):369-80. 
PubMed PMID: 17410613.  doi: http://dx.doi.org/10.1002/jgm.1026 
213. Wang XD, Tang JG, Xie XL, Yang JC, Li S, Ji JG, et al. A comprehensive 
study of optimal conditions for naked plasmid DNA transfer into skeletal muscle by 
electroporation. J Gene Med. 2005 Sep;7(9):1235-45. PubMed PMID: 15880605.  
doi: http://dx.doi.org/10.1002/jgm.765 
214. Liang KW, Nishikawa M, Liu F, Sun B, Ye Q, Huang L. Restoration of 
dystrophin expression in mdx mice by intravascular injection of naked DNA 
containing full-length dystrophin cDNA. Gene Ther. 2004 Jun;11(11):901-8. 
PubMed PMID: 14985786. Epub 2004/02/27.  doi: 
http://dx.doi.org/10.1038/sj.gt.3302239 
215. Burke CW, Suk JS, Kim AJ, Hsiang YHJ, Klibanov AL, Hanes J, et al. 
Markedly enhanced skeletal muscle transfection achieved by the ultrasound-
targeted delivery of non-viral gene nanocarriers with microbubbles. J Control 
Release. 2012 Sep 10;162(2):414-21. PubMed PMID: WOS:000310506400019. 
English.  doi: http://dx.doi.org/Doi 10.1016/J.Jconrel.2012.07.005 
216. Brandl C, Ortiz O, Rottig B, Wefers B, Wurst W, Kuhn R. Creation of 
targeted genomic deletions using TALEN or CRISPR/Cas nuclease pairs in one-
cell mouse embryos. FEBS Open Bio. 2015;5:26-35. PubMed PMID: 25685662. 
PMCID: PMC4309836.  doi: http://dx.doi.org/10.1016/j.fob.2014.11.009 
217. Pu J, Frescas D, Zhang B, Feng J. Utilization of TALEN and CRISPR/Cas9 
technologies for gene targeting and modification. Exp Biol Med (Maywood). 2015 
Aug;240(8):1065-70. PubMed PMID: 25956682.  doi: 
http://dx.doi.org/10.1177/1535370215584932 
218. Radev Z, Hermel JM, Elipot Y, Bretaud S, Arnould S, Duchateau P, et al. A 
TALEN-Exon Skipping Design for a Bethlem Myopathy Model in Zebrafish. PLoS 
One. 2015;10(7):e0133986. PubMed PMID: 26221953. PMCID: PMC4519248.  
doi: http://dx.doi.org/10.1371/journal.pone.0133986 
219. Dreyer AK, Hoffmann D, Lachmann N, Ackermann M, Steinemann D, 
Timm B, et al. TALEN-mediated functional correction of X-linked chronic 
granulomatous disease in patient-derived induced pluripotent stem cells. 
Biomaterials. 2015 Nov;69:191-200. PubMed PMID: 26295532.  doi: 
http://dx.doi.org/10.1016/j.biomaterials.2015.07.057 
220. Cui C, Song Y, Liu J, Ge H, Li Q, Huang H, et al. Gene targeting by 
TALEN-induced homologous recombination in goats directs production of beta-
lactoglobulin-free, high-human lactoferrin milk. Sci Rep. 2015;5:10482. PubMed 
PMID: 25994151.  doi: http://dx.doi.org/10.1038/srep10482 
221. Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN. 
Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of 
germline DNA. Science. 2014 Sep 5;345(6201):1184-8. PubMed PMID: 
25123483. PMCID: PMC4398027.  doi: http://dx.doi.org/10.1126/science.1254445 
	 217	
222. Chen Y, Zheng Y, Kang Y, Yang W, Niu Y, Guo X, et al. Functional 
disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9. Hum 
Mol Genet. 2015 Jul 1;24(13):3764-74. PubMed PMID: 25859012.  doi: 
http://dx.doi.org/10.1093/hmg/ddv120 
223. Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach 
CA. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin 
mutations that cause Duchenne muscular dystrophy. Nat Commun. 2015;6:6244. 
PubMed PMID: 25692716. PMCID: PMC4335351.  doi: 
http://dx.doi.org/10.1038/ncomms7244 
224. Menoret S, De Cian A, Tesson L, Remy S, Usal C, Boule JB, et al. 
Homology-directed repair in rodent zygotes using Cas9 and TALEN engineered 
proteins. Sci Rep. 2015;5:14410. PubMed PMID: 26442875. PMCID: 
PMC4595769.  doi: http://dx.doi.org/10.1038/srep14410 
225. Ohtsuka Y, Udaka K, Yamashiro Y, Yagita H, Okumura K. Dystrophin acts 
as a transplantation rejection antigen in dystrophin-deficient mice: Implication for 
gene therapy. J Immunol. 1998 May 1;160(9):4635-40. PubMed PMID: 
WOS:000073225800062. English.   
226. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. 
Nature. 1998 Mar 19;392(6673):245-52. PubMed PMID: 9521319.  doi: 
http://dx.doi.org/10.1038/32588 
227. Jung S, Unutmaz D, Wong P, Sano GI, De los Santos K, Sparwasser T, et 
al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T 
cells by exogenous cell-associated antigens. Immunity. 2002 Aug;17(2):211-20. 
PubMed PMID: WOS:000177669400009. English.  doi: 
http://dx.doi.org/10.1016/S1074-7613(02)00365-5 
228. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by 
dendritic cells. Nat Rev Immunol. 2012 Jul 13;12(8):557-69. PubMed PMID: 
22790179.  doi: http://dx.doi.org/10.1038/nri3254 
229. Heath WR, Belz GT, Behrens GM, Smith CM, Forehan SP, Parish IA, et al. 
Cross-presentation, dendritic cell subsets, and the generation of immunity to 
cellular antigens. Immunol Rev. 2004 Jun;199:9-26. PubMed PMID: 15233723. 
Epub 2004/07/06. eng.  doi: http://dx.doi.org/10.1111/j.0105-2896.2004.00142.x 
230. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C. Spatial and mechanistic 
separation of cross-presentation and endogenous antigen presentation. Nat 
Immunol. 2008 May;9(5):558-66. PubMed PMID: 18376402. Epub 2008/04/01. 
eng.  doi: http://dx.doi.org/10.1038/ni.1601 
231. Segura E, Villadangos JA. A modular and combinatorial view of the antigen 
cross-presentation pathway in dendritic cells. Traffic. 2011 Dec;12(12):1677-85. 
PubMed PMID: 21777358. Epub 2011/07/23. eng.  doi: 
http://dx.doi.org/10.1111/j.1600-0854.2011.01254.x 
232. Zietara N, Lyszkiewicz M, Puchalka J, Pei G, Gutierrez MG, Lienenklaus S, 
et al. Immunoglobulins drive terminal maturation of splenic dendritic cells. Proc 
Natl Acad Sci U S A. 2013 Feb 5;110(6):2282-7. PubMed PMID: 23345431. 
PMCID: 3568358.  doi: http://dx.doi.org/10.1073/pnas.1210654110 
233. Hubo M, Trinschek B, Kryczanowsky F, Tuettenberg A, Steinbrink K, 
Jonuleit H. Costimulatory molecules on immunogenic versus tolerogenic human 
dendritic cells. Front Immunol. 2013;4:82. PubMed PMID: 23565116. PMCID: 
3615188.  doi: http://dx.doi.org/10.3389/fimmu.2013.00082 
	 218	
234. Schuurhuis DH, Laban S, Toes Ré EM, Ricciardi-Castagnoli P, Kleijmeer 
MJ, van der Voort EIH, et al. Immature Dendritic Cells Acquire Cd8(+)Cytotoxic T 
Lymphocyte Priming Capacity upon Activation by T Helper Cell–Independent or–
Dependent Stimuli. J Exp Med. 2000 Jul 3;192(1):145-50. PubMed PMID: 
10880536. PMCID: PMC1887717. eng.   
235. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-
specific inhibition of effector T cell function in humans after injection of immature 
dendritic cells. J Exp Med. 2001 Jan 15;193(2):233-8. PubMed PMID: 11208863. 
PMCID: PMC2193335. Epub 2001/02/24. eng.   
236. Ferguson TA, Herndon J, Elzey B, Griffith TS, Schoenberger S, Green DR. 
Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-
priming of CD8(+) T cells produce active immune unresponsiveness. J Immunol. 
2002 Jun 01;168(11):5589-95. PubMed PMID: 12023355. Epub 2002/05/23. eng.   
237. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. 
Dendritic cells induce peripheral T cell unresponsiveness under steady state 
conditions in vivo. J Exp Med. 2001 Sep 17;194(6):769-79. PubMed PMID: 
11560993. PMCID: PMC2195961.   
238. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman 
RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in 
the steady state leads to antigen presentation on major histocompatibility complex 
class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002 Dec 
16;196(12):1627-38. PubMed PMID: 12486105. PMCID: PMC2196060. Epub 
2002/12/18. eng.   
239. Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune 
tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med. 2002 
Oct 21;196(8):1091-7. PubMed PMID: 12391020. PMCID: PMC2194037. Epub 
2002/10/23. eng.   
240. Inaba K, Turley S, Iyoda T, Yamaide F, Shimoyama S, Reis e Sousa C, et 
al. The formation of immunogenic major histocompatibility complex class II-
peptide ligands in lysosomal compartments of dendritic cells is regulated by 
inflammatory stimuli. J Exp Med. 2000 Mar 20;191(6):927-36. PubMed PMID: 
10727455. PMCID: PMC2193115. Epub 2000/03/23. eng.   
241. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J, 
et al. Rapid generation of broad T-cell immunity in humans after a single injection 
of mature dendritic cells. J Clin Invest. 1999 Jul;104(2):173-80. PubMed PMID: 
10411546. PMCID: PMC408478. Epub 1999/07/20. eng.  doi: 
http://dx.doi.org/10.1172/jci6909 
242. Legge KL, Gregg RK, Maldonado-Lopez R, Li L, Caprio JC, Moser M, et al. 
On the Role of Dendritic Cells in Peripheral T Cell Tolerance and Modulation of 
Autoimmunity. J Exp Med. 2002 Jul 15;196(2):217-27. PubMed PMID: 12119346. 
PMCID: PMC2193920. eng.  doi: http://dx.doi.org/10.1084/jem.20011061 
243. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. 
Annu Rev Immunol. 2003;21:685-711. PubMed PMID: 12615891.  doi: 
http://dx.doi.org/10.1146/annurev.immunol.21.120601.141040 
244. Rodrigues CP, Ferreira AC, Pinho MP, de Moraes CJ, Bergami-Santos PC, 
Barbuto JA. Tolerogenic IDO(+) Dendritic Cells Are Induced by PD-1-Expressing 
Mast Cells. Front Immunol. 2016;7:9. PubMed PMID: 26834749. PMCID: 
PMC4724729.  doi: http://dx.doi.org/10.3389/fimmu.2016.00009 
	 219	
245. Li Q, Harden JL, Anderson CD, Egilmez NK. Tolerogenic Phenotype of 
IFN-gamma-Induced IDO+ Dendritic Cells Is Maintained via an Autocrine IDO-
Kynurenine/AhR-IDO Loop. J Immunol. 2016 Aug 1;197(3):962-70. PubMed 
PMID: 27316681.  doi: http://dx.doi.org/10.4049/jimmunol.1502615 
246. Zheng X, Koropatnick J, Chen D, Velenosi T, Ling H, Zhang X, et al. 
Silencing IDO in dendritic cells: a novel approach to enhance cancer 
immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 
15;132(4):967-77. PubMed PMID: 22870862.  doi: 
http://dx.doi.org/10.1002/ijc.27710 
247. Yoo S, Ha SJ. Generation of Tolerogenic Dendritic Cells and Their 
Therapeutic Applications. Immune Netw. 2016 Feb;16(1):52-60. PubMed PMID: 
26937232. PMCID: PMC4770100.  doi: http://dx.doi.org/10.4110/in.2016.16.1.52 
248. Colonna M, Trinchieri G, Liu Y-J. Plasmacytoid dendritic cells in immunity. 
Nat Immunol. 2004 12//print;5(12):1219-26.   
249. Dobrzynski E, Herzog RW. Tolerance Induction by Viral In Vivo Gene 
Transfer. Clin Med Res. 2005;3(4):234-40.   
250. Buhlmann JE, Foy TM, Aruffo A, Crassi KM, Ledbetter JA, Green WR, et 
al. In the absence of a CD40 signal, B cells are tolerogenic. Immunity. 1995 
Jun;2(6):645-53. PubMed PMID: 7540943.   
251. Grohmann U, Bronte V. Control of immune response by amino acid 
metabolism. Immunol Rev. 2010 Jul;236:243-64. PubMed PMID: 20636821. Epub 
2010/07/20. eng.  doi: http://dx.doi.org/10.1111/j.1600-065X.2010.00915.x 
252. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et 
al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by 
dendritic cells. Nat Immunol. 2011 Sep;12(9):870-8. PubMed PMID: 21804557.  
doi: http://dx.doi.org/10.1038/ni.2077 
253. Delle H, Noronha IL. Induction of indoleamine 2,3-dioxygenase by gene 
delivery in allogeneic islets prolongs allograft survival. Am J Transplant. 2010 
Aug;10(8):1918-24. PubMed PMID: 20636452.  doi: 
http://dx.doi.org/10.1111/j.1600-6143.2010.03190.x 
254. Thomas SR, Terentis AC, Cai H, Takikawa O, Levina A, Lay PA, et al. 
Post-translational regulation of human indoleamine 2,3-dioxygenase activity by 
nitric oxide. J Biol Chem. 2007 Aug 17;282(33):23778-87. PubMed PMID: 
17535808.  doi: http://dx.doi.org/10.1074/jbc.M700669200 
255. Ravishankar B, Liu H, Shinde R, Chandler P, Baban B, Tanaka M, et al. 
Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc 
Natl Acad Sci U S A. 2012 Mar 6;109(10):3909-14. PubMed PMID: 22355111. 
PMCID: 3309765.  doi: http://dx.doi.org/10.1073/pnas.1117736109 
256. Yamazaki S, Morita A. Dendritic cells in the periphery control antigen-
specific natural and induced regulatory T cells. Front Immunol. 2013;4:151. 
PubMed PMID: 23801989. PMCID: 3689032.  doi: 
http://dx.doi.org/10.3389/fimmu.2013.00151 
257. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, et al. 
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-
dioxygenase. Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2497-502. PubMed 
PMID: 22308364. PMCID: 3289319.  doi: 
http://dx.doi.org/10.1073/pnas.1113873109 
	 220	
258. Bahar MA, Nabai L, Ghahary A. Immunoprotective role of indoleamine 2,3-
dioxygenase in engraftment of allogenic skin substitute in wound healing. J Burn 
Care Res. 2012 May-Jun;33(3):364-70. PubMed PMID: 22249100.  doi: 
http://dx.doi.org/10.1097/BCR.0b013e318235836e 
259. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and 
tryptophan catabolism. Nat Rev Immunol. 2004 Oct;4(10):762-74. PubMed PMID: 
15459668.  doi: http://dx.doi.org/10.1038/nri1457 
260. Theate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, et al. 
Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein 
in normal and tumoral human tissues. Cancer Immunol Res. 2015 Feb;3(2):161-
72. PubMed PMID: 25271151.  doi: http://dx.doi.org/10.1158/2326-6066.CIR-14-
0137 
261. Kuan YD, Lee CH. Salmonella overcomes tumor immune tolerance by 
inhibition of tumor indoleamine 2, 3-dioxygenase 1 expression. Oncotarget. 2015 
Oct 28. PubMed PMID: 26517244.  doi: http://dx.doi.org/10.18632/oncotarget.6258 
262. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular 
and humoral immune responses to adenoviral vectors containing factor IX gene: 
tolerization of factor IX and vector antigens allows for long-term expression. Proc 
Natl Acad Sci U S A. 1995 Feb 28;92(5):1401-5. PubMed PMID: 7877990. 
PMCID: 42527. English.  doi: http://dx.doi.org/10.1073/Pnas.92.5.1401 
263. Wu C, Zhang Y, Jiang Y, Wang Q, Long Y, Wang C, et al. Apoptotic cell 
administration enhances pancreatic islet engraftment by induction of regulatory T 
cells and tolerogenic dendritic cells. Cell Mol Immunol. 2013 Sep;10(5):393-402. 
PubMed PMID: 23872920.  doi: http://dx.doi.org/10.1038/cmi.2013.16 
264. Manthorpe M, Cornefert-Jensen F, Hartikka J, Felgner J, Rundell A, 
Margalith M, et al. Gene therapy by intramuscular injection of plasmid DNA: 
studies on firefly luciferase gene expression in mice. Hum Gene Ther. 1993 
Aug;4(4):419-31. PubMed PMID: 8399489.  doi: 
http://dx.doi.org/10.1089/hum.1993.4.4-419 
265. Lavigne MD, Pohlschmidt M, Novo JF, Higgins B, Alakhov V, Lochmuller H, 
et al. Promoter dependence of plasmid-pluronics targeted alpha galactosidase A 
expression in skeletal muscle of Fabry mice. Mol Ther. 2005 Nov;12(5):985-90. 
PubMed PMID: WOS:000233292900025. English.  doi: 
http://dx.doi.org/10.1016/J.Ymthe.2005.02.032 
266. Mesin L, Merlo E, Merletti R, Orizio C. Investigation of motor unit 
recruitment during stimulated contractions of tibialis anterior muscle. J 
Electromyogr Kinesiol. 2010 Aug;20(4):580-9. PubMed PMID: 20044273.  doi: 
http://dx.doi.org/10.1016/j.jelekin.2009.11.008 
267. Dellorusso C, Crawford RW, Chamberlain JS, Brooks SV. Tibialis anterior 
muscles in mdx mice are highly susceptible to contraction-induced injury. J 
Muscle Res Cell Motil. 2001;22(5):467-75.  doi: 
http://dx.doi.org/10.1023/a:1014587918367 
268. Jones DA, Turner DL, McIntyre DB, Newham DJ. Energy turnover in 
relation to slowing of contractile properties during fatiguing contractions of the 
human anterior tibialis muscle. J Physiol. 2009 Sep 1;587(Pt 17):4329-38. 
PubMed PMID: 19596896. PMCID: PMC2754369. Epub 2009/07/15. eng.  doi: 
http://dx.doi.org/10.1113/jphysiol.2009.175265 
	 221	
269. Yang Y, Ehlen Haecker S, Su Q, Wilson JM. Immunology of Gene Therapy 
with Adenoviral Vectors in Mouse Skeletal Muscle. Hum Mol Genet. 1996 
November 1, 1996;5(11):1703-12.  doi: http://dx.doi.org/10.1093/hmg/5.11.1703 
270. Rando TA, Disatnik M-H, Zhou LZH. Rescue of dystrophin expression in 
mdx mouse muscle by RNA/DNA oligonucleotides. Proc Natl Acad Sci U S A. 
2000 08/10/received 
02/29/accepted;97(10):5363-8. PubMed PMID: PMC25834.   
271. Nalbantoglu J, Larochelle N, Wolf E, Karpati G, Lochmuller H, Holland PC. 
Muscle-Specific Overexpression of the Adenovirus Primary Receptor CAR 
Overcomes Low Efficiency of Gene Transfer to Mature Skeletal Muscle. J Virol. 
2001 May 1, 2001;75(9):4276-82.  doi: http://dx.doi.org/10.1128/jvi.75.9.4276-
4282.2001 
272. Renald Giblert DRWR, AnBang Lu, Basil J. Petrof, Josephine Nalbantoglu, 
George Karpati. Prolonged dystrophin expression and functional correction of mdx 
mouse muscle following gene transfer with a helper dependent (gutted) 
adenovirus-encoding murine dystrophin. Hum Mol Genet. 2003;12(11):1287-99.  
doi: http://dx.doi.org/10.1093/hmg/ddg141 
273. Reay DP, Bilbao R, Koppanati BM, Cai L, O'Day TL, Jiang Z, et al. Full-
length dystrophin gene transfer to the mdx mouse in utero. Gene Ther. 2008 
02/14/online;15(7):531-6.   
274. Hakim CH, Li D, Duan D. Monitoring murine skeletal muscle function for 
muscle gene therapy. Methods Mol Biol. 2011;709:75-89. PubMed PMID: 
21194022. PMCID: PMC3118041. Epub 2011/01/05. Eng.  doi: 
http://dx.doi.org/10.1007/978-1-61737-982-6_5 
275. Guse K, Suzuki M, Sule G, Bertin TK, Tyynismaa H, Ahola-Erkkilä S, et al. 
Capsid-Modified Adenoviral Vectors for Improved Muscle-Directed Gene Therapy. 
Hum Gene Ther. 2012 06/26 
01/08/received 
06/14/accepted;23(10):1065-70. PubMed PMID: PMC3472516.  doi: 
http://dx.doi.org/10.1089/hum.2012.003 
276. Sahenk Z, Galloway G, Clark KR, Malik V, Rodino-Klapac LR, Kaspar BK, 
et al. AAV1.NT-3 Gene Therapy for Charcot-Marie-Tooth Neuropathy. Mol Ther. 
2014 03//print;22(3):511-21.  doi: http://dx.doi.org/10.1038/mt.2013.250 
277. Todd AG, McElroy JA, Grange RW, Fuller DD, Walter GA, Byrne BJ, et al. 
Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease. Ann 
Neurol. 2015 Aug;78(2):222-34. PubMed PMID: 25925726. PMCID: 
PMC4520217. Epub 2015/05/01. Eng.  doi: http://dx.doi.org/10.1002/ana.24433 
278. Carberry S, Zweyer M, Swandulla D, Ohlendieck K. Profiling of age-related 
changes in the tibialis anterior muscle proteome of the mdx mouse model of 
dystrophinopathy. J Biomed Biotechnol. 2012;2012:691641. PubMed PMID: 
23093855. PMCID: PMC3471022.  doi: http://dx.doi.org/10.1155/2012/691641 
279. Iachettini S, Valaperta R, Marchesi A, Perfetti A, Cuomo G, Fossati B, et al. 
Tibialis anterior muscle needle biopsy and sensitive biomolecular methods: a 
useful tool in myotonic dystrophy type 1. Eur J Histochem. 2015;59(4):2562. 
PubMed PMID: 26708183. PMCID: PMC4698615.  doi: 
http://dx.doi.org/10.4081/ejh.2015.2562 
280. Sacco P, Jones DA, Dick JR, Vrbova G. Contractile properties and 
susceptibility to exercise-induced damage of normal and mdx mouse tibialis 
	 222	
anterior muscle. Clin Sci (Lond). 1992 Feb;82(2):227-36. PubMed PMID: 
1311662.   
281. Mazia D, Schatten G, Sale W. Adhesion of cells to surfaces coated with 
polylysine. Applications to electron microscopy. J Cell Biol. 1975 Jul;66(1):198-
200. PubMed PMID: 1095595. PMCID: PMC2109515.   
282. Hou WR, Xie SN, Wang HJ, Su YY, Lu JL, Li LL, et al. Intramuscular 
delivery of a naked DNA plasmid encoding proinsulin and pancreatic regenerating 
III protein ameliorates type 1 diabetes mellitus. Pharmacol Res. 2011 
Apr;63(4):320-7. PubMed PMID: 21185938.  doi: 
http://dx.doi.org/10.1016/j.phrs.2010.12.009 
283. Maeda S, Ohmori K, Kurata K, Sakaguchi M, Masuda K, Ohno K, et al. 
Expression of LacZ gene in canine muscle by intramuscular inoculation of a 
plasmid DNA. J Vet Med Sci. 2004 Mar;66(3):337-9. PubMed PMID: 
WOS:000220918600024. English.  doi: http://dx.doi.org/10.1292/Jvms.66.337 
284. Braun S, Thioudellet C, Rodriguez P, Ali-Hadji D, Perraud F, Accart N, et 
al. Immune rejection of human dystrophin following intramuscular injections of 
naked DNA in mdx mice. Gene Ther. 2000 Sep;7(17):1447-57. PubMed PMID: 
11001364. Epub 2000/09/23.  doi: http://dx.doi.org/10.1038/sj.gt.3301261 
285. Aubert D, Menoret S, Chiari E, Pichard V, Durand S, Tesson L, et al. 
Cytotoxic immune response blunts long-term transgene expression after efficient 
retroviral-mediated hepatic gene transfer in rat. Mol Ther. 2002 Apr;5(4):388-96. 
PubMed PMID: WOS:000174871500009. English.  doi: 
http://dx.doi.org/10.1006/mthe.2002.0561 
286. Macgregor GR, Nolan GP, Fiering S, Roederer M, Herzenberg LA. Use of 
Escherichiu coli (E. coli) lacZ (beta-Galactosidase) as a Reporter Gene. Methods 
Mol Biol. 1991;7:217-35. PubMed PMID: 21416358. Epub 1991/01/01. eng.  doi: 
http://dx.doi.org/10.1385/0-89603-178-0:217 
287. Edwards N, Farookhi R, Clarke HJ. Identification of a beta-galactosidase 
transgene that provides a live-cell marker of transcriptional activity in growing 
oocytes and embryos. Mol Hum Reprod. 2015 Jul;21(7):583-93. PubMed PMID: 
25882542. PMCID: PMC4487448.  doi: http://dx.doi.org/10.1093/molehr/gav020 
288. Deressa T, Stoecklinger A, Wallner M, Himly M, Kofler S, Hainz K, et al. 
Structural integrity of the antigen is a determinant for the induction of T-helper 
type-1 immunity in mice by gene gun vaccines against E. coli beta-galactosidase. 
PLoS One. 2014;9(7):e102280. PubMed PMID: 25025197. PMCID: 
PMC4099185.  doi: http://dx.doi.org/10.1371/journal.pone.0102280 
289. Naderian H, Rezvani Z, Atlasi MA, Nikzad H, Antoine Ade V. Expression 
Cloning of Recombinant Escherichia coli lacZ Genes Encoding Cytoplasmic and 
Nuclear beta-galactosidase Variants. Iran J Basic Med Sci. 2011 Jul;14(4):369-75. 
PubMed PMID: 23493052. PMCID: PMC3586830.   
290. Sarkar G, Curran GL, Mahlum E, Decklever T, Wengenack TM, Blahnik A, 
et al. A carrier for non-covalent delivery of functional beta-galactosidase and 
antibodies against amyloid plaques and IgM to the brain. PLoS One. 
2011;6(12):e28881. PubMed PMID: 22216132. PMCID: PMC3244419.  doi: 
http://dx.doi.org/10.1371/journal.pone.0028881 
291. Zhang Y, Ruest LB. Analysis of neural crest cell fate during cardiovascular 
development using Cre-activated lacZ/beta-galactosidase staining. Methods Mol 
	 223	
Biol. 2012;843:125-38. PubMed PMID: 22222527.  doi: 
http://dx.doi.org/10.1007/978-1-61779-523-7_12 
292. Dejean AS, Beisner DR, Ch'en IL, Kerdiles YM, Babour A, Arden KC, et al. 
Transcription factor Foxo3 controls the magnitude of T cell immune responses by 
modulating the function of dendritic cells. Nat Immunol. 2009 May;10(5):504-13. 
PubMed PMID: 19363483. PMCID: PMC2712214.  doi: 
http://dx.doi.org/10.1038/ni.1729 
293. Ni J, Nolte B, Arnold A, Fournier P, Schirrmacher V. Targeting anti-tumor 
DNA vaccines to dendritic cells via a short CD11c promoter sequence. Vaccine. 
2009 Sep 4;27(40):5480-7. PubMed PMID: 19616491.  doi: 
http://dx.doi.org/10.1016/j.vaccine.2009.07.001 
294. Turner DL, Weintraub H. Expression of achaete-scute homolog 3 in 
Xenopus embryos converts ectodermal cells to a neural fate. Genes Dev. 1994 
June 15, 1994;8(12):1434-47.  doi: http://dx.doi.org/10.1101/gad.8.12.1434 
295. Rupp RA, Snider L, Weintraub H. Xenopus embryos regulate the nuclear 
localization of XMyoD. Genes Dev. 1994 Jun 1;8(11):1311-23. PubMed PMID: 
7926732. Epub 1994/06/01. Eng.   
296. Anderson CL, De Repentigny Y, Cifelli C, Marshall P, Renaud JM, Worton 
RG, et al. The mouse dystrophin muscle promoter/enhancer drives expression of 
mini-dystrophin in transgenic mdx mice and rescues the dystrophy in these mice. 
Mol Ther. 2006 Nov;14(5):724-34. PubMed PMID: 16807118.  doi: 
http://dx.doi.org/10.1016/j.ymthe.2006.04.013 
297. Ernst H, Walsh K, Harrison CA, Rosenthal N. The myosin light chain 
enhancer and the skeletal actin promoter share a binding site for factors involved 
in muscle-specific gene expression. Mol Cell Biol. 1991 Jul;11(7):3735-44. 
PubMed PMID: 2046675. PMCID: PMC361142.   
298. Hara M, Yokoyama H, Fukuyama K, Kitamura N, Shimokawa N, Maeda K, 
et al. Transcriptional regulation of the mouse CD11c promoter by AP-1 complex 
with JunD and Fra2 in dendritic cells. Mol Immunol. 2013 Mar;53(3):295-301. 
PubMed PMID: 22990073.  doi: http://dx.doi.org/10.1016/j.molimm.2012.08.004 
299. Grundemann D, Schomig E. Protection of DNA during preparative agarose 
gel electrophoresis against damage induced by ultraviolet light. Biotechniques. 
1996 Nov;21(5):898-903. PubMed PMID: 8922632.   
300. Sberro H, Leavitt A, Kiro R, Koh E, Peleg Y, Qimron U, et al. Discovery of 
functional toxin/antitoxin systems in bacteria by shotgun cloning. Mol Cell. 2013 
Apr 11;50(1):136-48. PubMed PMID: 23478446. PMCID: PMC3644417.  doi: 
http://dx.doi.org/10.1016/j.molcel.2013.02.002 
301. Lin YC, Boone M, Meuris L, Lemmens I, Van Roy N, Soete A, et al. 
Genome dynamics of the human embryonic kidney 293 lineage in response to cell 
biology manipulations. Nat Commun. 2014;5:4767. PubMed PMID: 25182477. 
PMCID: PMC4166678.  doi: http://dx.doi.org/10.1038/ncomms5767 
302. Thomas P, Smart TG. HEK293 cell line: a vehicle for the expression of 
recombinant proteins. J Pharmacol Toxicol Methods. 2005 May-Jun;51(3):187-
200. PubMed PMID: 15862464.  doi: http://dx.doi.org/10.1016/j.vascn.2004.08.014 
303. Rio DC, Clark SG, Tjian R. A Mammalian Host-Vector System That 
Regulates Expression and Amplification of Transfected Genes by Temperature 
Induction. Science. 1985;227(4682):23-8. PubMed PMID: 
WOS:A1985TX67700007. English.  doi: http://dx.doi.org/10.1126/science.2981116 
	 224	
304. Jat PS, Noble MD, Ataliotis P, Tanaka Y, Yannoutsos N, Larsen L, et al. 
Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 
transgenic mouse. Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5096-100. 
PubMed PMID: 1711218. PMCID: PMC51818.   
305. Morgan JE, Beauchamp JR, Pagel CN, Peckham M, Ataliotis P, Jat PS, et 
al. Myogenic cell lines derived from transgenic mice carrying a thermolabile T 
antigen: a model system for the derivation of tissue-specific and mutation-specific 
cell lines. Dev Biol. 1994 Apr;162(2):486-98. PubMed PMID: 8150209.  doi: 
http://dx.doi.org/10.1006/dbio.1994.1103 
306. Rao S, Morales AA, Pearse DD. The Comparative Utility of Viromer RED 
and Lipofectamine for Transient Gene Introduction into Glial Cells. Biomed Res 
Int. 2015;2015:458624. PubMed PMID: 26539498. PMCID: PMC4619820.  doi: 
http://dx.doi.org/10.1155/2015/458624 
307. Arnold AS, Laporte V, Dumont S, Appert-Collin A, Erbacher P, Coupin G, 
et al. Comparing reagents for efficient transfection of human primary myoblasts: 
FuGENE 6, Effectene and ExGen 500. Fundam Clin Pharmacol. 2006 
Feb;20(1):81-9. PubMed PMID: 16448398.  doi: http://dx.doi.org/10.1111/j.1472-
8206.2005.00344.x 
308. Pitard B, Aguerre O, Airiau M, Lachages AM, Boukhnikachvili T, Byk G, et 
al. Virus-sized self-assembling lamellar complexes between plasmid DNA and 
cationic micelles promote gene transfer. Proc Natl Acad Sci U S A. 1997 Dec 
23;94(26):14412-7. PubMed PMID: WOS:000071182800036. PMCID: 
PMC25002. English.  doi: http://dx.doi.org/10.1073/pnas.94.26.14412 
309. Pollard H. Polyethylenimine but Not Cationic Lipids Promotes Transgene 
Delivery to the Nucleus in Mammalian Cells. J Biol Chem. 1998;273(13):7507-11.  
doi: http://dx.doi.org/10.1074/jbc.273.13.7507 
310. Gillard M, Jia Z, Hou JJ, Song M, Gray PP, Munro TP, et al. Intracellular 
trafficking pathways for nuclear delivery of plasmid DNA complexed with highly 
efficient endosome escape polymers. Biomacromolecules. 2014 Oct 
13;15(10):3569-76. PubMed PMID: 25156109.  doi: 
http://dx.doi.org/10.1021/bm5008376 
311. Crawford GE, Lu QL, Partridge TA, Chamberlain JS. Suppression of 
revertant fibers in mdx mice by expression of a functional dystrophin. Hum Mol 
Genet. 2001 Nov 15;10(24):2745-50. PubMed PMID: 11734539.   
312. Stenler S, Wiklander OP, Badal-Tejedor M, Turunen J, Nordin JZ, 
Hallengard D, et al. Micro-minicircle Gene Therapy: Implications of Size on 
Fermentation, Complexation, Shearing Resistance, and Expression. Mol Ther 
Nucleic Acids. 2014;2:e140. PubMed PMID: 24399204. PMCID: 3910003.  doi: 
http://dx.doi.org/10.1038/mtna.2013.67 
313. De Paiva CS, Corrales RM, Villarreal AL, Farley WJ, Li DQ, Stern ME, et 
al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine 
expression, MAPK activation in the corneal epithelium in experimental dry eye. 
Exp Eye Res. 2006 Sep;83(3):526-35. PubMed PMID: 16643899.  doi: 
http://dx.doi.org/10.1016/j.exer.2006.02.004 
314. Pereira JA, Matsumura CY, Minatel E, Marques MJ, Santo Neto H. 
Understanding the beneficial effects of doxycycline on the dystrophic phenotype 
of the mdx mouse. Muscle Nerve. 2014 Aug;50(2):283-6. PubMed PMID: 
24435758.  doi: http://dx.doi.org/10.1002/mus.24177 
	 225	
315. Shiba N, Miyazaki D, Yoshizawa T, Fukushima K, Shiba Y, Inaba Y, et al. 
Differential roles of MMP-9 in early and late stages of dystrophic muscles in a 
mouse model of Duchenne muscular dystrophy. Biochim Biophys Acta. 2015 
Oct;1852(10 Pt A):2170-82. PubMed PMID: 26170062.  doi: 
http://dx.doi.org/10.1016/j.bbadis.2015.07.008 
316. Lu QL, Morris GE, Wilton SD, Ly T, Artem'yeva OV, Strong P, et al. 
Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic 
mouse muscle and produces functional revertant fibers by clonal expansion. J 
Cell Biol. 2000 Mar 6;148(5):985-95. PubMed PMID: WOS:000085775700015. 
English.  doi: http://dx.doi.org/10.1083/jcb.148.5.985 
317. Le ThietThanh NtM, T.R.Heliwel, G.E.Moris. Characterization of Revertant 
Muscle Fibers in Duchenne Muscular Dystrophy, Using Exon-Specific Monoclonal 
Antibodies against Dystrophin. The American Society of Human Genetics. 
1995;56:725-31.   
318. Pigozzo SR, Da Re L, Romualdi C, Mazzara PG, Galletta E, Fletcher S, et 
al. Revertant Fibers in the mdx Murine Model of Duchenne Muscular Dystrophy: 
An Age- and Muscle-Related Reappraisal. PLoS One. 2013;8(8):e72147. PubMed 
PMID: 24015212. PMCID: 3756063.  doi: 
http://dx.doi.org/10.1371/journal.pone.0072147 
319. Echigoya Y, Lee J, Rodrigues M, Nagata T, Tanihata J, 
Nozohourmehrabad A, et al. Mutation Types and Aging Differently Affect 
Revertant Fiber Expansion in Dystrophic Mdx and Mdx52 Mice. PLoS One. 2013 
Jul 24;8(7). PubMed PMID: WOS:000322167900045. English.  doi: 
http://dx.doi.org/10.1371/journal.pone.0069194 
320. Jacobsen LB, Calvin SA, Wang J. Transfection of PCR fragments into-
human tumor cells using FuGENE (R) HD Transfection Reagent. Nature Methods. 
2007:3-5. PubMed PMID: WOS:000251671600002. English.   
321. Kirchenbuechler I, Kirchenbuechler D, Elbaum M. Correlation between 
cationic lipid-based transfection and cell division. Exp Cell Res. 2015 Jan 1. 
PubMed PMID: 25556666.  doi: http://dx.doi.org/10.1016/j.yexcr.2014.11.019 
322. Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L. Endogenous 
microRNA regulation suppresses transgene expression in hematopoietic lineages 
and enables stable gene transfer. Nat Med. 2006 May;12(5):585-91. PubMed 
PMID: 16633348.  doi: http://dx.doi.org/10.1038/nm1398 
323. Pelosi L, Coggi A, Forcina L, Musaro A. MicroRNAs modulated by local 
mIGF-1 expression in mdx dystrophic mice. Front Aging Neurosci. 2015;7:69. 
PubMed PMID: 25999854. PMCID: PMC4419723.  doi: 
http://dx.doi.org/10.3389/fnagi.2015.00069 
324. Chen B, Chen X, Wu X, Wang X, Wang Y, Lin TY, et al. Disruption of 
microRNA-21 by TALEN leads to diminished cell transformation and increased 
expression of cell-environment interaction genes. Cancer Lett. 2015 Jan 28;356(2 
Pt B):506-16. PubMed PMID: 25304376. PMCID: PMC4615566.  doi: 
http://dx.doi.org/10.1016/j.canlet.2014.09.034 
325. Yang G, Yin B. The advance of application for microRNAs in cancer gene 
therapy. Biomed Pharmacother. 2014 Feb;68(1):137-42. PubMed PMID: 
24183203.  doi: http://dx.doi.org/10.1016/j.biopha.2013.10.002 
326. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, et 
al. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression 
	 226	
and membrane localization of dystrophin and dystrophin-associated proteins. Am 
J Pathol. 2003 Oct;163(4):1663-75. PubMed PMID: 14507673. PMCID: 
PMC1868305.  doi: http://dx.doi.org/10.1016/S0002-9440(10)63523-7 
327. Chen CN, Graber TG, Bratten WM, Ferrington DA, Thompson LV. 
Immunoproteasome in animal models of Duchenne muscular dystrophy. J Muscle 
Res Cell Motil. 2014 Apr;35(2):191-201. PubMed PMID: 24934129. PMCID: 
PMC4130177.  doi: http://dx.doi.org/10.1007/s10974-014-9385-x 
328. England SB, Nicholson LVB, Johnson MA, Forrest SM, Love DR, 
Zubrzyckagaarn EE, et al. Very Mild Muscular-Dystrophy Associated with the 
Deletion of 46-Percent of Dystrophin. Nature. 1990 Jan 11;343(6254):180-2. 
PubMed PMID: WOS:A1990CH52700063. English.  doi: 
http://dx.doi.org/10.1038/343180a0 
329. Mirabella M, Galluzzi G, Manfredi G, Bertini E, Ricci E, De Leo R, et al. 
Giant dystrophin deletion associated with congenital cataract and mild muscular 
dystrophy. Neurology. 1998 Aug;51(2):592-5. PubMed PMID: 
WOS:000075387400051. English.   
330. Ervasti JM, Rybakova IN, Amann KJ. A multiple site, side binding model for 
the interaction of dystrophin with F-actin. Soc Gen Physiol Ser. 1997;52:31-44. 
PubMed PMID: 9210218.   
331. Rybakova IN, Amann KJ, Ervasti JM. A new model for the interaction of 
dystrophin with F-actin. J Cell Biol. 1996 Nov;135(3):661-72. PubMed PMID: 
8909541. PMCID: PMC2121071.   
332. Larochelle N, Oualikene W, Dunant P, Massie B, Karpati G, Nalbantoglu J, 
et al. The short MCK1350 promoter/enhancer allows for sufficient dystrophin 
expression in skeletal muscles of mdx mice. Biochem Biophys Res Commun. 
2002 Apr 5;292(3):626-31. PubMed PMID: 11922612.  doi: 
http://dx.doi.org/10.1006/bbrc.2002.6715 
333. Zimowska M, Swierczynska M, Ciemerych MA. Nuclear MMP-9 role in the 
regulation of rat skeletal myoblasts proliferation. Biol Cell. 2013 Aug;105(8):334-
44. PubMed PMID: 23646930.  doi: http://dx.doi.org/10.1111/boc.201300020 
334. Ogura Y, Tajrishi MM, Sato S, Hindi SM, Kumar A. Therapeutic potential of 
matrix metalloproteinases in Duchenne muscular dystrophy. Front Cell Dev Biol. 
2014;2:11. PubMed PMID: 25364719. PMCID: PMC4207008.  doi: 
http://dx.doi.org/10.3389/fcell.2014.00011 
335. Buchholz B, Perez V, Siachoque N, Miksztowicz V, Berg G, Rodriguez M, 
et al. Dystrophin proteolysis: a potential target for MMP-2 and its prevention by 
ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2014 Jul 1;307(1):H88-
96. PubMed PMID: 24791785.  doi: http://dx.doi.org/10.1152/ajpheart.00242.2013 
336. Miyazaki D, Nakamura A, Fukushima K, Yoshida K, Takeda S, Ikeda S. 
Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces 
angiogenesis resulting in impaired growth of regenerated muscle fibers. Hum Mol 
Genet. 2011 May 1;20(9):1787-99. PubMed PMID: 21320869.  doi: 
http://dx.doi.org/10.1093/hmg/ddr062 
337. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of 
novel genes coding for small expressed RNAs. Science. 2001 Oct 
26;294(5543):853-8. PubMed PMID: 11679670.  doi: 
http://dx.doi.org/10.1126/science.1064921 
	 227	
338. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. 
Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002 Apr 
30;12(9):735-9. PubMed PMID: 12007417.   
339. Dmitriev P, Barat A, Polesskaya A, O'Connell MJ, Robert T, Dessen P, et 
al. Simultaneous miRNA and mRNA transcriptome profiling of human myoblasts 
reveals a novel set of myogenic differentiation-associated miRNAs and their target 
genes. BMC Genomics. 2013;14:265. PubMed PMID: 23597168. PMCID: 
3639941.  doi: http://dx.doi.org/10.1186/1471-2164-14-265 
340. Sethi A, Kulkarni N, Sonar S, Lal G. Role of miRNAs in CD4 T cell plasticity 
during inflammation and tolerance. Front Genet. 2013;4:8. PubMed PMID: 
23386861. PMCID: PMC3560369.  doi: http://dx.doi.org/10.3389/fgene.2013.00008 
341. Annoni A, Brown BD, Cantore A, Sergi LS, Naldini L, Roncarolo MG. In 
vivo delivery of a microRNA-regulated transgene induces antigen-specific 
regulatory T cells and promotes immunologic tolerance. Blood. 2009 Dec 
10;114(25):5152-61. PubMed PMID: 19794140. PMCID: PMC2792211. English.  
doi: http://dx.doi.org/10.1182/blood-2009-04-214569 
342. McGowan R, Campbell R, Peterson A, Sapienza C. Cellular mosaicism in 
the methylation and expression of hemizygous loci in the mouse. Genes Dev. 
1989 Nov;3(11):1669-76. PubMed PMID: 2606343.   
343. Chen ZY, Riu E, He CY, Xu H, Kay MA. Silencing of episomal transgene 
expression in liver by plasmid bacterial backbone DNA is independent of CpG 
methylation. Mol Ther. 2008 Mar;16(3):548-56. PubMed PMID: 18253155.  doi: 
http://dx.doi.org/10.1038/sj.mt.6300399 
344. Reyes-Sandoval A, Ertl HC. CpG methylation of a plasmid vector results in 
extended transgene product expression by circumventing induction of immune 
responses. Mol Ther. 2004 Feb;9(2):249-61. PubMed PMID: 14759809.  doi: 
http://dx.doi.org/10.1016/j.ymthe.2003.11.008 
345. Collas P. Modulation of plasmid DNA methylation and expression in 
zebrafish embryos. Nucleic Acids Res. 1998 Oct 1;26(19):4454-61. PubMed 
PMID: 9742249. PMCID: PMC147846.   
346. Hong K, Sherley J, Lauffenburger DA. Methylation of episomal plasmids as 
a barrier to transient gene expression via a synthetic delivery vector. Biomolecular 
Engineering. 2001;18(4):185-92.  doi: http://dx.doi.org/10.1016/s1389-
0344(01)00100-9 
347. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. 
Nat Rev Genet. 2002 Jun;3(6):415-28. PubMed PMID: 12042769. Epub 
2002/06/04. eng.  doi: http://dx.doi.org/10.1038/nrg816 
348. Yew NS, Zhao H, Przybylska M, Wu IH, Tousignant JD, Scheule RK, et al. 
CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene 
expression in vivo. Mol Ther. 2002 Jun;5(6):731-8. PubMed PMID: 12027557.  
doi: http://dx.doi.org/10.1006/mthe.2002.0598 
349. Hodges BL, Taylor KM, Joseph MF, Bourgeois SA, Scheule RK. Long-term 
transgene expression from plasmid DNA gene therapy vectors is negatively 
affected by CpG dinucleotides. Mol Ther. 2004 Aug;10(2):269-78. PubMed PMID: 
15294174.  doi: http://dx.doi.org/10.1016/j.ymthe.2004.04.018 
350. de Wolf HK, Johansson N, Thong AT, Snel CJ, Mastrobattista E, Hennink 
WE, et al. Plasmid CpG depletion improves degree and duration of tumor gene 
expression after intravenous administration of polyplexes. Pharm Res. 2008 
	 228	
Jul;25(7):1654-62. PubMed PMID: 18317886. PMCID: PMC2440937.  doi: 
http://dx.doi.org/10.1007/s11095-008-9558-7 
351. Mitsui M, Nishikawa M, Zang L, Ando M, Hattori K, Takahashi Y, et al. 
Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the 
sustainability of transgene expression. J Gene Med. 2009 May;11(5):435-43. 
PubMed PMID: 19291673.  doi: http://dx.doi.org/10.1002/jgm.1317 
352. Lesina E, Dames P, Rudolph C. The effect of CpG motifs on gene 
expression and clearance kinetics of aerosol administered polyethylenimine (PEI)-
plasmid DNA complexes in the lung. J Control Release. 2010 Apr 19;143(2):243-
50. PubMed PMID: 20074600.  doi: http://dx.doi.org/10.1016/j.jconrel.2010.01.003 
353. Davis HL, Demeneix BA, Quantin B, Coulombe J, Whalen RG. Plasmid 
DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal 
muscle. Hum Gene Ther. 1993 Dec;4(6):733-40. PubMed PMID: 8186288.  doi: 
http://dx.doi.org/10.1089/hum.1993.4.6-733 
354. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard 
PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point 
mutation. Science. 1989 Jun 30;244(4912):1578-80. PubMed PMID: 2662404.   
355. Riva D, Bulgheroni S, Pantaleoni C. Mental retardation. Montrouge, 
FRANCE: Montrouge, France : John Libbey Eurotext; 2007. 9782742006878 
356. Lynch GS, Hinkle RT, Chamberlain JS, Brooks SV, Faulkner JA. Force and 
power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J 
Physiol. 2001 Sep 1;535(Pt 2):591-600. PubMed PMID: 11533147. PMCID: 
PMC2278782.   
357. Bostick B, Yue Y, Duan D. Gender influences cardiac function in the mdx 
model of Duchenne cardiomyopathy. Muscle Nerve. 2010 Oct;42(4):600-3. 
PubMed PMID: 20878741. PMCID: PMC3109082.  doi: 
http://dx.doi.org/10.1002/mus.21763 
358. Glenmark B, Nilsson M, Gao H, Gustafsson JA, Dahlman-Wright K, 
Westerblad H. Difference in skeletal muscle function in males vs. females: role of 
estrogen receptor-beta. Am J Physiol Endocrinol Metab. 2004 Dec;287(6):E1125-
31. PubMed PMID: 15280152.  doi: http://dx.doi.org/10.1152/ajpendo.00098.2004 
359. Lemieux P, Guerin N, Paradis G, Proulx R, Chistyakova L, Kabanov A, et 
al. A combination of poloxamers increases gene expression of plasmid DNA in 
skeletal muscle. Gene Ther. 2000 Jun;7(11):986-91. PubMed PMID: 
WOS:000087395900012. English.  doi: http://dx.doi.org/10.1038/Sj.Gt.3301189 
360. Lavigne MD, Yates L, Coxhead P, Gorecki DC. Nuclear-targeted chimeric 
vector enhancing nonviral gene transfer into skeletal muscle of Fabry mice in vivo. 
FASEB J. 2008 Jun;22(6):2097-107. PubMed PMID: 18202142.  doi: 
http://dx.doi.org/10.1096/fj.07-093765 
361. Andre FM, Cournil-Henrionnet C, Vernerey D, Opolon P, Mir LM. Variability 
of naked DNA expression after direct local injection: the influence of the injection 
speed. Gene Ther. 2006 Dec;13(23):1619-27. PubMed PMID: 
WOS:000242169000002. English.  doi: http://dx.doi.org/10.1038/sj.gt.3302827 
362. Kawase A, Nomura T, Yasuda K, Kobayashi N, Hashida M, Takakura Y. 
Disposition and gene expression characteristics in solid tumors and skeletal 
muscle after direct injection of naked plasmid DNA in mice. J Pharm Sci. 2003 
Jun;92(6):1295-304. PubMed PMID: WOS:000183282200017. English.  doi: 
http://dx.doi.org/10.1002/Jps.10392 
	 229	
363. Taniyama Y, Tachibana K, Hiraoka K, Aoki M, Yamamoto S, Matsumoto K, 
et al. Development of safe and efficient novel nonviral gene transfer using 
ultrasound: enhancement of transfection efficiency of naked plasmid DNA in 
skeletal muscle. Gene Ther. 2002 Mar;9(6):372-80. PubMed PMID: 
WOS:000174694000002. English.  doi: http://dx.doi.org/10.1038/Sj/Gt/3301678 
364. Li Y, Wang JQ, Satter A, Wu QQ, Wang J, Liu F. Gene transfer to skeletal 
muscle by site-specific delivery of electroporation and ultrasound. Biochem 
Biophys Res Commun. 2012 Jul 27;424(2):203-7. PubMed PMID: 
WOS:000307369100001. English.  doi: http://dx.doi.org/10.1016/J.Bbrc.2012.06.090 
365. Liu F, Sag D, Wang J, Shollenberger LM, Niu F, Yuan X, et al. Sine-wave 
current for efficient and safe in vivo gene transfer. Mol Ther. 2007 
Oct;15(10):1842-7. PubMed PMID: 17637717.  doi: 
http://dx.doi.org/10.1038/sj.mt.6300261 
366. Li Y, Wang J, Grebogi C, Foote M, Liu F. A syringe-focused ultrasound 
device for simultaneous injection of DNA and gene transfer. J Gene Med. 2012 
Jan;14(1):54-61. PubMed PMID: 22114052.  doi: 
http://dx.doi.org/10.1002/jgm.1633 
367. Whitley P, Mingarro I. Stitching proteins into membranes, not sew simple. 
Biol Chem. 2014 Dec;395(12):1417-24. PubMed PMID: 25153236. Epub 
2014/08/26. eng.  doi: http://dx.doi.org/10.1515/hsz-2014-0205 
368. Do H, Falcone D, Lin JL, Andrews DW, Johnson AE. The cotranslational 
integration of membrane proteins into the phospholipid bilayer is a multistep 
process. Cell. 1996 May 3;85(3):369-78. PubMed PMID: 
WOS:A1996UK14000010. English.  doi: http://dx.doi.org/10.1016/S0092-
8674(00)81115-0 
369. Martinez-Gil L, Sauri A, Marti-Renom MA, Mingarro I. Membrane protein 
integration into the endoplasmic reticulum. FEBS J. 2011 Oct;278(20):3846-58. 
PubMed PMID: 21592307.  doi: http://dx.doi.org/10.1111/j.1742-4658.2011.08185.x 
370. Rapoport TA, Goder V, Heinrich SU, Matlack KE. Membrane-protein 
integration and the role of the translocation channel. Trends Cell Biol. 2004 
Oct;14(10):568-75. PubMed PMID: 15450979.  doi: 
http://dx.doi.org/10.1016/j.tcb.2004.09.002 
371. Akopian D, Shen K, Zhang X, Shan SO. Signal recognition particle: an 
essential protein-targeting machine. Annu Rev Biochem. 2013;82:693-721. 
PubMed PMID: 23414305. PMCID: PMC3805129.  doi: 
http://dx.doi.org/10.1146/annurev-biochem-072711-164732 
372. Prilusky J, Bibi E. Studying membrane proteins through the eyes of the 
genetic code revealed a strong uracil bias in their coding mRNAs. Proc Natl Acad 
Sci U S A. 2009 Apr 21;106(16):6662-6. PubMed PMID: 19366666. PMCID: 
PMC2672546.  doi: http://dx.doi.org/10.1073/pnas.0902029106 
373. Kraft C, Peter M, Hofmann K. Selective autophagy: ubiquitin-mediated 
recognition and beyond. Nat Cell Biol. 2010 Sep;12(9):836-41. PubMed PMID: 
WOS:000281561900005. English.   
374. Brown O, Cowen RL, Preston CM, Castro MG, Lowenstein PR. Subcellular 
post-transcriptional targeting: delivery of an intracellular protein to the extracellular 
leaflet of the plasma membrane using a glycosyl-phosphatidylinositol (GPI) 
membrane anchor in neurons and polarised epithelial cells. Gene Ther. 2000 
	 230	
Nov;7(22):1947-53. PubMed PMID: 11127583.  doi: 
http://dx.doi.org/10.1038/sj.gt.3301325 
375. Bonet-Kerrache A, Fortier M, Comunale F, Gauthier-Rouviere C. The 
GTPase RhoA increases utrophin expression and stability, as well as its 
localization at the plasma membrane. Biochem J. 2005 Oct 15;391(Pt 2):261-8. 
PubMed PMID: 15963030. PMCID: PMC1276923.  doi: 
http://dx.doi.org/10.1042/BJ20050024 
376. Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis JM, et al. 
Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat 
Med. 1998 Dec;4(12):1441-4. PubMed PMID: 9846586.  doi: 
http://dx.doi.org/10.1038/4033 
377. Deconinck N, Tinsley J, De Backer F, Fisher R, Kahn D, Phelps S, et al. 
Expression of truncated utrophin leads to major functional improvements in 
dystrophin-deficient muscles of mice. Nat Med. 1997 Nov;3(11):1216-21. PubMed 
PMID: 9359695.   
378. Goldberg AL. Protein degradation and protection against misfolded or 
damaged proteins. Nature. 2003 Dec 18;426(6968):895-9. PubMed PMID: 
14685250.  doi: http://dx.doi.org/10.1038/nature02263 
379. Guo L, Giasson BI, Glavis-Bloom A, Brewer MD, Shorter J, Gitler AD, et al. 
A cellular system that degrades misfolded proteins and protects against 
neurodegeneration. Mol Cell. 2014 Jul 3;55(1):15-30. PubMed PMID: 24882209. 
PMCID: PMC4445634.  doi: http://dx.doi.org/10.1016/j.molcel.2014.04.030 
380. Bureau MF, Naimi S, Torero Ibad R, Seguin J, Georger C, Arnould E, et al. 
Intramuscular plasmid DNA electrotransfer: biodistribution and degradation. 
Biochim Biophys Acta. 2004 Jan 20;1676(2):138-48. PubMed PMID: 14746908.   
381. Pollard H, Toumaniantz G, Amos JL, Avet-Loiseau H, Guihard G, Behr JP, 
et al. Ca2+-sensitive cytosolic nucleases prevent efficient delivery to the nucleus 
of injected plasmids. J Gene Med. 2001 Mar-Apr;3(2):153-64. PubMed PMID: 
11318114.  doi: http://dx.doi.org/10.1002/jgm.160 
382. Sakae M, Ito T, Yoshihara C, Iida-Tanaka N, Yanagie H, Eriguchi M, et al. 
Highly efficient in vivo gene transfection by plasmid/PEI complexes coated by 
anionic PEG derivatives bearing carboxyl groups and RGD peptide. Biomed 
Pharmacother. 2008 Sep;62(7):448-53. PubMed PMID: 18255250.  doi: 
http://dx.doi.org/10.1016/j.biopha.2007.12.009 
383. Lechardeur D, Sohn KJ, Haardt M, Joshi PB, Monck M, Graham RW, et al. 
Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene 
transfer. Gene Ther. 1999 Apr;6(4):482-97. PubMed PMID: 10476208.  doi: 
http://dx.doi.org/10.1038/sj.gt.3300867 
384. Rattan R, Bielinska AU, Banaszak Holl MM. Quantification of cytosolic 
plasmid DNA degradation using high-throughput sequencing: implications for 
gene delivery. J Gene Med. 2014 Mar-Apr;16(3-4):75-83. PubMed PMID: 
24700644. PMCID: PMC4071455.  doi: http://dx.doi.org/10.1002/jgm.2761 
385. Ribeiro SC, Monteiro GA, Prazeres DM. The role of polyadenylation signal 
secondary structures on the resistance of plasmid vectors to nucleases. J Gene 
Med. 2004 May;6(5):565-73. PubMed PMID: 15133767.  doi: 
http://dx.doi.org/10.1002/jgm.536 
386. Molano A, Erdjument-Bromage H, Fremont DH, Messaoudi I, Tempst P, 
Nikolic-Zugic J. Peptide selection by an MHC H-2Kb class I molecule devoid of 
	 231	
the central anchor ("C") pocket. J Immunol. 1998 Mar 15;160(6):2815-23. PubMed 
PMID: 9510184. Epub 1998/03/24. eng.   
387. Eghtesad S, Zheng H, Nakai H, Epperly MW, Clemens PR. Effects of 
irradiating adult mdx mice before full-length dystrophin cDNA transfer on host anti-
dystrophin immunity. Gene Ther. 2010 Sep;17(9):1181-90. PubMed PMID: 
20827278. PMCID: PMC3050623.  doi: http://dx.doi.org/10.1038/gt.2010.108 
388. Eghtesad S, Jhunjhunwala S, Little SR, Clemens PR. Effect of rapamycin 
on immunity induced by vector-mediated dystrophin expression in mdx skeletal 
muscle. Sci Rep. 2012;2:399. PubMed PMID: 22570764. PMCID: 3347316.  doi: 
http://dx.doi.org/10.1038/srep00399 
389. Frimpong-Boateng K, van Rooijen N, Geiben-Lynn R. Regulatory T cells 
suppress natural killer cells during plasmid DNA vaccination in mice, blunting the 
CD8+ T cell immune response by the cytokine TGFbeta. PLoS One. 
2010;5(8):e12281. PubMed PMID: 20808850. PMCID: PMC2924372.  doi: 
http://dx.doi.org/10.1371/journal.pone.0012281 
390. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by 
DNA viral vectors directs the immune response to transgene products in muscle 
fibers. J Virol. 1998 May;72(5):4212-23. PubMed PMID: 9557710. PMCID: 
PMC109650.   
391. Yuasa K, Sakamoto M, Miyagoe-Suzuki Y, Tanouchi A, Yamamoto H, Li J, 
et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-
deficient skeletal muscles evokes enhanced immune response against the 
transgene product. Gene Ther. 2002 Dec;9(23):1576-88. PubMed PMID: 
12424610.  doi: http://dx.doi.org/10.1038/sj.gt.3301829 
392. Chen ZK, Frick T. Blockade of CD4 is more tolerogenic than blockade of 
Ag presentation via self MHC class II antigens. Transplant Proc. 2000 
Nov;32(7):2000. PubMed PMID: 11120038.   
393. Carpentier M, Lorain S, Chappert P, Lalfer M, Hardet R, Urbain D, et al. 
Intrinsic transgene immunogenicity gears CD8(+) T-cell priming after rAAV-
mediated muscle gene transfer. Mol Ther. 2015 Apr;23(4):697-706. PubMed 
PMID: 25492560. PMCID: PMC4395773.  doi: 
http://dx.doi.org/10.1038/mt.2014.235 
394. Beauchamp JR, Heslop L, Yu DS, Tajbakhsh S, Kelly RG, Wernig A, et al. 
Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal 
muscle satellite cells. J Cell Biol. 2000 Dec 11;151(6):1221-34. PubMed PMID: 
11121437. PMCID: PMC2190588.   
395. Ieronimakis N, Balasundaram G, Rainey S, Srirangam K, Yablonka-
Reuveni Z, Reyes M. Absence of CD34 on murine skeletal muscle satellite cells 
marks a reversible state of activation during acute injury. PLoS One. 
2010;5(6):e10920. PubMed PMID: 20532193. PMCID: PMC2880004.  doi: 
http://dx.doi.org/10.1371/journal.pone.0010920 
396. Alfaro LA, Dick SA, Siegel AL, Anonuevo AS, McNagny KM, Megeney LA, 
et al. CD34 promotes satellite cell motility and entry into proliferation to facilitate 
efficient skeletal muscle regeneration. Stem Cells. 2011 Dec;29(12):2030-41. 
PubMed PMID: 21997891. PMCID: PMC3638793.  doi: 
http://dx.doi.org/10.1002/stem.759 
397. Rabinowitz SS, Gordon S. Macrosialin, a macrophage-restricted 
membrane sialoprotein differentially glycosylated in response to inflammatory 
	 232	
stimuli. J Exp Med. 1991 Oct 1;174(4):827-36. PubMed PMID: 1919437. PMCID: 
PMC2118958.   
398. Ramprasad MP, Fischer W, Witztum JL, Sambrano GR, Quehenberger O, 
Steinberg D. The 94-Kda to 97-Kda Mouse Macrophage Membrane-Protein That 
Recognizes Oxidized Low-Density-Lipoprotein and Phosphatidylserine-Rich 
Liposomes Is Identical to Macrosialin, the Mouse Homolog of Human Cd68. Proc 
Natl Acad Sci U S A. 1995 Oct 10;92(21):9580-4. PubMed PMID: 
WOS:A1995RZ07200031. PMCID: PMC40845. English.  doi: 
http://dx.doi.org/10.1073/pnas.92.21.9580 
399. Wang JX, Bair AM, King SL, Shnayder R, Huang YF, Shieh CC, et al. Ly6G 
ligation blocks recruitment of neutrophils via a beta2-integrin-dependent 
mechanism. Blood. 2012 Aug 16;120(7):1489-98. PubMed PMID: 22661700. 
PMCID: PMC3423786.  doi: http://dx.doi.org/10.1182/blood-2012-01-404046 
400. Hickey MJ. Has Ly6G finally found a job? Blood. 2012 Aug 16;120(7):1352-
3. PubMed PMID: 22899474.  doi: http://dx.doi.org/10.1182/blood-2012-06-435164 
401. Pizza FX, McLoughlin TJ, McGregor SJ, Calomeni EP, Gunning WT. 
Neutrophils injure cultured skeletal myotubes. Am J Physiol Cell Physiol. 2001 
Jul;281(1):C335-41. PubMed PMID: 11401857.   
402. Hodgetts S, Radley H, Davies M, Grounds MD. Reduced necrosis of 
dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function 
with Etanercept in mdx mice. Neuromuscul Disord. 2006 Oct;16(9-10):591-602. 
PubMed PMID: 16935507.  doi: http://dx.doi.org/10.1016/j.nmd.2006.06.011 
403. Pan F, Yu H, Dang EV, Barbi J, Pan X, Grosso JF, et al. Eos mediates 
Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science. 2009 Aug 
28;325(5944):1142-6. PubMed PMID: 19696312. PMCID: 2859703.  doi: 
http://dx.doi.org/10.1126/science.1176077 
404. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al. 
A special population of regulatory T cells potentiates muscle repair. Cell. 2013 
Dec 5;155(6):1282-95. PubMed PMID: 24315098. PMCID: PMC3894749.  doi: 
http://dx.doi.org/10.1016/j.cell.2013.10.054 
405. Castiglioni A, Corna G, Rigamonti E, Basso V, Vezzoli M, Monno A, et al. 
FOXP3+ T Cells Recruited to Sites of Sterile Skeletal Muscle Injury Regulate the 
Fate of Satellite Cells and Guide Effective Tissue Regeneration. PLoS One. 
2015;10(6):e0128094. PubMed PMID: 26039259. PMCID: PMC4454513.  doi: 
http://dx.doi.org/10.1371/journal.pone.0128094 
406. Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in 
inflammation. Receptor. 1994 Spring;4(1):17-23. PubMed PMID: 8038702.   
407. Nitahara-Kasahara Y, Hayashita-Kinoh H, Chiyo T, Nishiyama A, Okada H, 
Takeda S, et al. Dystrophic mdx mice develop severe cardiac and respiratory 
dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10. 
Hum Mol Genet. 2014 Aug 1;23(15):3990-4000. PubMed PMID: 24659498.  doi: 
http://dx.doi.org/10.1093/hmg/ddu113 
408. Hedrich CM, Bream JH. Cell type-specific regulation of IL-10 expression in 
inflammation and disease. Immunol Res. 2010 Jul;47(1-3):185-206. PubMed 
PMID: 20087682. PMCID: PMC2892196.  doi: http://dx.doi.org/10.1007/s12026-
009-8150-5 
409. Deng B, Wehling-Henricks M, Villalta SA, Wang Y, Tidball JG. IL-10 
triggers changes in macrophage phenotype that promote muscle growth and 
	 233	
regeneration. J Immunol. 2012 Oct 1;189(7):3669-80. PubMed PMID: 22933625. 
PMCID: PMC3448810.  doi: http://dx.doi.org/10.4049/jimmunol.1103180 
410. Altin JA, Goodnow CC, Cook MC. IL-10+ CTLA-4+ Th2 inhibitory cells form 
in a Foxp3-independent, IL-2-dependent manner from Th2 effectors during 
chronic inflammation. J Immunol. 2012 Jun 1;188(11):5478-88. PubMed PMID: 
22547705.  doi: http://dx.doi.org/10.4049/jimmunol.1102994 
411. Hsieh C, Macatonia S, Tripp C, Wolf S, O'Garra A, Murphy K. Development 
of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. 
Science. 1993;260(5107):547-9.  doi: http://dx.doi.org/10.1126/science.8097338 
412. Eickhoff CS, Schnapp AR, Sagartz JE, Hoft DF. Lethal NK-mediated 
inflammation induced by IL-12 in the absence of polymorphic and nonpolymorphic 
MHC class I molecules. Cytokine. 2013 Oct;64(1):25-9. PubMed PMID: 
23891392. PMCID: PMC3770801.  doi: http://dx.doi.org/10.1016/j.cyto.2013.06.320 
413. Agaugue S, Marcenaro E, Ferranti B, Moretta L, Moretta A. Human natural 
killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of 
naive T cells by monocyte-derived dendritic cells. Blood. 2008 Sep 1;112(5):1776-
83. PubMed PMID: 18579793.  doi: http://dx.doi.org/10.1182/blood-2008-02-135871 
414. Aliberti J, Viola JP, Vieira-de-Abreu A, Bozza PT, Sher A, Scharfstein J. 
Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger 
signal that drives Th1 polarization. J Immunol. 2003 Jun 1;170(11):5349-53. 
PubMed PMID: 12759407.   
415. Aliberti J, Reis e Sousa C, Schito M, Hieny S, Wells T, Huffnagle GB, et al. 
CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ 
dendritic cells. Nat Immunol. 2000 Jul;1(1):83-7. PubMed PMID: 10881180.  doi: 
http://dx.doi.org/10.1038/76957 
416. DeBenedette MA, Calderhead DM, Tcherepanova IY, Nicolette CA, Healey 
DG. Potency of mature CD40L RNA electroporated dendritic cells correlates with 
IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell 
responses in vitro. J Immunother. 2011 Jan;34(1):45-57. PubMed PMID: 
21150712.  doi: http://dx.doi.org/10.1097/CJI.0b013e3181fb651a 
417. Akiyama Y, Maruyama K, Watanabe M, Yamaguchi K. Retroviral-mediated 
IL-12 gene transduction into human CD34+ cell-derived dendritic cells. Int J 
Oncol. 2002 Sep;21(3):509-14. PubMed PMID: 12168093.   
418. Felzmann T, Huttner KG, Breuer SK, Wimmer D, Ressmann G, Wagner D, 
et al. Semi-mature IL-12 secreting dendritic cells present exogenous antigen to 
trigger cytolytic immune responses. Cancer Immunol Immunother. 2005 
Aug;54(8):769-80. PubMed PMID: 15647926.  doi: 
http://dx.doi.org/10.1007/s00262-004-0637-2 
419. Durrant DM, Metzger DW. IL-12 can alleviate Th17-mediated allergic lung 
inflammation through induction of pulmonary IL-10 expression. Mucosal Immunol. 
2010 May;3(3):301-11. PubMed PMID: 20237464. PMCID: PMC3816527.  doi: 
http://dx.doi.org/10.1038/mi.2010.9 
420. Weiss DJ, Liggitt D, Clark JG. Histochemical discrimination of endogenous 
mammalian beta-galactosidase activity from that resulting from lac-Z gene 
expression. Histochem J. 1999 Apr;31(4):231-6. PubMed PMID: 
WOS:000080754100004. English.  doi: http://dx.doi.org/10.1023/A:1003642025421 
	 234	
421. Narita S, Yorifuji H. Centrally nucleated fibers (CNFs) compensate the 
fragility of myofibers in mdx mouse. Neuroreport. 1999 Oct 19;10(15):3233-5. 
PubMed PMID: 10574566. Epub 1999/11/26. eng.   
422. Metghalchi S, Ponnuswamy P, Simon T, Haddad Y, Laurans L, Clement M, 
et al. Indoleamine 2,3-Dioxygenase Fine-Tunes Immune Homeostasis in 
Atherosclerosis and Colitis through Repression of Interleukin-10 Production. Cell 
Metab. 2015 Sep 1;22(3):460-71. PubMed PMID: 26235422.  doi: 
http://dx.doi.org/10.1016/j.cmet.2015.07.004 
423. Doh SG, Vahlsing HL, Hartikka J, Liang X, Manthorpe M. Spatial-temporal 
patterns of gene expression in mouse skeletal muscle after injection of lacZ 
plasmid DNA. Gene Ther. 1997 Jul;4(7):648-63. PubMed PMID: 
WOS:A1997XJ58200004. English.  doi: http://dx.doi.org/10.1038/Sj.Gt.3300460 
424. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory 
T cells: how do they suppress immune responses? Int Immunol. 2009 
Oct;21(10):1105-11. PubMed PMID: 19737784.  doi: 
http://dx.doi.org/10.1093/intimm/dxp095 
425. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and 
immune tolerance. Cell. 2008 May 30;133(5):775-87. PubMed PMID: 18510923.  
doi: http://dx.doi.org/10.1016/j.cell.2008.05.009 
426. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-
tolerance and negative control of immune responses. Annu Rev Immunol. 
2004;22:531-62. PubMed PMID: 15032588.  doi: 
http://dx.doi.org/10.1146/annurev.immunol.21.120601.141122 
427. Hawrylowicz CM, O'Garra A. Potential role of interleukin-10-secreting 
regulatory T cells in allergy and asthma. Nat Rev Immunol. 2005 Apr;5(4):271-83. 
PubMed PMID: 15775993.  doi: http://dx.doi.org/10.1038/nri1589 
428. Hawrylowicz CM. Regulatory T cells and IL-10 in allergic inflammation. J 
Exp Med. 2005 Dec 5;202(11):1459-63. PubMed PMID: 16330811. PMCID: 
PMC2213335.  doi: http://dx.doi.org/10.1084/jem.20052211 
429. Boks MA, Kager-Groenland JR, Haasjes MS, Zwaginga JJ, van Ham SM, 
ten Brinke A. IL-10-generated tolerogenic dendritic cells are optimal for functional 
regulatory T cell induction--a comparative study of human clinical-applicable DC. 
Clin Immunol. 2012 Mar;142(3):332-42. PubMed PMID: 22225835.  doi: 
http://dx.doi.org/10.1016/j.clim.2011.11.011 
430. Boks MA, Zwaginga JJ, van Ham SM, ten Brinke A. An optimized CFSE-
based T-cell suppression assay to evaluate the suppressive capacity of regulatory 
T-cells induced by human tolerogenic dendritic cells. Scand J Immunol. 2010 
Aug;72(2):158-68. PubMed PMID: 20618775.  doi: http://dx.doi.org/10.1111/j.1365-
3083.2010.02414.x 
431. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine 
modulation comes of age. Blood. 2006 Sep 1;108(5):1435-40. PubMed PMID: 
16684955.  doi: http://dx.doi.org/10.1182/blood-2006-03-006403 
432. Rutella S, Lemoli RM. Regulatory T cells and tolerogenic dendritic cells: 
from basic biology to clinical applications. Immunol Lett. 2004 Jun 15;94(1-2):11-
26. PubMed PMID: 15234530.  doi: http://dx.doi.org/10.1016/j.imlet.2004.04.015 
433. Yu G, Dai H, Chen J, Duan L, Gong M, Liu L, et al. Gene delivery of 
indoleamine 2,3-dioxygenase prolongs cardiac allograft survival by shaping the 
	 235	
types of T-cell responses. J Gene Med. 2008 Jul;10(7):754-61. PubMed PMID: 
18452241.  doi: http://dx.doi.org/10.1002/jgm.1201 
434. Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C, et al. 
Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene 
product following hepatic in vivo gene transfer. Blood. 2007 Aug 15;110(4):1132-
40. PubMed PMID: 17438084. PMCID: PMC1939896.  doi: 
http://dx.doi.org/10.1182/blood-2007-02-073304 
435. Dobrzynski E, Fitzgerald JC, Cao O, Mingozzi F, Wang LX, Herzog RW. 
Prevention of cytotoxic T lymphocyte responses to factor IX-expressing 
hepatocytes by gene transfer-induced regulatory T cells. Proc Natl Acad Sci U S 
A. 2006 Mar 21;103(12):4592-7. PubMed PMID: WOS:000236362600049. 
English.  doi: http://dx.doi.org/10.1073/pnas.0508685103 
436. Kullberg MC, Jankovic D, Gorelick PL, Caspar P, Letterio JJ, Cheever AW, 
et al. Bacteria-triggered CD4(+) T regulatory cells suppress Helicobacter 
hepaticus-induced colitis. J Exp Med. 2002 Aug 19;196(4):505-15. PubMed PMID: 
12186842. PMCID: PMC2196050.  doi: http://dx.doi.org/10.1084/jem.20020556 
437. Baeyens A, Saadoun D, Billiard F, Rouers A, Gregoire S, Zaragoza B, et 
al. Effector T cells boost regulatory T cell expansion by IL-2, TNF, OX40, and 
plasmacytoid dendritic cells depending on the immune context. J Immunol. 2015 
Feb 1;194(3):999-1010. PubMed PMID: 25548233.  doi: 
http://dx.doi.org/10.4049/jimmunol.1400504 
438. Metidji A, Rieder SA, Glass DD, Cremer I, Punkosdy GA, Shevach EM. 
IFN-alpha/beta Receptor Signaling Promotes Regulatory T Cell Development and 
Function under Stress Conditions. J Immunol. 2015 May 1;194(9):4265-76. 
PubMed PMID: 25795758. PMCID: 4402260.  doi: 
http://dx.doi.org/10.4049/jimmunol.1500036 
439. Henderson JG, Opejin A, Jones A, Gross C, Hawiger D. CD5 instructs 
extrathymic regulatory T cell development in response to self and tolerizing 
antigens. Immunity. 2015 Mar 17;42(3):471-83. PubMed PMID: 25786177.  doi: 
http://dx.doi.org/10.1016/j.immuni.2015.02.010 
440. Kim YC, Zhang AH, Su Y, Rieder SA, Rossi RJ, Ettinger RA, et al. 
Engineered antigen-specific human regulatory T cells: immunosuppression of 
FVIII-specific T- and B-cell responses. Blood. 2015 Feb 12;125(7):1107-15. 
PubMed PMID: 25498909. PMCID: 4326771.  doi: http://dx.doi.org/10.1182/blood-
2014-04-566786 
441. Villalta SA, Rosenthal W, Martinez L, Kaur A, Sparwasser T, Tidball JG, et 
al. Regulatory T cells suppress muscle inflammation and injury in muscular 
dystrophy. Sci Transl Med. 2014 Oct 15;6(258):258ra142. PubMed PMID: 
25320234.  doi: http://dx.doi.org/10.1126/scitranslmed.3009925 
442. Stone TW, Darlington LG. Endogenous kynurenines as targets for drug 
discovery and development. Nat Rev Drug Discov. 2002 Aug;1(8):609-20. 
PubMed PMID: 12402501.  doi: http://dx.doi.org/10.1038/nrd870 
443. Grohmann U. Tolerance, DCs and tryptophan: much ado about IDO. 
Trends Immunol. 2003;24(5):242-8.  doi: http://dx.doi.org/10.1016/s1471-
4906(03)00072-3 
444. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, et al. 
T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002 Oct;9(10):1069-
77. PubMed PMID: 12232795.  doi: http://dx.doi.org/10.1038/sj.cdd.4401073 
	 236	
445. Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, et al. 
Modulation of tryptophan catabolism by human leukemic cells results in the 
conversion of CD25- into CD25+ T regulatory cells. Blood. 2007 Apr 
1;109(7):2871-7. PubMed PMID: 17164341.  doi: http://dx.doi.org/10.1182/blood-
2006-07-036863 
446. Liu Z, Dai H, Wan N, Wang T, Bertera S, Trucco M, et al. Suppression of 
Memory CD8 T Cell Generation and Function by Tryptophan Catabolism. The 
Journal of Immunology. 2007;178(7):4260-6.  doi: 
http://dx.doi.org/10.4049/jimmunol.178.7.4260 
447. Vavrincova-Yaghi D, Deelman LE, van Goor H, Seelen MA, Vavrinec P, 
Kema IP, et al. Local gene therapy with indoleamine 2,3-dioxygenase protects 
against development of transplant vasculopathy in chronic kidney transplant 
dysfunction. Gene Ther. 2016 Nov;23(11):797-806. PubMed PMID: 27454318.  
doi: http://dx.doi.org/10.1038/gt.2016.59 
448. Wells KE, Maule J, Kingston R, Foster K, McMahon J, Damien E, et al. 
Immune responses, not promoter inactivation, are responsible for decreased long-
term expression following plasmid gene transfer into skeletal muscle. FEBS Lett. 
1997;407(2):164-8.  doi: http://dx.doi.org/10.1016/s0014-5793(97)00329-3 
449. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, 
et al. A chronic inflammatory response dominates the skeletal muscle molecular 
signature in dystrophin-deficient mdx mice. Hum Mol Genet. 2002 Feb 
01;11(3):263-72. PubMed PMID: 11823445. Epub 2002/02/02. eng.   
450. Virgilio KM, Martin KS, Peirce SM, Blemker SS. Multiscale models of 
skeletal muscle reveal the complex effects of muscular dystrophy on tissue 
mechanics and damage susceptibility. Interface Focus. 2015 Apr 
6;5(2):20140080. PubMed PMID: 25844152. PMCID: PMC4342948.  doi: 
http://dx.doi.org/10.1098/rsfs.2014.0080 
451. Wang Z, Storb R, Halbert CL, Banks GB, Butts TM, Finn EE, et al. 
Successful regional delivery and long-term expression of a dystrophin gene in 
canine muscular dystrophy: a preclinical model for human therapies. Mol Ther. 
2012 Aug;20(8):1501-7. PubMed PMID: 22692496. PMCID: 3412492.  doi: 
http://dx.doi.org/10.1038/mt.2012.111 
452. Li J, Meinhardt A, Roehrich ME, Golshayan D, Dudler J, Pagnotta M, et al. 
Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival. 
Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3415-23. PubMed PMID: 
17933973.  doi: http://dx.doi.org/10.1152/ajpheart.00532.2007 
453. Edelmann SL, Nelson PJ, Brocker T. Comparative promoter analysis in 
vivo: identification of a dendritic cell-specific promoter module. Blood. 2011 Sep 
15;118(11):e40-9. PubMed PMID: 21659543.  doi: http://dx.doi.org/10.1182/blood-
2011-03-342261 
454. Jung ID, Lee MG, Chang JH, Lee JS, Jeong YI, Lee CM, et al. Blockade of 
indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced 
endotoxin shock. J Immunol. 2009 Mar 1;182(5):3146-54. PubMed PMID: 
19234212.  doi: http://dx.doi.org/10.4049/jimmunol.0803104 
455. Gu T, Rowswell-Turner RB, Kilinc MO, Egilmez NK. Central role of 
IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-
mediated antitumor immunity. Cancer Res. 2010 Jan 1;70(1):129-38. PubMed 
	 237	
PMID: 20028855. PMCID: PMC2805056.  doi: http://dx.doi.org/10.1158/0008-
5472.CAN-09-3170 
456. Verma ND, Hall BM, Plain KM, Robinson CM, Boyd R, Tran GT, et al. 
Interleukin-12 (IL-12p70) Promotes Induction of Highly Potent Th1-Like 
CD4(+)CD25(+) T Regulatory Cells That Inhibit Allograft Rejection in Unmodified 
Recipients. Front Immunol. 2014;5:190. PubMed PMID: 24847323. PMCID: 
PMC4023029.  doi: http://dx.doi.org/10.3389/fimmu.2014.00190 
457. Matino D, Gargaro M, Santagostino E, Di Minno MND, Castaman G, 
Morfini M, et al. IDO1 suppresses inhibitor development in hemophilia A treated 
with factor VIII. The Journal of Clinical Investigation. 2015/10/01;125(10):3766-81.  
doi: http://dx.doi.org/10.1172/JCI81859 
458. Shinde R, Shimoda M, Chaudhary K, Liu H, Mohamed E, Bradley J, et al. B 
Cell-Intrinsic IDO1 Regulates Humoral Immunity to T Cell-Independent Antigens. 
J Immunol. 2015 Sep 1;195(5):2374-82. PubMed PMID: 26216892. PMCID: 
PMC4546929.  doi: http://dx.doi.org/10.4049/jimmunol.1402854 
459. Vavrincova-Yaghi D, Deelman LE, van Goor H, Seelen MA, Vavrinec P, 
Kema IP, et al. Local gene therapy with indoleamine 2,3-dioxygenase protects 
against development of transplant vasculopathy in chronic kidney transplant 
dysfsunction. Gene Ther. 2016 Aug 4. PubMed PMID: 27454318.  doi: 
http://dx.doi.org/10.1038/gt.2016.59 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 238	
Chapter 9 Appendix 
 
9.1 Maps and Sequences of Plasmids 
A-PX61MCK 
 
     1 GACGGATCGG GAGATCCGCT ATTAATCCCA GAGCCCTTGG AAGCCAGAGG AAGATGTATC 
    61 TCTGAGTTTG AGGCTACCTA CTCTACAGAA AGAGTTCCAG GACAGACATT ACACGAGAAG 
   121 CCCTGCCCCC TCTCTAAAAT AAAAGTATTT TCAGAAGCAT AAAGGTCACA GTGTAGAGAA 
   181 AATGACTGCT ACACGTAGTC TTAATTATAG AGGGCTCTTT TTTTTTTTTT TTTGATCTGT 
   241 GGTGTACATG TCTTTACATT TTTTTCAAGA TAGAAAAGCA TGATGTCTGT GCGGTATAAA 
   301 TTGTTCGTTT TGAGCCTTGT GTATAACGCT TTCCTCTCAA GATTTTATAA TAGTGCTTTA 
   361 ACTGTCCCCA CGGGCTAACT TCAGCACACT GTCATGGGAC CTAACCTTAT TAAATTACCA 
   421 TGTGTGAACC GCTCATAACT CAAGTCGCAG CAGGTGCAAA AATGGAGCTG CGCAGGCAGA 
   481 AGAGTGATCG TCATTTTTAA AATCCCCACC AGCTGGCGAA GCAACAGGTG CCTAATTCCT 
   541 CATCTTTTAA AAATAACTTT TCAAAAGCCT GTGCTGTATA AGCAAATATT TTCAAGTTTG 
   601 TTTTTAAACC ATCTTCAAGT TACCTTCCTC ACAAAATACA TTATGTGCTG ATTTTTTTGT 
   661 CTCAAAATGA CATTTGAAGT CTAAGCATAT AAAAATTTAT TTCTTTTTAG AAATGAAATT 
   721 ATTATTTAAC TGGAGACTTA AATTGTGTCT TAACTCTTGC TCCTCCCCTT TTCCCCTTTT 
   781 GTCCCTTCTC TCCCCACTCC CCTCCCCTTC TCTTCACATG CTCATGGCGG GCTCTTCTCT 
   841 TTCCTACTCT TCTTCTTTCT CTCATCCCTC TCCCTTGTCT TGTCCTTTCA CTAAACCTTT 
   901 CCACATGGAA AAAATAAATT GTATCTTAAA GCTCGGATCT CCCGATCCCC TATGGTCGAC 
   961 TCTCAGTACA ATCTGCTCTG ATGCCGCATA GTTAAGCCAG TATCTGCTCC CTGCTTGTGT 
  1021 GTTGGAGGTC GCTGAGTAGT GCGCGAGCAA AATTTAAGCT ACAACAAGGC AAGGCTTGAC 
  1081 CGACAATTGC ATGAAGAATC TGCTTAGGGT TAGGCGTTTT GCGCTGCTTC GCGATGTACG 
  1141 GGCCAGATAT ACGCGTCTGG TGCGGGTCTC ATCGTACCTC AGCACCTTCC AGATCCAGAT 
  1201 CTCAGCTGAG GTGCAAAAGG CTCCTGTCAT ATTGTGTCCT GCTCTGGTCT GCCTTCCACA 
  1261 GCTTGGGGGC CACCTAGCCC ACCTCTCCCT AGGGATGAGA GCAGCCACTA CGGGTCTAGG 
  1321 CTGCCCATGT AAGGAGGCAA GGCCTGGGGA CACCCGAGAT GCCTGGTTAT AATTAACCCA 
  1381 GACATGTGGC TGCCCCCCCC CCCCCAACAC CTGCTGCCTG AGCCTCACCC CCACCCCGGT 
  1441 GCCTGGGTCT TAGGCTCTGT ACACCATGGA GGAGAAGCTC GCTCTAAAAA TAACCCTGTC 
  1501 CCTGGTGGAT CCAGGGTGAG GGGCAGGCTG AGGGCGGCCA CTTCCCTCAG CCGCAGGTTT 
  1561 GTTTTCCCAA GAATGGTTTT TCTGCTTCTG TAGCTTTTCC TGTCAATTCT GCCATGGTGG 
  1621 AGCAGCCTGC ACTGGGCTTC TGGGAGAAAC CAAACCGGGT TCTAACCTTT CAGCTACAGT 
  1681 TATTGCCTTT CCTGTAGATG GGCGACTACA GCCCCACCCC CACCCCCGTC TCCTGTATCC 
  1741 TTCCTGGGCC TGGGGATCCT AGGCTTTCAC TGGAAATTTC CCCCCAGGTG CTGTAGGCTA 
  1801 GAGTCACGGC TCCCAAGAAC AGTGCTTGCC TGGCATGCAT GGTTCTGAAC CTCCAACTGC 
  1861 AAAAAATGAC ACATACCTTG ACCCTTGGAA GGCTGAGGCA GGGGGATTGC CATGAGTGCA 
  1921 AAGCCAGACT GGGTGGCATA GTTAGACCCT GTCTCAAAAA ACCAAAAACA ATTAAATAAC 
  1981 TAAAGTCAGG CAAGTAATCC TACTCGGGAG ACTGAGGCAG AGGGATTGTT ACATGTCTGA 
  2041 GGCCAGCCTG GACTACATAG GGTTTCAGGC TAGCCCTGTC TACAGAGTAA GGCCCTATTT 
  2101 CAAAAACACA AACAAAATGG TTCTCCCAGC TGCTAATGCT CACCAGGCAA TGAAGCCTGG 
  2161 TGAGCATTAG CAATGAAGGC AATGAAGGAG GGTGCTGGCT ACAATCAAGG CTGTGGGGGA 
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  2221 CTGAGGGCAG GCTGTAACAG GCTTGGGGGC CAGGGCTTAT ACGTGCCTGG GACTCCCAAA 
  2281 GTATTACTGT TCCATGTTCC CGGCGAAGGG CCAGCTGTCC CCCGCCAGCT AGACTCAGCA 
  2341 CTTAGTTTAG GAACCAGTGA GCAAGTCAGC CCTTGGGGCA GCCCATACAA GGCCATGGGG 
  2401 CTGGGCAAGC TGCACGCCTG GGTCCGGGGT GGGCACGGTG CCCGGGCAAC GAGCTGAAAG 
  2461 CTCATCTGCT CTCAGGGGCC CCTCCCTGGG GACAGCCCCT CCTGGCTAGT CACACCCTGT 
  2521 AGGCTCCTCT ATATAACCCA GGGGCACAGG GGCTGCCCCC AAGCTGGCCG CTCTAGAGGA 
  2581 TCCCCGGGTA CCGAGCTCGA ATTCCGGGGT CACCGTGACA ATGCAGCTGA GGAACCCAGA 
  2641 ACTACATCTG GGCTGCGCGC TTGCGCTTCG CTTCCTGGCC CTCGTTTCCT GGGACATCCC 
  2701 TGGGGCTAGA GCACTGGACA ATGGATTGGC AAGGACGCCT ACCATGGGCT GGCTGCACTG 
  2761 GGAGCGCTTC ATGTGCAACC TTGACTGCCA GGAAGAGCCA GATTCCTGCA TCAGTGAGAA 
  2821 GCTCTTCATG GAGATGGCAG AGCTCATGGT CTCAGAAGGC TGGAAGGATG CAGGTTATGA 
  2881 GTACCTCTGC ATTGATGACT GTTGGATGGC TCCCCAAAGA GATTCAGAAG GCAGACTTCA 
  2941 GGCAGACCCT CAGCGCTTTC CTCATGGGAT TCGCCAGCTA GCTAATTATG TTCACAGCAA 
  3001 AGGACTGAAG CTAGGGATTT ATGCAGATGT TGGAAATAAA ACCTGCGCAG GCTTCCCTGG 
  3061 GAGTTTTGGA TACTACGACA TTGATGCCCA GACCTTTGCT GACTGGGGAG TAGATCTGCT 
  3121 AAAATTTGAT GGTTGTTACT GTGACAGTTT GGAAAATTTG GCAGATGGTT ATAAGCACAT 
  3181 GTCCTTGGCC CTGAATAGGA CTGGCAGAAG CATTGTGTAC TCCTGTGAGT GGCCTCTTTA 
  3241 TATGTGGCCC TTTCAAAAGC CCAATTATAC AGAAATCCGA CAGTACTGCA ATCACTGGCG 
  3301 AAATTTTGCT GACATTGATG ATTCCTGGAA AAGTATAAAG AGTATCTTGG ACTGGACATC 
  3361 TTTTAACCAG GAGAGAATTG TTGATGTTGC TGGACCAGGG GGTTGGAATG ACCCAGATAT 
  3421 GTTAGTGATT GGCAACTTTG GCCTCAGCTG GAATCAGCAA GTAACTCAGA TGGCCCTCTG 
  3481 GGCTATCATG GCTGCTCCTT TATTCATGTC TAATGACCTC CGACACATCA GCCCTCAAGC 
  3541 CAAAGCTCTC CTTCAGGATA AGGACGTAAT TGCCATCAAT CAGGACCCCT TGGGCAAGCA 
  3601 AGGGTACCAG CTTAGACAGG GAGACAACTT TGAAGTGTGG GAACGACCTC TCTCAGGCTT 
  3661 AGCCTGGGCT GTAGCTATGA TAAACCGGCA GGAGATTGGT GGACCTCGCT CTTATACCAT 
  3721 CGCAGTTGCT TCCCTGGGTA AAGGAGTGGC CTGTAATCCT GCCTGCTTCA TCACACAGCT 
  3781 CCTCCCTGTG AAAAGGAAGC TAGGGTTCTA TGAATGGACT TCAAGGTTAA GAAGTCACAT 
  3841 AAATCCCACA GGCACTGTTT TGCTTCAGCT AGAAAATACA ATGCAGATGT CATTAAAAGA 
  3901 CTTACTTTAA GAATTCTGCA GATATCCATC ACACTGGCGG CCGCTCGAGC ATGCATCTAG 
  3961 AGGGCCCTAT TCTATAGTGT CACCTAAATG CTAGAGCTCG CTGATCAGCC TCGACTGTGC 
  4021 CTTCTAGTTG CCAGCCATCT GTTGTTTGCC CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG 
  4081 GTGCCACTCC CACTGTCCTT TCCTAATAAA ATGAGGAAAT TGCATCGCAT TGTCTGAGTA 
  4141 GGTGTCATTC TATTCTGGGG GGTGGGGTGG GGCAGGACAG CAAGGGGGAG GATTGGGAAG 
  4201 ACAATAGCAG GCATGCTGGG GATGCGGTGG GCTCTATGGC TTCTGAGGCG GAAAGAACCA 
  4261 GCTGGGGCTC TAGGGGGTAT CCCCACGCGC CCTGTAGCGG CGCATTAAGC GCGGCGGGTG 
  4321 TGGTGGTTAC GCGCAGCGTG ACCGCTACAC TTGCCAGCGC CCTAGCGCCC GCTCCTTTCG 
  4381 CTTTCTTCCC TTCCTTTCTC GCCACGTTCG CCGGTACCGT CGACCTCTAG CTAGAGCTTG 
  4441 GCGTAATCAT GGTCATAGCT GTTTCCTGTG TGAAATTGTT ATCCGCTCAC AATTCCACAC 
  4501 AACATACGAG CCGGAAGCAT AAAGTGTAAA GCCTGGGGTG CCTAATGAGT GAGCTAACTC 
  4561 ACATTAATTG CGTTGCGCTC ACTGCCCGCT TTCCAGTCGG GAAACCTGTC GTGCCAGCTG 
  4621 CATTAATGAA TCGGCCAACG CGCGGGGAGA GGCGGTTTGC GTATTGGGCG CTCTTCCGCT 
  4681 TCCTCGCTCA CTGACTCGCT GCGCTCGGTC GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC 
  4741 TCAAAGGCGG TAATACGGTT ATCCACAGAA TCAGGGGATA ACGCAGGAAA GAACATGTGA 
  4801 GCAAAAGGCC AGCAAAAGGC CAGGAACCGT AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT 
  4861 AGGCTCCGCC CCCCTGACGA GCATCACAAA AATCGACGCT CAAGTCAGAG GTGGCGAAAC 
  4921 CCGACAGGAC TATAAAGATA CCAGGCGTTT CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT 
  4981 GTTCCGACCC TGCCGCTTAC CGGATACCTG TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG 
  5041 CTTTCTCAAT GCTCACGCTG TAGGTATCTC AGTTCGGTGT AGGTCGTTCG CTCCAAGCTG 
  5101 GGCTGTGTGC ACGAACCCCC CGTTCAGCCC GACCGCTGCG CCTTATCCGG TAACTATCGT 
  5161 CTTGAGTCCA ACCCGGTAAG ACACGACTTA TCGCCACTGG CAGCAGCCAC TGGTAACAGG 
  5221 ATTAGCAGAG CGAGGTATGT AGGCGGTGCT ACAGAGTTCT TGAAGTGGTG GCCTAACTAC 
  5281 GGCTACACTA GAAGGACAGT ATTTGGTATC TGCGCTCTGC TGAAGCCAGT TACCTTCGGA 
  5341 AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA CAAACCACCG CTGGTAGCGG TGGTTTTTTT 
  5401 GTTTGCAAGC AGCAGATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT 
  5461 TCTACGGGGT CTGACGCTCA GTGGAACGAA AACTCACGTT AAGGGATTTT GGTCATGGAT 
  5521 CCGTCGACCT GCAGGGGGGG GGGGGAAAGC CACGTTGTGT CTCAAAATCT CTGATGTTAC 
  5581 ATTGCACAAG ATAAAAATAT ATCATCATGA ACAATAAAAC TGTCTGCTTA CATAAACAGT 
  5641 AATACAAGGG GTGTTATGAG CCATATTCAA CGGGAAACGT CTTGCTCGAG GCCGCGATTA 
  5701 AATTCCAACA TGGATGCTGA TTTATATGGG TATAAATGGG CTCGCGATAA TGTCGGGCAA 
  5761 TCAGGTGCGA CAATCTATCG ATTGTATGGG AAGCCCGATG CGCCAGAGTT GTTTCTGAAA 
  5821 CATGGCAAAG GTAGCGTTGC CAATGATGTT ACAGATGAGA TGGTCAGACT AAACTGGCTG 
  5881 ACGGAATTTA TGCCTCTTCC GACCATCAAG CATTTTATCC GTACTCCTGA TGATGCATGG 
  5941 TTACTCACCA CTGCGATCCC CGGGAAAACA GCATTCCAGG TATTAGAAGA ATATCCTGAT 
  6001 TCAGGTGAAA ATATTGTTGA TGCGCTGGCA GTGTTCCTGC GCCGGTTGCA TTCGATTCCT 
  6061 GTTTGTAATT GTCCTTTTAA CAGCGATCGC GTATTTCGTC TCGCTCAGGC GCAATCACGA 
  6121 ATGAATAACG GTTTGGTTGA TGCGAGTGAT TTTGATGACG AGCGTAATGG CTGGCCTGTT 
  6181 GAACAAGTCT GGAAAGAAAT GCATAAGCTT TTGCCATTCT CACCGGATTC AGTCGTCACT 
  6241 CATGGTGATT TCTCACTTGA TAACCTTATT TTTGACGAGG GGAAATTAAT AGGTTGTATT 
  6301 GATGTTGGAC GAGTCGGAAT CGCAGACCGA TACCAGGATC TTGCCATCCT ATGGAACTGC 
  6361 CTCGGTGAGT TTTCTCCTTC ATTACAGAAA CGGCTTTTTC AAAAATATGG TATTGATAAT 
	 240	
  6421 CCTGATATGA ATAAATTGCA GTTTCATTTG ATGCTCGATG AGTTTTTCTA ATCAGAATTG 
  6481 GTTAATTGGT TGTAACACTG GCAGAGCATT ACGCTGACTT GACGGGACGG CGGCTTTGTT 
  6541 GAATAAATCG AACTTTTGCT GAGTTGAAGG ATCAGATCAC GCATCTTCCC GACAACGCAG 
  6601 ACCGTTCCGT GGCAAAGCAA AAGTTCAAAA TCACCAACTG GTCCACCTAC AACAAAGCTC 
  6661 TCATCAACCG TGGCTCCCTC ACTTTCTGGC TGGATGATGG GGCGATTCAG GCCTGGTATG 
  6721 AGTCAGCAAC ACCTTCTTCA CGAGGCAGAC CTCAGCGCCC CCCCCCCCCT GCAGGTCGAC 
  6781 GGATCCATGA GCGGATACAT ATTTGAATGT ATTTAGAAAA ATAAACAAAT AGGGGTTCCG 
  6841 CGCACATTTC CCCGAAAAGT GCCACCTGAC GTC 
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     1 GGGCGAATTG GGCCCGACGT CGCATGCTCC CGGCCGCCAT GGCGGCCGCG GGAATTCGAT 
    61 TATGAGAATT CGCCGGCATA TGGCGCGCCT GAGAATTCGC CGGCATATGG CGCGCCCTTT 
   121 CCGCCTCAGA AGCCATAGAG CCCACCGCAT CCCCAGCATG CCTGCTATTG TCTTCCCAAT 
   181 CCTCCCCCTT GCTGTCCTGC CCCACCCCAC CCCCCAGAAT AGAATGACAC CTACTCAGAC 
   241 AATGCGATGC AATTTCCTCA TTTTATTAGG AAAGGACAGT GGGAGTGGCA CCTTCCAGGG 
   301 TCAAGGAAGG CACGGGGGAG GGGCAAACAA CAGATGGCTG GCAACTAGAA GGCACAGTCG 
   361 AGGCTGATCA GCGAGCTCTA GCATTTAGGT GACACTATAG AATAGGGCCC TCTAGAGGAT 
   421 CCCCAACAAA ACAATAACAG ACTTAGAAAC TACTGAAATC TACAGTATAA TACCACTACC 
   481 CTTCACAAAA ATATAGATTT ATTTCTTGTA AACTCTTACT GTCTAATCCT CTTTGTTGTA 
   541 TGAATATTAT AAAAACCATG CGGGAATCAG GAGTTGTAAA ACATTTATTC TGCTCCTTCT 
   601 TCATCTGTCA TGACTGATAC TAAGGACTCC ATCGCTCTGC CCAAATCATC TGCCATGTGG 
   661 AAAAGACTTC CTACATTGTG TCCTCTCTCA TTGGCTTTCC AGGGGTATTT CTTCCTCTTG 
   721 AACTAGGGAA GGAGTTGTTG AGTTGCTCCA TCACCTCCTC TAACCCTGTG CTTGTGTCCT 
   781 GGGGAGGACT GAGAAGATCT TCCTCACCCA TGGAGTCCGA AGTTTGACTG CCAACCACTC 
   841 GGAGCAGCAT AGGCTGACTG CTGTCGGACC TCTGTAGAGA GGTAGAAGGA GAGGACACCG 
   901 TTGTGCCATT CACTTTGGCC TCTGCCTGGG GTTGCTCCAG CAGCTGCCTT AGCCTGTGTA 
   961 ACTGTGACTC CAGCTGTTTA TTGTGGTCTT CCAGGATTTG CATCCTGGCT TCCAGGCGGC 
  1021 CTTTGTGTTG ACGCAGTAGC TTGGCCTCAG CAATGAGCTC AGCATCCCGG GGACTCTGGG 
  1081 GAGAGGTGGG CATCATTTCA GGAGGGGACG GCAGTGGGGA CAGGCCTTTA TGTTCGTGCT 
  1141 GCTGCTTTAG ACGGTCATAT TCTGCTTGCA GATTCCTGTT TTCTTCCTCA AGATCTGCTA 
  1201 GGATTCTCTC TAGCTCCCCT CTTTCCTCAC TCTCTAAGGA AATCAAGATC TGGGCAGGAC 
  1261 TACGAGGCTG GCTCAGGGGG GAGTCCTGGT TCAAACTTTG GCAGTAATGC TGGATTAACA 
  1321 AATGTTCATC ATCTATGCTC TCATTAGGAG AGATGCTATC ATTTAGATAA GATCCATTGC 
  1381 TGTTTTCCAT TTCTGCTAGC CTGCTAGCAT AATGTTCAAT GCGTGAATGA GTATCATCGT 
  1441 GTGAAAGCTG AGGGGACGAG GCAGGCGCAG AATCTACTGG CCAGAAGTTG ATCAGAGTAA 
  1501 CGGGAGTTTC CATGTTGTCC CCCTCTAAGA CAGTCTGCAC TGGCAGGTAG CCCATTCGGG 
  1561 GATGCTTCGC AAAATACCTT TTGGTTCGAA ATTTGTTTTT TAGTACCTTG GCAAAGTCTC 
  1621 GAACATCTTC TCCTGATGTA GTCGGAGTGC AATATTCCAC CATGGGATAG TGCATTTTAT 
  1681 GGCCTTTTGC AACTCGACCA GAAAAAAAGC AGCTTTGGCA GATGTCATAA TTAAAGTGCT 
	 241	
  1741 TTAGACTCCT GTACCTGAAT CCAATGATTG GACACTCTTT GCAGATGTTA CATTTGGCCT 
  1801 GATGCTTGGC AGTTTCTGCA GCAGCCACTC TGTGCAGGAC GGGCAGCCAC ACCATGGACT 
  1861 GGGGTTCCAG TCTCATCCAG TCTAGGAAGA GGGCCGCTTC GATCTCTGGC TTATTATTAG 
  1921 CAAATTGGAA GCAGCTCCGG ACACTTGGCT CAATGTTACT GCCCCCAAAG GATGCAACTT 
  1981 CACCCAACTG TCTTGGAATT TGGATAGAAT CATGCAGAAG GAGGCCCAGC CTGCGCTGGT 
  2041 CACAAAATCC TGTTGAACTT GCCACTTGCT TGAAAAGGTA TCTGTACTTG TCTTCCAAAT 
  2101 GTGCTTTACA CAGGGAAATG ATGCCAGTTT TAAAAGACAG GACACGGATC CTCCCTGTTC 
  2161 GTCCCGTATC ATAAACATTC AGCAGCCAGT TCAGACACAT ATCCACGCAG AGAGGGACGT 
  2221 TGACCAAATT GTTGTGCTCT TGCTCCAGGC GGTCATAAAT AGTGGTCAAA CAATTAATAA 
  2281 TCTGCAGGAT ATCCATGGGC TGGTCATTTT GCTTGAGGTT GTGCTGGTCC AAGGCATCAC 
  2341 ATGCAGCTGA CAGGCTCAAG AGATCCAAGC AAAGGGCCTT CTGCAGTCTT CGGAGTTTCA 
  2401 TGGCAGTCCT ATAAGCTGAG AATCTGACAT TATTCAGGTC AGCTAAAGAC TGGTAGAGCT 
  2461 CTGTCATTTT GGGATGGTCC CAGCAAGTTG TTTGAGTCTC GTGGTTGATA TAGTAGGGCA 
  2521 CTTTGTTTGG CGAGATGGCT CTCTCCCAGG GACCCTGGAC AGACGTGGAA AGAAAGTGCT 
  2581 GAGATGCTGG ACCAAAGTCC CTGTGGGCTT CATGCAGCTG CCTGACTCGG TCCTCGACGG 
  2641 CCACCTGCAG AAGCTTCCAT CTGGTGTTCA GGTCTTCCAG AGTGCTGAGG TTATACGGTG 
  2701 AGAGCTGAAT GCCCAAAGTG GTAAGCTGGC GAGCAAGGTC ATTGACGTGG CTCACGTTCT 
  2761 CTTTCAGAGG CGCAATTTCT CCTCGAAGTG CCTTGACTTT CTCGAGGTGA TCTTGGAGAG 
  2821 AGTCAATGAG GAGATCGCCC ACGGGCTGCC AGGATCCCTT GATCACCTCA GCTTGGCGCA 
  2881 GCTTGAGGTC CAGCTCATCC GTGGCCTCTT GAAGTTCCTG GAGTCTTTCA AGGGTCTCAT 
  2941 CTATTTTTCT CTGCCAGTCA GCGGAGTGCA GGTTCAATTT TTCCCACTCA GTATTGACCT 
  3001 CCTCAGCCTG CTTTCGTAGT GACTTGTCTT CAGGAGCTTC CAAATGCTGT GAAGGAAATG 
  3061 GGCTCCGTGT AGGGTCAGAG GTGGTGACAT AAGCAGCCTG TGTGTAGGCA TAGCTCTTGA 
  3121 ATCGAGGCTT AGGGGAAGAA GTTCTCTCAT ATCCCTGTGC TAGACTGACC GTGATCTGTT 
  3181 GAGAATAGTG CATTTGATGA TGTAACTGAA AATGTTCTTC TTTAGTCACT TTAGGTGGCC 
  3241 TTGGCAACAT TTCCACTTCC TGGATGGCTT CAATGCTCAC TTGTTGAGGC AAAACTTGGA 
  3301 AGAGTGATGT GATGTACATT AAGATGGACT TCTTATCTGG ATAGGTGGTA TCAACATCTT 
  3361 CAGGATCGAG TAGTTTCTCT ATGCCTAATT GATATCTGGC GATGTTGAAT GCATGTTCCA 
  3421 GTCGTTGTGT GGCTGACTGC TGGCAAACCA CACTATTCCA GTCAAATAGG TCTGGCCTAT 
  3481 GACTATGGAT GAGAGCATTC AAAGCCAGGC CATCAGACCA GCTGGTGGTG AAGTTGATTA 
  3541 CATTAACCTG TGGATAATTA CGAGTTGATT GTCGGACCCA GCTCAGGAGA ATCTTTTCAC 
  3601 TGTTGGTTTG TTGCAATCCA GCCATGATAT TTTTCATTAC ATTTTTGACC TGCCAGTGGA 
  3661 GGATTATATT CCAAATCAAA CCAAGAGTCA GTTTATGATT TCCATCTACG ATGTCAGTAC 
  3721 TTCCAATATT CACTAAATCA ACATTATTGT TCTGCAAAAC CCGCAGTGCC TTGTTGACAT 
  3781 TGTTCAGGGC ATGAACTCTT GTGGATCCTT TTTCTTTTGG CAGTTTTTGC CCTGTCAGGC 
  3841 CTTCGAGGAG GTCTAGGAGG CGCCTCCCAT CCTGTAGGTC ACTGAAGAGG TTCTCAATAT 
  3901 GCTGCTTCCC AAACTTAGAA AATTGTGCAT TTACCCATTT TGTGAATGTT TTCTTTTGAA 
  3961 CATCTTCTCT TTCATAACAG TCCTCTACTT CTTCCCACCA AAGCATGGTG GAATTCTGAA 
  4021 TCACTAGTGA ATTCGCGGCC GCCTGCAGGT CGACCATATG GGAGAGCTCC CAACGCGTTG 
  4081 GATGCATAGC TTGAGTATTC TATAGTGTCA CCTAAATAGC TTGGCGTAAT CATGGTCATA 
  4141 GCTGTTTCCT GTGTGAAATT GTTATCCGCT CACAATTCCA CACAACATAC GAGCCGGAAG 
  4201 CATAAAGTGT AAAGCCTGGG GTGCCTAATG AGTGAGCTAA CTCACATTAA TTGCGTTGCG 
  4261 CTCACTGCCC GCTTTCCAGT CGGGAAACCT GTCGTGCCAG CTGCATTAAT GAATCGGCCA 
  4321 ACGCGCGGGG AGAGGCGGTT TGCGTATTGG GCGCTCTTCC GCTTCCTCGC TCACTGACTC 
  4381 GCTGCGCTCG GTCGTTCGGC TGCGGCGAGC GGTATCAGCT CACTCAAAGG CGGTAATACG 
  4441 GTTATCCACA GAATCAGGGG ATAACGCAGG AAAGAACATG TGAGCAAAAG GCCAGCAAAA 
  4501 GGCCAGGAAC CGTAAAAAGG CCGCGTTGCT GGCGTTTTTC CATAGGCTCC GCCCCCCTGA 
  4561 CGAGCATCAC AAAAATCGAC GCTCAAGTCA GAGGTGGCGA AACCCGACAG GACTATAAAG 
  4621 ATACCAGGCG TTTCCCCCTG GAAGCTCCCT CGTGCGCTCT CCTGTTCCGA CCCTGCCGCT 
  4681 TACCGGATAC CTGTCCGCCT TTCTCCCTTC GGGAAGCGTG GCGCTTTCTC ATAGCTCACG 
  4741 CTGTAGGTAT CTCAGTTCGG TGTAGGTCGT TCGCTCCAAG CTGGGCTGTG TGCACGAACC 
  4801 CCCCGTTCAG CCCGACCGCT GCGCCTTATC CGGTAACTAT CGTCTTGAGT CCAACCCGGT 
  4861 AAGACACGAC TTATCGCCAC TGGCAGCAGC CACTGGTAAC AGGATTAGCA GAGCGAGGTA 
  4921 TGTAGGCGGT GCTACAGAGT TCTTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGAAC 
  4981 AGTATTTGGT ATCTGCGCTC TGCTGAAGCC AGTTACCTTC GGAAAAAGAG TTGGTAGCTC 
  5041 TTGATCCGGC AAACAAACCA CCGCTGGTAG CGGTGGTTTT TTTGTTTGCA AGCAGCAGAT 
  5101 TACGCGCAGA AAAAAAGGAT CTCAAGAAGA TCCTTTGATC TTTTCTACGG GGTCTGACGC 
  5161 TCAGTGGAAC GAAAACTCAC GTTAAGGGAT TTTGGTCATG AGATTATCAA AAAGGATCTT 
  5221 CACCTAGATC CTTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA TATATGAGTA 
  5281 AACTTGGTCT GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG CGATCTGTCT 
  5341 ATTTCGTTCA TCCATAGTTG CCTGACTCCC CGTCGTGTAG ATAACTACGA TACGGGAGGG 
  5401 CTTACCATCT GGCCCCAGTG CTGCAATGAT ACCGCGAGAC CCACGCTCAC CGGCTCCAGA 
  5461 TTTATCAGCA ATAAACCAGC CAGCCGGAAG GGCCGAGCGC AGAAGTGGTC CTGCAACTTT 
  5521 ATCCGCCTCC ATCCAGTCTA TTAATTGTTG CCGGGAAGCT AGAGTAAGTA GTTCGCCAGT 
  5581 TAATAGTTTG CGCAACGTTG TTGCCATTGC TACAGGCATC GTGGTGTCAC GCTCGTCGTT 
  5641 TGGTATGGCT TCATTCAGCT CCGGTTCCCA ACGATCAAGG CGAGTTACAT GATCCCCCAT 
  5701 GTTGTGCAAA AAAGCGGTTA GCTCCTTCGG TCCTCCGATC GTTGTCAGAA GTAAGTTGGC 
  5761 CGCAGTGTTA TCACTCATGG TTATGGCAGC ACTGCATAAT TCTCTTACTG TCATGCCATC 
  5821 CGTAAGATGC TTTTCTGTGA CTGGTGAGTA CTCAACCAAG TCATTCTGAG AATAGTGTAT 
  5881 GCGGCGACCG AGTTGCTCTT GCCCGGCGTC AATACGGGAT AATACCGCGC CACATAGCAG 
	 242	
  5941 AACTTTAAAA GTGCTCATCA TTGGAAAACG TTCTTCGGGG CGAAAACTCT CAAGGATCTT 
  6001 ACCGCTGTTG AGATCCAGTT CGATGTAACC CACTCGTGCA CCCAACTGAT CTTCAGCATC 
  6061 TTTTACTTTC ACCAGCGTTT CTGGGTGAGC AAAAACAGGA AGGCAAAATG CCGCAAAAAA 
  6121 GGGAATAAGG GCGACACGGA AATGTTGAAT ACTCATACTC TTCCTTTTTC AATATTATTG 
  6181 AAGCATTTAT CAGGGTTATT GTCTCATGAG CGGATACATA TTTGAATGTA TTTAGAAAAA 
  6241 TAAACAAATA GGGGTTCCGC GCACATTTCC CCGAAAAGTG CCACCTGATG CGGTGTGAAA 
  6301 TACCGCACAG ATGCGTAAGG AGAAAATACC GCATCAGGAA ATTGTAAGCG TTAATATTTT 
  6361 GTTAAAATTC GCGTTAAATT TTTGTTAAAT CAGCTCATTT TTTAACCAAT AGGCCGAAAT 
  6421 CGGCAAAATC CCTTATAAAT CAAAAGAATA GACCGAGATA GGGTTGAGTG TTGTTCCAGT 
  6481 TTGGAACAAG AGTCCACTAT TAAAGAACGT GGACTCCAAC GTCAAAGGGC GAAAAACCGT 
  6541 CTATCAGGGC GATGGCCCAC TACGTGAACC ATCACCCTAA TCAAGTTTTT TGGGGTCGAG 
  6601 GTGCCGTAAA GCACTAAATC GGAACCCTAA AGGGAGCCCC CGATTTAGAG CTTGACGGGG 
  6661 AAAGCCGGCG AACGTGGCGA GAAAGGAAGG GAAGAAAGCG AAAGGAGCGG GCGCTAGGGC 
  6721 GCTGGCAAGT GTAGCGGTCA CGCTGCGCGT AACCACCACA CCCGCCGCGC TTAATGCGCC 
  6781 GCTACAGGGC GCGTCCATTC GCCATTCAGG CTGCGCAACT GTTGGGAAGG GCGATCGGTG 
  6841 CGGGCCTCTT CGCTATTACG CCAGCTGGCG AAAGGGGGAT GTGCTGCAAG GCGATTAAGT 
  6901 TGGGTAACGC CAGGGTTTTC CCAGTCACGA CGTTGTAAAA CGACGGCCAG TGAATTGTAA 
  6961 TACGACTCAC TATA 
 
C-PX61MCK.Dyst FWD 
 
 
 
     1 GACGGATCGG GAGATCCGCT ATTAATCCCA GAGCCCTTGG AAGCCAGAGG AAGATGTATC 
    61 TCTGAGTTTG AGGCTACCTA CTCTACAGAA AGAGTTCCAG GACAGACATT ACACGAGAAG 
   121 CCCTGCCCCC TCTCTAAAAT AAAAGTATTT TCAGAAGCAT AAAGGTCACA GTGTAGAGAA 
   181 AATGACTGCT ACACGTAGTC TTAATTATAG AGGGCTCTTT TTTTTTTTTT TTTGATCTGT 
   241 GGTGTACATG TCTTTACATT TTTTTCAAGA TAGAAAAGCA TGATGTCTGT GCGGTATAAA 
   301 TTGTTCGTTT TGAGCCTTGT GTATAACGCT TTCCTCTCAA GATTTTATAA TAGTGCTTTA 
   361 ACTGTCCCCA CGGGCTAACT TCAGCACACT GTCATGGGAC CTAACCTTAT TAAATTACCA 
   421 TGTGTGAACC GCTCATAACT CAAGTCGCAG CAGGTGCAAA AATGGAGCTG CGCAGGCAGA 
   481 AGAGTGATCG TCATTTTTAA AATCCCCACC AGCTGGCGAA GCAACAGGTG CCTAATTCCT 
   541 CATCTTTTAA AAATAACTTT TCAAAAGCCT GTGCTGTATA AGCAAATATT TTCAAGTTTG 
   601 TTTTTAAACC ATCTTCAAGT TACCTTCCTC ACAAAATACA TTATGTGCTG ATTTTTTTGT 
   661 CTCAAAATGA CATTTGAAGT CTAAGCATAT AAAAATTTAT TTCTTTTTAG AAATGAAATT 
   721 ATTATTTAAC TGGAGACTTA AATTGTGTCT TAACTCTTGC TCCTCCCCTT TTCCCCTTTT 
   781 GTCCCTTCTC TCCCCACTCC CCTCCCCTTC TCTTCACATG CTCATGGCGG GCTCTTCTCT 
   841 TTCCTACTCT TCTTCTTTCT CTCATCCCTC TCCCTTGTCT TGTCCTTTCA CTAAACCTTT 
   901 CCACATGGAA AAAATAAATT GTATCTTAAA GCTCGGATCT CCCGATCCCC TATGGTCGAC 
   961 TCTCAGTACA ATCTGCTCTG ATGCCGCATA GTTAAGCCAG TATCTGCTCC CTGCTTGTGT 
  1021 GTTGGAGGTC GCTGAGTAGT GCGCGAGCAA AATTTAAGCT ACAACAAGGC AAGGCTTGAC 
  1081 CGACAATTGC ATGAAGAATC TGCTTAGGGT TAGGCGTTTT GCGCTGCTTC GCGATGTACG 
  1141 GGCCAGATAT ACGCGTCTGG TGCGGGTCTC ATCGTACCTC AGCACCTTCC AGATCCAGAT 
  1201 CTCAGCTGAG GTGCAAAAGG CTCCTGTCAT ATTGTGTCCT GCTCTGGTCT GCCTTCCACA 
  1261 GCTTGGGGGC CACCTAGCCC ACCTCTCCCT AGGGATGAGA GCAGCCACTA CGGGTCTAGG 
  1321 CTGCCCATGT AAGGAGGCAA GGCCTGGGGA CACCCGAGAT GCCTGGTTAT AATTAACCCA 
  1381 GACATGTGGC TGCCCCCCCC CCCCCAACAC CTGCTGCCTG AGCCTCACCC CCACCCCGGT 
  1441 GCCTGGGTCT TAGGCTCTGT ACACCATGGA GGAGAAGCTC GCTCTAAAAA TAACCCTGTC 
  1501 CCTGGTGGAT CCAGGGTGAG GGGCAGGCTG AGGGCGGCCA CTTCCCTCAG CCGCAGGTTT 
	 243	
  1561 GTTTTCCCAA GAATGGTTTT TCTGCTTCTG TAGCTTTTCC TGTCAATTCT GCCATGGTGG 
  1621 AGCAGCCTGC ACTGGGCTTC TGGGAGAAAC CAAACCGGGT TCTAACCTTT CAGCTACAGT 
  1681 TATTGCCTTT CCTGTAGATG GGCGACTACA GCCCCACCCC CACCCCCGTC TCCTGTATCC 
  1741 TTCCTGGGCC TGGGGATCCT AGGCTTTCAC TGGAAATTTC CCCCCAGGTG CTGTAGGCTA 
  1801 GAGTCACGGC TCCCAAGAAC AGTGCTTGCC TGGCATGCAT GGTTCTGAAC CTCCAACTGC 
  1861 AAAAAATGAC ACATACCTTG ACCCTTGGAA GGCTGAGGCA GGGGGATTGC CATGAGTGCA 
  1921 AAGCCAGACT GGGTGGCATA GTTAGACCCT GTCTCAAAAA ACCAAAAACA ATTAAATAAC 
  1981 TAAAGTCAGG CAAGTAATCC TACTCGGGAG ACTGAGGCAG AGGGATTGTT ACATGTCTGA 
  2041 GGCCAGCCTG GACTACATAG GGTTTCAGGC TAGCCCTGTC TACAGAGTAA GGCCCTATTT 
  2101 CAAAAACACA AACAAAATGG TTCTCCCAGC TGCTAATGCT CACCAGGCAA TGAAGCCTGG 
  2161 TGAGCATTAG CAATGAAGGC AATGAAGGAG GGTGCTGGCT ACAATCAAGG CTGTGGGGGA 
  2221 CTGAGGGCAG GCTGTAACAG GCTTGGGGGC CAGGGCTTAT ACGTGCCTGG GACTCCCAAA 
  2281 GTATTACTGT TCCATGTTCC CGGCGAAGGG CCAGCTGTCC CCCGCCAGCT AGACTCAGCA 
  2341 CTTAGTTTAG GAACCAGTGA GCAAGTCAGC CCTTGGGGCA GCCCATACAA GGCCATGGGG 
  2401 CTGGGCAAGC TGCACGCCTG GGTCCGGGGT GGGCACGGTG CCCGGGCAAC GAGCTGAAAG 
  2461 CTCATCTGCT CTCAGGGGCC CCTCCCTGGG GACAGCCCCT CCTGGCTAGT CACACCCTGT 
  2521 AGGCTCCTCT ATATAACCCA GGGGCACAGG GGCTGCCCCC AAGCTGGCCG CTCTAGAGGA 
  2581 TCCCCGGGTA CCGAGCTCGA ATTCCACCAT GCTTTGGTGG GAAGAAGTAG AGGACTGTTA 
  2641 TGAAAGAGAA GATGTTCAAA AGAAAACATT CACAAAATGG GTAAATGCAC AATTTTCTAA 
  2701 GTTTGGGAAG CAGCATATTG AGAACCTCTT CAGTGACCTA CAGGATGGGA GGCGCCTCCT 
  2761 AGACCTCCTC GAAGGCCTGA CAGGGCAAAA ACTGCCAAAA GAAAAAGGAT CCACAAGAGT 
  2821 TCATGCCCTG AACAATGTCA ACAAGGCACT GCGGGTTTTG CAGAACAATA ATGTTGATTT 
  2881 AGTGAATATT GGAAGTACTG ACATCGTAGA TGGAAATCAT AAACTGACTC TTGGTTTGAT 
  2941 TTGGAATATA ATCCTCCACT GGCAGGTCAA AAATGTAATG AAAAATATCA TGGCTGGATT 
  3001 GCAACAAACC AACAGTGAAA AGATTCTCCT GAGCTGGGTC CGACAATCAA CTCGTAATTA 
  3061 TCCACAGGTT AATGTAATCA ACTTCACCAC CAGCTGGTCT GATGGCCTGG CTTTGAATGC 
  3121 TCTCATCCAT AGTCATAGGC CAGACCTATT TGACTGGAAT AGTGTGGTTT GCCAGCAGTC 
  3181 AGCCACACAA CGACTGGAAC ATGCATTCAA CATCGCCAGA TATCAATTAG GCATAGAGAA 
  3241 ACTACTCGAT CCTGAAGATG TTGATACCAC CTATCCAGAT AAGAAGTCCA TCTTAATGTA 
  3301 CATCACATCA CTCTTCCAAG TTTTGCCTCA ACAAGTGAGC ATTGAAGCCA TCCAGGAAGT 
  3361 GGAAATGTTG CCAAGGCCAC CTAAAGTGAC TAAAGAAGAA CATTTTCAGT TACATCATCA 
  3421 AATGCACTAT TCTCAACAGA TCACGGTCAG TCTAGCACAG GGATATGAGA GAACTTCTTC 
  3481 CCCTAAGCCT CGATTCAAGA GCTATGCCTA CACACAGGCT GCTTATGTCA CCACCTCTGA 
  3541 CCCTACACGG AGCCCATTTC CTTCACAGCA TTTGGAAGCT CCTGAAGACA AGTCATAAAA 
  3601 AGAGACGGTC AGTCGCCTCA CGTCCAAGTT AAAAAGGGTG AGTCATAACT GGAGGAGTCG 
  3661 GACGAAAGCA TCAGAGTCCA GAGCTTGAAA GACTCCAGGA ACTTCAAGAG GCCACGGATG 
  3721 AGCTGGACCT CAAGCTGCGC CAAGCTGAGG TGATCAAGGG ATCCTGGCAG CCCGTGGGCG 
  3781 ATCTCCTCAT TGACTCTCTC CAAGATCACC TCGAGAAAGT CAAGGCACTT CGAGGAGAAA 
  3841 TTGCGCCTCT GAAAGAGAAC GTGAGCCACG TCAATGACCT TGCTCGCCAG CTTACCACTT 
  3901 TGGGCATTCA GCTCTCACCG TATAACCTCA GCACTCTGGA AGACCTGAAC ACCAGATGGA 
  3961 AGCTTCTGCA GGTGGCCGTC GAGGACCGAG TCAGGCAGCT GCATGAAGCC CACAGGGACT 
  4021 TTGGTCCAGC ATCTCAGCAC TTTCTTTCCA CGTCTGTCCA GGGTCCCTGG GAGAGAGCCA 
  4081 TCTCGCCAAA CAAAGTGCCC TACTATATCA ACCACGAGAC TCAAACAACT TGCTGGGACC 
  4141 ATCCCAAAAT GACAGAGCTC TACCAGTCTT TAGCTGACCT GAATAATGTC AGATTCTCAG 
  4201 CTTATAGGAC TGCCATGAAA CTCCGAAGAC TGCAGAAGGC CCTTTGCTTG GATCTCTTGA 
  4261 GCCTGTCAGC TGCATGTGAT GCCTTGGACC AGCACAACCT CAAGCAAAAT GACCAGCCCA 
  4321 TGGATATCCT GCAGATTATT AATTGTTTGA CCACTATTTA TGACCGCCTG GAGCAAGAGC 
  4381 ACAACAATTT GGTCAACGTC CCTCTCTGCG TGGATATGTG TCTGAACTGG CTGCTGAATG 
  4441 TTTATGATAC GGGACGAACA GGGAGGATCC GTGTCCTGTC TTTTAAAACT GGCATCATTT 
  4501 CCCTGTGTAA AGCACATTTG GAAGACAAGT ACAGATACCT TTTCAAGCAA GTGGCAAGTT 
  4561 CAACAGGATT TTGTGACCAG CGCAGGCTGG GCCTCTTCTG CATGATTCTA TCCAAATTCC 
  4621 AAGACAGTTG GGTGAAGTTG CATCCTTTGG GGGCAGTAAC ATTGAGCCAA GTGTCCGGAG 
  4681 CTGCTTCCAA TTTGCTAATA ATAAGCCAGA GATCGAAGCG GCCCTCTTCC TAGACTGGAT 
  4741 GAGACTGGAA CCCCAGTCCA TGGTGTGGCT GCCCGTCCTG CACAGAGTGG CTGCTGCAGA 
  4801 AACTGCCAAG CATCAGGCCA AATGTAACAT CTGCAAAGAG TGTCCAATCA TTGGATTCAG 
  4861 GTACAGGAGT CTAAAGCACT TTAATTATGA CATCTGCCAA AGCTGCTTTT TTTCTGGTCG 
  4921 AGTTGCAAAA GGCCATAAAA TGCACTATCC CATGGTGGAA TATTGCACTC CGACTACATC 
  4981 AGGAGAAGAT GTTCGAGACT TTGCCAAGGT ACTAAAAAAC AAATTTCGAA CCAAAAGGTA 
  5041 TTTTGCGAAG CATCCCCGAA TGGGCTACCT GCCAGTGCAG ACTGTCTTAG AGGGGGACAA 
  5101 CATGGAAACT CCCGTTACTC TGATCAACTT CTGGCCAGTA GATTCTGCGC CTGCCTCGTC 
  5161 CCCTCAGCTT TCACACGATG ATACTCATTC ACGCATTGAA CATTATGCTA GCAGGCTAGC 
  5221 AGAAATGGAA AACAGCAATG GATCTTATCT AAATGATAGC ATCTCTCCTA ATGAGAGCAT 
  5281 AGATGATGAA CATTTGTTAA TCCAGCATTA CTGCCAAAGT TTGAACCAGG ACTCCCCCCT 
  5341 GAGCCAGCCT CGTAGTCCTG CCCAGATCTT GATTTCCTTA GAGAGTGAGG AAAGAGGGGA 
  5401 GCTAGAGAGA ATCCTAGCAG ATCTGAGGAA GAAAACAGGA ATCTGCAAGC AGAATATGAC 
  5461 CGTCTAAAGC AGCAGCACGA ACATAAAGGC CTGTCCCCAC TGCCGTCCCC TCCTGAAATG 
  5521 ATGCCCACCT CTCCCCAGAG TCCCCGGGAT GCTGAGCTCA TTGCTGAGGC CAAGCTACTG 
  5581 CGTCAACACA AAGGCCGCCT GGAAGCCAGG ATGCAAATCC TGGAAGACCA CAATAAACAG 
  5641 CTGGAGTCAC AGTTACACAG GCTAAGGCAG CTGCTGGAGC AACCCCAGGC AGAGGCCAAA 
  5701 GTGAATGGCA CAACGGTGTC CTCTCTTTCT ACCTCTCTAC AGAGGTCCGA CAGCAGTCAG 
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  5761 CCTATGCTGC TCCGAGTGGT TGGCAGTCAA ACTTCGGACT CCATGGGTGA GGAAGATCTT 
  5821 CTCAGTCCTC CCCAGGACAC AAGCACAGGG TTAGAGGAGG TGATGGAGCA ACTCAACAAC 
  5881 TCCTTCCCTA GTTCAAGAGG AAGAAATACC CCTGGAAAGC CAATGAGAGA GGACACAATG 
  5941 TAGGAAGTCT TTTCCACATG GCAGATGATT TGGGCAGAGC GATGGAGTCC TTAGTATCAG 
  6001 TCATGACAGA TGAAGAAGGA GCAGAATAAA TGTTTTACAA CTCCTGATTC CCGCATGGTT 
  6061 TTTATAATAT TCATACAACA AAGAGGATTA GACAGTAAGA GTTTACAAGA AATAAATCTA 
  6121 TATTTTTGTG AAGGGTAGTG GTATTATACT GTAGATTTCA GTAGTTTCTA AGTCTGTTAT 
  6181 TGTTTTGTTG GGGATCCTCT AGAGGGCCCT ATTCTATAGT GTCACCTAAA TGCTAGAGCT 
  6241 CGCTGATCAG CCTCGACTGT GCCTTCTAGT TGCCAGCCAT CTGTTGTTTG CCCCTCCCCC 
  6301 GTGCCTTCCT TGACCCTGGA AGGTGCCACT CCCACTGTCC TTTCCTAATA AAATGAGGAA 
  6361 ATTGCATCGC ATTGTCTGAG TAGGTGTCAT TCTATTCTGG GGGGTGGGGT GGGGCAGGAC 
  6421 AGCAAGGGGG AGGATTGGGA AGACAATAGC AGGCATGCTG GGGATGCGGT GGGCTCTATG 
  6481 GCTTCTGAGG CGGAAAGGGC GCGCCATATG CCGGCGAATT CTGCAGATAT CCATCACACT 
  6541 GGCGGCCGCT CGAGCATGCA TCTAGAGGGC CCTATTCTAT AGTGTCACCT AAATGCTAGA 
  6601 GCTCGCTGAT CAGCCTCGAC TGTGCCTTCT AGTTGCCAGC CATCTGTTGT TTGCCCCTCC 
  6661 CCCGTGCCTT CCTTGACCCT GGAAGGTGCC ACTCCCACTG TCCTTTCCTA ATAAAATGAG 
  6721 GAAATTGCAT CGCATTGTCT GAGTAGGTGT CATTCTATTC TGGGGGGTGG GGTGGGGCAG 
  6781 GACAGCAAGG GGGAGGATTG GGAAGACAAT AGCAGGCATG CTGGGGATGC GGTGGGCTCT 
  6841 ATGGCTTCTG AGGCGGAAAG AACCAGCTGG GGCTCTAGGG GGTATCCCCA CGCGCCCTGT 
  6901 AGCGGCGCAT TAAGCGCGGC GGGTGTGGTG GTTACGCGCA GCGTGACCGC TACACTTGCC 
  6961 AGCGCCCTAG CGCCCGCTCC TTTCGCTTTC TTCCCTTCCT TTCTCGCCAC GTTCGCCGGT 
  7021 ACCGTCGACC TCTAGCTAGA GCTTGGCGTA ATCATGGTCA TAGCTGTTTC CTGTGTGAAA 
  7081 TTGTTATCCG CTCACAATTC CACACAACAT ACGAGCCGGA AGCATAAAGT GTAAAGCCTG 
  7141 GGGTGCCTAA TGAGTGAGCT AACTCACATT AATTGCGTTG CGCTCACTGC CCGCTTTCCA 
  7201 GTCGGGAAAC CTGTCGTGCC AGCTGCATTA ATGAATCGGC CAACGCGCGG GGAGAGGCGG 
  7261 TTTGCGTATT GGGCGCTCTT CCGCTTCCTC GCTCACTGAC TCGCTGCGCT CGGTCGTTCG 
  7321 GCTGCGGCGA GCGGTATCAG CTCACTCAAA GGCGGTAATA CGGTTATCCA CAGAATCAGG 
  7381 GGATAACGCA GGAAAGAACA TGTGAGCAAA AGGCCAGCAA AAGGCCAGGA ACCGTAAAAA 
  7441 GGCCGCGTTG CTGGCGTTTT TCCATAGGCT CCGCCCCCCT GACGAGCATC ACAAAAATCG 
  7501 ACGCTCAAGT CAGAGGTGGC GAAACCCGAC AGGACTATAA AGATACCAGG CGTTTCCCCC 
  7561 TGGAAGCTCC CTCGTGCGCT CTCCTGTTCC GACCCTGCCG CTTACCGGAT ACCTGTCCGC 
  7621 CTTTCTCCCT TCGGGAAGCG TGGCGCTTTC TCAATGCTCA CGCTGTAGGT ATCTCAGTTC 
  7681 GGTGTAGGTC GTTCGCTCCA AGCTGGGCTG TGTGCACGAA CCCCCCGTTC AGCCCGACCG 
  7741 CTGCGCCTTA TCCGGTAACT ATCGTCTTGA GTCCAACCCG GTAAGACACG ACTTATCGCC 
  7801 ACTGGCAGCA GCCACTGGTA ACAGGATTAG CAGAGCGAGG TATGTAGGCG GTGCTACAGA 
  7861 GTTCTTGAAG TGGTGGCCTA ACTACGGCTA CACTAGAAGG ACAGTATTTG GTATCTGCGC 
  7921 TCTGCTGAAG CCAGTTACCT TCGGAAAAAG AGTTGGTAGC TCTTGATCCG GCAAACAAAC 
  7981 CACCGCTGGT AGCGGTGGTT TTTTTGTTTG CAAGCAGCAG ATTACGCGCA GAAAAAAAGG 
  8041 ATCTCAAGAA GATCCTTTGA TCTTTTCTAC GGGGTCTGAC GCTCAGTGGA ACGAAAACTC 
  8101 ACGTTAAGGG ATTTTGGTCA TGGATCCGTC GACCTGCAGG GGGGGGGGGG AAAGCCACGT 
  8161 TGTGTCTCAA AATCTCTGAT GTTACATTGC ACAAGATAAA AATATATCAT CATGAACAAT 
  8221 AAAACTGTCT GCTTACATAA ACAGTAATAC AAGGGGTGTT ATGAGCCATA TTCAACGGGA 
  8281 AACGTCTTGC TCGAGGCCGC GATTAAATTC CAACATGGAT GCTGATTTAT ATGGGTATAA 
  8341 ATGGGCTCGC GATAATGTCG GGCAATCAGG TGCGACAATC TATCGATTGT ATGGGAAGCC 
  8401 CGATGCGCCA GAGTTGTTTC TGAAACATGG CAAAGGTAGC GTTGCCAATG ATGTTACAGA 
  8461 TGAGATGGTC AGACTAAACT GGCTGACGGA ATTTATGCCT CTTCCGACCA TCAAGCATTT 
  8521 TATCCGTACT CCTGATGATG CATGGTTACT CACCACTGCG ATCCCCGGGA AAACAGCATT 
  8581 CCAGGTATTA GAAGAATATC CTGATTCAGG TGAAAATATT GTTGATGCGC TGGCAGTGTT 
  8641 CCTGCGCCGG TTGCATTCGA TTCCTGTTTG TAATTGTCCT TTTAACAGCG ATCGCGTATT 
  8701 TCGTCTCGCT CAGGCGCAAT CACGAATGAA TAACGGTTTG GTTGATGCGA GTGATTTTGA 
  8761 TGACGAGCGT AATGGCTGGC CTGTTGAACA AGTCTGGAAA GAAATGCATA AGCTTTTGCC 
  8821 ATTCTCACCG GATTCAGTCG TCACTCATGG TGATTTCTCA CTTGATAACC TTATTTTTGA 
  8881 CGAGGGGAAA TTAATAGGTT GTATTGATGT TGGACGAGTC GGAATCGCAG ACCGATACCA 
  8941 GGATCTTGCC ATCCTATGGA ACTGCCTCGG TGAGTTTTCT CCTTCATTAC AGAAACGGCT 
  9001 TTTTCAAAAA TATGGTATTG ATAATCCTGA TATGAATAAA TTGCAGTTTC ATTTGATGCT 
  9061 CGATGAGTTT TTCTAATCAG AATTGGTTAA TTGGTTGTAA CACTGGCAGA GCATTACGCT 
  9121 GACTTGACGG GACGGCGGCT TTGTTGAATA AATCGAACTT TTGCTGAGTT GAAGGATCAG 
  9181 ATCACGCATC TTCCCGACAA CGCAGACCGT TCCGTGGCAA AGCAAAAGTT CAAAATCACC 
  9241 AACTGGTCCA CCTACAACAA AGCTCTCATC AACCGTGGCT CCCTCACTTT CTGGCTGGAT 
  9301 GATGGGGCGA TTCAGGCCTG GTATGAGTCA GCAACACCTT CTTCACGAGG CAGACCTCAG 
  9361 CGCCCCCCCC CCCCTGCAGG TCGACGGATC CATGAGCGGA TACATATTTG AATGTATTTA 
  9421 GAAAAATAAA CAAATAGGGG TTCCGCGCAC ATTTCCCCGA AAAGTGCCAC CTGACGTC 
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     1 GACGGATCGG GAGATCCGCT ATTAATCCCA GAGCCCTTGG AAGCCAGAGG AAGATGTATC 
    61 TCTGAGTTTG AGGCTACCTA CTCTACAGAA AGAGTTCCAG GACAGACATT ACACGAGAAG 
   121 CCCTGCCCCC TCTCTAAAAT AAAAGTATTT TCAGAAGCAT AAAGGTCACA GTGTAGAGAA 
   181 AATGACTGCT ACACGTAGTC TTAATTATAG AGGGCTCTTT TTTTTTTTTT TTTGATCTGT 
   241 GGTGTACATG TCTTTACATT TTTTTCAAGA TAGAAAAGCA TGATGTCTGT GCGGTATAAA 
   301 TTGTTCGTTT TGAGCCTTGT GTATAACGCT TTCCTCTCAA GATTTTATAA TAGTGCTTTA 
   361 ACTGTCCCCA CGGGCTAACT TCAGCACACT GTCATGGGAC CTAACCTTAT TAAATTACCA 
   421 TGTGTGAACC GCTCATAACT CAAGTCGCAG CAGGTGCAAA AATGGAGCTG CGCAGGCAGA 
   481 AGAGTGATCG TCATTTTTAA AATCCCCACC AGCTGGCGAA GCAACAGGTG CCTAATTCCT 
   541 CATCTTTTAA AAATAACTTT TCAAAAGCCT GTGCTGTATA AGCAAATATT TTCAAGTTTG 
   601 TTTTTAAACC ATCTTCAAGT TACCTTCCTC ACAAAATACA TTATGTGCTG ATTTTTTTGT 
   661 CTCAAAATGA CATTTGAAGT CTAAGCATAT AAAAATTTAT TTCTTTTTAG AAATGAAATT 
   721 ATTATTTAAC TGGAGACTTA AATTGTGTCT TAACTCTTGC TCCTCCCCTT TTCCCCTTTT 
   781 GTCCCTTCTC TCCCCACTCC CCTCCCCTTC TCTTCACATG CTCATGGCGG GCTCTTCTCT 
   841 TTCCTACTCT TCTTCTTTCT CTCATCCCTC TCCCTTGTCT TGTCCTTTCA CTAAACCTTT 
   901 CCACATGGAA AAAATAAATT GTATCTTAAA GCTCGGATCT CCCGATCCCC TATGGTCGAC 
   961 TCTCAGTACA ATCTGCTCTG ATGCCGCATA GTTAAGCCAG TATCTGCTCC CTGCTTGTGT 
  1021 GTTGGAGGTC GCTGAGTAGT GCGCGAGCAA AATTTAAGCT ACAACAAGGC AAGGCTTGAC 
  1081 CGACAATTGC ATGAAGAATC TGCTTAGGGT TAGGCGTTTT GCGCTGCTTC GCGATGTACG 
  1141 GGCCAGATAT ACGCGTCTGG TGCGGGTCTC ATCGTACCTC AGCACCTTCC AGATCCAGAT 
  1201 CTCAGCTGAG GTGCAAAAGG CTCCTGTCAT ATTGTGTCCT GCTCTGGTCT GCCTTCCACA 
  1261 GCTTGGGGGC CACCTAGCCC ACCTCTCCCT AGGGATGAGA GCAGCCACTA CGGGTCTAGG 
  1321 CTGCCCATGT AAGGAGGCAA GGCCTGGGGA CACCCGAGAT GCCTGGTTAT AATTAACCCA 
  1381 GACATGTGGC TGCCCCCCCC CCCCCAACAC CTGCTGCCTG AGCCTCACCC CCACCCCGGT 
  1441 GCCTGGGTCT TAGGCTCTGT ACACCATGGA GGAGAAGCTC GCTCTAAAAA TAACCCTGTC 
  1501 CCTGGTGGAT CCAGGGTGAG GGGCAGGCTG AGGGCGGCCA CTTCCCTCAG CCGCAGGTTT 
  1561 GTTTTCCCAA GAATGGTTTT TCTGCTTCTG TAGCTTTTCC TGTCAATTCT GCCATGGTGG 
  1621 AGCAGCCTGC ACTGGGCTTC TGGGAGAAAC CAAACCGGGT TCTAACCTTT CAGCTACAGT 
  1681 TATTGCCTTT CCTGTAGATG GGCGACTACA GCCCCACCCC CACCCCCGTC TCCTGTATCC 
  1741 TTCCTGGGCC TGGGGATCCT AGGCTTTCAC TGGAAATTTC CCCCCAGGTG CTGTAGGCTA 
  1801 GAGTCACGGC TCCCAAGAAC AGTGCTTGCC TGGCATGCAT GGTTCTGAAC CTCCAACTGC 
  1861 AAAAAATGAC ACATACCTTG ACCCTTGGAA GGCTGAGGCA GGGGGATTGC CATGAGTGCA 
  1921 AAGCCAGACT GGGTGGCATA GTTAGACCCT GTCTCAAAAA ACCAAAAACA ATTAAATAAC 
  1981 TAAAGTCAGG CAAGTAATCC TACTCGGGAG ACTGAGGCAG AGGGATTGTT ACATGTCTGA 
  2041 GGCCAGCCTG GACTACATAG GGTTTCAGGC TAGCCCTGTC TACAGAGTAA GGCCCTATTT 
  2101 CAAAAACACA AACAAAATGG TTCTCCCAGC TGCTAATGCT CACCAGGCAA TGAAGCCTGG 
  2161 TGAGCATTAG CAATGAAGGC AATGAAGGAG GGTGCTGGCT ACAATCAAGG CTGTGGGGGA 
  2221 CTGAGGGCAG GCTGTAACAG GCTTGGGGGC CAGGGCTTAT ACGTGCCTGG GACTCCCAAA 
  2281 GTATTACTGT TCCATGTTCC CGGCGAAGGG CCAGCTGTCC CCCGCCAGCT AGACTCAGCA 
  2341 CTTAGTTTAG GAACCAGTGA GCAAGTCAGC CCTTGGGGCA GCCCATACAA GGCCATGGGG 
  2401 CTGGGCAAGC TGCACGCCTG GGTCCGGGGT GGGCACGGTG CCCGGGCAAC GAGCTGAAAG 
  2461 CTCATCTGCT CTCAGGGGCC CCTCCCTGGG GACAGCCCCT CCTGGCTAGT CACACCCTGT 
  2521 AGGCTCCTCT ATATAACCCA GGGGCACAGG GGCTGCCCCC AAGCTGGCCG CTCTAGAGGA 
  2581 TCCCCGGGTA CCGAGCTCGA ATTCGCCGGC ATATGGCGCG CCCTTTCCGC CTCAGAAGCC 
  2641 ATAGAGCCCA CCGCATCCCC AGCATGCCTG CTATTGTCTT CCCAATCCTC CCCCTTGCTG 
  2701 TCCTGCCCCA CCCCACCCCC CAGAATAGAA TGACACCTAC TCAGACAATG CGATGCAATT 
	 246	
  2761 TCCTCATTTT ATTAGGAAAG GACAGTGGGA GTGGCACCTT CCAGGGTCAA GGAAGGCACG 
  2821 GGGGAGGGGC AAACAACAGA TGGCTGGCAA CTAGAAGGCA CAGTCGAGGC TGATCAGCGA 
  2881 GCTCTAGCAT TTAGGTGACA CTATAGAATA GGGCCCTCTA GAGGATCCCC AACAAAACAA 
  2941 TAACAGACTT AGAAACTACT GAAATCTACA GTATAATACC ACTACCCTTC ACAAAAATAT 
  3001 AGATTTATTT CTTGTAAACT CTTACTGTCT AATCCTCTTT GTTGTATGAA TATTATAAAA 
  3061 ACCATGCGGG AATCAGGAGT TGTAAAACAT TTATTCTGCT CCTTCTTCAT CTGTCATGAC 
  3121 TGATACTAAG GACTCCATCG CTCTGCCCAA ATCATCTGCC ATGTGGAAAA GACTTCCTAC 
  3181 ATTGTGTCCT CTCTCATTGG CTTTCCAGGG GTATTTCTTC CTCTTGAACT AGGGAAGGAG 
  3241 TTGTTGAGTT GCTCCATCAC CTCCTCTAAC CCTGTGCTTG TGTCCTGGGG AGGACTGAGA 
  3301 AGATCTTCCT CACCCATGGA GTCCGAAGTT TGACTGCCAA CCACTCGGAG CAGCATAGGC 
  3361 TGACTGCTGT CGGACCTCTG TAGAGAGGTA GAAAGAGAGG ACACCGTTGT GCCATTCACT 
  3421 TTGGCCTCTG CCTGGGGTTG CTCCAGCAGC TGCCTTAGCC TGTGTAACTG TGACTCCAGC 
  3481 TGTTTATTGT GGTCTTCCAG GATTTGCATC CTGGCTTCCA GGCGGCCTTT GTGTTGACGC 
  3541 AGTAGCTTGG CCTCAGCAAT GAGCTCAGCA TCCCGGGGAC TCTGGGGAGA GGTGGGCATC 
  3601 ATTTCAGGAG GGGACGGCAG TGGGGACAGG CCTTTATGTT CGTGCTGCTG CTTTAGACGG 
  3661 TCATATTCTG CTTGCAGATT CCTGTTTTCT TCCTCAGATC TGCTAGGATT CTCTCTAGCT 
  3721 CCCCTCTTTC CTCACTCTCT AAGGAAATCA AGATCTGGGC AGGACTACGA GGCTGGCTCA 
  3781 GGGGGGAGTC CTGGTTCAAA CTTTGGCAGT AATGCTGGAT TAACAAATGT TCATCATCTA 
  3841 TGCTCTCATT AGGAGAGATG CTATCATTTA GATAAGATCC ATTGCTGTTT TCCATTTCTG 
  3901 CTAGCCTGCT AGCATAATGT TCAATGCGTG AATGAGTATC ATCGTGTGAA AGCTGAGGGG 
  3961 ACGAGGCAGG CGCAGAATCT ACTGGCCAGA AGTTGATCAG AGTAACGGGA GTTTCCATGT 
  4021 TGTCCCCCTC TAAGACAGTC TGCACTGGCA GGTAGCCCAT TCGGGGATGC TTCGCAAAAT 
  4081 ACCTTTTGGT TCGAAATTTG TTTTTTAGTA CCTTGGCAAA GTCTCGAACA TCTTCTCCTG 
  4141 ATGTAGTCGG AGTGCAATAT TCCACCATGG GATAGTGCAT TTTATGGCCT TTTGCAACTC 
  4201 GACCAGAAAA AAAGCAGCTT TGGCAGATGT CATAATTAAA GTGCTTTAGA CTCCTGTACC 
  4261 TGAATCCAAT GATTGGACAC TCTTTGCAGA TGTTACATTT GGCCTGATGC TTGGCAGTTT 
  4321 CTGCAGCAGC CACTCTGTGC AGGACGGGCA GCCACACCAT GGACTGGGGT TCCAGTCTCA 
  4381 TCCAGTCTAG GAAGAGGGCC GCTTCGATCT CTGGCTTATT ATTAGCAAAT TGGAAGCAGC 
  4441 TCCGGACACT TGGCTCAATG TTACTGCCCC CAAAGGATGC AACTTCACCC AACTGTCTTG 
  4501 GAATTTGGAT AGAATCATGC AGAAGAGGCC CAGCCTGCGC TGGTCACAAA ATCCTGTTGA 
  4561 ACTTGCCACT TGCTTGAAAA GGTATCTGTA CTTGTCTTCC AAATGTGCTT TACACAGGGA 
  4621 AATGATGCCA GTTTTAAAAG ACAGGACACG GATCCTCCCT GTTCGTCCCG TATCATAAAC 
  4681 ATTCAGCAGC CAGTTCAGAC ACATATCCAC GCAGAGAGGG ACGTTGACCA AATTGTTGTG 
  4741 CTCTTGCTCC AGGCGGTCAT AAATAGTGGT CAAACAATTA ATAATCTGCA GGATATCCAT 
  4801 GGGCTGGTCA TTTTGCTTGA GGTTGTGCTG GTCCAAGGCA TCACATGCAG CTGACAGGCT 
  4861 CAAGAGATCC AAGCAAAGGG CCTTCTGCAG TCTTCGGAGT TTCATGGCAG TCCTATAAGC 
  4921 TGAGAATCTG ACATTATTCA GGTCAGCTAA AGACTGGTAG AGCTCTGTCA TTTTGGGATG 
  4981 GTCCCAGCAA GTTGTTTGAG TCTCGTGGTT GATATAGTAG GGCACTTTGT TTGGCGAGAT 
  5041 GGCTCTCTCC CAGGGACCCT GGACAGACGT GGAAAGAAAG TGCTGAGATG CTGGACCAAA 
  5101 GTCCCTGTGG GCTTCATGCA GCTGCCTGAC TCGGTCCTCG ACGGCCACCT GCAGAAGCTT 
  5161 CCATCTGGTG TTCAGGTCTT CCAGAGTGCT GAGGTTATAC GGTGAGAGCT GAATGCCCAA 
  5221 AGTGGTAAGC TGGCGAGCAA GGTCATTGAC GTGGCTCACG TTCTCTTTCA GAGGCGCAAT 
  5281 TTCTCCTCGA AGTGCCTTGA CTTTCTCGAG GTGATCTTGG AGAGAGTCAA TGAGGAGATC 
  5341 GCCCACGGGC TGCCAGGATC CCTTGATCAC CTCAGCTTGG CGCAGCTTGA GGTCCAGCTC 
  5401 ATCCGTGGCC TCTTGAAGTT CCTGGAGTCT TTCAAGCTCT GGACTCTGAT GCTTTCGTCC 
  5461 GACTCCTCCA GTTATGACTC ACCCTTTTTA ACTTGGACGT GAGGCGACTG ACCGTCTCTT 
  5521 TTTATGACTT GTCTTCAGGA GCTTCCAAAT GCTGTGAAGG AAATGGGCTC CGTGTAGGGT 
  5581 CAGAGGTGGT GACATAAGCA GCCTGTGTGT AGGCATAGCT CTTGAATCGA GGCTTAGGGG 
  5641 AAGAAGTTCT CTCATATCCC TGTGCTAGAC TGACCGTGAT CTGTTGAGAA TAGTGCATTT 
  5701 GATGATGTAA CTGAAAATGT TCTTCTTTAG TCACTTTAGG TGGCCTTGGC AACATTTCCA 
  5761 CTTCCTGGAT GGCTTCAATG CTCACTTGTT GAGGCAAAAC TTGGAAGAGT GATGTGATGT 
  5821 ACATTAAGAT GGACTTCTTA TCTGGATAGG TGGTATCAAC ATCTTCAGGA TCGAGTAGTT 
  5881 TCTCTATGCC TAATTGATAT CTGGCGATGT TGAATGCATG TTCCAGTCGT TGTGTGGCTG 
  5941 ACTGCTGGCA AACCACACTA TTCCAGTCAA ATAGGTCTGG CCTATGACTA TGGATGAGAG 
  6001 CATTCAAAGC CAGGCCATCA GACCAGCTGG TGGTGAAGTT GATTACATTA ACCTGTGGAT 
  6061 AATTACGAGT TGATTGTCGG ACCCAGCTCA GGAGAATCTT TTCACTGTTG GTTTGTTGCA 
  6121 ATCCAGCCAT GATATTTTTC ATTACATTTT TGACCTGCCA GTGGAGGATT ATATTCCAAA 
  6181 TCAAACCAAG AGTCAGTTTA TGATTTCCAT CTACGATGTC AGTACTTCCA ATATTCACTA 
  6241 AATCAACATT ATTGTTCTGC AAAACCCGCA GTGCCTTGTT GACATTGTTC AGGGCATGAA 
  6301 CTCTTGTGGA TCCTTTTTCT TTTGGCAGTT TTTGCCCTGT CAGGCCTTCG AGGAGGTCTA 
  6361 GGAGGCGCCT CCCATCCTGT AGGTCACTGA AGAGGTTCTC AATATGCTGC TTCCCAAACT 
  6421 TAGAAAATTG TGCATTTACC CATTTTGTGA ATGTTTTCTT TTGAACATCT TCTCTTTCAT 
  6481 AACAGTCCTC TACTTCTTCC CACCAAAGCA TGGTGGAATT CTGCAGATAT CCATCACACT 
  6541 GGCGGCCGCT CGAGCATGCA TCTAGAGGGC CCTATTCTAT AGTGTCACCT AAATGCTAGA 
  6601 GCTCGCTGAT CAGCCTCGAC TGTGCCTTCT AGTTGCCAGC CATCTGTTGT TTGCCCCTCC 
  6661 CCCGTGCCTT CCTTGACCCT GGAAGGTGCC ACTCCCACTG TCCTTTCCTA ATAAAATGAG 
  6721 GAAATTGCAT CGCATTGTCT GAGTAGGTGT CATTCTATTC TGGGGGGTGG GGTGGGGCAG 
  6781 GACAGCAAGG GGGAGGATTG GGAAGACAAT AGCAGGCATG CTGGGGATGC GGTGGGCTCT 
  6841 ATGGCTTCTG AGGCGGAAAG AACCAGCTGG GGCTCTAGGG GGTATCCCCA CGCGCCCTGT 
  6901 AGCGGCGCAT TAAGCGCGGC GGGTGTGGTG GTTACGCGCA GCGTGACCGC TACACTTGCC 
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  6961 AGCGCCCTAG CGCCCGCTCC TTTCGCTTTC TTCCCTTCCT TTCTCGCCAC GTTCGCCGGT 
  7021 ACCGTCGACC TCTAGCTAGA GCTTGGCGTA ATCATGGTCA TAGCTGTTTC CTGTGTGAAA 
  7081 TTGTTATCCG CTCACAATTC CACACAACAT ACGAGCCGGA AGCATAAAGT GTAAAGCCTG 
  7141 GGGTGCCTAA TGAGTGAGCT AACTCACATT AATTGCGTTG CGCTCACTGC CCGCTTTCCA 
  7201 GTCGGGAAAC CTGTCGTGCC AGCTGCATTA ATGAATCGGC CAACGCGCGG GGAGAGGCGG 
  7261 TTTGCGTATT GGGCGCTCTT CCGCTTCCTC GCTCACTGAC TCGCTGCGCT CGGTCGTTCG 
  7321 GCTGCGGCGA GCGGTATCAG CTCACTCAAA GGCGGTAATA CGGTTATCCA CAGAATCAGG 
  7381 GGATAACGCA GGAAAGAACA TGTGAGCAAA AGGCCAGCAA AAGGCCAGGA ACCGTAAAAA 
  7441 GGCCGCGTTG CTGGCGTTTT TCCATAGGCT CCGCCCCCCT GACGAGCATC ACAAAAATCG 
  7501 ACGCTCAAGT CAGAGGTGGC GAAACCCGAC AGGACTATAA AGATACCAGG CGTTTCCCCC 
  7561 TGGAAGCTCC CTCGTGCGCT CTCCTGTTCC GACCCTGCCG CTTACCGGAT ACCTGTCCGC 
  7621 CTTTCTCCCT TCGGGAAGCG TGGCGCTTTC TCAATGCTCA CGCTGTAGGT ATCTCAGTTC 
  7681 GGTGTAGGTC GTTCGCTCCA AGCTGGGCTG TGTGCACGAA CCCCCCGTTC AGCCCGACCG 
  7741 CTGCGCCTTA TCCGGTAACT ATCGTCTTGA GTCCAACCCG GTAAGACACG ACTTATCGCC 
  7801 ACTGGCAGCA GCCACTGGTA ACAGGATTAG CAGAGCGAGG TATGTAGGCG GTGCTACAGA 
  7861 GTTCTTGAAG TGGTGGCCTA ACTACGGCTA CACTAGAAGG ACAGTATTTG GTATCTGCGC 
  7921 TCTGCTGAAG CCAGTTACCT TCGGAAAAAG AGTTGGTAGC TCTTGATCCG GCAAACAAAC 
  7981 CACCGCTGGT AGCGGTGGTT TTTTTGTTTG CAAGCAGCAG ATTACGCGCA GAAAAAAAGG 
  8041 ATCTCAAGAA GATCCTTTGA TCTTTTCTAC GGGGTCTGAC GCTCAGTGGA ACGAAAACTC 
  8101 ACGTTAAGGG ATTTTGGTCA TGGATCCGTC GACCTGCAGG GGGGGGGGGG AAAGCCACGT 
  8161 TGTGTCTCAA AATCTCTGAT GTTACATTGC ACAAGATAAA AATATATCAT CATGAACAAT 
  8221 AAAACTGTCT GCTTACATAA ACAGTAATAC AAGGGGTGTT ATGAGCCATA TTCAACGGGA 
  8281 AACGTCTTGC TCGAGGCCGC GATTAAATTC CAACATGGAT GCTGATTTAT ATGGGTATAA 
  8341 ATGGGCTCGC GATAATGTCG GGCAATCAGG TGCGACAATC TATCGATTGT ATGGGAAGCC 
  8401 CGATGCGCCA GAGTTGTTTC TGAAACATGG CAAAGGTAGC GTTGCCAATG ATGTTACAGA 
  8461 TGAGATGGTC AGACTAAACT GGCTGACGGA ATTTATGCCT CTTCCGACCA TCAAGCATTT 
  8521 TATCCGTACT CCTGATGATG CATGGTTACT CACCACTGCG ATCCCCGGGA AAACAGCATT 
  8581 CCAGGTATTA GAAGAATATC CTGATTCAGG TGAAAATATT GTTGATGCGC TGGCAGTGTT 
  8641 CCTGCGCCGG TTGCATTCGA TTCCTGTTTG TAATTGTCCT TTTAACAGCG ATCGCGTATT 
  8701 TCGTCTCGCT CAGGCGCAAT CACGAATGAA TAACGGTTTG GTTGATGCGA GTGATTTTGA 
  8761 TGACGAGCGT AATGGCTGGC CTGTTGAACA AGTCTGGAAA GAAATGCATA AGCTTTTGCC 
  8821 ATTCTCACCG GATTCAGTCG TCACTCATGG TGATTTCTCA CTTGATAACC TTATTTTTGA 
  8881 CGAGGGGAAA TTAATAGGTT GTATTGATGT TGGACGAGTC GGAATCGCAG ACCGATACCA 
  8941 GGATCTTGCC ATCCTATGGA ACTGCCTCGG TGAGTTTTCT CCTTCATTAC AGAAACGGCT 
  9001 TTTTCAAAAA TATGGTATTG ATAATCCTGA TATGAATAAA TTGCAGTTTC ATTTGATGCT 
  9061 CGATGAGTTT TTCTAATCAG AATTGGTTAA TTGGTTGTAA CACTGGCAGA GCATTACGCT 
  9121 GACTTGACGG GACGGCGGCT TTGTTGAATA AATCGAACTT TTGCTGAGTT GAAGGATCAG 
  9181 ATCACGCATC TTCCCGACAA CGCAGACCGT TCCGTGGCAA AGCAAAAGTT CAAAATCACC 
  9241 AACTGGTCCA CCTACAACAA AGCTCTCATC AACCGTGGCT CCCTCACTTT CTGGCTGGAT 
  9301 GATGGGGCGA TTCAGGCCTG GTATGAGTCA GCAACACCTT CTTCACGAGG CAGACCTCAG 
  9361 CGCCCCCCCC CCCCTGCAGG TCGACGGATC CATGAGCGGA TACATATTTG AATGTATTTA 
  9421 GAAAAATAAA CAAATAGGGG TTCCGCGCAC ATTTCCCCGA AAAGTGCCAC CTGACGTC 
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     1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC TGCTCTGATG 
    61 CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG 
   121 CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC 
   181 TTAGGGTTAG GCGTTTTGCG CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT 
   241 GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA 
   301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 
   361 CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC 
   421 ATTGACGTCA ATGGGTGGAC TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT 
   481 ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT 
   541 ATGCCCAGTA CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA 
   601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 
   661 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC 
   721 AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG 
   781 GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA 
   841 CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTTGGTACC 
   901 GAGCTCGGAT CCACTAGTAA CGGCCGCCAG TGTGCTGGAA TTCCACCATG CTTTGGTGGG 
   961 AAGAAGTAGA GGACTGTTAT GAAAGAGAAG ATGTTCAAAA GAAAACATTC ACAAAATGGG 
  1021 TAAATGCACA ATTTTCTAAG TTTGGGAAGC AGCATATTGA GAACCTCTTC AGTGACCTAC 
  1081 AGGATGGGAG GCGCCTCCTA GACCTCCTCG AAGGCCTGAC AGGGCAAAAA CTGCCAAAAG 
  1141 AAAAAGGATC CACAAGAGTT CATGCCCTGA ACAATGTCAA CAAGGCACTG CGGGTTTTGC 
  1201 AGAACAATAA TGTTGATTTA GTGAATATTG GAAGTACTGA CATCGTAGAT GGAAATCATA 
  1261 AACTGACTCT TGGTTTGATT TGGAATATAA TCCTCCACTG GCAGGTCAAA AATGTAATGA 
  1321 AAAATATCAT GGCTGGATTG CAACAAACCA ACAGTGAAAA GATTCTCCTG AGCTGGGTCC 
  1381 GACAATCAAC TCGTAATTAT CCACAGGTTA ATGTAATCAA CTTCACCACC AGCTGGTCTG 
  1441 ATGGCCTGGC TTTGAATGCT CTCATCCATA GTCATAGGCC AGACCTATTT GACTGGAATA 
  1501 GTGTGGTTTG CCAGCAGTCA GCCACACAAC GACTGGAACA TGCATTCAAC ATCGCCAGAT 
  1561 ATCAATTAGG CATAGAGAAA CTACTCGATC CTGAAGATGT TGATACCACC TATCCAGATA 
  1621 AGAAGTCCAT CTTAATGTAC ATCACATCAC TCTTCCAAGT TTTGCCTCAA CAAGTGAGCA 
  1681 TTGAAGCCAT CCAGGAAGTG GAAATGTTGC CAAGGCCACC TAAAGTGACT AAAGAAGAAC 
  1741 ATTTTCAGTT ACATCATCAA ATGCACTATT CTCAACAGAT CACGGTCAGT CTAGCACAGG 
  1801 GATATGAGAG AACTTCTTCC CCTAAGCCTC GATTCAAGAG CTATGCCTAC ACACAGGCTG 
  1861 CTTATGTCAC CACCTCTGAC CCTACACGGA GCCCATTTCC TTCACAGCAT TTGGAAGCTC 
  1921 CTGAAGACAA GTCATAAAAA GAGACGGTCA GTCGCCTCAC GTCCAAGTTA AAAAGGGTGA 
  1981 GTCATAACTG GAGGAGTCGG ACGAAAGCAT CAGAGTCCAG AGCTTGAAAG ACTCCAGGAA 
  2041 CTTCAAGAGG CCACGGATGA GCTGGACCTC AAGCTGCGCC AAGCTGAGGT GATCAAGGGA 
  2101 TCCTGGCAGC CCGTGGGCGA TCTCCTCATT GACTCTCTCC AAGATCACCT CGAGAAAGTC 
  2161 AAGGCACTTC GAGGAGAAAT TGCGCCTCTG AAAGAGAACG TGAGCCACGT CAATGACCTT 
  2221 GCTCGCCAGC TTACCACTTT GGGCATTCAG CTCTCACCGT ATAACCTCAG CACTCTGGAA 
  2281 GACCTGAACA CCAGATGGAA GCTTCTGCAG GTGGCCGTCG AGGACCGAGT CAGGCAGCTG 
  2341 CATGAAGCCC ACAGGGACTT TGGTCCAGCA TCTCAGCACT TTCTTTCCAC GTCTGTCCAG 
  2401 GGTCCCTGGG AGAGAGCCAT CTCGCCAAAC AAAGTGCCCT ACTATATCAA CCACGAGACT 
  2461 CAAACAACTT GCTGGGACCA TCCCAAAATG ACAGAGCTCT ACCAGTCTTT AGCTGACCTG 
  2521 AATAATGTCA GATTCTCAGC TTATAGGACT GCCATGAAAC TCCGAAGACT GCAGAAGGCC 
  2581 CTTTGCTTGG ATCTCTTGAG CCTGTCAGCT GCATGTGATG CCTTGGACCA GCACAACCTC 
  2641 AAGCAAAATG ACCAGCCCAT GGATATCCTG CAGATTATTA ATTGTTTGAC CACTATTTAT 
  2701 GACCGCCTGG AGCAAGAGCA CAACAATTTG GTCAACGTCC CTCTCTGCGT GGATATGTGT 
  2761 CTGAACTGGC TGCTGAATGT TTATGATACG GGACGAACAG GGAGGATCCG TGTCCTGTCT 
  2821 TTTAAAACTG GCATCATTTC CCTGTGTAAA GCACATTTGG AAGACAAGTA CAGATACCTT 
  2881 TTCAAGCAAG TGGCAAGTTC AACAGGATTT TGTGACCAGC GCAGGCTGGG CCTCTTCTGC 
  2941 ATGATTCTAT CCAAATTCCA AGACAGTTGG GTGAAGTTGC ATCCTTTGGG GGCAGTAACA 
  3001 TTGAGCCAAG TGTCCGGAGC TGCTTCCAAT TTGCTAATAA TAAGCCAGAG ATCGAAGCGG 
  3061 CCCTCTTCCT AGACTGGATG AGACTGGAAC CCCAGTCCAT GGTGTGGCTG CCCGTCCTGC 
  3121 ACAGAGTGGC TGCTGCAGAA ACTGCCAAGC ATCAGGCCAA ATGTAACATC TGCAAAGAGT 
  3181 GTCCAATCAT TGGATTCAGG TACAGGAGTC TAAAGCACTT TAATTATGAC ATCTGCCAAA 
  3241 GCTGCTTTTT TTCTGGTCGA GTTGCAAAAG GCCATAAAAT GCACTATCCC ATGGTGGAAT 
  3301 ATTGCACTCC GACTACATCA GGAGAAGATG TTCGAGACTT TGCCAAGGTA CTAAAAAACA 
  3361 AATTTCGAAC CAAAAGGTAT TTTGCGAAGC ATCCCCGAAT GGGCTACCTG CCAGTGCAGA 
  3421 CTGTCTTAGA GGGGGACAAC ATGGAAACTC CCGTTACTCT GATCAACTTC TGGCCAGTAG 
  3481 ATTCTGCGCC TGCCTCGTCC CCTCAGCTTT CACACGATGA TACTCATTCA CGCATTGAAC 
  3541 ATTATGCTAG CAGGCTAGCA GAAATGGAAA ACAGCAATGG ATCTTATCTA AATGATAGCA 
  3601 TCTCTCCTAA TGAGAGCATA GATGATGAAC ATTTGTTAAT CCAGCATTAC TGCCAAAGTT 
  3661 TGAACCAGGA CTCCCCCCTG AGCCAGCCTC GTAGTCCTGC CCAGATCTTG ATTTCCTTAG 
  3721 AGAGTGAGGA AAGAGGGGAG CTAGAGAGAA TCCTAGCAGA TCTGAGGAAG AAAACAGGAA 
  3781 TCTGCAAGCA GAATATGACC GTCTAAAGCA GCAGCACGAA CATAAAGGCC TGTCCCCACT 
  3841 GCCGTCCCCT CCTGAAATGA TGCCCACCTC TCCCCAGAGT CCCCGGGATG CTGAGCTCAT 
  3901 TGCTGAGGCC AAGCTACTGC GTCAACACAA AGGCCGCCTG GAAGCCAGGA TGCAAATCCT 
  3961 GGAAGACCAC AATAAACAGC TGGAGTCACA GTTACACAGG CTAAGGCAGC TGCTGGAGCA 
  4021 ACCCCAGGCA GAGGCCAAAG TGAATGGCAC AACGGTGTCC TCTCTTTCTA CCTCTCTACA 
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  4081 GAGGTCCGAC AGCAGTCAGC CTATGCTGCT CCGAGTGGTT GGCAGTCAAA CTTCGGACTC 
  4141 CATGGGTGAG GAAGATCTTC TCAGTCCTCC CCAGGACACA AGCACAGGGT TAGAGGAGGT 
  4201 GATGGAGCAA CTCAACAACT CCTTCCCTAG TTCAAGAGGA AGAAATACCC CTGGAAAGCC 
  4261 AATGAGAGAG GACACAATGT AGGAAGTCTT TTCCACATGG CAGATGATTT GGGCAGAGCG 
  4321 ATGGAGTCCT TAGTATCAGT CATGACAGAT GAAGAAGGAG CAGAATAAAT GTTTTACAAC 
  4381 TCCTGATTCC CGCATGGTTT TTATAATATT CATACAACAA AGAGGATTAG ACAGTAAGAG 
  4441 TTTACAAGAA ATAAATCTAT ATTTTTGTGA AGGGTAGTGG TATTATACTG TAGATTTCAG 
  4501 TAGTTTCTAA GTCTGTTATT GTTTTGTTGG GGATCCTCTA GAGGGCCCTA TTCTATAGTG 
  4561 TCACCTAAAT GCTAGAGCTC GCTGATCAGC CTCGACTGTG CCTTCTAGTT GCCAGCCATC 
  4621 TGTTGTTTGC CCCTCCCCCG TGCCTTCCTT GACCCTGGAA GGTGCCACTC CCACTGTCCT 
  4681 TTCCTAATAA AATGAGGAAA TTGCATCGCA TTGTCTGAGT AGGTGTCATT CTATTCTGGG 
  4741 GGGTGGGGTG GGGCAGGACA GCAAGGGGGA GGATTGGGAA GACAATAGCA GGCATGCTGG 
  4801 GGATGCGGTG GGCTCTATGG CTTCTGAGGC GGAAAGGGCG CGCCATATGC CGGCGAATTC 
  4861 TGCAGATATC CATCACACTG GCGGCCGCTC GAGCATGCAT CTAGAGGGCC CTATTCTATA 
  4921 GTGTCACCTA AATGCTAGAG CTCGCTGATC AGCCTCGACT GTGCCTTCTA GTTGCCAGCC 
  4981 ATCTGTTGTT TGCCCCTCCC CCGTGCCTTC CTTGACCCTG GAAGGTGCCA CTCCCACTGT 
  5041 CCTTTCCTAA TAAAATGAGG AAATTGCATC GCATTGTCTG AGTAGGTGTC ATTCTATTCT 
  5101 GGGGGGTGGG GTGGGGCAGG ACAGCAAGGG GGAGGATTGG GAAGACAATA GCAGGCATGC 
  5161 TGGGGATGCG GTGGGCTCTA TGGCTTCTGA GGCGGAAAGA ACCAGCTGGG GCTCTAGGGG 
  5221 GTATCCCCAC GCGCCCTGTA GCGGCGCATT AAGCGCGGCG GGTGTGGTGG TTACGCGCAG 
  5281 CGTGACCGCT ACACTTGCCA GCGCCCTAGC GCCCGCTCCT TTCGCTTTCT TCCCTTCCTT 
  5341 TCTCGCCACG TTCGCCGGCT TTCCCCGTCA AGCTCTAAAT CGGGGCATCC CTTTAGGGTT 
  5401 CCGATTTAGT GCTTTACGGC ACCTCGACCC CAAAAAACTT GATTAGGGTG ATGGTTCACG 
  5461 TAGTGGGCCA TCGCCCTGAT AGACGGTTTT TCGCCCTTTG ACGTTGGAGT CCACGTTCTT 
  5521 TAATAGTGGA CTCTTGTTCC AAACTGGAAC AACACTCAAC CCTATCTCGG TCTATTCTTT 
  5581 TGATTTATAA GGGATTTTGG GGATTTCGGC CTATTGGTTA AAAAATGAGC TGATTTAACA 
  5641 AAAATTTAAC GCGAATTAAT TCTGTGGAAT GTGTGTCAGT TAGGGTGTGG AAAGTCCCCA 
  5701 GGCTCCCCAG GCAGGCAGAA GTATGCAAAG CATGCATCTC AATTAGTCAG CAACCAGGTG 
  5761 TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG AAGTATGCAA AGCATGCATC TCAATTAGTC 
  5821 AGCAACCATA GTCCCGCCCC TAACTCCGCC CATCCCGCCC CTAACTCCGC CCAGTTCCGC 
  5881 CCATTCTCCG CCCCATGGCT GACTAATTTT TTTTATTTAT GCAGAGGCCG AGGCCGCCTC 
  5941 TGCCTCTGAG CTATTCCAGA AGTAGTGAGG AGGCTTTTTT GGAGGCCTAG GCTTTTGCAA 
  6001 AAAGCTCCCG GGAGCTTGTA TATCCATTTT CGGATCTGAT CAAGAGACAG GATGAGGATC 
  6061 GTTTCGCATG ATTGAACAAG ATGGATTGCA CGCAGGTTCT CCGGCCGCTT GGGTGGAGAG 
  6121 GCTATTCGGC TATGACTGGG CACAACAGAC AATCGGCTGC TCTGATGCCG CCGTGTTCCG 
  6181 GCTGTCAGCG CAGGGGCGCC CGGTTCTTTT TGTCAAGACC GACCTGTCCG GTGCCCTGAA 
  6241 TGAACTGCAG GACGAGGCAG CGCGGCTATC GTGGCTGGCC ACGACGGGCG TTCCTTGCGC 
  6301 AGCTGTGCTC GACGTTGTCA CTGAAGCGGG AAGGGACTGG CTGCTATTGG GCGAAGTGCC 
  6361 GGGGCAGGAT CTCCTGTCAT CTCACCTTGC TCCTGCCGAG AAAGTATCCA TCATGGCTGA 
  6421 TGCAATGCGG CGGCTGCATA CGCTTGATCC GGCTACCTGC CCATTCGACC ACCAAGCGAA 
  6481 ACATCGCATC GAGCGAGCAC GTACTCGGAT GGAAGCCGGT CTTGTCGATC AGGATGATCT 
  6541 GGACGAAGAG CATCAGGGGC TCGCGCCAGC CGAACTGTTC GCCAGGCTCA AGGCGCGCAT 
  6601 GCCCGACGGC GAGGATCTCG TCGTGACCCA TGGCGATGCC TGCTTGCCGA ATATCATGGT 
  6661 GGAAAATGGC CGCTTTTCTG GATTCATCGA CTGTGGCCGG CTGGGTGTGG CGGACCGCTA 
  6721 TCAGGACATA GCGTTGGCTA CCCGTGATAT TGCTGAAGAG CTTGGCGGCG AATGGGCTGA 
  6781 CCGCTTCCTC GTGCTTTACG GTATCGCCGC TCCCGATTCG CAGCGCATCG CCTTCTATCG 
  6841 CCTTCTTGAC GAGTTCTTCT GAGCGGGACT CTGGGGTTCG AAATGACCGA CCAAGCGACG 
  6901 CCCAACCTGC CATCACGAGA TTTCGATTCC ACCGCCGCCT TCTATGAAAG GTTGGGCTTC 
  6961 GGAATCGTTT TCCGGGACGC CGGCTGGATG ATCCTCCAGC GCGGGGATCT CATGCTGGAG 
  7021 TTCTTCGCCC ACCCCAACTT GTTTATTGCA GCTTATAATG GTTACAAATA AAGCAATAGC 
  7081 ATCACAAATT TCACAAATAA AGCATTTTTT TCACTGCATT CTAGTTGTGG TTTGTCCAAA 
  7141 CTCATCAATG TATCTTATCA TGTCTGTATA CCGTCGACCT CTAGCTAGAG CTTGGCGTAA 
  7201 TCATGGTCAT AGCTGTTTCC TGTGTGAAAT TGTTATCCGC TCACAATTCC ACACAACATA 
  7261 CGAGCCGGAA GCATAAAGTG TAAAGCCTGG GGTGCCTAAT GAGTGAGCTA ACTCACATTA 
  7321 ATTGCGTTGC GCTCACTGCC CGCTTTCCAG TCGGGAAACC TGTCGTGCCA GCTGCATTAA 
  7381 TGAATCGGCC AACGCGCGGG GAGAGGCGGT TTGCGTATTG GGCGCTCTTC CGCTTCCTCG 
  7441 CTCACTGACT CGCTGCGCTC GGTCGTTCGG CTGCGGCGAG CGGTATCAGC TCACTCAAAG 
  7501 GCGGTAATAC GGTTATCCAC AGAATCAGGG GATAACGCAG GAAAGAACAT GTGAGCAAAA 
  7561 GGCCAGCAAA AGGCCAGGAA CCGTAAAAAG GCCGCGTTGC TGGCGTTTTT CCATAGGCTC 
  7621 CGCCCCCCTG ACGAGCATCA CAAAAATCGA CGCTCAAGTC AGAGGTGGCG AAACCCGACA 
  7681 GGACTATAAA GATACCAGGC GTTTCCCCCT GGAAGCTCCC TCGTGCGCTC TCCTGTTCCG 
  7741 ACCCTGCCGC TTACCGGATA CCTGTCCGCC TTTCTCCCTT CGGGAAGCGT GGCGCTTTCT 
  7801 CAATGCTCAC GCTGTAGGTA TCTCAGTTCG GTGTAGGTCG TTCGCTCCAA GCTGGGCTGT 
  7861 GTGCACGAAC CCCCCGTTCA GCCCGACCGC TGCGCCTTAT CCGGTAACTA TCGTCTTGAG 
  7921 TCCAACCCGG TAAGACACGA CTTATCGCCA CTGGCAGCAG CCACTGGTAA CAGGATTAGC 
  7981 AGAGCGAGGT ATGTAGGCGG TGCTACAGAG TTCTTGAAGT GGTGGCCTAA CTACGGCTAC 
  8041 ACTAGAAGGA CAGTATTTGG TATCTGCGCT CTGCTGAAGC CAGTTACCTT CGGAAAAAGA 
  8101 GTTGGTAGCT CTTGATCCGG CAAACAAACC ACCGCTGGTA GCGGTGGTTT TTTTGTTTGC 
  8161 AAGCAGCAGA TTACGCGCAG AAAAAAAGGA TCTCAAGAAG ATCCTTTGAT CTTTTCTACG 
  8221 GGGTCTGACG CTCAGTGGAA CGAAAACTCA CGTTAAGGGA TTTTGGTCAT GAGATTATCA
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  8281 AAAAGGATCT TCACCTAGAT CCTTTTAAAT TAAAAATGAA GTTTTAAATC AATCTAAAGT 
  8341 ATATATGAGT AAACTTGGTC TGACAGTTAC CAATGCTTAA TCAGTGAGGC ACCTATCTCA 
  8401 GCGATCTGTC TATTTCGTTC ATCCATAGTT GCCTGACTCC CCGTCGTGTA GATAACTACG 
  8461 ATACGGGAGG GCTTACCATC TGGCCCCAGT GCTGCAATGA TACCGCGAGA CCCACGCTCA 
  8521 CCGGCTCCAG ATTTATCAGC AATAAACCAG CCAGCCGGAA GGGCCGAGCG CAGAAGTGGT 
  8581 CCTGCAACTT TATCCGCCTC CATCCAGTCT ATTAATTGTT GCCGGGAAGC TAGAGTAAGT 
  8641 AGTTCGCCAG TTAATAGTTT GCGCAACGTT GTTGCCATTG CTACAGGCAT CGTGGTGTCA 
  8701 CGCTCGTCGT TTGGTATGGC TTCATTCAGC TCCGGTTCCC AACGATCAAG GCGAGTTACA 
  8761 TGATCCCCCA TGTTGTGCAA AAAAGCGGTT AGCTCCTTCG GTCCTCCGAT CGTTGTCAGA 
  8821 AGTAAGTTGG CCGCAGTGTT ATCACTCATG GTTATGGCAG CACTGCATAA TTCTCTTACT 
  8881 GTCATGCCAT CCGTAAGATG CTTTTCTGTG ACTGGTGAGT ACTCAACCAA GTCATTCTGA 
  8941 GAATAGTGTA TGCGGCGACC GAGTTGCTCT TGCCCGGCGT CAATACGGGA TAATACCGCG 
  9001 CCACATAGCA GAACTTTAAA AGTGCTCATC ATTGGAAAAC GTTCTTCGGG GCGAAAACTC 
  9061 TCAAGGATCT TACCGCTGTT GAGATCCAGT TCGATGTAAC CCACTCGTGC ACCCAACTGA 
  9121 TCTTCAGCAT CTTTTACTTT CACCAGCGTT TCTGGGTGAG CAAAAACAGG AAGGCAAAAT 
  9181 GCCGCAAAAA AGGGAATAAG GGCGACACGG AAATGTTGAA TACTCATACT CTTCCTTTTT 
  9241 CAATATTATT GAAGCATTTA TCAGGGTTAT TGTCTCATGA GCGGATACAT ATTTGAATGT 
  9301 ATTTAGAAAA ATAAACAAAT AGGGGTTCCG CGCACATTTC CCCGAAAAGT GCCACCTGAC 
  9361 GTC 
 
F-pcDNA3.Dyst.RC 
 
 
 
     1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC TGCTCTGATG 
    61 CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG 
   121 CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC 
   181 TTAGGGTTAG GCGTTTTGCG CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT 
   241 GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA 
   301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 
   361 CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC 
   421 ATTGACGTCA ATGGGTGGAC TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT 
   481 ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT 
   541 ATGCCCAGTA CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA 
   601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 
   661 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC 
   721 AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG 
   781 GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA 
   841 CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTTGGTACC 
   901 GAGCTCGGAT CCACTAGTAA CGGCCGCCAG TGTGCTGGAA TTCGCCGGCA TATGGCGCGC 
   961 CCTTTCCGCC TCAGAAGCCA TAGAGCCCAC CGCATCCCCA GCATGCCTGC TATTGTCTTC 
  1021 CCAATCCTCC CCCTTGCTGT CCTGCCCCAC CCCACCCCCC AGAATAGAAT GACACCTACT 
  1081 CAGACAATGC GATGCAATTT CCTCATTTTA TTAGGAAAGG ACAGTGGGAG TGGCACCTTC 
  1141 CAGGGTCAAG GAAGGCACGG GGGAGGGGCA AACAACAGAT GGCTGGCAAC TAGAAGGCAC 
  1201 AGTCGAGGCT GATCAGCGAG CTCTAGCATT TAGGTGACAC TATAGAATAG GGCCCTCTAG 
  1261 AGGATCCCCA ACAAAACAAT AACAGACTTA GAAACTACTG AAATCTACAG TATAATACCA 
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  1321 CTACCCTTCA CAAAAATATA GATTTATTTC TTGTAAACTC TTACTGTCTA ATCCTCTTTG 
  1381 TTGTATGAAT ATTATAAAAA CCATGCGGGA ATCAGGAGTT GTAAAACATT TATTCTGCTC 
  1441 CTTCTTCATC TGTCATGACT GATACTAAGG ACTCCATCGC TCTGCCCAAA TCATCTGCCA 
  1501 TGTGGAAAAG ACTTCCTACA TTGTGTCCTC TCTCATTGGC TTTCCAGGGG TATTTCTTCC 
  1561 TCTTGAACTA GGGAAGGAGT TGTTGAGTTG CTCCATCACC TCCTCTAACC CTGTGCTTGT 
  1621 GTCCTGGGGA GGACTGAGAA GATCTTCCTC ACCCATGGAG TCCGAAGTTT GACTGCCAAC 
  1681 CACTCGGAGC AGCATAGGCT GACTGCTGTC GGACCTCTGT AGAGAGGTAG AAAGAGAGGA 
  1741 CACCGTTGTG CCATTCACTT TGGCCTCTGC CTGGGGTTGC TCCAGCAGCT GCCTTAGCCT 
  1801 GTGTAACTGT GACTCCAGCT GTTTATTGTG GTCTTCCAGG ATTTGCATCC TGGCTTCCAG 
  1861 GCGGCCTTTG TGTTGACGCA GTAGCTTGGC CTCAGCAATG AGCTCAGCAT CCCGGGGACT 
  1921 CTGGGGAGAG GTGGGCATCA TTTCAGGAGG GGACGGCAGT GGGGACAGGC CTTTATGTTC 
  1981 GTGCTGCTGC TTTAGACGGT CATATTCTGC TTGCAGATTC CTGTTTTCTT CCTCAGATCT 
  2041 GCTAGGATTC TCTCTAGCTC CCCTCTTTCC TCACTCTCTA AGGAAATCAA GATCTGGGCA 
  2101 GGACTACGAG GCTGGCTCAG GGGGGAGTCC TGGTTCAAAC TTTGGCAGTA ATGCTGGATT 
  2161 AACAAATGTT CATCATCTAT GCTCTCATTA GGAGAGATGC TATCATTTAG ATAAGATCCA 
  2221 TTGCTGTTTT CCATTTCTGC TAGCCTGCTA GCATAATGTT CAATGCGTGA ATGAGTATCA 
  2281 TCGTGTGAAA GCTGAGGGGA CGAGGCAGGC GCAGAATCTA CTGGCCAGAA GTTGATCAGA 
  2341 GTAACGGGAG TTTCCATGTT GTCCCCCTCT AAGACAGTCT GCACTGGCAG GTAGCCCATT 
  2401 CGGGGATGCT TCGCAAAATA CCTTTTGGTT CGAAATTTGT TTTTTAGTAC CTTGGCAAAG 
  2461 TCTCGAACAT CTTCTCCTGA TGTAGTCGGA GTGCAATATT CCACCATGGG ATAGTGCATT 
  2521 TTATGGCCTT TTGCAACTCG ACCAGAAAAA AAGCAGCTTT GGCAGATGTC ATAATTAAAG 
  2581 TGCTTTAGAC TCCTGTACCT GAATCCAATG ATTGGACACT CTTTGCAGAT GTTACATTTG 
  2641 GCCTGATGCT TGGCAGTTTC TGCAGCAGCC ACTCTGTGCA GGACGGGCAG CCACACCATG 
  2701 GACTGGGGTT CCAGTCTCAT CCAGTCTAGG AAGAGGGCCG CTTCGATCTC TGGCTTATTA 
  2761 TTAGCAAATT GGAAGCAGCT CCGGACACTT GGCTCAATGT TACTGCCCCC AAAGGATGCA 
  2821 ACTTCACCCA ACTGTCTTGG AATTTGGATA GAATCATGCA GAAGAGGCCC AGCCTGCGCT 
  2881 GGTCACAAAA TCCTGTTGAA CTTGCCACTT GCTTGAAAAG GTATCTGTAC TTGTCTTCCA 
  2941 AATGTGCTTT ACACAGGGAA ATGATGCCAG TTTTAAAAGA CAGGACACGG ATCCTCCCTG 
  3001 TTCGTCCCGT ATCATAAACA TTCAGCAGCC AGTTCAGACA CATATCCACG CAGAGAGGGA 
  3061 CGTTGACCAA ATTGTTGTGC TCTTGCTCCA GGCGGTCATA AATAGTGGTC AAACAATTAA 
  3121 TAATCTGCAG GATATCCATG GGCTGGTCAT TTTGCTTGAG GTTGTGCTGG TCCAAGGCAT 
  3181 CACATGCAGC TGACAGGCTC AAGAGATCCA AGCAAAGGGC CTTCTGCAGT CTTCGGAGTT 
  3241 TCATGGCAGT CCTATAAGCT GAGAATCTGA CATTATTCAG GTCAGCTAAA GACTGGTAGA 
  3301 GCTCTGTCAT TTTGGGATGG TCCCAGCAAG TTGTTTGAGT CTCGTGGTTG ATATAGTAGG 
  3361 GCACTTTGTT TGGCGAGATG GCTCTCTCCC AGGGACCCTG GACAGACGTG GAAAGAAAGT 
  3421 GCTGAGATGC TGGACCAAAG TCCCTGTGGG CTTCATGCAG CTGCCTGACT CGGTCCTCGA 
  3481 CGGCCACCTG CAGAAGCTTC CATCTGGTGT TCAGGTCTTC CAGAGTGCTG AGGTTATACG 
  3541 GTGAGAGCTG AATGCCCAAA GTGGTAAGCT GGCGAGCAAG GTCATTGACG TGGCTCACGT 
  3601 TCTCTTTCAG AGGCGCAATT TCTCCTCGAA GTGCCTTGAC TTTCTCGAGG TGATCTTGGA 
  3661 GAGAGTCAAT GAGGAGATCG CCCACGGGCT GCCAGGATCC CTTGATCACC TCAGCTTGGC 
  3721 GCAGCTTGAG GTCCAGCTCA TCCGTGGCCT CTTGAAGTTC CTGGAGTCTT TCAAGCTCTG 
  3781 GACTCTGATG CTTTCGTCCG ACTCCTCCAG TTATGACTCA CCCTTTTTAA CTTGGACGTG 
  3841 AGGCGACTGA CCGTCTCTTT TTATGACTTG TCTTCAGGAG CTTCCAAATG CTGTGAAGGA 
  3901 AATGGGCTCC GTGTAGGGTC AGAGGTGGTG ACATAAGCAG CCTGTGTGTA GGCATAGCTC 
  3961 TTGAATCGAG GCTTAGGGGA AGAAGTTCTC TCATATCCCT GTGCTAGACT GACCGTGATC 
  4021 TGTTGAGAAT AGTGCATTTG ATGATGTAAC TGAAAATGTT CTTCTTTAGT CACTTTAGGT 
  4081 GGCCTTGGCA ACATTTCCAC TTCCTGGATG GCTTCAATGC TCACTTGTTG AGGCAAAACT 
  4141 TGGAAGAGTG ATGTGATGTA CATTAAGATG GACTTCTTAT CTGGATAGGT GGTATCAACA 
  4201 TCTTCAGGAT CGAGTAGTTT CTCTATGCCT AATTGATATC TGGCGATGTT GAATGCATGT 
  4261 TCCAGTCGTT GTGTGGCTGA CTGCTGGCAA ACCACACTAT TCCAGTCAAA TAGGTCTGGC 
  4321 CTATGACTAT GGATGAGAGC ATTCAAAGCC AGGCCATCAG ACCAGCTGGT GGTGAAGTTG 
  4381 ATTACATTAA CCTGTGGATA ATTACGAGTT GATTGTCGGA CCCAGCTCAG GAGAATCTTT 
  4441 TCACTGTTGG TTTGTTGCAA TCCAGCCATG ATATTTTTCA TTACATTTTT GACCTGCCAG 
  4501 TGGAGGATTA TATTCCAAAT CAAACCAAGA GTCAGTTTAT GATTTCCATC TACGATGTCA 
  4561 GTACTTCCAA TATTCACTAA ATCAACATTA TTGTTCTGCA AAACCCGCAG TGCCTTGTTG 
  4621 ACATTGTTCA GGGCATGAAC TCTTGTGGAT CCTTTTTCTT TTGGCAGTTT TTGCCCTGTC 
  4681 AGGCCTTCGA GGAGGTCTAG GAGGCGCCTC CCATCCTGTA GGTCACTGAA GAGGTTCTCA 
  4741 ATATGCTGCT TCCCAAACTT AGAAAATTGT GCATTTACCC ATTTTGTGAA TGTTTTCTTT 
  4801 TGAACATCTT CTCTTTCATA ACAGTCCTCT ACTTCTTCCC ACCAAAGCAT GGTGGAATTC 
  4861 TGCAGATATC CATCACACTG GCGGCCGCTC GAGCATGCAT CTAGAGGGCC CTATTCTATA 
  4921 GTGTCACCTA AATGCTAGAG CTCGCTGATC AGCCTCGACT GTGCCTTCTA GTTGCCAGCC 
  4981 ATCTGTTGTT TGCCCCTCCC CCGTGCCTTC CTTGACCCTG GAAGGTGCCA CTCCCACTGT 
  5041 CCTTTCCTAA TAAAATGAGG AAATTGCATC GCATTGTCTG AGTAGGTGTC ATTCTATTCT 
  5101 GGGGGGTGGG GTGGGGCAGG ACAGCAAGGG GGAGGATTGG GAAGACAATA GCAGGCATGC 
  5161 TGGGGATGCG GTGGGCTCTA TGGCTTCTGA GGCGGAAAGA ACCAGCTGGG GCTCTAGGGG 
  5221 GTATCCCCAC GCGCCCTGTA GCGGCGCATT AAGCGCGGCG GGTGTGGTGG TTACGCGCAG 
  5281 CGTGACCGCT ACACTTGCCA GCGCCCTAGC GCCCGCTCCT TTCGCTTTCT TCCCTTCCTT 
  5341 TCTCGCCACG TTCGCCGGCT TTCCCCGTCA AGCTCTAAAT CGGGGCATCC CTTTAGGGTT 
  5401 CCGATTTAGT GCTTTACGGC ACCTCGACCC CAAAAAACTT GATTAGGGTG ATGGTTCACG 
  5461 TAGTGGGCCA TCGCCCTGAT AGACGGTTTT TCGCCCTTTG ACGTTGGAGT CCACGTTCTT 
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  5521 TAATAGTGGA CTCTTGTTCC AAACTGGAAC AACACTCAAC CCTATCTCGG TCTATTCTTT 
  5581 TGATTTATAA GGGATTTTGG GGATTTCGGC CTATTGGTTA AAAAATGAGC TGATTTAACA 
  5641 AAAATTTAAC GCGAATTAAT TCTGTGGAAT GTGTGTCAGT TAGGGTGTGG AAAGTCCCCA 
  5701 GGCTCCCCAG GCAGGCAGAA GTATGCAAAG CATGCATCTC AATTAGTCAG CAACCAGGTG 
  5761 TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG AAGTATGCAA AGCATGCATC TCAATTAGTC 
  5821 AGCAACCATA GTCCCGCCCC TAACTCCGCC CATCCCGCCC CTAACTCCGC CCAGTTCCGC 
  5881 CCATTCTCCG CCCCATGGCT GACTAATTTT TTTTATTTAT GCAGAGGCCG AGGCCGCCTC 
  5941 TGCCTCTGAG CTATTCCAGA AGTAGTGAGG AGGCTTTTTT GGAGGCCTAG GCTTTTGCAA 
  6001 AAAGCTCCCG GGAGCTTGTA TATCCATTTT CGGATCTGAT CAAGAGACAG GATGAGGATC 
  6061 GTTTCGCATG ATTGAACAAG ATGGATTGCA CGCAGGTTCT CCGGCCGCTT GGGTGGAGAG 
  6121 GCTATTCGGC TATGACTGGG CACAACAGAC AATCGGCTGC TCTGATGCCG CCGTGTTCCG 
  6181 GCTGTCAGCG CAGGGGCGCC CGGTTCTTTT TGTCAAGACC GACCTGTCCG GTGCCCTGAA 
  6241 TGAACTGCAG GACGAGGCAG CGCGGCTATC GTGGCTGGCC ACGACGGGCG TTCCTTGCGC 
  6301 AGCTGTGCTC GACGTTGTCA CTGAAGCGGG AAGGGACTGG CTGCTATTGG GCGAAGTGCC 
  6361 GGGGCAGGAT CTCCTGTCAT CTCACCTTGC TCCTGCCGAG AAAGTATCCA TCATGGCTGA 
  6421 TGCAATGCGG CGGCTGCATA CGCTTGATCC GGCTACCTGC CCATTCGACC ACCAAGCGAA 
  6481 ACATCGCATC GAGCGAGCAC GTACTCGGAT GGAAGCCGGT CTTGTCGATC AGGATGATCT 
  6541 GGACGAAGAG CATCAGGGGC TCGCGCCAGC CGAACTGTTC GCCAGGCTCA AGGCGCGCAT 
  6601 GCCCGACGGC GAGGATCTCG TCGTGACCCA TGGCGATGCC TGCTTGCCGA ATATCATGGT 
  6661 GGAAAATGGC CGCTTTTCTG GATTCATCGA CTGTGGCCGG CTGGGTGTGG CGGACCGCTA 
  6721 TCAGGACATA GCGTTGGCTA CCCGTGATAT TGCTGAAGAG CTTGGCGGCG AATGGGCTGA 
  6781 CCGCTTCCTC GTGCTTTACG GTATCGCCGC TCCCGATTCG CAGCGCATCG CCTTCTATCG 
  6841 CCTTCTTGAC GAGTTCTTCT GAGCGGGACT CTGGGGTTCG AAATGACCGA CCAAGCGACG 
  6901 CCCAACCTGC CATCACGAGA TTTCGATTCC ACCGCCGCCT TCTATGAAAG GTTGGGCTTC 
  6961 GGAATCGTTT TCCGGGACGC CGGCTGGATG ATCCTCCAGC GCGGGGATCT CATGCTGGAG 
  7021 TTCTTCGCCC ACCCCAACTT GTTTATTGCA GCTTATAATG GTTACAAATA AAGCAATAGC 
  7081 ATCACAAATT TCACAAATAA AGCATTTTTT TCACTGCATT CTAGTTGTGG TTTGTCCAAA 
  7141 CTCATCAATG TATCTTATCA TGTCTGTATA CCGTCGACCT CTAGCTAGAG CTTGGCGTAA 
  7201 TCATGGTCAT AGCTGTTTCC TGTGTGAAAT TGTTATCCGC TCACAATTCC ACACAACATA 
  7261 CGAGCCGGAA GCATAAAGTG TAAAGCCTGG GGTGCCTAAT GAGTGAGCTA ACTCACATTA 
  7321 ATTGCGTTGC GCTCACTGCC CGCTTTCCAG TCGGGAAACC TGTCGTGCCA GCTGCATTAA 
  7381 TGAATCGGCC AACGCGCGGG GAGAGGCGGT TTGCGTATTG GGCGCTCTTC CGCTTCCTCG 
  7441 CTCACTGACT CGCTGCGCTC GGTCGTTCGG CTGCGGCGAG CGGTATCAGC TCACTCAAAG 
  7501 GCGGTAATAC GGTTATCCAC AGAATCAGGG GATAACGCAG GAAAGAACAT GTGAGCAAAA 
  7561 GGCCAGCAAA AGGCCAGGAA CCGTAAAAAG GCCGCGTTGC TGGCGTTTTT CCATAGGCTC 
  7621 CGCCCCCCTG ACGAGCATCA CAAAAATCGA CGCTCAAGTC AGAGGTGGCG AAACCCGACA 
  7681 GGACTATAAA GATACCAGGC GTTTCCCCCT GGAAGCTCCC TCGTGCGCTC TCCTGTTCCG 
  7741 ACCCTGCCGC TTACCGGATA CCTGTCCGCC TTTCTCCCTT CGGGAAGCGT GGCGCTTTCT 
  7801 CAATGCTCAC GCTGTAGGTA TCTCAGTTCG GTGTAGGTCG TTCGCTCCAA GCTGGGCTGT 
  7861 GTGCACGAAC CCCCCGTTCA GCCCGACCGC TGCGCCTTAT CCGGTAACTA TCGTCTTGAG 
  7921 TCCAACCCGG TAAGACACGA CTTATCGCCA CTGGCAGCAG CCACTGGTAA CAGGATTAGC 
  7981 AGAGCGAGGT ATGTAGGCGG TGCTACAGAG TTCTTGAAGT GGTGGCCTAA CTACGGCTAC 
  8041 ACTAGAAGGA CAGTATTTGG TATCTGCGCT CTGCTGAAGC CAGTTACCTT CGGAAAAAGA 
  8101 GTTGGTAGCT CTTGATCCGG CAAACAAACC ACCGCTGGTA GCGGTGGTTT TTTTGTTTGC 
  8161 AAGCAGCAGA TTACGCGCAG AAAAAAAGGA TCTCAAGAAG ATCCTTTGAT CTTTTCTACG 
  8221 GGGTCTGACG CTCAGTGGAA CGAAAACTCA CGTTAAGGGA TTTTGGTCAT GAGATTATCA 
  8281 AAAAGGATCT TCACCTAGAT CCTTTTAAAT TAAAAATGAA GTTTTAAATC AATCTAAAGT 
  8341 ATATATGAGT AAACTTGGTC TGACAGTTAC CAATGCTTAA TCAGTGAGGC ACCTATCTCA 
  8401 GCGATCTGTC TATTTCGTTC ATCCATAGTT GCCTGACTCC CCGTCGTGTA GATAACTACG 
  8461 ATACGGGAGG GCTTACCATC TGGCCCCAGT GCTGCAATGA TACCGCGAGA CCCACGCTCA 
  8521 CCGGCTCCAG ATTTATCAGC AATAAACCAG CCAGCCGGAA GGGCCGAGCG CAGAAGTGGT 
  8581 CCTGCAACTT TATCCGCCTC CATCCAGTCT ATTAATTGTT GCCGGGAAGC TAGAGTAAGT 
  8641 AGTTCGCCAG TTAATAGTTT GCGCAACGTT GTTGCCATTG CTACAGGCAT CGTGGTGTCA 
  8701 CGCTCGTCGT TTGGTATGGC TTCATTCAGC TCCGGTTCCC AACGATCAAG GCGAGTTACA 
  8761 TGATCCCCCA TGTTGTGCAA AAAAGCGGTT AGCTCCTTCG GTCCTCCGAT CGTTGTCAGA 
  8821 AGTAAGTTGG CCGCAGTGTT ATCACTCATG GTTATGGCAG CACTGCATAA TTCTCTTACT 
  8881 GTCATGCCAT CCGTAAGATG CTTTTCTGTG ACTGGTGAGT ACTCAACCAA GTCATTCTGA 
  8941 GAATAGTGTA TGCGGCGACC GAGTTGCTCT TGCCCGGCGT CAATACGGGA TAATACCGCG 
  9001 CCACATAGCA GAACTTTAAA AGTGCTCATC ATTGGAAAAC GTTCTTCGGG GCGAAAACTC 
  9061 TCAAGGATCT TACCGCTGTT GAGATCCAGT TCGATGTAAC CCACTCGTGC ACCCAACTGA 
  9121 TCTTCAGCAT CTTTTACTTT CACCAGCGTT TCTGGGTGAG CAAAAACAGG AAGGCAAAAT 
  9181 GCCGCAAAAA AGGGAATAAG GGCGACACGG AAATGTTGAA TACTCATACT CTTCCTTTTT 
  9241 CAATATTATT GAAGCATTTA TCAGGGTTAT TGTCTCATGA GCGGATACAT ATTTGAATGT 
  9301 ATTTAGAAAA ATAAACAAAT AGGGGTTCCG CGCACATTTC CCCGAAAAGT GCCACCTGAC 
  9361 GTC 
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G-pcDNA3.IDO1 
 
  
 
     1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC TGCTCTGATG 
    61 CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG 
   121 CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC 
   181 TTAGGGTTAG GCGTTTTGCG CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT 
   241 GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA 
   301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 
   361 CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC 
   421 ATTGACGTCA ATGGGTGGAC TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT 
   481 ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT 
   541 ATGCCCAGTA CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA 
   601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 
   661 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC 
   721 AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG 
   781 GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA 
   841 CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTTGGTACC 
   901 ACCATGGCAC TCAGTAAAAT ATCTCCTACA GAAGGTTCTA GAAGGATCCT TGAAGACCAC 
   961 CACATAGATG AAGATGTGGG CTTTGCTCTA CCACATCCAC TGGTGGAGCT GCCCGACGCA 
  1021 TACAGCCCCT GGGTCCTTGT GGCTAGAAAT CTGCCTGTGC TGATTGAGAA CGGGCAGCTT 
  1081 CGAGAAGAAG TTGAAAAGCT GCCCACACTG AGCACGGACG GACTGAGAGG ACACAGGTTA 
  1141 CAGCGCCTGG CACACCTGGC CCTGGGGTAC ATCACCATGG CGTATGTGTG GAACCGAGGG 
  1201 GATGACGATG TTCGAAAGGT GCTGCCCCGC AATATTGCTG TTCCCTACTG CGAGCTCTCA 
  1261 GAGAAGTTGG GCCTGCCTCC TATTCTGTCT TATGCAGACT GTGTCCTGGC AAACTGGAAG 
  1321 AAAAAGGACC CCAATGGGCC CATGACATAC GAGAACATGG ACATTCTGTT CTCATTTCCT 
  1381 GGTGGGGACT GCGACAAGGG CTTCTTCCTC GTCTCTCTAT TGGTGGAAAT CGCAGCTTCT 
  1441 CCTGCAATCA AAGCAATCCC CACTGTATCC AGTGCAGTAG AGCGTCAAGA CCTGAAAGCA 
  1501 TTGGAAAAGG CACTGCACGA CATAGCTACC AGTCTGGAGA AAGCCAAGGA AATTTTTAAG 
  1561 AGGATGCGTG ACTTTGTGGA CCCAGACACG TTTTTCCACG TTCTCCGCAT ATATCTGTCT 
  1621 GGCTGGAAAT GCAGCTCCAA GCTGCCAGAA GGTCTGCTGT ATGAGGGGGT CTGGGACACC 
  1681 CCAAAAATGT TTTCAGGGGG CAGTGCAGGC CAGAGCAGCA TCTTCCAGAG TCTTGATGTC 
  1741 CTTCTGGGAA TAAAACACGA GGCTGGCAAA GAATCTCCTG CAGAATTCCT CCAGGAAATG 
  1801 AGAGAGTACA TGCCTCCAGC CCACCGGAAC TTCCTTTTCT TCTTAGAGTC AGCTCCCCCA 
  1861 GTCCGTGAGT TTGTCATTTC AAGACACAAT GAAGACTTGA CGAAAGCTTA TAACGAGTGT 
  1921 GTGAATGGTC TGGTCTCTGT GAGAAAGTTC CACCTCGCAA TAGTAGATAC TTACATTATG 
  1981 AAACCTTCGA AGAAGAAGCC CACTGATGGC GACAAGTCGG AAGAGCCCTC AAATGTGGAA 
  2041 AGCAGAGGGA CTGGGGGTAC GAATCCCATG ACTTTCCTAA GGAGTGTGAA AGATACAACC 
  2101 GAGAAAGCTC TTCTGAGTTG GCCTTAGGCG GCCGCTCGAG CATGCATCTA GAGGGCCCTA 
  2161 TTCTATAGTG TCACCTAAAT GCTAGAGCTC GCTGATCAGC CTCGACTGTG CCTTCTAGTT 
  2221 GCCAGCCATC TGTTGTTTGC CCCTCCCCCG TGCCTTCCTT GACCCTGGAA GGTGCCACTC 
  2281 CCACTGTCCT TTCCTAATAA AATGAGGAAA TTGCATCGCA TTGTCTGAGT AGGTGTCATT 
  2341 CTATTCTGGG GGGTGGGGTG GGGCAGGACA GCAAGGGGGA GGATTGGGAA GACAATAGCA 
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  2401 GGCATGCTGG GGATGCGGTG GGCTCTATGG CTTCTGAGGC GGAAAGAACC AGCTGGGGCT 
  2461 CTAGGGGGTA TCCCCACGCG CCCTGTAGCG GCGCATTAAG CGCGGCGGGT GTGGTGGTTA 
  2521 CGCGCAGCGT GACCGCTACA CTTGCCAGCG CCCTAGCGCC CGCTCCTTTC GCTTTCTTCC 
  2581 CTTCCTTTCT CGCCACGTTC GCCGGCTTTC CCCGTCAAGC TCTAAATCGG GGCATCCCTT 
  2641 TAGGGTTCCG ATTTAGTGCT TTACGGCACC TCGACCCCAA AAAACTTGAT TAGGGTGATG 
  2701 GTTCACGTAG TGGGCCATCG CCCTGATAGA CGGTTTTTCG CCCTTTGACG TTGGAGTCCA 
  2761 CGTTCTTTAA TAGTGGACTC TTGTTCCAAA CTGGAACAAC ACTCAACCCT ATCTCGGTCT 
  2821 ATTCTTTTGA TTTATAAGGG ATTTTGGGGA TTTCGGCCTA TTGGTTAAAA AATGAGCTGA 
  2881 TTTAACAAAA ATTTAACGCG AATTAATTCT GTGGAATGTG TGTCAGTTAG GGTGTGGAAA 
  2941 GTCCCCAGGC TCCCCAGGCA GGCAGAAGTA TGCAAAGCAT GCATCTCAAT TAGTCAGCAA 
  3001 CCAGGTGTGG AAAGTCCCCA GGCTCCCCAG CAGGCAGAAG TATGCAAAGC ATGCATCTCA 
  3061 ATTAGTCAGC AACCATAGTC CCGCCCCTAA CTCCGCCCAT CCCGCCCCTA ACTCCGCCCA 
  3121 GTTCCGCCCA TTCTCCGCCC CATGGCTGAC TAATTTTTTT TATTTATGCA GAGGCCGAGG 
  3181 CCGCCTCTGC CTCTGAGCTA TTCCAGAAGT AGTGAGGAGG CTTTTTTGGA GGCCTAGGCT 
  3241 TTTGCAAAAA GCTCCCGGGA GCTTGTATAT CCATTTTCGG ATCTGATCAA GAGACAGGAT 
  3301 GAGGATCGTT TCGCATGATT GAACAAGATG GATTGCACGC AGGTTCTCCG GCCGCTTGGG 
  3361 TGGAGAGGCT ATTCGGCTAT GACTGGGCAC AACAGACAAT CGGCTGCTCT GATGCCGCCG 
  3421 TGTTCCGGCT GTCAGCGCAG GGGCGCCCGG TTCTTTTTGT CAAGACCGAC CTGTCCGGTG 
  3481 CCCTGAATGA ACTGCAGGAC GAGGCAGCGC GGCTATCGTG GCTGGCCACG ACGGGCGTTC 
  3541 CTTGCGCAGC TGTGCTCGAC GTTGTCACTG AAGCGGGAAG GGACTGGCTG CTATTGGGCG 
  3601 AAGTGCCGGG GCAGGATCTC CTGTCATCTC ACCTTGCTCC TGCCGAGAAA GTATCCATCA 
  3661 TGGCTGATGC AATGCGGCGG CTGCATACGC TTGATCCGGC TACCTGCCCA TTCGACCACC 
  3721 AAGCGAAACA TCGCATCGAG CGAGCACGTA CTCGGATGGA AGCCGGTCTT GTCGATCAGG 
  3781 ATGATCTGGA CGAAGAGCAT CAGGGGCTCG CGCCAGCCGA ACTGTTCGCC AGGCTCAAGG 
  3841 CGCGCATGCC CGACGGCGAG GATCTCGTCG TGACCCATGG CGATGCCTGC TTGCCGAATA 
  3901 TCATGGTGGA AAATGGCCGC TTTTCTGGAT TCATCGACTG TGGCCGGCTG GGTGTGGCGG 
  3961 ACCGCTATCA GGACATAGCG TTGGCTACCC GTGATATTGC TGAAGAGCTT GGCGGCGAAT 
  4021 GGGCTGACCG CTTCCTCGTG CTTTACGGTA TCGCCGCTCC CGATTCGCAG CGCATCGCCT 
  4081 TCTATCGCCT TCTTGACGAG TTCTTCTGAG CGGGACTCTG GGGTTCGAAA TGACCGACCA 
  4141 AGCGACGCCC AACCTGCCAT CACGAGATTT CGATTCCACC GCCGCCTTCT ATGAAAGGTT 
  4201 GGGCTTCGGA ATCGTTTTCC GGGACGCCGG CTGGATGATC CTCCAGCGCG GGGATCTCAT 
  4261 GCTGGAGTTC TTCGCCCACC CCAACTTGTT TATTGCAGCT TATAATGGTT ACAAATAAAG 
  4321 CAATAGCATC ACAAATTTCA CAAATAAAGC ATTTTTTTCA CTGCATTCTA GTTGTGGTTT 
  4381 GTCCAAACTC ATCAATGTAT CTTATCATGT CTGTATACCG TCGACCTCTA GCTAGAGCTT 
  4441 GGCGTAATCA TGGTCATAGC TGTTTCCTGT GTGAAATTGT TATCCGCTCA CAATTCCACA 
  4501 CAACATACGA GCCGGAAGCA TAAAGTGTAA AGCCTGGGGT GCCTAATGAG TGAGCTAACT 
  4561 CACATTAATT GCGTTGCGCT CACTGCCCGC TTTCCAGTCG GGAAACCTGT CGTGCCAGCT 
  4621 GCATTAATGA ATCGGCCAAC GCGCGGGGAG AGGCGGTTTG CGTATTGGGC GCTCTTCCGC 
  4681 TTCCTCGCTC ACTGACTCGC TGCGCTCGGT CGTTCGGCTG CGGCGAGCGG TATCAGCTCA 
  4741 CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT AACGCAGGAA AGAACATGTG 
  4801 AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTTCCA 
  4861 TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA 
  4921 CCCGACAGGA CTATAAAGAT ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TGCGCTCTCC 
  4981 TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC 
  5041 GCTTTCTCAA TGCTCACGCT GTAGGTATCT CAGTTCGGTG TAGGTCGTTC GCTCCAAGCT 
  5101 GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC GCCTTATCCG GTAACTATCG 
  5161 TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG 
  5221 GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA 
  5281 CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG 
  5341 AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC GCTGGTAGCG GTGGTTTTTT 
  5401 TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT 
  5461 TTCTACGGGG TCTGACGCTC AGTGGAACGA AAACTCACGT TAAGGGATTT TGGTCATGAG 
  5521 ATTATCAAAA AGGATCTTCA CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT 
  5581 CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC 
  5641 TATCTCAGCG ATCTGTCTAT TTCGTTCATC CATAGTTGCC TGACTCCCCG TCGTGTAGAT 
  5701 AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT GCAATGATAC CGCGAGACCC 
  5761 ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG 
  5821 AAGTGGTCCT GCAACTTTAT CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGGAAGCTAG 
  5881 AGTAAGTAGT TCGCCAGTTA ATAGTTTGCG CAACGTTGTT GCCATTGCTA CAGGCATCGT 
  5941 GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC GGTTCCCAAC GATCAAGGCG 
  6001 AGTTACATGA TCCCCCATGT TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC CTCCGATCGT 
  6061 TGTCAGAAGT AAGTTGGCCG CAGTGTTATC ACTCATGGTT ATGGCAGCAC TGCATAATTC 
  6121 TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC 
  6181 ATTCTGAGAA TAGTGTATGC GGCGACCGAG TTGCTCTTGC CCGGCGTCAA TACGGGATAA 
  6241 TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT GGAAAACGTT CTTCGGGGCG 
  6301 AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTCG ATGTAACCCA CTCGTGCACC 
  6361 CAACTGATCT TCAGCATCTT TTACTTTCAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG 
  6421 GCAAAATGCC GCAAAAAAGG GAATAAGGGC GACACGGAAA TGTTGAATAC TCATACTCTT 
  6481 CCTTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT 
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  6541 TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC 
  6601 ACCTGACGTC 
 
 
 
 
H-pcDNA3.IDO2 
 
 
 
     1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC TGCTCTGATG 
    61 CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG 
   121 CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC 
   181 TTAGGGTTAG GCGTTTTGCG CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT 
   241 GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA 
   301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 
   361 CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC 
   421 ATTGACGTCA ATGGGTGGAC TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT 
   481 ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT 
   541 ATGCCCAGTA CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA 
   601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 
   661 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC 
   721 AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG 
   781 GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA 
   841 CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTTGGTACC 
   901 GAGCTCGGAT CCACTAGTAA CGGCCGCCAG TGTGCTGGAA TTCACCATGG AGCCTCAAAG 
   961 TCAGAGCATG ACGCTGGAGG TGCCGTTGTC CTTGGGGAGA TACCACATTT CTGAGGAATA 
  1021 TGGCTTTCTC CTTCCAAATC CTCTGGAAGC ACTTCCAGAT CATTACAAGC CTTGGATGGA 
  1081 AATTGCCCTC AGACTTCCTC ACTTAATCGA GAACCGCCAG CTCCGAGCTC ACGTGTACAG 
  1141 GATGCCTCTC CTGGACTGCA GATTCCTAAA GAGTTACCGT GAGCAGCGCC TGGCACACAT 
  1201 GGCGCTGGCC GCTATCACCA TGGGATTCGT CTGGCAGGAG GGGGAAGGCC AACCCCAAAA 
  1261 GGTGCTGCCA AGATCTCTTG CCATTCCTTT TGTTGAGGTA TCCAGGAACT TGGGACTCCC 
  1321 GCCTATCCTG GTCCACTCTG ACCTGGTGCT GACAAACTGG ACCAAAAGGA ACCCAGAAGG 
  1381 ACCGTTGGAA ATCAGTAACC TGGAAACCAT CATCTCATTT CCGGGGGGAG AGAGCCTGCG 
  1441 GGGCTTCATC CTAGTGACAG TCTTGGTGGA GAAGGCAGCA GTGCCCGGCC TTAAGGCCCT 
  1501 GGTTCAGGGA ATGGAGGCCA TTCGGCAACA CAGTCAGGAC ACCCTGCTAG AAGCCCTGCA 
  1561 GCAGCTGAGA CTCTCCATCC AGGATATCAC CAGAGCCTTG GCCCAAATGC ATGATTATGT 
  1621 GGACCCAGAC ATATTTTACT CGGTCATCCG GATCTTCCTC TCTGGGTGGA AGGACAATCC 
  1681 AGCCATGCCT GTGGGGCTGG TCTATGAAGG TGTTGCCACA GAGCCTCTGA AGTACTCTGG 
  1741 AGGAAGTGCA GCCCAGAGCT CCGTGCTTCA TGCCTTCGAT GAGTTCCTGG GCATTGAGCA 
  1801 TTGCAAGGAA AGTGTTGGCT TTCTACACAG AATGAGGGAC TACATGCCGC CTTCCCATAA 
  1861 GGCTTTCCTG GAAGATCTCC ACGTAGCTCC TTCTCTGAGA GACTACATAC TGGCCTCTGG 
  1921 TCCTGGGGAC TGCCTGATGG CCTATAACCA GTGTGTGGAG GCCCTGGGAG AGCTGCGCAG 
  1981 TTACCACATC AATGTCGTGG CCAGATACAT TATCTCCGCT GCCACCAGGG CCAGGAGCAG 
  2041 GGGGCTAACT AATCCCTCAC CCCATGCCTT GGAAGACAGG GGCACTGGGG GTACTGCCAT 
  2101 GCTGAGCTTC TTGAAGAGTG TCAGGGAGAA GACCATGGAG GCCCTCCTGT GTCCTGGTGC 
  2161 TTAGGCGGCC GCTCGAGCAT GCATCTAGAG GGCCCTATTC TATAGTGTCA CCTAAATGCT 
  2221 AGAGCTCGCT GATCAGCCTC GACTGTGCCT TCTAGTTGCC AGCCATCTGT TGTTTGCCCC 
  2281 TCCCCCGTGC CTTCCTTGAC CCTGGAAGGT GCCACTCCCA CTGTCCTTTC CTAATAAAAT 
  2341 GAGGAAATTG CATCGCATTG TCTGAGTAGG TGTCATTCTA TTCTGGGGGG TGGGGTGGGG 
  2401 CAGGACAGCA AGGGGGAGGA TTGGGAAGAC AATAGCAGGC ATGCTGGGGA TGCGGTGGGC 
  2461 TCTATGGCTT CTGAGGCGGA AAGAACCAGC TGGGGCTCTA GGGGGTATCC CCACGCGCCC 
  2521 TGTAGCGGCG CATTAAGCGC GGCGGGTGTG GTGGTTACGC GCAGCGTGAC CGCTACACTT 
  2581 GCCAGCGCCC TAGCGCCCGC TCCTTTCGCT TTCTTCCCTT CCTTTCTCGC CACGTTCGCC 
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  2641 GGCTTTCCCC GTCAAGCTCT AAATCGGGGC ATCCCTTTAG GGTTCCGATT TAGTGCTTTA 
  2701 CGGCACCTCG ACCCCAAAAA ACTTGATTAG GGTGATGGTT CACGTAGTGG GCCATCGCCC 
  2761 TGATAGACGG TTTTTCGCCC TTTGACGTTG GAGTCCACGT TCTTTAATAG TGGACTCTTG 
  2821 TTCCAAACTG GAACAACACT CAACCCTATC TCGGTCTATT CTTTTGATTT ATAAGGGATT 
  2881 TTGGGGATTT CGGCCTATTG GTTAAAAAAT GAGCTGATTT AACAAAAATT TAACGCGAAT 
  2941 TAATTCTGTG GAATGTGTGT CAGTTAGGGT GTGGAAAGTC CCCAGGCTCC CCAGGCAGGC 
  3001 AGAAGTATGC AAAGCATGCA TCTCAATTAG TCAGCAACCA GGTGTGGAAA GTCCCCAGGC 
  3061 TCCCCAGCAG GCAGAAGTAT GCAAAGCATG CATCTCAATT AGTCAGCAAC CATAGTCCCG 
  3121 CCCCTAACTC CGCCCATCCC GCCCCTAACT CCGCCCAGTT CCGCCCATTC TCCGCCCCAT 
  3181 GGCTGACTAA TTTTTTTTAT TTATGCAGAG GCCGAGGCCG CCTCTGCCTC TGAGCTATTC 
  3241 CAGAAGTAGT GAGGAGGCTT TTTTGGAGGC CTAGGCTTTT GCAAAAAGCT CCCGGGAGCT 
  3301 TGTATATCCA TTTTCGGATC TGATCAAGAG ACAGGATGAG GATCGTTTCG CATGATTGAA 
  3361 CAAGATGGAT TGCACGCAGG TTCTCCGGCC GCTTGGGTGG AGAGGCTATT CGGCTATGAC 
  3421 TGGGCACAAC AGACAATCGG CTGCTCTGAT GCCGCCGTGT TCCGGCTGTC AGCGCAGGGG 
  3481 CGCCCGGTTC TTTTTGTCAA GACCGACCTG TCCGGTGCCC TGAATGAACT GCAGGACGAG 
  3541 GCAGCGCGGC TATCGTGGCT GGCCACGACG GGCGTTCCTT GCGCAGCTGT GCTCGACGTT 
  3601 GTCACTGAAG CGGGAAGGGA CTGGCTGCTA TTGGGCGAAG TGCCGGGGCA GGATCTCCTG 
  3661 TCATCTCACC TTGCTCCTGC CGAGAAAGTA TCCATCATGG CTGATGCAAT GCGGCGGCTG 
  3721 CATACGCTTG ATCCGGCTAC CTGCCCATTC GACCACCAAG CGAAACATCG CATCGAGCGA 
  3781 GCACGTACTC GGATGGAAGC CGGTCTTGTC GATCAGGATG ATCTGGACGA AGAGCATCAG 
  3841 GGGCTCGCGC CAGCCGAACT GTTCGCCAGG CTCAAGGCGC GCATGCCCGA CGGCGAGGAT 
  3901 CTCGTCGTGA CCCATGGCGA TGCCTGCTTG CCGAATATCA TGGTGGAAAA TGGCCGCTTT 
  3961 TCTGGATTCA TCGACTGTGG CCGGCTGGGT GTGGCGGACC GCTATCAGGA CATAGCGTTG 
  4021 GCTACCCGTG ATATTGCTGA AGAGCTTGGC GGCGAATGGG CTGACCGCTT CCTCGTGCTT 
  4081 TACGGTATCG CCGCTCCCGA TTCGCAGCGC ATCGCCTTCT ATCGCCTTCT TGACGAGTTC 
  4141 TTCTGAGCGG GACTCTGGGG TTCGAAATGA CCGACCAAGC GACGCCCAAC CTGCCATCAC 
  4201 GAGATTTCGA TTCCACCGCC GCCTTCTATG AAAGGTTGGG CTTCGGAATC GTTTTCCGGG 
  4261 ACGCCGGCTG GATGATCCTC CAGCGCGGGG ATCTCATGCT GGAGTTCTTC GCCCACCCCA 
  4321 ACTTGTTTAT TGCAGCTTAT AATGGTTACA AATAAAGCAA TAGCATCACA AATTTCACAA 
  4381 ATAAAGCATT TTTTTCACTG CATTCTAGTT GTGGTTTGTC CAAACTCATC AATGTATCTT 
  4441 ATCATGTCTG TATACCGTCG ACCTCTAGCT AGAGCTTGGC GTAATCATGG TCATAGCTGT 
  4501 TTCCTGTGTG AAATTGTTAT CCGCTCACAA TTCCACACAA CATACGAGCC GGAAGCATAA 
  4561 AGTGTAAAGC CTGGGGTGCC TAATGAGTGA GCTAACTCAC ATTAATTGCG TTGCGCTCAC 
  4621 TGCCCGCTTT CCAGTCGGGA AACCTGTCGT GCCAGCTGCA TTAATGAATC GGCCAACGCG 
  4681 CGGGGAGAGG CGGTTTGCGT ATTGGGCGCT CTTCCGCTTC CTCGCTCACT GACTCGCTGC 
  4741 GCTCGGTCGT TCGGCTGCGG CGAGCGGTAT CAGCTCACTC AAAGGCGGTA ATACGGTTAT 
  4801 CCACAGAATC AGGGGATAAC GCAGGAAAGA ACATGTGAGC AAAAGGCCAG CAAAAGGCCA 
  4861 GGAACCGTAA AAAGGCCGCG TTGCTGGCGT TTTTCCATAG GCTCCGCCCC CCTGACGAGC 
  4921 ATCACAAAAA TCGACGCTCA AGTCAGAGGT GGCGAAACCC GACAGGACTA TAAAGATACC 
  4981 AGGCGTTTCC CCCTGGAAGC TCCCTCGTGC GCTCTCCTGT TCCGACCCTG CCGCTTACCG 
  5041 GATACCTGTC CGCCTTTCTC CCTTCGGGAA GCGTGGCGCT TTCTCAATGC TCACGCTGTA 
  5101 GGTATCTCAG TTCGGTGTAG GTCGTTCGCT CCAAGCTGGG CTGTGTGCAC GAACCCCCCG 
  5161 TTCAGCCCGA CCGCTGCGCC TTATCCGGTA ACTATCGTCT TGAGTCCAAC CCGGTAAGAC 
  5221 ACGACTTATC GCCACTGGCA GCAGCCACTG GTAACAGGAT TAGCAGAGCG AGGTATGTAG 
  5281 GCGGTGCTAC AGAGTTCTTG AAGTGGTGGC CTAACTACGG CTACACTAGA AGGACAGTAT 
  5341 TTGGTATCTG CGCTCTGCTG AAGCCAGTTA CCTTCGGAAA AAGAGTTGGT AGCTCTTGAT 
  5401 CCGGCAAACA AACCACCGCT GGTAGCGGTG GTTTTTTTGT TTGCAAGCAG CAGATTACGC 
  5461 GCAGAAAAAA AGGATCTCAA GAAGATCCTT TGATCTTTTC TACGGGGTCT GACGCTCAGT 
  5521 GGAACGAAAA CTCACGTTAA GGGATTTTGG TCATGAGATT ATCAAAAAGG ATCTTCACCT 
  5581 AGATCCTTTT AAATTAAAAA TGAAGTTTTA AATCAATCTA AAGTATATAT GAGTAAACTT 
  5641 GGTCTGACAG TTACCAATGC TTAATCAGTG AGGCACCTAT CTCAGCGATC TGTCTATTTC 
  5701 GTTCATCCAT AGTTGCCTGA CTCCCCGTCG TGTAGATAAC TACGATACGG GAGGGCTTAC 
  5761 CATCTGGCCC CAGTGCTGCA ATGATACCGC GAGACCCACG CTCACCGGCT CCAGATTTAT 
  5821 CAGCAATAAA CCAGCCAGCC GGAAGGGCCG AGCGCAGAAG TGGTCCTGCA ACTTTATCCG 
  5881 CCTCCATCCA GTCTATTAAT TGTTGCCGGG AAGCTAGAGT AAGTAGTTCG CCAGTTAATA 
  5941 GTTTGCGCAA CGTTGTTGCC ATTGCTACAG GCATCGTGGT GTCACGCTCG TCGTTTGGTA 
  6001 TGGCTTCATT CAGCTCCGGT TCCCAACGAT CAAGGCGAGT TACATGATCC CCCATGTTGT 
  6061 GCAAAAAAGC GGTTAGCTCC TTCGGTCCTC CGATCGTTGT CAGAAGTAAG TTGGCCGCAG 
  6121 TGTTATCACT CATGGTTATG GCAGCACTGC ATAATTCTCT TACTGTCATG CCATCCGTAA 
  6181 GATGCTTTTC TGTGACTGGT GAGTACTCAA CCAAGTCATT CTGAGAATAG TGTATGCGGC 
  6241 GACCGAGTTG CTCTTGCCCG GCGTCAATAC GGGATAATAC CGCGCCACAT AGCAGAACTT 
  6301 TAAAAGTGCT CATCATTGGA AAACGTTCTT CGGGGCGAAA ACTCTCAAGG ATCTTACCGC 
  6361 TGTTGAGATC CAGTTCGATG TAACCCACTC GTGCACCCAA CTGATCTTCA GCATCTTTTA 
  6421 CTTTCACCAG CGTTTCTGGG TGAGCAAAAA CAGGAAGGCA AAATGCCGCA AAAAAGGGAA 
  6481 TAAGGGCGAC ACGGAAATGT TGAATACTCA TACTCTTCCT TTTTCAATAT TATTGAAGCA 
  6541 TTTATCAGGG TTATTGTCTC ATGAGCGGAT ACATATTTGA ATGTATTTAG AAAAATAAAC 
  6601 AAATAGGGGT TCCGCGCACA TTTCCCCGAA AAGTGCCACC TGACGTC 
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I-pcDNA3.TDO 
 
     
    1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC TGCTCTGATG 
    61 CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG 
   121 CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC 
   181 TTAGGGTTAG GCGTTTTGCG CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT 
   241 GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA 
   301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 
   361 CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC 
   421 ATTGACGTCA ATGGGTGGAC TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT 
   481 ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT 
   541 ATGCCCAGTA CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA 
   601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 
   661 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC 
   721 AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG 
   781 GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA 
   841 CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTTGGTACC 
   901 GAGCTCGGAT CCACTAGTAA CGGCCGCCAG TGTGCTGGAA TTCACCATGA GTGGGTGCCC 
   961 GTTTGCAGGA AACAGTGTAG GATACACTTT GAAAAACTTA TCTATGGAGG ACAATGAAGA 
  1021 AGACAGAGCT CAAACTGGTG TAAACAGAGC CAGCAAAGGA GGACTTATCT ATGGCAATTA 
  1081 CTTGCAGTTG GAAAAGATTT TGAATGCGCA AGAACTTCAG AGTGAAGTAA AAGGGAACAA 
  1141 AATCCATGAC GAGCACCTAT TCATCATAAC TCATCAAGCT TATGAACTTT GGTTTAAACA 
  1201 AATCCTCTGG GAACTAGATT CTGTTCGTGA AATCTTCCAA AATGGCCATG TCAGGGATGA 
  1261 GAGGAACATG CTCAAGGTGA TAGCTCGGAT GCATCGTGTG GTGGTCATCT TCAAGCTCCT 
  1321 GGTACAGCAG TTCTCGGTTC TGGAAACAAT GACTGCTTTG GACTTCAATG ACTTCAGAGA 
  1381 ATACCTGTCT CCAGCATCAG GCTTCCAGAG TCTTCAGTTC CGGCTGCTGG AAAATAAGAT 
  1441 TGGTGTTCTT CAGAGCTTGA GAGTCCCTTA CAACAGGAAA CACTATCGTG ATAACTTTGG 
  1501 AGGAGACTAC AATGAGCTGT TGCTGAAATC AGAGCAGGAG CAGACGCTGT TGCAGCTGGT 
  1561 GGAGGCATGG CTGGAAAGAA CACCTGGTTT AGAGCCAAAT GGATTTAATT TCTGGGGAAA 
  1621 GTTTGAAAAA AATATCTTGA AAGGCCTGGA AGAAGAATTT CTAAGGATTC AGGCTAAAAC 
  1681 CGACTCTGAA GAAAAAGAGG AACAGATGGC AGAGTTCCGG AAGCAGAAGG AGGTGCTGCT 
  1741 CTGCTTGTTT GATGAGAAGC GTCATGACTA CCTTCTGAGT AAAGGTGAAC GACGACTGTC 
  1801 ATACCGTGCA CTCCAGGGAG CACTGATGAT ATATTTTTAC AGGGAAGAGC CTCGATTCCA 
  1861 GGTCCCTTTC CAGCTGCTGA CCTCACTTAT GGACATTGAC ACGCTCATGA CCAAATGGAG 
  1921 ATATAATCAT GTGTGCATGG TGCACAGAAT GCTGGGCACC AAGGCTGGCA CTGGGGGATC 
  1981 CTCAGGCTAT CATTACCTGC GTTCAACTGT GAGCGACAGG TACAAGGTTT TTGTGGATTT 
  2041 ATTTAACCTC TCAACATATC TGGTTCCCAG ACACTGGGTA CCAAAGATGA ATCCGATCAT 
  2101 TCACAAATTC CTTTACACAG CCGAGTACAG TGACAGCTCT TACTTCAGCA GCGATGAATC 
  2161 GGATTGAGCG GCCGCTCGAG CATGCATCTA GAGGGCCCTA TTCTATAGTG TCACCTAAAT 
  2221 GCTAGAGCTC GCTGATCAGC CTCGACTGTG CCTTCTAGTT GCCAGCCATC TGTTGTTTGC 
  2281 CCCTCCCCCG TGCCTTCCTT GACCCTGGAA GGTGCCACTC CCACTGTCCT TTCCTAATAA 
  2341 AATGAGGAAA TTGCATCGCA TTGTCTGAGT AGGTGTCATT CTATTCTGGG GGGTGGGGTG 
  2401 GGGCAGGACA GCAAGGGGGA GGATTGGGAA GACAATAGCA GGCATGCTGG GGATGCGGTG 
  2461 GGCTCTATGG CTTCTGAGGC GGAAAGAACC AGCTGGGGCT CTAGGGGGTA TCCCCACGCG 
  2521 CCCTGTAGCG GCGCATTAAG CGCGGCGGGT GTGGTGGTTA CGCGCAGCGT GACCGCTACA 
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  2581 CTTGCCAGCG CCCTAGCGCC CGCTCCTTTC GCTTTCTTCC CTTCCTTTCT CGCCACGTTC 
  2641 GCCGGCTTTC CCCGTCAAGC TCTAAATCGG GGCATCCCTT TAGGGTTCCG ATTTAGTGCT 
  2701 TTACGGCACC TCGACCCCAA AAAACTTGAT TAGGGTGATG GTTCACGTAG TGGGCCATCG 
  2761 CCCTGATAGA CGGTTTTTCG CCCTTTGACG TTGGAGTCCA CGTTCTTTAA TAGTGGACTC 
  2821 TTGTTCCAAA CTGGAACAAC ACTCAACCCT ATCTCGGTCT ATTCTTTTGA TTTATAAGGG 
  2881 ATTTTGGGGA TTTCGGCCTA TTGGTTAAAA AATGAGCTGA TTTAACAAAA ATTTAACGCG 
  2941 AATTAATTCT GTGGAATGTG TGTCAGTTAG GGTGTGGAAA GTCCCCAGGC TCCCCAGGCA 
  3001 GGCAGAAGTA TGCAAAGCAT GCATCTCAAT TAGTCAGCAA CCAGGTGTGG AAAGTCCCCA 
  3061 GGCTCCCCAG CAGGCAGAAG TATGCAAAGC ATGCATCTCA ATTAGTCAGC AACCATAGTC 
  3121 CCGCCCCTAA CTCCGCCCAT CCCGCCCCTA ACTCCGCCCA GTTCCGCCCA TTCTCCGCCC 
  3181 CATGGCTGAC TAATTTTTTT TATTTATGCA GAGGCCGAGG CCGCCTCTGC CTCTGAGCTA 
  3241 TTCCAGAAGT AGTGAGGAGG CTTTTTTGGA GGCCTAGGCT TTTGCAAAAA GCTCCCGGGA 
  3301 GCTTGTATAT CCATTTTCGG ATCTGATCAA GAGACAGGAT GAGGATCGTT TCGCATGATT 
  3361 GAACAAGATG GATTGCACGC AGGTTCTCCG GCCGCTTGGG TGGAGAGGCT ATTCGGCTAT 
  3421 GACTGGGCAC AACAGACAAT CGGCTGCTCT GATGCCGCCG TGTTCCGGCT GTCAGCGCAG 
  3481 GGGCGCCCGG TTCTTTTTGT CAAGACCGAC CTGTCCGGTG CCCTGAATGA ACTGCAGGAC 
  3541 GAGGCAGCGC GGCTATCGTG GCTGGCCACG ACGGGCGTTC CTTGCGCAGC TGTGCTCGAC 
  3601 GTTGTCACTG AAGCGGGAAG GGACTGGCTG CTATTGGGCG AAGTGCCGGG GCAGGATCTC 
  3661 CTGTCATCTC ACCTTGCTCC TGCCGAGAAA GTATCCATCA TGGCTGATGC AATGCGGCGG 
  3721 CTGCATACGC TTGATCCGGC TACCTGCCCA TTCGACCACC AAGCGAAACA TCGCATCGAG 
  3781 CGAGCACGTA CTCGGATGGA AGCCGGTCTT GTCGATCAGG ATGATCTGGA CGAAGAGCAT 
  3841 CAGGGGCTCG CGCCAGCCGA ACTGTTCGCC AGGCTCAAGG CGCGCATGCC CGACGGCGAG 
  3901 GATCTCGTCG TGACCCATGG CGATGCCTGC TTGCCGAATA TCATGGTGGA AAATGGCCGC 
  3961 TTTTCTGGAT TCATCGACTG TGGCCGGCTG GGTGTGGCGG ACCGCTATCA GGACATAGCG 
  4021 TTGGCTACCC GTGATATTGC TGAAGAGCTT GGCGGCGAAT GGGCTGACCG CTTCCTCGTG 
  4081 CTTTACGGTA TCGCCGCTCC CGATTCGCAG CGCATCGCCT TCTATCGCCT TCTTGACGAG 
  4141 TTCTTCTGAG CGGGACTCTG GGGTTCGAAA TGACCGACCA AGCGACGCCC AACCTGCCAT 
  4201 CACGAGATTT CGATTCCACC GCCGCCTTCT ATGAAAGGTT GGGCTTCGGA ATCGTTTTCC 
  4261 GGGACGCCGG CTGGATGATC CTCCAGCGCG GGGATCTCAT GCTGGAGTTC TTCGCCCACC 
  4321 CCAACTTGTT TATTGCAGCT TATAATGGTT ACAAATAAAG CAATAGCATC ACAAATTTCA 
  4381 CAAATAAAGC ATTTTTTTCA CTGCATTCTA GTTGTGGTTT GTCCAAACTC ATCAATGTAT 
  4441 CTTATCATGT CTGTATACCG TCGACCTCTA GCTAGAGCTT GGCGTAATCA TGGTCATAGC 
  4501 TGTTTCCTGT GTGAAATTGT TATCCGCTCA CAATTCCACA CAACATACGA GCCGGAAGCA 
  4561 TAAAGTGTAA AGCCTGGGGT GCCTAATGAG TGAGCTAACT CACATTAATT GCGTTGCGCT 
  4621 CACTGCCCGC TTTCCAGTCG GGAAACCTGT CGTGCCAGCT GCATTAATGA ATCGGCCAAC 
  4681 GCGCGGGGAG AGGCGGTTTG CGTATTGGGC GCTCTTCCGC TTCCTCGCTC ACTGACTCGC 
  4741 TGCGCTCGGT CGTTCGGCTG CGGCGAGCGG TATCAGCTCA CTCAAAGGCG GTAATACGGT 
  4801 TATCCACAGA ATCAGGGGAT AACGCAGGAA AGAACATGTG AGCAAAAGGC CAGCAAAAGG 
  4861 CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTTCCA TAGGCTCCGC CCCCCTGACG 
  4921 AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAAGAT 
  4981 ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TGCGCTCTCC TGTTCCGACC CTGCCGCTTA 
  5041 CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC GCTTTCTCAA TGCTCACGCT 
  5101 GTAGGTATCT CAGTTCGGTG TAGGTCGTTC GCTCCAAGCT GGGCTGTGTG CACGAACCCC 
  5161 CCGTTCAGCC CGACCGCTGC GCCTTATCCG GTAACTATCG TCTTGAGTCC AACCCGGTAA 
  5221 GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG 
  5281 TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA CGGCTACACT AGAAGGACAG 
  5341 TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG AAAAAGAGTT GGTAGCTCTT 
  5401 GATCCGGCAA ACAAACCACC GCTGGTAGCG GTGGTTTTTT TGTTTGCAAG CAGCAGATTA 
  5461 CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC 
  5521 AGTGGAACGA AAACTCACGT TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA 
  5581 CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT CTAAAGTATA TATGAGTAAA 
  5641 CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC TATCTCAGCG ATCTGTCTAT 
  5701 TTCGTTCATC CATAGTTGCC TGACTCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT 
  5761 TACCATCTGG CCCCAGTGCT GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT 
  5821 TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT 
  5881 CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGGAAGCTAG AGTAAGTAGT TCGCCAGTTA 
  5941 ATAGTTTGCG CAACGTTGTT GCCATTGCTA CAGGCATCGT GGTGTCACGC TCGTCGTTTG 
  6001 GTATGGCTTC ATTCAGCTCC GGTTCCCAAC GATCAAGGCG AGTTACATGA TCCCCCATGT 
  6061 TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG 
  6121 CAGTGTTATC ACTCATGGTT ATGGCAGCAC TGCATAATTC TCTTACTGTC ATGCCATCCG 
  6181 TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC ATTCTGAGAA TAGTGTATGC 
  6241 GGCGACCGAG TTGCTCTTGC CCGGCGTCAA TACGGGATAA TACCGCGCCA CATAGCAGAA 
  6301 CTTTAAAAGT GCTCATCATT GGAAAACGTT CTTCGGGGCG AAAACTCTCA AGGATCTTAC 
  6361 CGCTGTTGAG ATCCAGTTCG ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT 
  6421 TTACTTTCAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAAGG 
  6481 GAATAAGGGC GACACGGAAA TGTTGAATAC TCATACTCTT CCTTTTTCAA TATTATTGAA 
  6541 GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT TAGAAAAATA 
  6601 AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC ACCTGACGTC 
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J-pcDNA3.IDO1.CD11c 
 
    1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC TGCTCTGATG 
    61 CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG 
   121 CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGAGTA TTCTCTTGAC 
   181 CTTGGCTGCC TTTAAGACTC AGCTCAAGTG CTACTTCCCC CAGAAAGCAG TCTGAGGTCC 
   241 TCTCGGTCTG AGTAATACTT CTAGTGGTTG GTCTCTGTAC CTCTTTTCTC ACAGGGCCCA 
   301 CTTTAGTGTT CACCCATCTG CTTTTACTCT GATCTCTGGG TTATGTTTCT CCTATACCTA 
   361 GCAAAAGGCT CAGACCACCC CTCTTGATTA TGTTGAGCAA ATGACTAATC CACTGAATGA 
   421 ATGAATGAGT GAGTGAATGA ATGAATGAAT GAATGAATGC CAGCCTGTGC TCCCTACATG 
   481 GATCATGTGC TTACTTCTTA GTCTACTTCC AGGCCAGAAG TGGAGGGCTC CGTCATCTGT 
   541 TCTCTCTCCT CCTGTGGCTG ACTCACACTT CAAGGTCAAG GGAAACTTCT GCCAGTACAA 
   601 AAGTCTGAGA GGGATCAGAT AATCCGGGAG TTTACATATA TCCATCCGGG CAAGAATTGG 
   661 GGAACCAGAA CAATATGTCA CCAAGTCGTT TCAAGTAGAG CAACTCTTCC CTGGAAGTGT 
   721 GTAGGCTGCC TCGGTCCCCA CTCTATCCAT TTCATCTCAG TTTGCCCCCA CCTCCTCTGA 
   781 GTCACGCTGA CAACTTCCCT CCTGGTCTCT GGCCTCCTGA CCACCTTTCT TCTCATTTGC 
   841 TTCTTCTGTG GTGACTTGGC AGCTGTCTCC AAGTTGCTCA GAGCCTGCTT CTGTTCTCCA 
   901 GTCGGTACCA CCATGGCACT CAGTAAAATA TCTCCTACAG AAGGTTCTAG AAGGATCCTT 
   961 GAAGACCACC ACATAGATGA AGATGTGGGC TTTGCTCTAC CACATCCACT GGTGGAGCTG 
  1021 CCCGACGCAT ACAGCCCCTG GGTCCTTGTG GCTAGAAATC TGCCTGTGCT GATTGAGAAC 
  1081 GGGCAGCTTC GAGAAGAAGT TGAAAAGCTG CCCACACTGA GCACGGACGG ACTGAGAGGA 
  1141 CACAGGTTAC AGCGCCTGGC ACACCTGGCC CTGGGGTACA TCACCATGGC GTATGTGTGG 
  1201 AACCGAGGGG ATGACGATGT TCGAAAGGTG CTGCCCCGCA ATATTGCTGT TCCCTACTGC 
  1261 GAGCTCTCAG AGAAGTTGGG CCTGCCTCCT ATTCTGTCTT ATGCAGACTG TGTCCTGGCA 
  1321 AACTGGAAGA AAAAGGACCC CAATGGGCCC ATGACATACG AGAACATGGA CATTCTGTTC 
  1381 TCATTTCCTG GTGGGGACTG CGACAAGGGC TTCTTCCTCG TCTCTCTATT GGTGGAAATC 
  1441 GCAGCTTCTC CTGCAATCAA AGCAATCCCC ACTGTATCCA GTGCAGTAGA GCGTCAAGAC 
  1501 CTGAAAGCAT TGGAAAAGGC ACTGCACGAC ATAGCTACCA GTCTGGAGAA AGCCAAGGAA 
  1561 ATTTTTAAGA GGATGCGTGA CTTTGTGGAC CCAGACACGT TTTTCCACGT TCTCCGCATA 
  1621 TATCTGTCTG GCTGGAAATG CAGCTCCAAG CTGCCAGAAG GTCTGCTGTA TGAGGGGGTC 
  1681 TGGGACACCC CAAAAATGTT TTCAGGGGGC AGTGCAGGCC AGAGCAGCAT CTTCCAGAGT 
  1741 CTTGATGTCC TTCTGGGAAT AAAACACGAG GCTGGCAAAG AATCTCCTGC AGAATTCCTC 
  1801 CAGGAAATGA GAGAGTACAT GCCTCCAGCC CACCGGAACT TCCTTTTCTT CTTAGAGTCA 
  1861 GCTCCCCCAG TCCGTGAGTT TGTCATTTCA AGACACAATG AAGACTTGAC GAAAGCTTAT 
  1921 AACGAGTGTG TGAATGGTCT GGTCTCTGTG AGAAAGTTCC ACCTCGCAAT AGTAGATACT 
  1981 TACATTATGA AACCTTCGAA GAAGAAGCCC ACTGATGGCG ACAAGTCGGA AGAGCCCTCA 
  2041 AATGTGGAAA GCAGAGGGAC TGGGGGTACG AATCCCATGA CTTTCCTAAG GAGTGTGAAA 
  2101 GATACAACCG AGAAAGCTCT TCTGAGTTGG CCTTAGGCGG CCGCTCGAGC ATGCATCTAG 
  2161 AGGGCCCTAT TCTATAGTGT CACCTAAATG CTAGAGCTCG CTGATCAGCC TCGACTGTGC 
  2221 CTTCTAGTTG CCAGCCATCT GTTGTTTGCC CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG 
  2281 GTGCCACTCC CACTGTCCTT TCCTAATAAA ATGAGGAAAT TGCATCGCAT TGTCTGAGTA 
	 260	
  2341 GGTGTCATTC TATTCTGGGG GGTGGGGTGG GGCAGGACAG CAAGGGGGAG GATTGGGAAG 
  2401 ACAATAGCAG GCATGCTGGG GATGCGGTGG GCTCTATGGC TTCTGAGGCG GAAAGAACCA 
  2461 GCTGGGGCTC TAGGGGGTAT CCCCACGCGC CCTGTAGCGG CGCATTAAGC GCGGCGGGTG 
  2521 TGGTGGTTAC GCGCAGCGTG ACCGCTACAC TTGCCAGCGC CCTAGCGCCC GCTCCTTTCG 
  2581 CTTTCTTCCC TTCCTTTCTC GCCACGTTCG CCGGCTTTCC CCGTCAAGCT CTAAATCGGG 
  2641 GCATCCCTTT AGGGTTCCGA TTTAGTGCTT TACGGCACCT CGACCCCAAA AAACTTGATT 
  2701 AGGGTGATGG TTCACGTAGT GGGCCATCGC CCTGATAGAC GGTTTTTCGC CCTTTGACGT 
  2761 TGGAGTCCAC GTTCTTTAAT AGTGGACTCT TGTTCCAAAC TGGAACAACA CTCAACCCTA 
  2821 TCTCGGTCTA TTCTTTTGAT TTATAAGGGA TTTTGGGGAT TTCGGCCTAT TGGTTAAAAA 
  2881 ATGAGCTGAT TTAACAAAAA TTTAACGCGA ATTAATTCTG TGGAATGTGT GTCAGTTAGG 
  2941 GTGTGGAAAG TCCCCAGGCT CCCCAGGCAG GCAGAAGTAT GCAAAGCATG CATCTCAATT 
  3001 AGTCAGCAAC CAGGTGTGGA AAGTCCCCAG GCTCCCCAGC AGGCAGAAGT ATGCAAAGCA 
  3061 TGCATCTCAA TTAGTCAGCA ACCATAGTCC CGCCCCTAAC TCCGCCCATC CCGCCCCTAA 
  3121 CTCCGCCCAG TTCCGCCCAT TCTCCGCCCC ATGGCTGACT AATTTTTTTT ATTTATGCAG 
  3181 AGGCCGAGGC CGCCTCTGCC TCTGAGCTAT TCCAGAAGTA GTGAGGAGGC TTTTTTGGAG 
  3241 GCCTAGGCTT TTGCAAAAAG CTCCCGGGAG CTTGTATATC CATTTTCGGA TCTGATCAAG 
  3301 AGACAGGATG AGGATCGTTT CGCATGATTG AACAAGATGG ATTGCACGCA GGTTCTCCGG 
  3361 CCGCTTGGGT GGAGAGGCTA TTCGGCTATG ACTGGGCACA ACAGACAATC GGCTGCTCTG 
  3421 ATGCCGCCGT GTTCCGGCTG TCAGCGCAGG GGCGCCCGGT TCTTTTTGTC AAGACCGACC 
  3481 TGTCCGGTGC CCTGAATGAA CTGCAGGACG AGGCAGCGCG GCTATCGTGG CTGGCCACGA 
  3541 CGGGCGTTCC TTGCGCAGCT GTGCTCGACG TTGTCACTGA AGCGGGAAGG GACTGGCTGC 
  3601 TATTGGGCGA AGTGCCGGGG CAGGATCTCC TGTCATCTCA CCTTGCTCCT GCCGAGAAAG 
  3661 TATCCATCAT GGCTGATGCA ATGCGGCGGC TGCATACGCT TGATCCGGCT ACCTGCCCAT 
  3721 TCGACCACCA AGCGAAACAT CGCATCGAGC GAGCACGTAC TCGGATGGAA GCCGGTCTTG 
  3781 TCGATCAGGA TGATCTGGAC GAAGAGCATC AGGGGCTCGC GCCAGCCGAA CTGTTCGCCA 
  3841 GGCTCAAGGC GCGCATGCCC GACGGCGAGG ATCTCGTCGT GACCCATGGC GATGCCTGCT 
  3901 TGCCGAATAT CATGGTGGAA AATGGCCGCT TTTCTGGATT CATCGACTGT GGCCGGCTGG 
  3961 GTGTGGCGGA CCGCTATCAG GACATAGCGT TGGCTACCCG TGATATTGCT GAAGAGCTTG 
  4021 GCGGCGAATG GGCTGACCGC TTCCTCGTGC TTTACGGTAT CGCCGCTCCC GATTCGCAGC 
  4081 GCATCGCCTT CTATCGCCTT CTTGACGAGT TCTTCTGAGC GGGACTCTGG GGTTCGAAAT 
  4141 GACCGACCAA GCGACGCCCA ACCTGCCATC ACGAGATTTC GATTCCACCG CCGCCTTCTA 
  4201 TGAAAGGTTG GGCTTCGGAA TCGTTTTCCG GGACGCCGGC TGGATGATCC TCCAGCGCGG 
  4261 GGATCTCATG CTGGAGTTCT TCGCCCACCC CAACTTGTTT ATTGCAGCTT ATAATGGTTA 
  4321 CAAATAAAGC AATAGCATCA CAAATTTCAC AAATAAAGCA TTTTTTTCAC TGCATTCTAG 
  4381 TTGTGGTTTG TCCAAACTCA TCAATGTATC TTATCATGTC TGTATACCGT CGACCTCTAG 
  4441 CTAGAGCTTG GCGTAATCAT GGTCATAGCT GTTTCCTGTG TGAAATTGTT ATCCGCTCAC 
  4501 AATTCCACAC AACATACGAG CCGGAAGCAT AAAGTGTAAA GCCTGGGGTG CCTAATGAGT 
  4561 GAGCTAACTC ACATTAATTG CGTTGCGCTC ACTGCCCGCT TTCCAGTCGG GAAACCTGTC 
  4621 GTGCCAGCTG CATTAATGAA TCGGCCAACG CGCGGGGAGA GGCGGTTTGC GTATTGGGCG 
  4681 CTCTTCCGCT TCCTCGCTCA CTGACTCGCT GCGCTCGGTC GTTCGGCTGC GGCGAGCGGT 
  4741 ATCAGCTCAC TCAAAGGCGG TAATACGGTT ATCCACAGAA TCAGGGGATA ACGCAGGAAA 
  4801 GAACATGTGA GCAAAAGGCC AGCAAAAGGC CAGGAACCGT AAAAAGGCCG CGTTGCTGGC 
  4861 GTTTTTCCAT AGGCTCCGCC CCCCTGACGA GCATCACAAA AATCGACGCT CAAGTCAGAG 
  4921 GTGGCGAAAC CCGACAGGAC TATAAAGATA CCAGGCGTTT CCCCCTGGAA GCTCCCTCGT 
  4981 GCGCTCTCCT GTTCCGACCC TGCCGCTTAC CGGATACCTG TCCGCCTTTC TCCCTTCGGG 
  5041 AAGCGTGGCG CTTTCTCAAT GCTCACGCTG TAGGTATCTC AGTTCGGTGT AGGTCGTTCG 
  5101 CTCCAAGCTG GGCTGTGTGC ACGAACCCCC CGTTCAGCCC GACCGCTGCG CCTTATCCGG 
  5161 TAACTATCGT CTTGAGTCCA ACCCGGTAAG ACACGACTTA TCGCCACTGG CAGCAGCCAC 
  5221 TGGTAACAGG ATTAGCAGAG CGAGGTATGT AGGCGGTGCT ACAGAGTTCT TGAAGTGGTG 
  5281 GCCTAACTAC GGCTACACTA GAAGGACAGT ATTTGGTATC TGCGCTCTGC TGAAGCCAGT 
  5341 TACCTTCGGA AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA CAAACCACCG CTGGTAGCGG 
  5401 TGGTTTTTTT GTTTGCAAGC AGCAGATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC 
  5461 TTTGATCTTT TCTACGGGGT CTGACGCTCA GTGGAACGAA AACTCACGTT AAGGGATTTT 
  5521 GGTCATGAGA TTATCAAAAA GGATCTTCAC CTAGATCCTT TTAAATTAAA AATGAAGTTT 
  5581 TAAATCAATC TAAAGTATAT ATGAGTAAAC TTGGTCTGAC AGTTACCAAT GCTTAATCAG 
  5641 TGAGGCACCT ATCTCAGCGA TCTGTCTATT TCGTTCATCC ATAGTTGCCT GACTCCCCGT 
  5701 CGTGTAGATA ACTACGATAC GGGAGGGCTT ACCATCTGGC CCCAGTGCTG CAATGATACC 
  5761 GCGAGACCCA CGCTCACCGG CTCCAGATTT ATCAGCAATA AACCAGCCAG CCGGAAGGGC 
  5821 CGAGCGCAGA AGTGGTCCTG CAACTTTATC CGCCTCCATC CAGTCTATTA ATTGTTGCCG 
  5881 GGAAGCTAGA GTAAGTAGTT CGCCAGTTAA TAGTTTGCGC AACGTTGTTG CCATTGCTAC 
  5941 AGGCATCGTG GTGTCACGCT CGTCGTTTGG TATGGCTTCA TTCAGCTCCG GTTCCCAACG 
  6001 ATCAAGGCGA GTTACATGAT CCCCCATGTT GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC 
  6061 TCCGATCGTT GTCAGAAGTA AGTTGGCCGC AGTGTTATCA CTCATGGTTA TGGCAGCACT 
  6121 GCATAATTCT CTTACTGTCA TGCCATCCGT AAGATGCTTT TCTGTGACTG GTGAGTACTC 
  6181 AACCAAGTCA TTCTGAGAAT AGTGTATGCG GCGACCGAGT TGCTCTTGCC CGGCGTCAAT 
  6241 ACGGGATAAT ACCGCGCCAC ATAGCAGAAC TTTAAAAGTG CTCATCATTG GAAAACGTTC 
  6301 TTCGGGGCGA AAACTCTCAA GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAACCCAC 
  6361 TCGTGCACCC AACTGATCTT CAGCATCTTT TACTTTCACC AGCGTTTCTG GGTGAGCAAA 
  6421 AACAGGAAGG CAAAATGCCG CAAAAAAGGG AATAAGGGCG ACACGGAAAT GTTGAATACT 
  6481 CATACTCTTC CTTTTTCAAT ATTATTGAAG CATTTATCAG GGTTATTGTC TCATGAGCGG 
	 261	
  6541 ATACATATTT GAATGTATTT AGAAAAATAA ACAAATAGGG GTTCCGCGCA CATTTCCCCG 
  6601 AAAAGTGCCA CCTGACGTC 
 
 
K-pcDNA3.IDO2.CD11c 
 
     1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC TGCTCTGATG 
    61 CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG    
   121 CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGAGTA TTCTCTTGAC 
   181 CTTGGCTGCC TTTAAGACTC AGCTCAAGTG CTACTTCCCC CAGAAAGCAG TCTGAGGTCC 
   241 TCTCGGTCTG AGTAATACTT CTAGTGGTTG GTCTCTGTAC CTCTTTTCTC ACAGGGCCCA 
   301 CTTTAGTGTT CACCCATCTG CTTTTACTCT GATCTCTGGG TTATGTTTCT CCTATACCTA 
   361 GCAAAAGGCT CAGACCACCC CTCTTGATTA TGTTGAGCAA ATGACTAATC CACTGAATGA 
   421 ATGAATGAGT GAGTGAATGA ATGAATGAAT GAATGAATGC CAGCCTGTGC TCCCTACATG 
   481 GATCATGTGC TTACTTCTTA GTCTACTTCC AGGCCAGAAG TGGAGGGCTC CGTCATCTGT 
   541 TCTCTCTCCT CCTGTGGCTG ACTCACACTT CAAGGTCAAG GGAAACTTCT GCCAGTACAA 
   601 AAGTCTGAGA GGGATCAGAT AATCCGGGAG TTTACATATA TCCATCCGGG CAAGAATTGG 
   661 GGAACCAGAA CAATATGTCA CCAAGTCGTT TCAAGTAGAG CAACTCTTCC CTGGAAGTGT 
   721 GTAGGCTGCC TCGGTCCCCA CTCTATCCAT TTCATCTCAG TTTGCCCCCA CCTCCTCTGA 
   781 GTCACGCTGA CAACTTCCCT CCTGGTCTCT GGCCTCCTGA CCACCTTTCT TCTCATTTGC 
   841 TTCTTCTGTG GTGACTTGGC AGCTGTCTCC AAGTTGCTCA GAGCCTGCTT CTGTTCTCCA 
   901 GTCGGTACCG AGCTCGGATC CACTAGTAAC GGCCGCCAGT GTGCTGGAAT TCACCATGGA 
   961 GCCTCAAAGT CAGAGCATGA CGCTGGAGGT GCCGTTGTCC TTGGGGAGAT ACCACATTTC 
  1021 TGAGGAATAT GGCTTTCTCC TTCCAAATCC TCTGGAAGCA CTTCCAGATC ATTACAAGCC 
  1081 TTGGATGGAA ATTGCCCTCA GACTTCCTCA CTTAATCGAG AACCGCCAGC TCCGAGCTCA 
  1141 CGTGTACAGG ATGCCTCTCC TGGACTGCAG ATTCCTAAAG AGTTACCGTG AGCAGCGCCT 
  1201 GGCACACATG GCGCTGGCCG CTATCACCAT GGGATTCGTC TGGCAGGAGG GGGAAGGCCA 
  1261 ACCCCAAAAG GTGCTGCCAA GATCTCTTGC CATTCCTTTT GTTGAGGTAT CCAGGAACTT 
  1321 GGGACTCCCG CCTATCCTGG TCCACTCTGA CCTGGTGCTG ACAAACTGGA CCAAAAGGAA 
  1381 CCCAGAAGGA CCGTTGGAAA TCAGTAACCT GGAAACCATC ATCTCATTTC CGGGGGGAGA 
  1441 GAGCCTGCGG GGCTTCATCC TAGTGACAGT CTTGGTGGAG AAGGCAGCAG TGCCCGGCCT 
  1501 TAAGGCCCTG GTTCAGGGAA TGGAGGCCAT TCGGCAACAC AGTCAGGACA CCCTGCTAGA 
  1561 AGCCCTGCAG CAGCTGAGAC TCTCCATCCA GGATATCACC AGAGCCTTGG CCCAAATGCA 
  1621 TGATTATGTG GACCCAGACA TATTTTACTC GGTCATCCGG ATCTTCCTCT CTGGGTGGAA 
  1681 GGACAATCCA GCCATGCCTG TGGGGCTGGT CTATGAAGGT GTTGCCACAG AGCCTCTGAA 
  1741 GTACTCTGGA GGAAGTGCAG CCCAGAGCTC CGTGCTTCAT GCCTTCGATG AGTTCCTGGG 
  1801 CATTGAGCAT TGCAAGGAAA GTGTTGGCTT TCTACACAGA ATGAGGGACT ACATGCCGCC 
  1861 TTCCCATAAG GCTTTCCTGG AAGATCTCCA CGTAGCTCCT TCTCTGAGAG ACTACATACT 
  1921 GGCCTCTGGT CCTGGGGACT GCCTGATGGC CTATAACCAG TGTGTGGAGG CCCTGGGAGA 
  1981 GCTGCGCAGT TACCACATCA ATGTCGTGGC CAGATACATT ATCTCCGCTG CCACCAGGGC 
  2041 CAGGAGCAGG GGGCTAACTA ATCCCTCACC CCATGCCTTG GAAGACAGGG GCACTGGGGG 
  2101 TACTGCCATG CTGAGCTTCT TGAAGAGTGT CAGGGAGAAG ACCATGGAGG CCCTCCTGTG 
  2161 TCCTGGTGCT TAGGCGGCCG CTCGAGCATG CATCTAGAGG GCCCTATTCT ATAGTGTCAC 
  2221 CTAAATGCTA GAGCTCGCTG ATCAGCCTCG ACTGTGCCTT CTAGTTGCCA GCCATCTGTT 
  2281 GTTTGCCCCT CCCCCGTGCC TTCCTTGACC CTGGAAGGTG CCACTCCCAC TGTCCTTTCC 
  2341 TAATAAAATG AGGAAATTGC ATCGCATTGT CTGAGTAGGT GTCATTCTAT TCTGGGGGGT 
	 262	
  2401 GGGGTGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA TGCTGGGGAT 
  2461 GCGGTGGGCT CTATGGCTTC TGAGGCGGAA AGAACCAGCT GGGGCTCTAG GGGGTATCCC 
  2521 CACGCGCCCT GTAGCGGCGC ATTAAGCGCG GCGGGTGTGG TGGTTACGCG CAGCGTGACC 
  2581 GCTACACTTG CCAGCGCCCT AGCGCCCGCT CCTTTCGCTT TCTTCCCTTC CTTTCTCGCC 
  2641 ACGTTCGCCG GCTTTCCCCG TCAAGCTCTA AATCGGGGCA TCCCTTTAGG GTTCCGATTT 
  2701 AGTGCTTTAC GGCACCTCGA CCCCAAAAAA CTTGATTAGG GTGATGGTTC ACGTAGTGGG 
  2761 CCATCGCCCT GATAGACGGT TTTTCGCCCT TTGACGTTGG AGTCCACGTT CTTTAATAGT 
  2821 GGACTCTTGT TCCAAACTGG AACAACACTC AACCCTATCT CGGTCTATTC TTTTGATTTA 
  2881 TAAGGGATTT TGGGGATTTC GGCCTATTGG TTAAAAAATG AGCTGATTTA ACAAAAATTT 
  2941 AACGCGAATT AATTCTGTGG AATGTGTGTC AGTTAGGGTG TGGAAAGTCC CCAGGCTCCC 
  3001 CAGGCAGGCA GAAGTATGCA AAGCATGCAT CTCAATTAGT CAGCAACCAG GTGTGGAAAG 
  3061 TCCCCAGGCT CCCCAGCAGG CAGAAGTATG CAAAGCATGC ATCTCAATTA GTCAGCAACC 
  3121 ATAGTCCCGC CCCTAACTCC GCCCATCCCG CCCCTAACTC CGCCCAGTTC CGCCCATTCT 
  3181 CCGCCCCATG GCTGACTAAT TTTTTTTATT TATGCAGAGG CCGAGGCCGC CTCTGCCTCT 
  3241 GAGCTATTCC AGAAGTAGTG AGGAGGCTTT TTTGGAGGCC TAGGCTTTTG CAAAAAGCTC 
  3301 CCGGGAGCTT GTATATCCAT TTTCGGATCT GATCAAGAGA CAGGATGAGG ATCGTTTCGC 
  3361 ATGATTGAAC AAGATGGATT GCACGCAGGT TCTCCGGCCG CTTGGGTGGA GAGGCTATTC 
  3421 GGCTATGACT GGGCACAACA GACAATCGGC TGCTCTGATG CCGCCGTGTT CCGGCTGTCA 
  3481 GCGCAGGGGC GCCCGGTTCT TTTTGTCAAG ACCGACCTGT CCGGTGCCCT GAATGAACTG 
  3541 CAGGACGAGG CAGCGCGGCT ATCGTGGCTG GCCACGACGG GCGTTCCTTG CGCAGCTGTG 
  3601 CTCGACGTTG TCACTGAAGC GGGAAGGGAC TGGCTGCTAT TGGGCGAAGT GCCGGGGCAG 
  3661 GATCTCCTGT CATCTCACCT TGCTCCTGCC GAGAAAGTAT CCATCATGGC TGATGCAATG 
  3721 CGGCGGCTGC ATACGCTTGA TCCGGCTACC TGCCCATTCG ACCACCAAGC GAAACATCGC 
  3781 ATCGAGCGAG CACGTACTCG GATGGAAGCC GGTCTTGTCG ATCAGGATGA TCTGGACGAA 
  3841 GAGCATCAGG GGCTCGCGCC AGCCGAACTG TTCGCCAGGC TCAAGGCGCG CATGCCCGAC 
  3901 GGCGAGGATC TCGTCGTGAC CCATGGCGAT GCCTGCTTGC CGAATATCAT GGTGGAAAAT 
  3961 GGCCGCTTTT CTGGATTCAT CGACTGTGGC CGGCTGGGTG TGGCGGACCG CTATCAGGAC 
  4021 ATAGCGTTGG CTACCCGTGA TATTGCTGAA GAGCTTGGCG GCGAATGGGC TGACCGCTTC 
  4081 CTCGTGCTTT ACGGTATCGC CGCTCCCGAT TCGCAGCGCA TCGCCTTCTA TCGCCTTCTT 
  4141 GACGAGTTCT TCTGAGCGGG ACTCTGGGGT TCGAAATGAC CGACCAAGCG ACGCCCAACC 
  4201 TGCCATCACG AGATTTCGAT TCCACCGCCG CCTTCTATGA AAGGTTGGGC TTCGGAATCG 
  4261 TTTTCCGGGA CGCCGGCTGG ATGATCCTCC AGCGCGGGGA TCTCATGCTG GAGTTCTTCG 
  4321 CCCACCCCAA CTTGTTTATT GCAGCTTATA ATGGTTACAA ATAAAGCAAT AGCATCACAA 
  4381 ATTTCACAAA TAAAGCATTT TTTTCACTGC ATTCTAGTTG TGGTTTGTCC AAACTCATCA 
  4441 ATGTATCTTA TCATGTCTGT ATACCGTCGA CCTCTAGCTA GAGCTTGGCG TAATCATGGT 
  4501 CATAGCTGTT TCCTGTGTGA AATTGTTATC CGCTCACAAT TCCACACAAC ATACGAGCCG 
  4561 GAAGCATAAA GTGTAAAGCC TGGGGTGCCT AATGAGTGAG CTAACTCACA TTAATTGCGT 
  4621 TGCGCTCACT GCCCGCTTTC CAGTCGGGAA ACCTGTCGTG CCAGCTGCAT TAATGAATCG 
  4681 GCCAACGCGC GGGGAGAGGC GGTTTGCGTA TTGGGCGCTC TTCCGCTTCC TCGCTCACTG 
  4741 ACTCGCTGCG CTCGGTCGTT CGGCTGCGGC GAGCGGTATC AGCTCACTCA AAGGCGGTAA 
  4801 TACGGTTATC CACAGAATCA GGGGATAACG CAGGAAAGAA CATGTGAGCA AAAGGCCAGC 
  4861 AAAAGGCCAG GAACCGTAAA AAGGCCGCGT TGCTGGCGTT TTTCCATAGG CTCCGCCCCC 
  4921 CTGACGAGCA TCACAAAAAT CGACGCTCAA GTCAGAGGTG GCGAAACCCG ACAGGACTAT 
  4981 AAAGATACCA GGCGTTTCCC CCTGGAAGCT CCCTCGTGCG CTCTCCTGTT CCGACCCTGC 
  5041 CGCTTACCGG ATACCTGTCC GCCTTTCTCC CTTCGGGAAG CGTGGCGCTT TCTCAATGCT 
  5101 CACGCTGTAG GTATCTCAGT TCGGTGTAGG TCGTTCGCTC CAAGCTGGGC TGTGTGCACG 
  5161 AACCCCCCGT TCAGCCCGAC CGCTGCGCCT TATCCGGTAA CTATCGTCTT GAGTCCAACC 
  5221 CGGTAAGACA CGACTTATCG CCACTGGCAG CAGCCACTGG TAACAGGATT AGCAGAGCGA 
  5281 GGTATGTAGG CGGTGCTACA GAGTTCTTGA AGTGGTGGCC TAACTACGGC TACACTAGAA 
  5341 GGACAGTATT TGGTATCTGC GCTCTGCTGA AGCCAGTTAC CTTCGGAAAA AGAGTTGGTA 
  5401 GCTCTTGATC CGGCAAACAA ACCACCGCTG GTAGCGGTGG TTTTTTTGTT TGCAAGCAGC 
  5461 AGATTACGCG CAGAAAAAAA GGATCTCAAG AAGATCCTTT GATCTTTTCT ACGGGGTCTG 
  5521 ACGCTCAGTG GAACGAAAAC TCACGTTAAG GGATTTTGGT CATGAGATTA TCAAAAAGGA 
  5581 TCTTCACCTA GATCCTTTTA AATTAAAAAT GAAGTTTTAA ATCAATCTAA AGTATATATG 
  5641 AGTAAACTTG GTCTGACAGT TACCAATGCT TAATCAGTGA GGCACCTATC TCAGCGATCT 
  5701 GTCTATTTCG TTCATCCATA GTTGCCTGAC TCCCCGTCGT GTAGATAACT ACGATACGGG 
  5761 AGGGCTTACC ATCTGGCCCC AGTGCTGCAA TGATACCGCG AGACCCACGC TCACCGGCTC 
  5821 CAGATTTATC AGCAATAAAC CAGCCAGCCG GAAGGGCCGA GCGCAGAAGT GGTCCTGCAA 
  5881 CTTTATCCGC CTCCATCCAG TCTATTAATT GTTGCCGGGA AGCTAGAGTA AGTAGTTCGC 
  5941 CAGTTAATAG TTTGCGCAAC GTTGTTGCCA TTGCTACAGG CATCGTGGTG TCACGCTCGT 
  6001 CGTTTGGTAT GGCTTCATTC AGCTCCGGTT CCCAACGATC AAGGCGAGTT ACATGATCCC 
  6061 CCATGTTGTG CAAAAAAGCG GTTAGCTCCT TCGGTCCTCC GATCGTTGTC AGAAGTAAGT 
  6121 TGGCCGCAGT GTTATCACTC ATGGTTATGG CAGCACTGCA TAATTCTCTT ACTGTCATGC 
  6181 CATCCGTAAG ATGCTTTTCT GTGACTGGTG AGTACTCAAC CAAGTCATTC TGAGAATAGT 
  6241 GTATGCGGCG ACCGAGTTGC TCTTGCCCGG CGTCAATACG GGATAATACC GCGCCACATA 
  6301 GCAGAACTTT AAAAGTGCTC ATCATTGGAA AACGTTCTTC GGGGCGAAAA CTCTCAAGGA 
  6361 TCTTACCGCT GTTGAGATCC AGTTCGATGT AACCCACTCG TGCACCCAAC TGATCTTCAG 
  6421 CATCTTTTAC TTTCACCAGC GTTTCTGGGT GAGCAAAAAC AGGAAGGCAA AATGCCGCAA 
  6481 AAAAGGGAAT AAGGGCGACA CGGAAATGTT GAATACTCAT ACTCTTCCTT TTTCAATATT 
	 263	
  6541 ATTGAAGCAT TTATCAGGGT TATTGTCTCA TGAGCGGATA CATATTTGAA TGTATTTAGA 
  6601 AAAATAAACA AATAGGGGTT CCGCGCACAT TTCCCCGAAA AGTGCCACCT GACGTC 
 
 
L-pcDNA3.TDO.CD11c 
 
     1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC TGCTCTGATG 
    61 CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGC 
   121 CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGAGTA TTCTCTTGAC 
   181 CTTGGCTGCC TTTAAGACTC AGCTCAAGTG CTACTTCCCC CAGAAAGCAG TCTGAGGTCC 
   241 TCTCGGTCTG AGTAATACTT CTAGTGGTTG GTCTCTGTAC CTCTTTTCTC ACAGGGCCCA 
   301 CTTTAGTGTT CACCCATCTG CTTTTACTCT GATCTCTGGG TTATGTTTCT CCTATACCTA 
   361 GCAAAAGGCT CAGACCACCC CTCTTGATTA TGTTGAGCAA ATGACTAATC CACTGAATGA 
   421 ATGAATGAGT GAGTGAATGA ATGAATGAAT GAATGAATGC CAGCCTGTGC TCCCTACATG 
   481 GATCATGTGC TTACTTCTTA GTCTACTTCC AGGCCAGAAG TGGAGGGCTC CGTCATCTGT 
   541 TCTCTCTCCT CCTGTGGCTG ACTCACACTT CAAGGTCAAG GGAAACTTCT GCCAGTACAA 
   601 AAGTCTGAGA GGGATCAGAT AATCCGGGAG TTTACATATA TCCATCCGGG CAAGAATTGG 
   661 GGAACCAGAA CAATATGTCA CCAAGTCGTT TCAAGTAGAG CAACTCTTCC CTGGAAGTGT 
   721 GTAGGCTGCC TCGGTCCCCA CTCTATCCAT TTCATCTCAG TTTGCCCCCA CCTCCTCTGA 
   781 GTCACGCTGA CAACTTCCCT CCTGGTCTCT GGCCTCCTGA CCACCTTTCT TCTCATTTGC 
   841 TTCTTCTGTG GTGACTTGGC AGCTGTCTCC AAGTTGCTCA GAGCCTGCTT CTGTTCTCCA 
   901 GTCGGTACCT CAATATCACT AGTGAATTCA CCATGAGTGG GTGCCCGTTT GCAGGAAACA 
   961 GTGTAGGATA CACTTTGAAA AACTTATCTA TGGAGGACAA TGAAGAAGAC AGAGCTCAAA 
  1021 CTGGTGTAAA CAGAGCCAGC AAAGGAGGAC TTATCTATGG CAATTACTTG CAGTTGGAAA 
  1081 AGATTTTGAA TGCGCAAGAA CTTCAGAGTG AAGTAAAAGG GAACAAAATC CATGACGAGC 
  1141 ACCTATTCAT CATAACTCAT CAAGCTTATG AACTTTGGTT TAAACAAATC CTCTGGGAAC 
  1201 TAGATTCTGT TCGTGAAATC TTCCAAAATG GCCATGTCAG GGATGAGAGG AACATGCTCA 
  1261 AGGTGATAGC TCGGATGCAT CGTGTGGTGG TCATCTTCAA GCTCCTGGTA CAGCAGTTCT 
  1321 CGGTTCTGGA AACAATGACT GCTTTGGACT TCAATGACTT CAGAGAATAC CTGTCTCCAG 
  1381 CATCAGGCTT CCAGAGTCTT CAGTTCCGGC TGCTGGAAAA TAAGATTGGT GTTCTTCAGA 
  1441 GCTTGAGAGT CCCTTACAAC AGGAAACACT ATCGTGATAA CTTTGGAGGA GACTACAATG 
  1501 AGCTGTTGCT GAAATCAGAG CAGGAGCAGA CGCTGTTGCA GCTGGTGGAG GCATGGCTGG 
  1561 AAAGAACACC TGGTTTAGAG CCAAATGGAT TTAATTTCTG GGGAAAGTTT GAAAAAAATA 
  1621 TCTTGAAAGG CCTGGAAGAA GAATTTCTAA GGATTCAGGC TAAAACCGAC TCTGAAGAAA 
  1681 AAGAGGAACA GATGGCAGAG TTCCGGAAGC AGAAGGAGGT GCTGCTCTGC TTGTTTGATG 
  1741 AGAAGCGTCA TGACTACCTT CTGAGTAAAG GTGAACGACG ACTGTCATAC CGTGCACTCC 
  1801 AGGGAGCACT GATGATATAT TTTTACAGGG AAGAGCCTCG ATTCCAGGTC CCTTTCCAGC 
  1861 TGCTGACCTC ACTTATGGAC ATTGACACGC TCATGACCAA ATGGAGATAT AATCATGTGT 
  1921 GCATGGTGCA CAGAATGCTG GGCACCAAGG CTGGCACTGG GGGATCCTCA GGCTATCATT 
  1981 ACCTGCGTTC AACTGTGAGC GACAGGTACA AGGTTTTTGT GGATTTATTT AACCTCTCAA 
  2041 CATATCTGGT TCCCAGACAC TGGGTACCAA AGATGAATCC GATCATTCAC AAATTCCTTT 
  2101 ACACAGCCGA GTACAGTGAC AGCTCTTACT TCAGCAGCGA TGAATCGGAT TGAGCGGCCG 
  2161 CTCGAGCATG CATCTAGAGG GCCCTATTCT ATAGTGTCAC CTAAATGCTA GAGCTCGCTG 
	 264	
  2221 ATCAGCCTCG ACTGTGCCTT CTAGTTGCCA GCCATCTGTT GTTTGCCCCT CCCCCGTGCC 
  2281 TTCCTTGACC CTGGAAGGTG CCACTCCCAC TGTCCTTTCC TAATAAAATG AGGAAATTGC 
  2341 ATCGCATTGT CTGAGTAGGT GTCATTCTAT TCTGGGGGGT GGGGTGGGGC AGGACAGCAA 
  2401 GGGGGAGGAT TGGGAAGACA ATAGCAGGCA TGCTGGGGAT GCGGTGGGCT CTATGGCTTC 
  2461 TGAGGCGGAA AGAACCAGCT GGGGCTCTAG GGGGTATCCC CACGCGCCCT GTAGCGGCGC 
  2521 ATTAAGCGCG GCGGGTGTGG TGGTTACGCG CAGCGTGACC GCTACACTTG CCAGCGCCCT 
  2581 AGCGCCCGCT CCTTTCGCTT TCTTCCCTTC CTTTCTCGCC ACGTTCGCCG GCTTTCCCCG 
  2641 TCAAGCTCTA AATCGGGGCA TCCCTTTAGG GTTCCGATTT AGTGCTTTAC GGCACCTCGA 
  2701 CCCCAAAAAA CTTGATTAGG GTGATGGTTC ACGTAGTGGG CCATCGCCCT GATAGACGGT 
  2761 TTTTCGCCCT TTGACGTTGG AGTCCACGTT CTTTAATAGT GGACTCTTGT TCCAAACTGG 
  2821 AACAACACTC AACCCTATCT CGGTCTATTC TTTTGATTTA TAAGGGATTT TGGGGATTTC 
  2881 GGCCTATTGG TTAAAAAATG AGCTGATTTA ACAAAAATTT AACGCGAATT AATTCTGTGG 
  2941 AATGTGTGTC AGTTAGGGTG TGGAAAGTCC CCAGGCTCCC CAGGCAGGCA GAAGTATGCA 
  3001 AAGCATGCAT CTCAATTAGT CAGCAACCAG GTGTGGAAAG TCCCCAGGCT CCCCAGCAGG 
  3061 CAGAAGTATG CAAAGCATGC ATCTCAATTA GTCAGCAACC ATAGTCCCGC CCCTAACTCC 
  3121 GCCCATCCCG CCCCTAACTC CGCCCAGTTC CGCCCATTCT CCGCCCCATG GCTGACTAAT 
  3181 TTTTTTTATT TATGCAGAGG CCGAGGCCGC CTCTGCCTCT GAGCTATTCC AGAAGTAGTG 
  3241 AGGAGGCTTT TTTGGAGGCC TAGGCTTTTG CAAAAAGCTC CCGGGAGCTT GTATATCCAT 
  3301 TTTCGGATCT GATCAAGAGA CAGGATGAGG ATCGTTTCGC ATGATTGAAC AAGATGGATT 
  3361 GCACGCAGGT TCTCCGGCCG CTTGGGTGGA GAGGCTATTC GGCTATGACT GGGCACAACA 
  3421 GACAATCGGC TGCTCTGATG CCGCCGTGTT CCGGCTGTCA GCGCAGGGGC GCCCGGTTCT 
  3481 TTTTGTCAAG ACCGACCTGT CCGGTGCCCT GAATGAACTG CAGGACGAGG CAGCGCGGCT 
  3541 ATCGTGGCTG GCCACGACGG GCGTTCCTTG CGCAGCTGTG CTCGACGTTG TCACTGAAGC 
  3601 GGGAAGGGAC TGGCTGCTAT TGGGCGAAGT GCCGGGGCAG GATCTCCTGT CATCTCACCT 
  3661 TGCTCCTGCC GAGAAAGTAT CCATCATGGC TGATGCAATG CGGCGGCTGC ATACGCTTGA 
  3721 TCCGGCTACC TGCCCATTCG ACCACCAAGC GAAACATCGC ATCGAGCGAG CACGTACTCG 
  3781 GATGGAAGCC GGTCTTGTCG ATCAGGATGA TCTGGACGAA GAGCATCAGG GGCTCGCGCC 
  3841 AGCCGAACTG TTCGCCAGGC TCAAGGCGCG CATGCCCGAC GGCGAGGATC TCGTCGTGAC 
  3901 CCATGGCGAT GCCTGCTTGC CGAATATCAT GGTGGAAAAT GGCCGCTTTT CTGGATTCAT 
  3961 CGACTGTGGC CGGCTGGGTG TGGCGGACCG CTATCAGGAC ATAGCGTTGG CTACCCGTGA 
  4021 TATTGCTGAA GAGCTTGGCG GCGAATGGGC TGACCGCTTC CTCGTGCTTT ACGGTATCGC 
  4081 CGCTCCCGAT TCGCAGCGCA TCGCCTTCTA TCGCCTTCTT GACGAGTTCT TCTGAGCGGG 
  4141 ACTCTGGGGT TCGAAATGAC CGACCAAGCG ACGCCCAACC TGCCATCACG AGATTTCGAT 
  4201 TCCACCGCCG CCTTCTATGA AAGGTTGGGC TTCGGAATCG TTTTCCGGGA CGCCGGCTGG 
  4261 ATGATCCTCC AGCGCGGGGA TCTCATGCTG GAGTTCTTCG CCCACCCCAA CTTGTTTATT 
  4321 GCAGCTTATA ATGGTTACAA ATAAAGCAAT AGCATCACAA ATTTCACAAA TAAAGCATTT 
  4381 TTTTCACTGC ATTCTAGTTG TGGTTTGTCC AAACTCATCA ATGTATCTTA TCATGTCTGT 
  4441 ATACCGTCGA CCTCTAGCTA GAGCTTGGCG TAATCATGGT CATAGCTGTT TCCTGTGTGA 
  4501 AATTGTTATC CGCTCACAAT TCCACACAAC ATACGAGCCG GAAGCATAAA GTGTAAAGCC 
  4561 TGGGGTGCCT AATGAGTGAG CTAACTCACA TTAATTGCGT TGCGCTCACT GCCCGCTTTC 
  4621 CAGTCGGGAA ACCTGTCGTG CCAGCTGCAT TAATGAATCG GCCAACGCGC GGGGAGAGGC 
  4681 GGTTTGCGTA TTGGGCGCTC TTCCGCTTCC TCGCTCACTG ACTCGCTGCG CTCGGTCGTT 
  4741 CGGCTGCGGC GAGCGGTATC AGCTCACTCA AAGGCGGTAA TACGGTTATC CACAGAATCA 
  4801 GGGGATAACG CAGGAAAGAA CATGTGAGCA AAAGGCCAGC AAAAGGCCAG GAACCGTAAA 
  4861 AAGGCCGCGT TGCTGGCGTT TTTCCATAGG CTCCGCCCCC CTGACGAGCA TCACAAAAAT 
  4921 CGACGCTCAA GTCAGAGGTG GCGAAACCCG ACAGGACTAT AAAGATACCA GGCGTTTCCC 
  4981 CCTGGAAGCT CCCTCGTGCG CTCTCCTGTT CCGACCCTGC CGCTTACCGG ATACCTGTCC 
  5041 GCCTTTCTCC CTTCGGGAAG CGTGGCGCTT TCTCAATGCT CACGCTGTAG GTATCTCAGT 
  5101 TCGGTGTAGG TCGTTCGCTC CAAGCTGGGC TGTGTGCACG AACCCCCCGT TCAGCCCGAC 
  5161 CGCTGCGCCT TATCCGGTAA CTATCGTCTT GAGTCCAACC CGGTAAGACA CGACTTATCG 
  5221 CCACTGGCAG CAGCCACTGG TAACAGGATT AGCAGAGCGA GGTATGTAGG CGGTGCTACA 
  5281 GAGTTCTTGA AGTGGTGGCC TAACTACGGC TACACTAGAA GGACAGTATT TGGTATCTGC 
  5341 GCTCTGCTGA AGCCAGTTAC CTTCGGAAAA AGAGTTGGTA GCTCTTGATC CGGCAAACAA 
  5401 ACCACCGCTG GTAGCGGTGG TTTTTTTGTT TGCAAGCAGC AGATTACGCG CAGAAAAAAA 
  5461 GGATCTCAAG AAGATCCTTT GATCTTTTCT ACGGGGTCTG ACGCTCAGTG GAACGAAAAC 
  5521 TCACGTTAAG GGATTTTGGT CATGAGATTA TCAAAAAGGA TCTTCACCTA GATCCTTTTA 
  5581 AATTAAAAAT GAAGTTTTAA ATCAATCTAA AGTATATATG AGTAAACTTG GTCTGACAGT 
  5641 TACCAATGCT TAATCAGTGA GGCACCTATC TCAGCGATCT GTCTATTTCG TTCATCCATA 
  5701 GTTGCCTGAC TCCCCGTCGT GTAGATAACT ACGATACGGG AGGGCTTACC ATCTGGCCCC 
  5761 AGTGCTGCAA TGATACCGCG AGACCCACGC TCACCGGCTC CAGATTTATC AGCAATAAAC 
  5821 CAGCCAGCCG GAAGGGCCGA GCGCAGAAGT GGTCCTGCAA CTTTATCCGC CTCCATCCAG 
  5881 TCTATTAATT GTTGCCGGGA AGCTAGAGTA AGTAGTTCGC CAGTTAATAG TTTGCGCAAC 
  5941 GTTGTTGCCA TTGCTACAGG CATCGTGGTG TCACGCTCGT CGTTTGGTAT GGCTTCATTC 
  6001 AGCTCCGGTT CCCAACGATC AAGGCGAGTT ACATGATCCC CCATGTTGTG CAAAAAAGCG 
  6061 GTTAGCTCCT TCGGTCCTCC GATCGTTGTC AGAAGTAAGT TGGCCGCAGT GTTATCACTC 
  6121 ATGGTTATGG CAGCACTGCA TAATTCTCTT ACTGTCATGC CATCCGTAAG ATGCTTTTCT 
  6181 GTGACTGGTG AGTACTCAAC CAAGTCATTC TGAGAATAGT GTATGCGGCG ACCGAGTTGC 
  6241 TCTTGCCCGG CGTCAATACG GGATAATACC GCGCCACATA GCAGAACTTT AAAAGTGCTC 
  6301 ATCATTGGAA AACGTTCTTC GGGGCGAAAA CTCTCAAGGA TCTTACCGCT GTTGAGATCC 
  6361 AGTTCGATGT AACCCACTCG TGCACCCAAC TGATCTTCAG CATCTTTTAC TTTCACCAGC 
	 265	
  6421 GTTTCTGGGT GAGCAAAAAC AGGAAGGCAA AATGCCGCAA AAAAGGGAAT AAGGGCGACA 
  6481 CGGAAATGTT GAATACTCAT ACTCTTCCTT TTTCAATATT ATTGAAGCAT TTATCAGGGT 
  6541 TATTGTCTCA TGAGCGGATA CATATTTGAA TGTATTTAGA AAAATAAACA AATAGGGGTT 
  6601 CCGCGCACAT TTCCCCGAAA AGTGCCACCT GACGT   
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LOCUS       PCS2+CBGAL   7162 BP SS-DNA   CIRCULAR  SYN       
15-JAN-2001 
DEFINITION  - 
ACCESSION   - 
KEYWORDS    - 
SOURCE      - 
FEATURES             Location/Qualifiers 
     mRNA            1..1 
                     /note="base1 = cap site for sCMV 
IE94 promoter" 
	 266	
     frag            35..51 
                     /note="SP6 promoter" 
     frag            54..>63 
                     /note="CS2 insertion" 
     frag            <64..78 
                     /note="B-globin 5' mRNA sequence" 
     frag            79..3167 
                     /note="cytBgal: BamH1-EcoR1 frag" 
     CDS             96..3186 
                     /note="Bgal ORF" 
     frag            <3167..3187 
                     /note="polylinker" 
     frag            3190..3206 
                     /note="T7 promoter (reverse 
orientation)" 
     frag            3211..3406 
                     /note="SV40 late polyadenylation 
site (Bam to Dra1)" 
     frag            3407..3439 
                     /note="donwstream polylinker (from 
pVZ1)" 
     frag            3440..6175 
                     /note="Bluescript II KS+ from 
Kpn1(759) to old Pvu2(529; 
                     destroyed)" 
     frag            3460..3476 
                     /note="T3 promoter (reverse 
orientation)" 
     frag            3493..3508 
                     /note="M13 reverse primer binding 
site" 
     frag            5647..6107 
                     /note="f1 ori" 
     frag            79..3166 
                     /note="68 to 3155 of pCS-cytBgal" 
     frag            108..3098 
                     /note="31 to 3021 of Bgal frag. 
from pJ3" 
     frag            80..104 
                     /note="3 to 27 of Bgal frag. from 
pJ3" 
     frag            6176..7162 
                     /note="3109 to 4095 of pCS2+" 
     frag            6176..>7162 
                     /note="simian CMV IE94 
enhancer/promoter " 
     frag            6967..7162 
                     /note="based on DT sequences" 
	 267	
     frag            6176..6966 
                     /note="based on database 
sequences" 
BASE COUNT     1723 A   1831 C   1893 G   1715 T      0 
OTHER 
ORIGIN      - 
        1 CGCCATTCTG CCTGGGGACG TCGGAGCAAG CTTGATTTAG 
GTGACACTAT AGAATACAAG 
       61 CTACTTGTTC TTTTTGCAGG ATCTGCTAGA CTGACATGGC 
GGATCCCGTC GTTTTACAAC 
      121 GTCGTGACTG GGAAAACCCT GGCGTTACCC AACTTAATCG 
CCTTGCAGCA CATCCCCCTT 
      181 TCGCCAGCTG GCGTAATAGC GAAGAGGCCC GCACCGATCG 
CCCTTCCCAA CAGTTGCGCA 
      241 GCCTGAATGG CGAATGGCGC TTTGCCTGGT TTCCGGCACC 
AGAAGCGGTG CCGGAAAGCT 
      301 GGCTGGAGTG CGATCTTCCT GAGGCCGATA CTGTCGTCGT 
CCCCTCAAAC TGGCAGATGC 
      361 ACGGTTACGA TGCGCCCATC TACACCAACG TAACCTATCC 
CATTACGGTC AATCCGCCGT 
      421 TTGTTCCCAC GGAGAATCCG ACGGGTTGTT ACTCGCTCAC 
ATTTAATGTT GATGAAAGCT 
      481 GGCTACAGGA AGGCCAGACG CGAATTATTT TTGATGGCGT 
TAACTCGGCG TTTCATCTGT 
      541 GGTGCAACGG GCGCTGGGTC GGTTACGGCC AGGACAGTCG 
TTTGCCGTCT GAATTTGACC 
      601 TGAGCGCATT TTTACGCGCC GGAGAAAACC GCCTCGCGGT 
GATGGTGCTG CGTTGGAGTG 
      661 ACGGCAGTTA TCTGGAAGAT CAGGATATGT GGCGGATGAG 
CGGCATTTTC CGTGACGTCT 
      721 CGTTGCTGCA TAAACCGACT ACACAAATCA GCGATTTCCA 
TGTTGCCACT CGCTTTAATG 
      781 ATGATTTCAG CCGCGCTGTA CTGGAGGCTG AAGTTCAGAT 
GTGCGGCGAG TTGCGTGACT 
      841 ACCTACGGGT AACAGTTTCT TTATGGCAGG GTGAAACGCA 
GGTCGCCAGC GGCACCGCGC 
      901 CTTTCGGCGG TGAAATTATC GATGAGCGTG GTGGTTATGC 
CGATCGCGTC ACACTACGTC 
      961 TGAACGTCGA AAACCCGAAA CTGTGGAGCG CCGAAATCCC 
GAATCTCTAT CGTGCGGTGG 
     1021 TTGAACTGCA CACCGCCGAC GGCACGCTGA TTGAAGCAGA 
AGCCTGCGAT GTCGGTTTCC 
     1081 GCGAGGTGCG GATTGAAAAT GGTCTGCTGC TGCTGAACGG 
CAAGCCGTTG CTGATTCGAG 
     1141 GCGTTAACCG TCACGAGCAT CATCCTCTGC ATGGTCAGGT 
CATGGATGAG CAGACGATGG 
     1201 TGCAGGATAT CCTGCTGATG AAGCAGAACA ACTTTAACGC 
CGTGCGCTGT TCGCATTATC 
	 268	
     1261 CGAACCATCC GCTGTGGTAC ACGCTGTGCG ACCGCTACGG 
CCTGTATGTG GTGGATGAAG 
     1321 CCAATATTGA AACCCACGGC ATGGTGCCAA TGAATCGTCT 
GACCGATGAT CCGCGCTGGC 
     1381 TACCGGCGAT GAGCGAACGC GTAACGCGAA TGGTGCAGCG 
CGATCGTAAT CACCCGAGTG 
     1441 TGATCATCTG GTCGCTGGGG AATGAATCAG GCCACGGCGC 
TAATCACGAC GCGCTGTATC 
     1501 GCTGGATCAA ATCTGTCGAT CCTTCCCGCC CGGTGCAGTA 
TGAAGGCGGC GGAGCCGACA 
     1561 CCACGGCCAC CGATATTATT TGCCCGATGT ACGCGCGCGT 
GGATGAAGAC CAGCCCTTCC 
     1621 CGGCTGTGCC GAAATGGTCC ATCAAAAAAT GGCTTTCGCT 
ACCTGGAGAG ACGCGCCCGC 
     1681 TGATCCTTTG CGAATACGCC CACGCGATGG GTAACAGTCT 
TGGCGGTTTC GCTAAATACT 
     1741 GGCAGGCGTT TCGTCAGTAT CCCCGTTTAC AGGGCGGCTT 
CGTCTGGGAC TGGGTGGATC 
     1801 AGTCGCTGAT TAAATATGAT GAAAACGGCA ACCCGTGGTC 
GGCTTACGGC GGTGATTTTG 
     1861 GCGATACGCC GAACGATCGC CAGTTCTGTA TGAACGGTCT 
GGTCTTTGCC GACCGCACGC 
     1921 CGCATCCAGC GCTGACGGAA GCAAAACACC AGCAGCAGTT 
TTTCCAGTTC CGTTTATCCG 
     1981 GGCAAACCAT CGAAGTGACC AGCGAATACC TGTTCCGTCA 
TAGCGATAAC GAGCTCCTGC 
     2041 ACTGGATGGT GGCGCTGGAT GGTAAGCCGC TGGCAAGCGG 
TGAAGTGCCT CTGGATGTCG 
     2101 CTCCACAAGG TAAACAGTTG ATTGAACTGC CTGAACTACC 
GCAGCCGGAG AGCGCCGGGC 
     2161 AACTCTGGCT CACAGTACGC GTAGTGCAAC CGAACGCGAC 
CGCATGGTCA GAAGCCGGGC 
     2221 ACATCAGCGC CTGGCAGCAG TGGCGTCTGG CGGAAAACCT 
CAGTGTGACG CTCCCCGCCG 
     2281 CGTCCCACGC CATCCCGCAT CTGACCACCA GCGAAATGGA 
TTTTTGCATC GAGCTGGGTA 
     2341 ATAAGCGTTG GCAATTTAAC CGCCAGTCAG GCTTTCTTTC 
ACAGATGTGG ATTGGCGATA 
     2401 AAAAACAACT GCTGACGCCG CTGCGCGATC AGTTCACCCG 
TGCACCGCTG GATAACGACA 
     2461 TTGGCGTAAG TGAAGCGACC CGCATTGACC CTAACGCCTG 
GGTCGAACGC TGGAAGGCGG 
     2521 CGGGCCATTA CCAGGCCGAA GCAGCGTTGT TGCAGTGCAC 
GGCAGATACA CTTGCTGATG 
     2581 CGGTGCTGAT TACGACCGCT CACGCGTGGC AGCATCAGGG 
GAAAACCTTA TTTATCAGCC 
     2641 GGAAAACCTA CCGGATTGAT GGTAGTGGTC AAATGGCGAT 
TACCGTTGAT GTTGAAGTGG 
	 269	
     2701 CGAGCGATAC ACCGCATCCG GCGCGGATTG GCCTGAACTG 
CCAGCTGGCG CAGGTAGCAG 
     2761 AGCGGGTAAA CTGGCTCGGA TTAGGGCCGC AAGAAAACTA 
TCCCGACCGC CTTACTGCCG 
     2821 CCTGTTTTGA CCGCTGGGAT CTGCCATTGT CAGACATGTA 
TACCCCGTAC GTCTTCCCGA 
     2881 GCGAAAACGG TCTGCGCTGC GGGACGCGCG AATTGAATTA 
TGGCCCACAC CAGTGGCGCG 
     2941 GCGACTTCCA GTTCAACATC AGCCGCTACA GTCAACAGCA 
ACTGATGGAA ACCAGCCATC 
     3001 GCCATCTGCT GCACGCGGAA GAAGGCACAT GGCTGAATAT 
CGACGGTTTC CATATGGGGA 
     3061 TTGGTGGCGA CGACTCCTGG AGCCCGTCAG TATCGGCGGA 
ATTTCAACTG AGCGCCGGTC 
     3121 GCTACCATTA CCAACTTGTC TGGTGTCAAA AAAGATCTGG 
GAATTCAAGG CCTCTCGAGC 
     3181 CTCTAGAACT ATAGTGAGTC GTATTACGTA GATCCAGACA 
TGATAAGATA CATTGATGAG 
     3241 TTTGGACAAA CCACAACTAG AATGCAGTGA AAAAAATGCT 
TTATTTGTGA AATTTGTGAT 
     3301 GCTATTGCTT TATTTGTAAC CATTATAAGC TGCAATAAAC 
AAGTTAACAA CAACAATTGC 
     3361 ATTCATTTTA TGTTTCAGGT TCAGGGGGAG GTGTGGGAGG 
TTTTTTAATT CGCGGCCGCG 
     3421 GCGCCAATGC ATTGGGCCCG GTACCCAGCT TTTGTTCCCT 
TTAGTGAGGG TTAATTGCGC 
     3481 GCTTGGCGTA ATCATGGTCA TAGCTGTTTC CTGTGTGAAA 
TTGTTATCCG CTCACAATTC 
     3541 CACACAACAT ACGAGCCGGA AGCATAAAGT GTAAAGCCTG 
GGGTGCCTAA TGAGTGAGCT 
     3601 AACTCACATT AATTGCGTTG CGCTCACTGC CCGCTTTCCA 
GTCGGGAAAC CTGTCGTGCC 
     3661 AGCTGCATTA ATGAATCGGC CAACGCGCGG GGAGAGGCGG 
TTTGCGTATT GGGCGCTCTT 
     3721 CCGCTTCCTC GCTCACTGAC TCGCTGCGCT CGGTCGTTCG 
GCTGCGGCGA GCGGTATCAG 
     3781 CTCACTCAAA GGCGGTAATA CGGTTATCCA CAGAATCAGG 
GGATAACGCA GGAAAGAACA 
     3841 TGTGAGCAAA AGGCCAGCAA AAGGCCAGGA ACCGTAAAAA 
GGCCGCGTTG CTGGCGTTTT 
     3901 TCCATAGGCT CCGCCCCCCT GACGAGCATC ACAAAAATCG 
ACGCTCAAGT CAGAGGTGGC 
     3961 GAAACCCGAC AGGACTATAA AGATACCAGG CGTTTCCCCC 
TGGAAGCTCC CTCGTGCGCT 
     4021 CTCCTGTTCC GACCCTGCCG CTTACCGGAT ACCTGTCCGC 
CTTTCTCCCT TCGGGAAGCG 
     4081 TGGCGCTTTC TCATAGCTCA CGCTGTAGGT ATCTCAGTTC 
GGTGTAGGTC GTTCGCTCCA 
	 270	
     4141 AGCTGGGCTG TGTGCACGAA CCCCCCGTTC AGCCCGACCG 
CTGCGCCTTA TCCGGTAACT 
     4201 ATCGTCTTGA GTCCAACCCG GTAAGACACG ACTTATCGCC 
ACTGGCAGCA GCCACTGGTA 
     4261 ACAGGATTAG CAGAGCGAGG TATGTAGGCG GTGCTACAGA 
GTTCTTGAAG TGGTGGCCTA 
     4321 ACTACGGCTA CACTAGAAGG ACAGTATTTG GTATCTGCGC 
TCTGCTGAAG CCAGTTACCT 
     4381 TCGGAAAAAG AGTTGGTAGC TCTTGATCCG GCAAACAAAC 
CACCGCTGGT AGCGGTGGTT 
     4441 TTTTTGTTTG CAAGCAGCAG ATTACGCGCA GAAAAAAAGG 
ATCTCAAGAA GATCCTTTGA 
     4501 TCTTTTCTAC GGGGTCTGAC GCTCAGTGGA ACGAAAACTC 
ACGTTAAGGG ATTTTGGTCA 
     4561 TGAGATTATC AAAAAGGATC TTCACCTAGA TCCTTTTAAA 
TTAAAAATGA AGTTTTAAAT 
     4621 CAATCTAAAG TATATATGAG TAAACTTGGT CTGACAGTTA 
CCAATGCTTA ATCAGTGAGG 
     4681 CACCTATCTC AGCGATCTGT CTATTTCGTT CATCCATAGT 
TGCCTGACTC CCCGTCGTGT 
     4741 AGATAACTAC GATACGGGAG GGCTTACCAT CTGGCCCCAG 
TGCTGCAATG ATACCGCGAG 
     4801 ACCCACGCTC ACCGGCTCCA GATTTATCAG CAATAAACCA 
GCCAGCCGGA AGGGCCGAGC 
     4861 GCAGAAGTGG TCCTGCAACT TTATCCGCCT CCATCCAGTC 
TATTAATTGT TGCCGGGAAG 
     4921 CTAGAGTAAG TAGTTCGCCA GTTAATAGTT TGCGCAACGT 
TGTTGCCATT GCTACAGGCA 
     4981 TCGTGGTGTC ACGCTCGTCG TTTGGTATGG CTTCATTCAG 
CTCCGGTTCC CAACGATCAA 
     5041 GGCGAGTTAC ATGATCCCCC ATGTTGTGCA AAAAAGCGGT 
TAGCTCCTTC GGTCCTCCGA 
     5101 TCGTTGTCAG AAGTAAGTTG GCCGCAGTGT TATCACTCAT 
GGTTATGGCA GCACTGCATA 
     5161 ATTCTCTTAC TGTCATGCCA TCCGTAAGAT GCTTTTCTGT 
GACTGGTGAG TACTCAACCA 
     5221 AGTCATTCTG AGAATAGTGT ATGCGGCGAC CGAGTTGCTC 
TTGCCCGGCG TCAATACGGG 
     5281 ATAATACCGC GCCACATAGC AGAACTTTAA AAGTGCTCAT 
CATTGGAAAA CGTTCTTCGG 
     5341 GGCGAAAACT CTCAAGGATC TTACCGCTGT TGAGATCCAG 
TTCGATGTAA CCCACTCGTG 
     5401 CACCCAACTG ATCTTCAGCA TCTTTTACTT TCACCAGCGT 
TTCTGGGTGA GCAAAAACAG 
     5461 GAAGGCAAAA TGCCGCAAAA AAGGGAATAA GGGCGACACG 
GAAATGTTGA ATACTCATAC 
     5521 TCTTCCTTTT TCAATATTAT TGAAGCATTT ATCAGGGTTA 
TTGTCTCATG AGCGGATACA 
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     5581 TATTTGAATG TATTTAGAAA AATAAACAAA TAGGGGTTCC 
GCGCACATTT CCCCGAAAAG 
     5641 TGCCACCTAA ATTGTAAGCG TTAATATTTT GTTAAAATTC 
GCGTTAAATT TTTGTTAAAT 
     5701 CAGCTCATTT TTTAACCAAT AGGCCGAAAT CGGCAAAATC 
CCTTATAAAT CAAAAGAATA 
     5761 GACCGAGATA GGGTTGAGTG TTGTTCCAGT TTGGAACAAG 
AGTCCACTAT TAAAGAACGT 
     5821 GGACTCCAAC GTCAAAGGGC GAAAAACCGT CTATCAGGGC 
GATGGCCCAC TACGTGAACC 
     5881 ATCACCCTAA TCAAGTTTTT TGGGGTCGAG GTGCCGTAAA 
GCACTAAATC GGAACCCTAA 
     5941 AGGGAGCCCC CGATTTAGAG CTTGACGGGG AAAGCCGGCG 
AACGTGGCGA GAAAGGAAGG 
     6001 GAAGAAAGCG AAAGGAGCGG GCGCTAGGGC GCTGGCAAGT 
GTAGCGGTCA CGCTGCGCGT 
     6061 AACCACCACA CCCGCCGCGC TTAATGCGCC GCTACAGGGC 
GCGTCCCATT CGCCATTCAG 
     6121 GCTGCGCAAC TGTTGGGAAG GGCGATCGGT GCGGGCCTCT 
TCGCTATTAC GCCAGTCGAC 
     6181 CATAGCCAAT TCAATATGGC GTATATGGAC TCATGCCAAT 
TCAATATGGT GGATCTGGAC 
     6241 CTGTGCCAAT TCAATATGGC GTATATGGAC TCGTGCCAAT 
TCAATATGGT GGATCTGGAC 
     6301 CCCAGCCAAT TCAATATGGC GGACTTGGCA CCATGCCAAT 
TCAATATGGC GGACTTGGCA 
     6361 CTGTGCCAAC TGGGGAGGGG TCTACTTGGC ACGGTGCCAA 
GTTTGAGGAG GGGTCTTGGC 
     6421 CCTGTGCCAA GTCCGCCATA TTGAATTGGC ATGGTGCCAA 
TAATGGCGGC CATATTGGCT 
     6481 ATATGCCAGG ATCAATATAT AGGCAATATC CAATATGGCC 
CTATGCCAAT ATGGCTATTG 
     6541 GCCAGGTTCA ATACTATGTA TTGGCCCTAT GCCATATAGT 
ATTCCATATA TGGGTTTTCC 
     6601 TATTGACGTA GATAGCCCCT CCCAATGGGC GGTCCCATAT 
ACCATATATG GGGCTTCCTA 
     6661 ATACCGCCCA TAGCCACTCC CCCATTGACG TCAATGGTCT 
CTATATATGG TCTTTCCTAT 
     6721 TGACGTCATA TGGGCGGTCC TATTGACGTA TATGGCGCCT 
CCCCCATTGA CGTCAATTAC 
     6781 GGTAAATGGC CCGCCTGGCT CAATGCCCAT TGACGTCAAT 
AGGACCACCC ACCATTGACG 
     6841 TCAATGGGAT GGCTCATTGC CCATTCATAT CCGTTCTCAC 
GCCCCCTATT GACGTCAATG 
     6901 ACGGTAAATG GCCCACTTGG CAGTACATCA ATATCTATTA 
ATAGTAACTT GGCAAGTACA 
     6961 TTACTATTGG AAGGACGCCA GGGTACATTG GCAGTACTCC 
CATTGACGTC AATGGCGGTA 
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     7021 AATGGCCCGC GATGGCTGCC AAGTACATCC CCATTGACGT 
CAATGGGGAG GGGCAATGAC 
     7081 GCAAATGGGC GTTCCATTGA CGTAAATGGG CGGTAGGCGT 
GCCTAATGGG AGGTCTATAT 
     7141 AAGCAATGCT CGTTTAGGGA AC// 
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